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The Group A Streptococcus (GAS), or Streptococcus pyogenes, is a strict 
human pathogen that colonizes a variety of sites within the host. Infections can vary 
from minor and easily treatable, to life-threatening, invasive forms of disease. In 
order to adapt to niches, GAS utilizes environmental cues, such as carbohydrates, to 
coordinate the expression of virulence factors. Research efforts to date have focused 
on identifying how either components of the phosphoenolpyruvate-
phosphotransferase system (PTS) or global transcriptional networks affect the 
regulation of virulence factors, but not the synergistic relationship between the two. 
The present study investigates the role of a putative PTS-fructose operon encoded by 
fruRBA and its role in virulence in the M1T1 strain 5448. Growth in fructose resulted 
in induction of fruRBA. RT-PCR showed that fruRBA formed an operon, which was 
repressed by FruR in the absence of fructose. Growth and carbon 
  
utilization profiles revealed that although the entire fruRBA operon was required for 
growth in fructose, FruA was the main fructose transporter. The ability of both 
ΔfruR and ΔfruB mutants to survive in whole human blood or neutrophils was 
impaired. However, the phenotypes were not reproduced in murine whole blood or in 
a mouse intraperitoneal infection, indicating a human-specific mechanism. While it is 
known that the PTS can affect activity of the Mga virulence regulator, further 
characterization of the mechanism by which sugars and its protein domains affect 
activity have not been studied. Transcriptional studies revealed that the core Mga 
regulon is activated more in a glucose-rich than a glucose-poor environment. This 
activation correlates with the differential phosphorylation of Mga at its PTS 
regulatory domains (PRDs). Using a 5448 mga mutant, transcriptome studies in THY 
or C media established that the Mga regulon reflects the media used. Interestingly, 
Mga regulates phage-encoded DNases in a low glucose environment. We also show 
that Mga activity is dependent on C-terminal amino acid interactions that aid in the 
formation of homodimers. Overall, the studies presented sought to define how 
external environmental cues, specifically carbohydrates, control complex regulatory 
networks used by GAS, contribute to pathogenesis, and aid in adaptation to various 
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Chapter 1: Introduction 
 
The Group A Streptococcus (GAS) or Streptococcus pyogenes is a Gram-
positive pathogen that can colonize a variety of tissues in the human host, resulting in 
a wide range of invasive or non-invasive diseases. Worldwide, GAS is estimated to 
cause over 700 million cases of non-invasive infections such as pharyngitis and 
impetigo yearly (1). In contrast, invasive forms of disease, including necrotizing 
fasciitis (NF), puerperal sepsis, and streptococcal toxic shock syndrome (STSS) (2, 3) 
are much more life threatening. GAS infections can also lead to nonsuppurative 
sequelae such as acute rheumatic fever (ARF) and acute poststreptococcal 
glomerulonephritis (3) that combined lead to over half a million deaths worldwide 
each year (1). While a licensed vaccine is not readily available for prevention of GAS 
disease, self-limiting GAS infections are still treatable with penicillin. However, 
treatment of invasive GAS infections requires intensive care, and treatment with 
antibiotics is not always successful.  
GAS can successfully colonize and adapt to variety of niches in the human 
host by coordinating environmental cues and its nutritional status with global 
transcriptional networks. One of the major factors in the host environment that GAS 
can sense is the availability of nutrients such as carbohydrates. Given that GAS is a 
fastidious fermentative organism, it is dependent on the phosphoenolpyruvate-
phosphotransferase system (PTS) as the primary source for carbon uptake and 
utilization for the cell. Interestingly, metabolic operons and genes under carbon 




virulence in GAS (4-9), which directly links GAS carbohydrate metabolism and 
virulence factor production. In addition, since GAS does not encode for alternate 
sigma factors to coordinately regulate expression of genes, GAS utilizes global 
transcriptional regulators to coordinate transcriptome changes, including 13 two-
component systems (TCS) and several “stand-alone” regulators (e.g., RofA-like 
proteins [RALPs], Rgg, and Mga) that control virulence gene expression in response 
to environmental stimuli (10). 
This study begins with the characterization of a putative PTS-fructose operon 
encoded by the fruRBA and its role in virulence. The expression of the fruRBA operon 
was highly induced in the presence of fructose as determined by RNA-Seq. FruR 
acted as a repressor of the operon likely in conjunction with carbon catabolite protein 
A (CcpA), and FruA was the main transporter of fructose for GAS. fruR and fruB 
were also identified as being important for GAS survival in whole human blood and 
for evasion of human neutrophils. However, neither showed a defect during growth in 
whole mouse blood nor intraperitoneal (i.p.) infection in mice. The results of this 
study showed that FruR and FruB, but not FruA, were important for GAS survival in 
a human-specific environment.  
The multiple gene regulator of GAS, or Mga, is ubiquitous in all sequenced 
strains of GAS (11). Mga has been shown to be critical for multiple in vivo 
phenotypes and is critical for genetic fitness in ex vivo screens (11-16). Several 
studies have shown that Mga and its regulon are intimately linked to the PTS and 
sugar utilization. For example, CcpA was found to regulate mga expression via an 




Mga, exhibited increased expression in medium with glucose as the sole carbon 
source in comparison to alternative sugar sources (18). The most salient piece of 
evidence demonstrating the link between sugar utilization and Mga lies within the 
recent studies that show the PTS of GAS to directly phosphorylate and affect the 
activity of Mga both in vitro (19) and in vivo (20). 
The second focus of my research assessed how glucose availability affects 
Mga activity and its regulon. We demonstrated the mechanism by which Mga alters 
its activity and regulon expression was a direct response to glucose through 
phosphorylation on the phosphohistidines, presumably via the PTS. We used RNA-
Seq to identify transcriptomic differences between the Mga regulon under either a 
high or low glucose environment. Interestingly only 19 genes were found to overlap 
between the high and low glucose regulons, most of which were part of the core Mga 
regulon. Mga was found to be necessary for expression of all three phage associated 
nucleases under low glucose conditions, but this could not be correlated to an in vivo 
phenotype. Moreover, the majority phenotypes that were associated with a low 
glucose environment were complemented upon supplementation of glucose in the 
growth medium. Thus, the results from this study show that Mga activity is directly 
linked to glucose availability and this is correlated to the phosphorylation of Mga 
through its PTS-regulatory domain (PRD) histidines. 
PTS phosphorylation of Mga is hypothesized to impact the dimerization state 
and the ability to activate virulence gene transcription (19). The final study of this 
dissertation was designed to identify individual amino acid residues within the C-




activity. Data generated from a bacterial two-hybrid screen was used to select a 
representative group of mutations that showed a putative defect in dimerization. Mga 
was also modeled to the crystal structure of AtxA, a functional homolog from B. 
anthracis, to identify additional residues important for dimerization. Interestingly, 
only two mutations that were identified resulted in expression of a full-length protein 
and a functional defect in transcriptional activation. Overall, the results of these 
experiments demonstrated that mutations in the C-terminal tail of Mga are highly 
unstable because they most likely contribute to proper protein conformation, making 
it difficult to assess individual amino acid contributions to dimerization and activity. 
The results presented within this dissertation emphasize that the PTS and 
carbohydrate metabolism, through the ability to stimulate signal transduction and 
regulation of global transcriptional networks, play an important role in the 
pathogenesis for GAS.  Furthermore, the C-terminal of Mga is crucial for not only 









Chapter 2: Literature Review 
Historical Perspectives 
The Group A Streptococcus (GAS, Streptococcus pyogenes) is a strict human 
pathogen that has led to several disease outbreaks throughout human history. Skulls 
dating back to 8000-6500 BC presented the first evidence of GAS infection (21). The 
first detailed epidemic of GAS infection was documented to have occurred during the 
Age of Pericles (430 BC) in ancient Greece; those afflicted were documented as 
having a red rash over their body, which today correlates with scarlet fever (22).   
With the advent of modern microbiology and the microscope, GAS was first 
described as a spherical chain-growing microorganism found at the site of infection, 
allowing for its identification as the etiologic agent of disease. However, it was not 
until 1874 that Billroth named these organisms Streptococcus; the word streptococcus 
itself contains two roots: strepto, meaning twisted or chain and kokhos, meaning berry 
or seed (21). Concurrently, streptococci began to be classified based on the type of 
disease they caused. In 1903, Hugo Schottmüler began categorizing streptococci 
based on their ability to hemolyze red blood cells (21). In 1933, Rebecca Lancefield 
developed a classification system for β-hemolytic streptococci that is based on the 
type of carbohydrate present on the cell surface (21, 23). All β-hemolytic streptococci 
that belonged to the serotype A group in Lancefield’s classification included the 
majority of the pathogenic strains that infected humans, and thus these were 




Classification of GAS 
Standard microbiology and growth requirements 
GAS is non-motile, Gram-positive cocci that can form chains of varying 
length.  GAS is catalase and oxidase negative, and is non-spore forming. Typically, 
colonies are opaque in color, and have a variety of appearances, ranging from flat, 
dry, glossy, matte or mucoid. The colonies that are mucoid appear large, wet, and 
glistening, which is attributed to an increased production of hyaluronic acid capsule 
(24). GAS can be distinguished from other streptococci by the type of hemolysis 
present on a 5% blood agar plate, where it exhibits β-hemolysis (total lysis of red 
blood cells).  GAS is a fastidious organism that relies on the fermentation of sugars 
for growth, as it does not encode for the necessary enzymes of a functional 
tricarboxylic acid cycle (TCA). In the laboratory, GAS can be grown in nutrient-rich 
media such as Todd-Hewitt yeast extract (THY) either statically at 37oC in ambient 
air or 5-10% CO2 (25, 26). GAS is considered auxotrophic for multiple amino acids, 
and therefore requires all amino acids to be present in its growth media with the 
exception of alanine, asparagine, aspartic acid, and glutamic acid (27). GAS can also 
grow in a chemically defined media (CDM) supplemented with all of the necessary 
amino acids (28).    
Lancefield grouping 
Rebecca Lancefield established the Lancefield serological differentiation of 
streptococci in 1933 by splitting hemolytic streptococci into five different groups (A, 




rabbits immunized with 106 different strains of hemolytic streptococci. The 106 
strains were washed with hot acid in order to extract their C-substance, which is now 
known to be a carbohydrate. The acid extracts were incubated with the anti-sera to all 
other streptococcal strains and the formation of precipitate was observed when the 
anti-sera of one strain reacted with cell wall extract of a strain within the same group 
(23). This agglutination assay was later adapted and employed during the creation of 
the rapid strep test for pharyngitis that is used in the clinical laboratory (29).   
M, T, and OF typing 
The Group A Streptococcus can be broken down further into serotypes based 
on the presence of M and T proteins. The M protein is present on the cell surface of 
all GAS strains, and historically is the primary way to categorize different GAS 
strains. Much like the detection of the “C-substance”, the M protein is detected by a 
precipitation of extracted M protein using M type-specific antisera prepared against 
reference type strains (30, 31). Currently, there are over 200 different M types, based 
on sequence typing of the emm gene (32). Recently, a new adjunct method of 
classification, known as the “emm-cluster system” has been developed, which 
organizes the 223 emm-types into 48 distinct emm-clusters based on the phylogenetic 
analysis of the whole M protein and its structural and binding properties (33).  The T 
typing assay, which detects the presence of pili, is also performed as a slide 
agglutination test (34). T typing can be used in conjunction or as a replacement for M 
typing as certain T types correlate to M types (35).   
The presence of a serum opacity factor (OF) can also be utilized to subdivide 




lipoproteinase that causes various types of serum to increase in opacity. Antibodies 
against OF are used in the OF-inhibition test (36), and these results can be used to 
divide GAS into two different categories, Class I and Class II. The OF type is closely 
correlated to the M type (37), where Class I typically contains an extended conserved 
surface region of M protein and cannot opacify serum. Class II, however, lacks this 
conserved region of the M protein but contains the ability to opacify serum (3).   
 
Disease Manifestations 
The Group A Streptococcus colonizes many different tissues in the human 
host, eliciting a wide range of disease. Worldwide, GAS is estimated to cause over 
700 million cases of non-invasive infections each year. In addition, invasive GAS 
diseases and nonsuppurative sequelae lead to over half a million deaths worldwide 
each year making GAS the ninth leading cause of mortality (1). This section will 
focus on the hallmarks of different GAS diseases along with treatments currently used 
to treat each type of disease.    
Non-invasive Infections 
Pharyngitis 
Pharyngitis is one of the most common forms of GAS infections. In 2005, the 
World Health Organization (WHO) estimated that there are over 616 million cases of 
GAS pharyngitis each year (1). Symptoms include an abrupt sudden onset of severe 
throat pain accompanied by tonsilar exudates, a fever greater than 38oC that usually 




aged children, infecting approximately 15% of children in developed countries, and 
incidence is estimated to be five to ten times greater in under developed countries (1).   
Clinical procedures to identify GAS attributed pharyngitis are as follows: 
swabbing the patients’ throat, culturing the swab on blood agar, and observing the 
presence of β-hemolytic colonies within 24-48 hours. Since streptococcal pharyngitis 
symptoms can be similar to viral pharyngitis, a Centor score can be used to evaluate a 
patient presenting symptoms. This test uses a point system that determines the 
presence or absence of symptoms including presence of cough, swollen or tender 
anterior cervical nodes, temperature greater than 38oC, tonsilar exudates, and the age 
of the patient. Patients with a score of 0 to 1 are at very low risk for streptococcal 
pharyngitis and do not require testing. Patients with a score of 2 or 3 should be tested 
using a rapid strep test or throat culture; positive results warrant antibiotic therapy. 
Patients with a score of 4 or higher are at high risk of having contracted 
streptococcal-associated pharyngitis, and empiric treatment may be considered (39).  
 Although pharyngitis infections are self-limiting and usually resolve 
themselves within a few days, treatment with antibiotics is often recommended, not 
only to decrease the risk of spreading the disease and decrease the amount of time 
presenting symptoms, but also to avoid the risk of suppurative complications such as 
scarlet fever and acute rheumatic fever (ARF) (both discussed below). The antibiotics 
that are prescribed for treatment are usually penicillin and penicillin derivatives, but 
macrolides and cephalosporins can be prescribed for those who have allergic 





Scarlet fever, or scarlatina, is usually associated with pharyngitis. Today, 
scarlet fever is a mild disease with a significantly decreased morbidity and mortality 
rate, which is a stark contrast to the devastating infections seen in the 19th century 
(40). During the 1800s and prior, scarlet fever was more malignant due to the lack of 
antibiotic treatment and manifested in three types of disease: atactic, hemorrhagic, 
and anginose (40). Today, symptoms of scarlet fever often present themselves as a 
deep red, finely papular, erythematous rash, otherwise called “strawberry tongue” in 
conjunction with pharyngitis (32). GAS strains that produce scarlet fever often carry 
one or more of the pyrogenic exotoxins A, B, and C that are either phage- or 
chromosomally-encoded (3).   
Impetigo 
Impetigo or pyoderma is estimated to affect 111 million children under the 
age of 15 in under developed countries at any one time (1). Infections are usually 
seasonal, occurring mostly in the summer months and in a temperate climate, and are 
often linked to the development of acute glomerulonephritis (discussed below) (3). 
Symptoms include pustules that gradually enlarge and rupture, forming thick, honey-
colored scabs (32). Lesions often occur on exposed skin such as the face and 
extremities (41). Local symptoms are minimal and include itching and an 
erythematous halo around the lesion (42). The disease is spread through direct skin 
contact and most commonly affects children with poor hygiene that are living in 
crowded living conditions. Treatment for impetigo includes administration of 




Cellulitis and Erysipelas  
Cellulitis and Erysipelas are caused when GAS enters the skin through 
abrasions and other types of lesions and penetrate the epidermis. Erysipelas, or St 
Anthony’s fire, is a distinct form of cellulitis where the superficial layer of the skin 
and cutaneous lymphatics are affected, as opposed to cellulitis that affects 
subcutaneous tissues (3, 41). Erysipelas is characterized by an abrupt onset of a fiery-
red, salmon, or scarlet rash and well-defined margins particularly on the nasolabial 
fold. There is rapid progression and intense pain also associated with this disease.  
Erysipelas mostly affects elderly people, and recurring infections are likely (43).   
Symptoms associated with cellulitis include local swelling, erythema and 
pain.  The skin becomes indurated and unlike the brilliant redness of erysipelas, turns 
a pinkish color. In addition, the clear demarcation that is present between infected and 
uninfected skin is not present in cellulitis as it is in erysipelas. It is important to 
diagnose GAS cellulitis correctly, as many other bacteria (e.g., S. aureus) can cause 
similar symptoms and the correct course of antibiotics must be given to treat the 
disease (41).   
Invasive Infections 
Puerperal fever 
During the 18th century, puerperal fever or childbed fever had a mortality rate 
of 50%, which made it one of the most deadly diseases of its time. Historically, 
puerperal fever was contracted during pregnancy or abortion when an attending 
physician infected women post childbirth. During infection, GAS invades and 




bloodstream and produces severe abdominal pain (43). The Hungarian physician, 
Semmelweiss, introduced the concept of septic technique and in conjunction with the 
use of antibiotics, the number of cases of childbed fever has been greatly reduced and 
is now rarely fatal (21).  
Streptococcal Toxic Shock Syndrome 
Streptococcal toxic shock syndrome (STSS) is associated with bacteremia 
(discussed below) (44). It can affect persons of all ages and most do not have a 
predisposing disease, although most cases occur sporadically in individuals who are 
between the ages of 20 and 50 years old (43).   The abrupt onset of severe pain, often 
in an extremity, is a common initial symptom. This is followed by fever that can lead 
to a coma, although some patients have hypothermia secondary to shock. Other 
symptoms may include deep soft-tissue infection, shock, multiple organ failure, and 
confusion. Eighty percent of patients have clinical signs of soft tissue infection, such 
as localized swelling and erythema, that progresses to necrotizing fasciitis or myositis 
in 70% of patients and requires surgical debridement, fasciotomy or amputation (44). 
Penicillin can be used to treat STSS, however there is a decrease in efficacy at 
clearing infection due to the invasiveness of this disease.   
Bacteremia 
Streptococcal-associated bacteremia, or the presence of bacteria in the blood 
stream, is historically most common in the very young and elderly. Although rare, 
scarlet fever can be a predisposing factor, occurring previously in 0.3% of bacteria 
presenting patients. In children, predisposing factors including burns, infection with 




probability of contracting bacteremia. For the elderly, susceptibility to bacteremia 
increases after skin infections, diabetes, peripheral vascular disease, malignancy, and 
corticosteroid use (40). Mortality rates between 35-80% have been reported. Since the 
mid-1980’s, the 14 to 40 year old demographic has seen a surge in cases of 
bacteremia due to drug use (40).  STSS presents itself in conjunction to bacteremia in 
30-70% of cases (44). 
Necrotizing Fasciitis 
Hippocrates first reported necrotizing fasciitis, also known as the “flesh eating 
disease”, in the fifth century BCE (45). The first modern report that gives a detailed 
clinical description of the disease is from a U.S. Army surgeon who practiced during 
the American Civil War (46). The hallmark of necrotizing fasciitis is a rapidly 
progressing infection of the subcutaneous skin, deep soft tissues, and muscle. The 
infection can spread from being a small lesion to a highly lethal disease within 24 
hours (40, 46). In addition to surgical intervention to remove large portions of 
affected tissues, aggressive use of intravenous antibiotics with volume resuscitation is 
crucial to successful therapy (46).  However, even with aggressive surgical 
amputation of the affected area, mortality rates are often greater than 50%. This 
disease can affect patients of any age, but mortality rates increases in those who are 
50 or older (40).  
Sequelae  
Acute Rheumatic Fever 
Acute rheuamatic fever (ARF) was first described by Guillaume and 




definition of the symptoms associated with ARF in 1898. It wasn’t until the 1930s, 
that Coburn first showed convincingly that the development of rheumatic fever is 
correlated with previous GAS infection (21). ARF typically affects school-aged 
children, with approximately 2.4 million 5-14 year olds being affected worldwide; 
there are 282,000 new cases annually. Taken together, ARF is the most common 
cause of pediatric heart disease (1).   
ARF is an autoimmune collagen-vascular disease that manifests about 3 
weeks after GAS infection of the upper respiratory tract, specifically pharyngitis (3). 
Symptoms of ARF include arthritis, carditis, Sydenham’s chorea (discussed below), 
and subcutaneous nodules (3, 47). It is believed that the underlying mechanism for 
this autoimmune disorder is attributed to either the formation of antibodies directed 
against streptococcal antigens that cross-react with host tissues, or a cell-mediated 
response that is toxic to tissues (48). In 1944, T. Duckett Jones developed a series of 
guidelines, which are now commonly referred to as the Jones criteria, for identifying 
clinical manifestations of ARF (49). The patient must exhibit two major (arthritis, 
carditis, chorea) or one major and two minor (fever, increased erythrocyte 
sedimentation, arthralgia, prolonged P-R intervals on electrocardiograms, etc.) criteria 
for a positive diagnosis (3, 47). Patients diagnosed with ARF receive antibiotics, anti-
inflammatories, and supportive care (50).    
Acute Post-Streptococcal Glomerulonephritis 
Acute post-streptococcal glomerulonephritis (APSGN) is an immune 
complex-mediated disorder of the kidneys, resulting in symptoms such as edema, 




complement components in serum (3, 32). It is estimated that there are over 470,000 
cases of APSGN annually, which result in approximately 5,000 deaths (1). APSGN 
arises after skin associated GAS infections, specifically impetigo (21). APSGN 
presents itself in children and young adults, with males being affected twice as often 
as females. Those living in southern and temperate climates are more susceptible to 
APSGN, especially in the summer months, correlating with the disease cycle of 
impetigo (3). Symptoms usually arise 3 to 6 weeks after GAS infection, lasting for 
about a week (51). Treatment for APSGN includes blood pressure control with 
vasodilators, dialysis (used to treat uremia), and prophylactic antibiotic treatment 
(51).  
Neurologic Disorders 
Sydenham’s chorea (SC) is a major neurological manifestation of acute 
rheumatic fever and symptoms can appear in 10 to 50% of patients presenting with 
ARF (52). Sir Thomas Sydenham is credited for first description of the disease in 
1686, although the symptoms of the disease were known for several decades before as 
“St. Vitus Dance” (52). Children and adolescents, specifically females, are the 
predominant population who are affected by SC. However, cases in adults have also 
been reported. Symptoms of SC include hyper kinetic moves, typically of the face 
and limbs, motor impersistence, and motor and vocal tics (47, 52). Behavioral 
alterations are also common in SC, including emotional labiality and anxiety. SC is a 
self-limiting, non-progressing disorder that resolves itself after 3-18 months, however 




Pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infections, or PANDAS, were first described in 1998 with five clinical 
diagnostic criteria:  presence of 1) obsessive-compulsive disorder (OCD) and/or tic 
disorder, 2) pre-pubescent symptom onset, 3) abrupt onset or exacerbation of 
symptoms with relapses, 4) temporal association between symptoms and GAS 
infections, and 5) associated neurological abnormalities including choreiform 
movements (52, 53). Symptoms can arise at any point after GAS infection, although a 
six-week interval has been suggested as the predominant timeframe (53).  
Although there is evidence of a correlation with GAS infection and the 
development of the neuropsychiatric disorders described above, several question the 
postulated etiologic role GAS plays in the development of these diseases. In fact, 
recent studies have failed to provide a conclusive link to the exacerbation of diseases 
symptoms (54-56). The exact pathogenesis of PANDAS remains unknown, but it is 
hypothesized that it is a result of anti-neuronal antibodies developed posted infection 
(32).  
 
Vaccination and Prevention 
Vaccine Development 
The need for a GAS vaccine is evident with 18.1 million cases of severe GAS 
disease and over half a million deaths each year worldwide (57). Currently, a licensed 
vaccine is not readily available, due in part to high rate of cross-reactivity of GAS 




ideal vaccine would provide protection against all GAS strains, and with over 200 
different serotypes (32), the abundance of diversity among GAS strains makes an all-
encompassing vaccine nearly impossible. However, to date, several vaccine 
candidates have reached various stages of preclinical development, and a limited 
number have also reached early phase clinical trials (59, 60). 
Historically, the M protein – a major virulence factor – has been the main 
target for vaccine development, using either the variable N-terminal or conserved C-
terminal region as an epitope (3, 61). However, due to the hypervariablity of the N-
terminal and the highly immunogenic C-terminal (cross reacts with human cardiac 
myosin) (62), these strategies have not been successful. Two vaccine strategies have 
been developed that utilize the N-terminus of the M protein: a hexavalent- and a 26-
valent preparation (59, 60). The newest 30-valent vaccine was developed by Dale in 
2011 and contains M protein peptides from the most prevalent strains in North 
America and Europe. This vaccine strategy was immunogenic in rabbits and had 
bactericidal effects; however, this formulation has not been tested in human to date 
(63). 
Vaccines have also been developed that target non-M protein virulence factors 
such as C5a peptidase, lipoteichoic acid, protein F, the group A carbohydrate, 
streptococcal protective antigen, serum opacity factor, streptococcal pili, 
streptcococcal cell envelope protease, and streptococcal fibronectin-binding protein. 
All have been shown in animal studies to raise protective antibodies that contribute to 
host immunity, particularly in preventing colonization (3, 64-66). The streptococcal 




immunity, and have been proposed as potential vaccine candidates (3).   
 
Antibiotic Treatment 
Since the advent of antibiotic therapy with penicillin and penicillin 
derivatives, GAS has remained expressly sensitive to treatment with this family of 
antibiotics. In some cases however, GAS infections may fail to be cleared by 
penicillin treatment and may lead to asymptomatic carriage. There are two different 
hypotheses about this phenomenon: 1) GAS can enter epithelial cells and thereby 
evades penicillin, or 2) there is a co-infection with another β-lactamase-producing 
bacteria, making GAS indirectly resistant to the antibiotic treatment (32).  
For patients who are allergic to penicillin, macrolides are often used. 
However, a recent longitudinal study saw a dramatic increase in macrolide resistance 
genes present in different GAS isolates; with resistance genes increasing from 12.1% 
in 2003 to 18.8% in 2006 (67). In addition, there has been evidence for both 
tetracycline and fluoroquinolone resistance in GAS (32).   
 
Virulence Factors 
 In order to successfully colonize its host, a bacterial pathogen must possess 
features that allow for adhesion, internalization, and immune evasion. Streptococcus 
pyogenes produces a wide array of virulence factors (Fig. 2.1) that are utilized at 
different points of the infection process. Some of these are surface associated, while 




details will be reserved for those virulence factors that are regulated by the Multiple 

































Figure 2.1. Virulence factors produced by S. pyogenes.  
Graphical depiction of select virulence factors that are surface-associated, secreted, 
and phage-associated encoded by GAS. Virulence factors with similar function are 






Streptococcal Inhibitor of Complement 
The streptococcal inhibitor of complement (SIC) is a signal sequence-
containing secreted protein possessing a central region with three tandem repeats that 
is present in only four serotypes (M1, M12, M55 and M57) of GAS. The gene is 
located within the mga locus and is part of the core Mga regulon. It was discovered in 
1996 as a putative inhibitor of the membrane attack complex (MAC), which is a part 
of the complement pathway (68, 69). Fernie-King and colleagues later confirmed that 
the direct mechanism of inhibition was attributed to disruption of the formation of the 
C5b67 MAC complex, thereby preventing lysis (69). SIC was also shown to bind 
secretory leukocyte proteinase inhibitor (SLPI), lysozyme, cystatin C, LL-37, β-
defensin, ezrin, and moesin, which could aid the modification of host defense systems 
and in the initial colonization of GAS on mucosal surfaces (70-73) (74).  
In addition to the interaction with human plasma proteins, a SIC-deficient M1 
strain showed a significant decrease in the ability to colonize and persist in the upper 
respiratory tract of mice after intranasal infection (75). It is also necessary for GAS 
resistance in a murine model of systemic infections, for growth in both whole human 
blood and human serum, as well as for intracellular macrophage survival (76, 77). 
Therefore, SIC contributes to GAS immune resistance through binding of 
complement-associated proteins and is a major contributor to GAS virulence 
phenotypes. 
Streptolysin O 




activated, cholesterol-dependent cytolysin that creates 30 nm pores within host cells 
(78). SLO can form pores in a number of cell types, including erythrocytes, 
leukocytes, macrophages, and platelets (79, 80). This cytolysin helps deliver the 
enzymatically active co-toxin NAD+-glycohydrolase (NADase) into the cytoplasm of 
eukaryotic cells, and is co-transcribed with slo. Together, these two virulence factors 
significantly contribute to GAS pathogenicity by inducing premature apoptosis of 
keratinocytes and affecting host cell signaling pathways (81). Most recently, it has 
been shown that these two effectors work together to mediate GAS intracellular 
survival and cytotoxicity for macrophages by preventing phagolysosome acidification 
(82). 
Streptococcal pyrogenic exotoxin B (SpeB) 
The cysteine protease, also known as the streptococcal pyrogenic exotoxin B 
or SpeB (encoded by speB), is a secreted zymogen that is auto-catalytically cleaved 
into its active form (83). Although SpeB is ubiquitous in GAS, its expression varies 
greatly among strains (84), and is highly correlated with the switch between localized 
to invasive GAS infections (85). SpeB is expressed at stationary phase of growth, and 
is associated with nutrient depletion, acid pH, and NaCl (4, 86). In addition, SpeB is 
responsible for cleavage of a variety of GAS surface-exposed and secreted antigens, 
including the M protein (discussed below) and SIC (32), that aid in dissemination. 
Furthermore, SpeB also degrades many host surface components such as fibronectin 
and IL-1β precursor (87) to inhibit internalization of GAS into host cells. SpeB is 
highly expressed in C Media, a low-glucose media, thereby linking speB expression 





Immunoglobulin G-degrading enzyme of S. pyogenes, Mac or IdeS, is a 
conserved secreted GAS protein with homology to a human β2-integrin (CD11b; 
Mac-1), which binds to CD16 on the surface of human PMNs and inhibits 
phagocytosis and bacterial killing (89). It has two alleles; where complex I is the most 
conserved to CD11b, and is present in serotypes M1 and M3. Mac was later found to 
also cleave immunoglobulin G (IgG) through endopeptidase activity (90, 91). Crystal 
structure of Mac confirmed its specificity for IgG (92). The cleavage of IgG by Mac 
results in the formation of high amounts of circulating ½Fc fragments that are specific 
for GAS and can still bind to the surface antigens, but no longer possess the ability to 
signal and activate complement. These antibody fragments exhibit a proactive effect 
and interfere with the recognition of surface-associated antigens (93). Therefore, it 
was found that antibodies against Mac were found to decrease bacterial survival in 
whole human blood (94).  
Surface-associated proteins 
 M and M-like proteins 
The M protein is a major virulence factor that plays a role in immune evasion 
and cellular adhesion based on its complex structure. The initial interaction of GAS 
with the human host occurs at the epithelial surface of the pharynx or the external 
skin. M protein mediates adherence to skin keratinocytes via the C repeat region of 
the keratinocyte membrane cofactor CD46 (95, 96). The antiphagocytic properties of 
the M protein interferes with opsonization via the alternate complement pathway (97). 




via the C repeat region of the M protein (98), or 2) by binding of fibrinogen to the M 
protein via the N-terminus (99). 
The M protein is a surface anchored, α-helical coiled-coil protein that is 
comprised of four distinct repeat regions (A, B, C, D) (3) and is anchored to the cell 
wall from the C-terminus by a LPXTG motif (100). The hypervariable A repeat, 
located on the N-terminus, is the basis for serological/sequence differentiation of 
GAS strains (3, 32).  As mentioned in the GAS classification section, M Proteins can 
be divided into two subclasses: Class I with an extended conserved surface region (no 
serum opacification, OF-) and Class II that lacks this conserved region (serum 
opacification, OF+) (101).  
The M protein was first described by Lancefield (30), and has been implicated 
in various GAS diseases and sequelae, specifically rheumatic fever (101). It is 
involved in mediating adhesion to host epithelial cells (96), and immune evasion 
through resistance to opsonophagocytosis by the binding of fibrinogen, complement 
inhibitory factor H, C4b-binding protein, and immunoglobulin (102, 103). During the 
later phases of infection, the M protein is released into the host by the cysteine 
proteinase SpeB (104, 105), which induces neutrophil activation and consequently 
vascular leakage. It also has been shown that soluble M protein also induced T cell 
proliferation and the Th1 response (106).  
Additional surface proteins related to M protein have now been identified. 
Although the structure of these so-called "M-like" proteins is overall quite similar to 
that of M protein, they differ in the types of repeats and in their ability to interact with 




superfamily due to their structural similarity in the cell wall associated region.  There 
have been more than 20 genes (mrp, enn, arp, sir, fcrA, etc.) that have been identified 
in this superfamily, and typically GAS may encode for one to three of these genes 
(107). The salient characteristics of the M protein family is its ability to bind to a 
wide range of host proteins, including but not limited to, albumin, fibrinogen, and 
plasminogen (108, 109). 
Streptococcal Collagen-like Surface Protein 
Streptococcal collagen-like protein, SclA or Scl-1, is a surface associated 
protein that contains 50 contiguous Gly-X-X triplet amino acid motifs that mimic 
human collagen (110, 111). It is a cell wall-anchored protein containing the canonical 
LPXTG motif on its C-terminus, and is identified in all serotypes of GAS (110, 111).  
SclA is important for adherence to alveolar epithelial cells, fibronectin, and laminin, 
and is important for soft tissue infection (110, 112). SclA has also been shown to 
mediate bacterial survival in neutrophil extracellular traps (NETs) by interfering with 
myeloperoxidase (MPO) release, which is a prerequisite for NET production. It was 
also found to provide protection for GAS from antimicrobial peptides found within 
NETs (113). SclA participates in biofilm formation through its interaction with 
cellular fibronectin in the extracellular matrix produced by dermal fibroblasts, 
directly correlating its role in host tissue colonization (114).  
  C5a Peptidase 
The streptococcal C5a peptidase, or ScpA  (encoded by scpA), is a surface-
associated serine protease that is present in all GAS isolates (115, 116). It can cleave 




binding site on the carboxyl terminus (117) allowing GAS to evade 
opsonophagocytosis. The crystal structure of active ScpA confirmed its interaction 
with C5a (118) and it has been implicated in the clearance and dissemination of GAS 
during infection (119). Due to the conservation of this gene across GAS serotypes, it 
has also been proposed as a vaccine candidate. Two studies have successfully used 
recombinant ScpA as an immunogen in order to confer protective immunity in mice 
when infected intranasally with GAS (119, 120). 
MSCRAMMs 
In order to adhere to host extracellular matrix components, specifically 
fibronectin and collagen, GAS encodes for several microbial surface component 
recognizing adhesive matrix molecules, or MSCRAMMs (121). Currently, there are 
15 known MSCRAMMS encoded by GAS, 11 of which are specific for fibronectin 
binding, two that uniquely bind collagen, and one that binds both (M protein) (122). 
The presence of so many hints at redundancy of these surface adhesins, but most of 
these are not ubiquitous in the GAS genome. In addition, they are expressed at 
different times during infection, and are under the tight control of different virulence 
regulators (122).   
Protein F1, or Sfb1 (encoded by prtF), is one of the most well characterized 
MSCRAMMs present in the GAS genome. Initially, attachment occurs when the N-
terminus of fibronectin is bound by dual binding sites on Protein F1; consequently, 
conformational changes in Protein F1 and alternative interaction with fibronectin lead 




Serum Opacity Factor 
The serum opacity factor, or SOF (encoded by sof), of GAS is present in Class 
II strains (see M protein). This α-lipoproteinase is known for its ability to opacify 
mammalian serum and bind fibronectin (125). The molecule is composed of three 
domains: an N-terminal domain responsible for the opacity reaction, a repeat domain 
with fibronectin-binding activity, and a C-terminal (LPXTG motif) cell attachment 
domain (126). It is an important virulence factor, as a strain lacking SOF saw 
significant attenuation during a murine intraperitoneal model of infection (127).   
Capsule 
 The hyaluronic acid (HA) capsule (encoded by hasABC) is a significant 
virulence determinant present on the surface of GAS. Composed of a polymer of 
glucuronic acid and N-acetylglucosamine, it exhibits molecular mimicry with 
connective tissue, playing a role in adhesion and immune evasion. Capsule is under 
tight transcriptional control by the CovRS (CsrRS) two-component system, RocA, 
and the more recently discovered sRNA HasS (128-130). Additionally, degrees of 
encapsulation have been implicated in severity of disease, where those strains that are 
highly encapsulated are often associated with rheumatic fever and invasive disease 
(131), and acapsular strains are significantly attenuated in a variety of infection 
models (132, 133). Interestingly, capsule was found to impede GAS adherence and 
internalization to Hep-2 cells and human keratinocytes. However, this paradox was 
clarified when capsule was identified to bind CD44 on human epithelial cells, which 
induces cytoskeletal rearrangements that disrupt cellular junctions and allow GAS to 





Streptolysin S, or SLS, is an oxygen stable hemolysin that is responsible for 
the characteristic zone of β-hemolysis of GAS.  It is encoded by a nine-gene operon 
(sagA-I), where sagA is the actual structural toxin and the remaining genes are 
necessary for production of an active toxin (135). SLS is primarily found in a to the 
cell surface of GAS in a cell-bound form (136) and is delivered to target cells by 
direct contact (137).  SLS has a broad range of cytotoxic effects, leading to lysis of 
lymphocytes, neutrophils, platelets, cancer cells, and even cellular organelles (138-
141).  It is also found to be critical for full GAS pathogenesis, since a strain defective 
in toxin production has a significant reduction in virulence in a murine skin model of 
infection through enhanced phagocytic clearing (135). 
Phage-associated proteins 
 DNases 
GAS M1T1 serotype possesses three different DNases, two of which are 
encoded by prophages (spd3 and sdaD2/sda1) and one that is chromosomally 
encoded (spd). Streptodornase 1 (Sda1) has been shown to degrade the DNA in NETs 
(142, 143), which allows GAS to escape from NET-mediated killing. It is believed 
that upon transitioning to an invasive form of infection, Sda1 is beneficial for GAS 
survival in whole human blood (144).  A M1T1 strain lacking all three DNases was 
attenuated in two mouse models of invasive infection and showed a decrease in its 
ability to colonize cynomolgus macaques (145). Interestingly, a lysogenic M1 strain 
expressing Sda1 showed no capacity to survive human neutrophil killing or cause 




the hypervirulence of the M1T1 clone is due to a unique synergic effect of Sda1 
acting in concert with the M1T1 clone-specific genetic scaffold (146).  
Streptococcal pyrogenic exotoxins 
The streptococcal pyrogenic exotoxins (Spe) are a family of bacterial 
superantigens believed to be associated with streptococcal toxic shock syndrome 
(STSS). This family includes the bacteriophage encoded SpeA and SpeC, historically 
known as the scarlatina toxins due to their association with scarlet fever (44). Other 
toxins include: SpeG, SpeH, SpeJ, SpeK, SpeL, streptococcal superantigen SSA, 
streptococcal mitogenic exotoxins SmeZ and SmeZ-2, SpeG, SpeJ, SpeH, SpeL, and 
SpeM. SmeZ interacts with host MHC class II and the T cell receptor, leading to 
activation of both cells. In vitro, these interactions lead to proliferation and cytokine 
production by these cells. Studies using humanized HLA class II transgenic mice and 
isogenic streptococcal strains have characterized the in vivo responses to 
superantigens produced in the context of live infection. However, due to the 
deleterious role of superantigens in toxic shock of the host, the evolutionary 
advantage conferred by these toxins remains a subject of speculation (147). 
 
Regulation of Virulence 
Due to its vast repertoire of virulence factors, GAS must have tight control 
over their expression in order to successfully adhere, colonize, and invade the host. 
Unlike other prokaryotes that use alternative sigma factors as a means of regulation 
for gene expression, GAS utilizes different methods of regulation, including its 13 




Two Component Systems 
Prokaryotes’ main method of signal transduction is through two-component 
systems (TCS). TCS consist of a membrane bound histidine sensor kinase (HK) and a 
cytosolic response regulator (RR). An external environmental signal causes auto-
phosphorylation of the histidine residue on the sensor kinase. The phosphate is then 
transferred to the response regulator on an aspartate residue, thus allowing for 
activation of the protein and transcriptional regulation (148).   
CovRS 
The control of virulence regulatory system (Cov; covRS), or capsule synthesis 
regulon (CsrRS), is the most well characterized TCS in the GAS genome. It was first 
identified as a regulator for the capsule synthesis operon (hasABC), where 
inactivation of covRS leads to hypermucoid colonies (129). It was subsequently found 
to regulate the transcription of other virulence factors, including streptokinase (ska), 
streptolysin S (sagA), and the cysteine protease (speB) (149-151). CovRS is 
functionally connected to the general stress response in GAS and is activated by 
changes in heat, low pH, salts, low iron, antimicrobial peptides, and Mg2+(152-155). 
A genome-wide regulatory study identified that 15% of the GAS genome is regulated 
by CovRS; genes regulated include other TCSs, as well as surface and secreted 
proteins mediating host–pathogen interaction (156). Interestingly, mutations in covRS 
have been linked to the switch between non-invasive and invasive disease. In addition 
to altering the expression of important virulence factors, these mutations lead to 
increased resistance to phagocytosis and killing by neutrophils (157) and cause 




CovRS affects the transcription of these genes is not completely understood. 
Although a consensus binding site (ATTARA) has been identified that maps at or 
near the putative promoter sequence of many genes that are directly regulated by 
CovRS, other promoters lacking this sequence exist (159).  
TrxSR 
The two-component regulatory system X or Trx (encoded by trxSR) is 
repressed by CovRS (156). It has been shown to play a role in virulence regulation 
whereby a trxR mutant was significantly attenuated in a subcutaneous murine module 
of infection (160). TrxR can also directly regulate Mga and its regulon via its ability 
to bind directly to Pmga in vitro (161).   
Stand-Alone Regulators 
A “stand-alone regulator” is a term used to describe a single regulator that 
does not have an identified sensor component and responds to environmental stimuli 
directly to alter gene expression. This subsection will focus on two of the main 
families of stand-alone regulators, and the third such regulator, Mga, which is the 
focus of this dissertation, will be discussed in greater detail in its own section below.   
 Rgg/RopB 
 The regulator of protease, or Rgg/RopB (encoded by ropB), is known to affect 
the transcription of several genes in stationary phase of growth such as the cysteine 
protease, SpeB (162). In a global transcriptional study, Rgg was shown to affect the 
expression of several regulatory networks including CovRS, and Mga in order to co-
regulate virulence factor networks (163). Rgg also regulates several amino acid 




with secondary metabolism and thermal stress responses (165), and participates in 
GAS quorum sensing through small-peptide signaling (166). Rgg has been shown to 
bind directly to about 65 targets through a ChIP-chip experiment (167), and it was 
later found that DNA binding of Rgg is dependent on environmental changes in a 
LacD.1-dependent manner (4). 
RALPs 
The RofA-like protein (RALPs) family contains four regulators that act at the 
transition between logarithmic and stationary phase of growth to control virulence 
gene expression. Each protein in this family (RALP1-4) will be further described in 
the subsection below.   
 RofA 
The regulator of F, or RofA/RALP1 (encoded by rofA), was first found to be a 
positive transcriptional activator of the fibronectin-binding adhesion protein F under 
anaerobic growth conditions (168). It is also shown to negatively regulate 
Streptolysin S, the cysteine protease SpeB, and Mga (169). It binds directly to DNA 
in its target promoters using a 17 base pair binding site (170), and autoregulates its 
own expression (168). Additionally, RofA is important for internalization and 
survival of GAS (169). 
 Nra 
The negative regulator of GAS, Nra/RALP2, was first found to negatively 
regulate its own expression alongside the MSCRAMM fibronectin-binding protein 
F2, the collagen-binding protein Cpa, Mga, SLS, the superantigen SpeA, and SpeB 




Nra-deficient strains also showed no defect on bacterial adhesion to epithelial cells, 
but showed a reduction in the internalization rates of the bacteria, and these mutant 
bacteria could also escape phagocytic vacuoles more efficiently (172). In addition, 
Nra has been shown to have varying effects on pilus gene expression, where in some 
serotypes it is negatively regulated and others it is an activator of pilus expression 
(175). 
RALP3 
The third member of the RALPs, RALP3, is thought to have been acquired 
from Streptococcus suis through a horizontal gene transfer event, and as such is only 
found in certain serotypes (M1, M4, M12, M28, and M49). ralp3 is located in a 
discrete genetic region of the genome designated as the ERES (for the genes eno, 
ralp3, epf, and sagA) pathogenicity region (173). RALP3 is known to negatively 
regulate numerous virulence factor genes, including those involved in hyaluronic acid 
capsule and cysteine protease production. It also contributes to GAS epithelial cell 
invasion and antimicrobial peptide resistance (176), and is critical for GAS survival 
in whole human blood (15). 
RivR 
The ralp IV protein (RivR) is cotranscribed with a sRNA rivX (177). Both of 
these genes are repressed by CovRS (178) and appear to enhance the transcription of 
Mga and its regulon in an M1T1 background (MGAS5005; cov-)(177). In vivo studies 
have shown that a rivR mutant is attenuated for virulence in an invasive subcutaneous 
murine model of infection (177). However a recent study in a different M1T1 strain 




hyaluronic acid capsule biosynthesis proteins and the G-related-α2-macroglobulin 
binding (GRAB) protein, and showed no effect on the Mga regulon. Moreover, RivR 
was shown to be important for adherence to human keratinocytes and in a bacteremia 
murine model of infection (179).   
 
The phosphoenolpyruvate-phosphotransferase system (PTS) and its role 
in virulence  
Overview 
The phosphoenolpyruvate phosphotransferase system (PTS) is a conserved 
multi-protein pathway that couples transport of sugar with their phosphorylation and 
further metabolism (180). In addition, the PTS is also a signal transduction system 
where the flow of phosphorylated sugars is monitored. The phosphate from PEP 
generated though glycolysis flows to the EI protein, then to Hpr, which can be 
phosphorylated on the His-15 residue, and continues to EII and then to the incoming 
sugar where it cycles back into glycolysis (Fig 2.2). Under favorable nutrient 
conditions (high glucose) Hpr can also be phosphorylated on Ser-46 residue, allowing 
for interaction with CcpA to mediate carbon catabolite repression (CCR) in the 
presence of glucose (180, 181).   
In Gram-positive bacteria, the HPr-CcpA complex mediates CCR by binding 
to catabolite response elements (cre) present within the promoters or coding regions 
of regulated genes. A 14 base-pair consensus cre site (TGWAARCGYTWNCW) was 




represses alternative sugar utilization genes or activate the transcription of genes that 
may function in glucose metabolism (183) (184).   
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Figure 2.2.  Phosphoenol-pyruvate phosphotransferase phosphorelay.  
PTS-specific sugars are brought into the cell via the PTS EIIABC(D) permease and 
enters glycolysis. The resulting PEP transfers the phosphate to EI, which in turn 
transfers the phosphate to the His15 residue of HPr. P∼His15-HPr and P∼EIIB can also 
phosphorylate PTS regulatory domains (PRDs) of sugar regulators, thereby 
modulating their activity. Alternatively, Hpr kinase recognizes intermediates of 
glycolysis and phosphorylates HPr on the Ser46 residue. P~Ser46-Hpr then complexes 




Carbon catabolite repression (CCR) is a global regulatory mechanism of 
carbon source utilization that both Gram-negative and Gram-positive bacteria use to 
promote efficient utilization of carbon sources when the preferred substrate (glucose) 
is present (185). In a nutrient rich environment, such as glucose, bacteria use CCR to 
inhibit the expression of enzymes and transporters necessary for consumption of 
alternative carbon sources. In addition, CCR and other PTS related genes have been 
shown to play an important role in virulence gene regulation for Gram-positive 
bacteria, specifically pathogens in the phylum Firmicutes. To mention a few, low 
glucose availability conveys methicillin resistance in Staphylococcus aureus, 
promotes successful colonization in Streptococcus pneumoniae, stimulates host cell 
invasion in Listeria monocytogenes, and increases toxin production in Clostridium 
perfringens (186). These pathogens, like all bacteria, rely on global regulatory 
networks and dedicated sugar transporters in order to detect the presence of preferred 
carbon sources as a reflection of the nutrient status of the host environment. This 
allows for the appropriate coordination of virulence gene expression and disease 
manifestations in response to surrounding conditions.  
GAS is a fastidious organism that lacks a functional tricarboxylic acid cycle 
(TCA) cycle, and relies on the transport of carbon sources through the PTS in order to 
generate energy. Components of the PTS and CcpA have been shown to be very 
important for the pathogenicity of GAS. The rest of this section will further outline 
and PTS and its importance in pathogenesis, as well as discuss the link between 




Virulence Regulation and Sugar Metabolism in Gram-Positive Pathogens 
Listeria monocytogenes  
The major activator of virulence in L. monocytogenes, PrfA, is under control 
of CCR (187). PrfA controls the expression of genes required for invading host cells 
and for release from phagolysosomes. However, the mechanism for CCR-mediated 
repression of PrfA was not a result of direct regulation by CcpA (188), but was a 
result of P~Ser46-HPr (189). PrfA was found to be repressed in the presence of 
glucose and fructose. Interestingly, several other virulence genes such as a hemolysin 
(hly) and a phospholipase (plcA) were also repressed in L. monocytogenes when it 
was grown on cellobiose, glucose, or other readily metabolized carbon source (181).  
Clostridium perfringens  
In the anaerobic, spore-forming pathogen C. perfringens, expression of a 
variety of virulence genes are shown to mediated by CCR. For example, CcpA 
regulates expression of enterotoxin (cpe), sporulation, collagenase, polysaccharide 
capsule, and motility through Type IV pilus (190-192). 
Staphylococcus aureus  
Studies on CcpA and CCR in the pathogen S. aureus found that CcpA-
mediates expression of genes involved in antibiotic resistance and other virulence 
determinants. In fact, a CcpA mutant showed reduced resistance to the antibiotic 
oxacillin (193). In addition, CcpA was also found to negatively regulate the 
expression of the staphylococcal α-hemolysin, capsule, and protein A. Furthermore, 
this study showed CcpA-mediated activation of the virulence regulator RNAIII, an 




Streptococcus pneumoniae  
In the pathogen S. pneumoniae, the CcpA ortholog RegM represses α-
glucosidase and β-galactosidase activities and the capsular polysaccharide synthesis 
(cps) locus, which is important for cell adhesion (180). A mutation in RegM is 
attenuated for both nasopharygeal colonization and virulence in the mouse pneumonia 
model of infection (194).  
Streptococcus mutans 
The pathogenic oral streptococci S. mutans relies on carbohydrates for energy 
production in order to successfully colonize and the oral cavity and cause dental 
caries. A ∆ccpA mutant exhibited diminished fructosyltransferase and 
glucosyltransferase gene expression, which are both important for biofilm formation 
(195). Interestingly, it has been demonstrated that CcpA has very little influence on 
CCR in S. mutans; however, HPr can exert effects on CCR in S. mutans. CCR in this 
organism is dominantly controlled by the glucose/mannose EIIAB permease (180). 
Virulence Regulation and Sugar Metabolism in GAS 
Enzyme I (EI) 
 The first enzyme in the PTS, EI (ptsI), initiates the phosphorelay of the PTS 
after autophosphorylation by PEP (180).  Recently, Gera et al. demonstrated that a 
∆ptsI mutant exhibited a hyper virulence phenotype in a subcutaneous murine model 
of infection. In addition, an increase in transcript levels of Streptolysin S, in 
conjunction with the early onset of its activity, correlated with the increased lesion 




not required for subcutaneous skin infection in mice; however, it does influence 
correct timing of virulence factor expression and limits disease progression (8). 
CcpA 
 The global catabolite repressor protein, a LacI/GalR family member, is a key 
regulator of carbon catabolite repression (CCR) in GAS. Numerous metabolic 
operons are under the control of CcpA through its ability to bind to the catabolite 
response element (cre) sequence when complexed with P~Ser46-Hpr (196). In GAS, 
CcpA has been shown to have an indirect regulatory effect on streptolysin S, however 
the directionality of this effect is not exactly clear. Shelburne et al. found SLS to be 
down regulated and a ∆ccpA mutant was attenuated in a mouse invasive model of 
infection, whereas Kinkel et al. found SLS to be up regulated and a ∆ccpA mutant 
was hypervirulent in a systemic infection model (5, 6). CcpA was also found to 
negatively regulate cfa (CAMP factor), but positively regulate the cysteine protease 
gene speB (7). In addition, CcpA is proposed to bind directly to the promoter region 
of mga (Pmga) via an identified alternative cre site, thereby affecting the expression 
of this major virulence regulator (17).  
Maltose Operon 
The maltose PTS transporter, MalE, in conjunction with another transporter 
MalT (ptsG), is responsible for the transport of maltose into the cell. Mutations in 
these genes, in addition to abrogating maltose uptake by GAS, were shown to 
influence the ability of GAS to grow in human saliva and impair colonization of the 
mouse oropharynx (197). In addition, MalR, a LacI/GalR-family repressor protein has 




not affect invasive infection. It also regulates the virulence gene pulA, which encodes 
a cell wall-anchored carbohydrate binding and degrading enzyme (198).   
CodY 
 The regulator CodY links carbon metabolism with the nitrogen cycle by 
sensing amino-acid starvation in several low G+C Gram-positive bacteria. This 
regulator has been shown to affect virulence gene regulation by subsequent activation 
of CovRS in GAS (199). Moreover, CodY affects the transcription of mga, ropB/rgg, 
fasBCAX, and pel (200)  Therefore, it is not surprising that CodY contributes to GAS 
survival and virulence gene regulation in whole human blood (201). 
 M protein  
In 1970, Pine and Reeves investigated the role of metabolism and sugar 
source on the production of M protein (18, 202), and their studies showed that 
expression of M protein was highest during exponential growth phase. However, they 
also observed a surge of M protein production in stationary phase as all growth 
substrates were being depleted. Additionally, they found that the highest levels of M 
protein were produced when GAS was grown in medium with glucose as the sole 
carbon source as compared to sucrose and trehalose (18). Thus, this suggested a link 
between sugar metabolism and production of this important virulence factor of the 
GAS.  
 
PRD Containing Regulators 
 PTS regulatory domains (PRD) are found in a large number of bacterial 




ability to respond to the availability of carbohydrates (Fig. 2.2). These metabolic 
regulatory proteins can be RNA-binding transcriptional anti-terminators or DNA-
binding transcription factors. Their activity is dependent on the concomitant 
phosphorylation of conserved histidine residues on their reiterated PRD domains 
(PRD1/2), which in turn influences homodimerization (180). Inactivity occurs in the 
absence of an inducing sugar, where the phosphorylated EIIB component of the sugar 
permease transfers its phosphate to a PRD, often inactivating the regulator. In the 
presence of the preferred sugar, the regulator is dephosphoryalated and the phosphate 
is transferred to the incoming sugar for further metabolism. 
PRD-containing regulators have been demonstrated to aid in CCR, whereby 
P~His15-Hpr can transfer its phosphate to the regulator and stimulate its activity 
(203). Importantly, newly recognized members of this regulator family have also 
been shown to regulate virulence pathways, which directly links sugar metabolism 
and growth to virulence and the disease process. This section will describe two 
paradigm PRD containing regulators as well as two homologs of Mga that are PRD-






Figure 2.3. Domain alignment of GAS Mga with other PRD containing 
regulators.  
Shown are B. subtilis MtlR and LicT, B. anthracis AtxA, and E faecalis EF3013. EII 
(purple), PRD (blue), DNA-binding (green) and conserved (pink) domains are 
indicated with conserved histidines (H). PRDMga and PRDLicT refer to Pfam 08270 






Archetype PRD Regulators  
LicT 
The Bacillus subtilis archetype PRD-containing regulator, LicT, is a BglG-
family anti-terminator that controls expression of the metabolic genes for lichenan 
and other β-glucosides utilization and import (204). Antiterminators are activated in 
the presence of a sugar inducer, and function by binding to an antiterminator RNA 
(RAT) site. This binding occludes the terminator on the nascent mRNA and prevents 




the operon. The crystal structure of the active form of LicT revealed a N-terminal 
RNA-binding domain followed by two PRD domains (Fig. 2.3). The two PRD 
domains each contain two conserved histidines (205) that are phosphorylated by 
P~His15-HPr (206) for full activity. Activity is reduced in the presence of P~Ser46-
Hpr and P~EIIBBgl (207). LicT froms a homodimer through interactions of its two 
PRD domains; PRD1 of one monomer interacts with PRD1 of the other, and the same 
holds true for PRD2. In silico models predicted that phosphorylation of the histidines 
on PRD lead to strong electrostatic repulsions, whereas phosphorylation of PRD2 
leaders to increased electrostatic complementarity between the homodimer (208).  
MtlR 
The DeoR-family mannose operon activator MtlR of Geobacillus 
stearothermophilus was the first PTS-regulated transcriptional activator identified 
(209). This sugar regulator is composed of a DNA-binding domain at the amino 
terminus, followed by two PRD domains and an EIIAMtl domain at its C-terminus 
(210). MtlR can be phosphorylated in a PEP-dependent manner through EI/Hpr 
(increase affinity for DNA) or through EIICBMtl (reduces affinity for DNA). Similar 
to LicT, MtlR encodes for two histidines on each PRD domain, and activity of the 
protein is dependent on the phosphorylation of both PRD2 histidines by Hpr. The 
EIIA domain of the protein can be phosphorylated by EIICBMtl, and can then 
commence a phosphorelay to PRD1 back to EIICBMtl and the incoming mannitol 
(210). MtlR is predicted to form a homodimer using the PRD1 and PRD2 of each 
subunit as the dimer interface (180).  MtlR also is found in Bacillus subtilis, and is 




secondary mechanism of regulation is also present in B. subtilis that involves the 
sequestration of MtlR to the cell membrane by EIIBMtl mediated by the EIIBGat 
domain on MtlR, which is necessary for full activity of the protein (211).  
PRD-Containing Virulence Regulators (PCVRs) 
AtxA 
The Bacillus anthracis transcription factor AtxA (Fig 2.3) is a master 
regulator that controls the expression of virulence genes encoded on both 
pathogenicity plasmids pXO1 and pXO2. It directly regulates toxin gene expression 
(pXO1) and indirectly regulates, capsule synthesis (pXO2) (212). Its activity is 
elevated during growth in media containing glucose and CO2/bicarbonate (213). This 
virulence regulator shares homology with Mga, and also shares similar predicted 
domain structures.  
Tsvetanova et al. identified two PRD domains in AtxA in silico, and 
determined that protein activity was dependent on phosphorylation by a functional 
PTS in vivo. Specifically, phosphorylation of H199 on PRD1 appeared to be 
necessary for activation, and phosphorylation of the H379 residue on PRD2 was 
shown to have inhibitory effects on toxin gene transcription. They also addressed the 
requirement of the histidine residues by performing phosphomimetic/phosphoablative 
experiments that mutagenized the H199 to H199D or A (214). Taken together, these 
findings suggest that AtxA is a PRD containing regulator, and virulence factor 
production is linked to sugar metabolism in B. anthracis.   
AtxA also contains an EIIB-like domain at its C-terminus that has been 




well as higher order structures under native conditions. From this study, it was also 
determined that the C402 residue that is located in the predicted EIIB-like domain is 
crucial for protein cross-linking. However, this residue was not found to be important 
for protein-protein interaction, as a C402S mutant exhibited multimerization similar 
to the native protein. Thereby, this data suggests that the EIIB-like region of AtxA is 
important for oligomerization. Additionally, under elevated CO2/bicarbonate 
conditions, AtxA exhibited higher rates of dimer formation, suggesting that host-
associated signals also enhance AtxA function by favoring the dimer configuration of 
the protein (215).    
 Recently, Hammerstrom et al. resolved the crystal structure of AtxA, and it 
was confirmed that the EIIB region of the protein is important for multimerization. 
The dimer interface formed contact between helices in PRD2 on one monomer and 
the EIIB-like domain of the other.  The key residues for these interactions are L375, 
T382, L386 and N389 from PRD2, and I403, Y407, E413 and K414 from the EIIB-
like domain. Additionally, they demonstrated the functional importance of the 
phosphohistidines located on PRD1/2 domains (216). As mentioned above, when 
AtxA is phosphorylated on H379 or a phosphomimetic H379D mutant was tested, 
AtxA was found to be inactive (214). Interestingly, the H379 residue is found on 
PRD2 and phosphorylation of this residue was found to inhibit dimer formation of 
AtxA. This indicates that phosphorylation of H379 destabilizes homodimer 
interaction, therefore affecting activity. Additionally, the H199 phospohistidine, 
which was also implicated in AtxA’s activity (214), was not found to affect 




adjacent to the linker between this region and the HTH2 domain. Therefore, it was 
hypothesized that phosphorylation of H199 may not affect dimerization, but affect 
DNA binding affinity (216).   
Mga 
 The multiple gene regulator of the Group A Streptococcus (Mga) is another 
PCVR and is the main focus of this dissertation, and its regulation by the PTS of GAS 
will be discussed below. 
 EF3013/MafR 
The Enterococcus faecalis protein is a PRD-containing regulator with a 
resolved crystal structure (PDB 3SQN) (217). It has overall structural homology to 
Mga, and up until very recently has had no biological significance associated with it. 
A recent study by Ruiz-Cruz characterized the role of this protein in E. faecalis 
pathogenesis rnamed it as mafR, for Mga/AtxA-like faecalis regulator. mafR was 
found to activate genes important for various steps in carbohydrate metabolism and 
affects the utilization of glycerol, maltose, and mannitol. In addition a mutation in 
mafR was less virulent in a mouse peritonitis model, indicating that it may be 
important for E. faecalis survival in host niches (218). Thus, it appears that MafR 
exhibits high degrees of similarities with other archetype PRD regulators, by its 
ability to regulate sugar metabolism, however it is similar to AtxA/Mga in that it also 





Multiple Gene Regulator of the Group A Streptococcus (Mga) 
Overview 
The multiple gene regulator of the Group A Streptococcus (Mga) is ubiquitous 
in all strains of GAS (219, 220). Its discovery is attributed to two independent studies 
that aimed at identifying regulators of the M protein (Fig. 2.1), a major virulence 
determinant that contributes to GAS adhesion and immune evasion. The first study 
aimed at identifying the genetic factor for strains lacking M protein. Strains lacking 
M protein expression exhibited random, 50 bp deletions that were mapped to a 
distinct locus upstream of the emm gene (221). This locus was subsequently found to 
affect the expression of the streptococcal C5a peptidase (scpA), and was consequently 
named virR (virulence regulator)(115). Concurrently, Caparon et al. identified a 
mutant in a Tn916 mutagenesis screen that caused a 50-fold reduction of emm 
transcript. The locus was then named mry for M protein RNA yield (222). Further 
characterization of Mry found it to act as a positive regulator of emm in trans (223).  
In 1995, VirR and Mry were found to be homologous and were renamed as Mga 
(Multiple gene regulator of the group A Streptococcus) (224).   
Mga has since been shown to be critical for multiple pathogenic phenotypes, 
including biofilm formation, growth in whole human blood, and resistance to 
phagocytosis, (11-14). Mga is also critical for survival in a mouse model of systemic 
infection and GAS attachment to keratinocytes (13). Two genetic fitness screens 
showed that mga is critical for GAS survival in both an ex vivo (15) and in vivo (16) 
environments. The mga gene was found to be maximally expressed 30 minutes post 




finding to the in vitro expression of the Mga regulon during exponential growth (226, 
227). Additionally, using a cynomolgus macaque pharyngeal model, the Mga regulon 
was shown to be maximally expressed during the acute phase of pharyngitis infection 
(228). Taken together, this data demonstrates that Mga is critical for GAS 
pathogenicity and its activity greatly depends on cellular metabolism. 
Mga-regulated genes 
A microarray study found Mga to affect the transcription of approximately 
10% of the GAS genome during exponential phase of growth under nutrient rich 
conditions (THY) (229). However, the ‘core’ Mga regulon consists mostly of cell 
wall-associated surface molecules important for adherence to host tissues, 
internalization into non-phagocytic cells and avoidance of host immune responses. 
Mga transcriptionally activates genes that are in its immediate chromosomal region 
(Mga locus), which includes the emm-superfamily of genes (emm, mrp, enn, arp, 
etc.), scpA, fba, and sic (13). It also acts as an autoregulator (230) by directly binding 
to its promoter (231). Additional virulence factors outside of the “Mga locus” have 
also been found to be regulated, and these include sof and sfbX, sclA and speB (232, 
233). In addition, microarray results found Mga to negatively regulate genes, albeit 
indirectly, but this was the first evidence that Mga can act as both an activator and a 
repressor. This study also revealed that Mga influenced several sugar transport and 
utilization operons as well as other metabolic processes such as amino acids and fatty 






Mga is a 530 amino acid protein with a molecular weight of 62 kDa, and is 
comprised of six domains (Fig. 2.3). There are two divergent alleles of mga, mga-1 
and mga-2, which possess 24.5% sequence identity at the nucleotide level. The mga-1 
allele is strongly associated with the class I/SOF- strains, and the mga-2 allele is class 
II/SOF+ strains (234). The amino-terminus contains a conserved Mga domain (CMD), 
followed by two helix-turn-helix DNA binding domains all of which are critical for 
binding to targets.  Mga also contains two PRD-domains, PRD-1 and PRD-2, which 
are involved in detecting nutrient status and play an important role in its activity, and 
an EIIBGat-like domain at the C-terminus that appears to be important for 
dimerization. This section will provide more in-depth detail of each of these domains 
in the Mga protein.   
DNA-binding 
The N-terminal portion of the Mga protein encodes for two helix-turn-helix 
(HTH) DNA binding domains, HTH-3 and wHTH-4, which are critical for DNA 
binding. Mutants in HTH-3 were found to have a slight effect on binding to emm and 
scpA; however, those that lack wHTH-4 completely abrogate the ability of Mga to 
bind to its promoter targets (235). In addition, both HTH-3 and wHTH-4 are 
necessary for the transcriptional activation of the same virulence genes in vivo (236). 
These domains, in conjunction with the consensus Mga binding site (discussed further 






Both Mga alleles possess three histidine residues (PRD1: H204 and H270; 
PRD2: H324) that are conserved and ubiquitous among all sequenced GAS genomes. 
In addition, these histidine residues correlate with those present on AtxA, (discussed 
above). Hondorp et al. created an in vivo phosphorelay in order to verify that the PTS 
system of GAS can phosphorylate and modify the activity of Mga in an M1 and M4 
serotype (representatives of Class I and Class II, respectively). Indeed, all three 
histidines can be phosphorylated by the PTS in vivo. The histidines on PRD1 are 
phosphorylated by P~His15-Hpr in the absence of glucose, and render the protein 
inactive; this is the dominant form of the protein. When no phosphorylation was 
present on any histidine, which occurs in the presence of the preferred sugar, glucose 
the phosphate is shunted to EIIB transporter, and Mga is active. Interestingly, when 
the histidine in PRD2 is phosphorylated, Mga showed an even greater increase in 
activity. However, overall inactivation of phosphorylation on PRD1 caused 
significant attenuation in a mouse model of disseminating subcutaneous skin 
infection, signifying the importance of proper expression of Mga and its regulon 
during infection (19).   
Other studies have shown that altering the phosphorylation status of the M59 
Mga using phosphomimetics on PRD1 (H207 and H273) and PRD2 (H327) were 
inhibitory to Mga-dependent gene expression. However, replacement with 
phosophoablative residues on PRD1/2 (H273A and H327A) was shown to relieve 
inhibition and restore the wild type phenotype. In virulence studies, the 




fasciitis whereas the phosphoablative (H273A) Mga was comparable to wild type in 
virulence (20). Furthermore, Mga59 showed an altered expression profile using 
phosphomimetics, and the PRD1 residue H273 was critical for proper regulon 
expression. 
While Hondorp et al. showed that the ability for Mga to be 
phosphorylated/dephosphorylated on PRD1 is essential for full virulence (19), Sanson 
et al. showed that only phosphorylation on PRD1 caused an inhibitory effect of 
regulon expression (20). Regardless, the results from both studies confirms that Mga 
is PRD-containing virulence regulator (PCVR) that interacts with the PTS to sense 
carbohydrate availability and utilization within the GAS cell, and phosphorylation 
status of the protein is important for proper expression of the Mga regulon and thus 
full virulence for GAS. 
C-terminal domain 
The C-terminal region of Mga was once predicted to be a CheY-like receiver 
domain (RD), indicating that Mga could be part of a TCS (223). However, Ribardo et 
al. found that when 12 of the 13 response regulators from GAS TCS were 
mutagenized, there was no reduction in the levels of emm transcripts or Mga protein 
levels in comparison to wild type (233). More recently, protein alignment with 
another PRD-containing regulator, MtlR, revealed that the C-terminus of Mga 
contains structural homology to an EIIBGat-like domain. A study conducted by 
Hondorp et al. revealed that the C-terminal tail also acts a dimer interface for Mga, 
and increasing NaCl concentrations caused higher-order structures to form (dimers, 




which eliminates the putative EIIBGat-like domain, led to the loss of dimerization. 
While this truncation did not affect DNA binding, Mga failed to activate the 
transcription of its target genes (237).  Taken together, the data suggests that DNA 
binding is important for Mga activity but not sufficient to induce full activity, and 
oligomerization is necessary for full activation of the Mga regulon.   
Regulation of Mga 
Optimal expression of the Mga regulon in vitro requires several growth 
conditions including elevated CO2 levels, 37oC, increased iron levels, and 
metabolizable sugars (18, 238, 239). Mga is also directly phosphorylated by the PTS 
of GAS within conserved PRD residues, and altering virulence gene expression 
leading to attenuation in vivo (19). Other up stream regulators have been identified 
and include AmrA (hypothetical flippase involved in O-antigen/cell wall synthesis) 
(240), RivR (RALP IV; stand alone regulator) (177), TrxR (TCS response regulator) 
(160), CcpA (carbon catabolite repressor protein) (17), and DltA (D-alanylated 
lipoteichoic acid) (241); however, the exact mechanism by which they regulate Mga 
is not clear, and are often serotype specific.   
Consensus Mga-binding site 
Mga can directly bind to three different categories of promoters (Category A-
C), which are separated based on size, number, and location of the Mga binding sites 
(MBS). In an M6 GAS background, Mga was found to bind to a single 45 base pair 
site 52 nucleotides upstream of the transcriptional start site of emm and scpA (235) 




associated with genes within the Mga locus. Further studies with Pemm1, a Category 
A promoter identified critical nucleotides that were necessary Mga binding, Mga-
dependent transcriptional activation, or both. This resulted in a minimal consensus of 
35 base pairs  (GGTCAAAAAGGTGGCAAAAGCTAAAAAAGCTGGTC) for 
















Pmga, 59bp sites, 
at -104bp and -185bp
 
 
Figure 2.4. Promoter architecture of Mga regulated genes.  
Three types of promoters regulated by Mga (shown in red) are categorized according 





Category B promoters are roughly 45 base pairs in length, and the MBS is 
centered at either 278 base pairs (Psof/sfbX) (244) or 153 bp (PsclA) (243) upstream 
of the regulated start of transcription (Fig. 2.4). Category B promoters are also 
associated with Mga regulated genes that are outside of the “Mga locus”. Mga is also 
autoregulated in some serotypes and therefore binds to its own promoter (Pmga) (11).  
However, the mechanisms for its binding are different than the other categories 
mentioned above. This type of binding, designated as Category C, contains two 
binding sites that are 59 bp in length and are centered around 108 bp and 180 bp 
upstream of the major P2 transcriptional start site (231). Although all three categories 
of MBS are considerably different at the DNA sequence level, they can compete with 
each other for binding of Mga in vitro (231, 235). The mechanism by which Mga is 
able to recognize and bind to these divergent binding sites is currently unknown.   




Chapter 3: Materials and Methods 
 
 
Bacterial Strains and growth  
E. coli strain, media, and growth conditions 
E. coli strains used in this study are listed in Table 3.1. Strains DH5α or C43 
[DE3] were used as the host strain for plasmid construction and were cultured in 
Luria-Bertani (LB) medium (EMD Biosciences). C41 [DE3] was used for protein 
expression and cultured in ZYP-5052 auto-induction media (245). E. coli was grown 
at 37oC with shaking under normal aerobic conditions. Growth was measured by a 
spectrophotometer (Ultraspec 2100 pro, Amersham Biosciences) at OD600. 
Antibiotics for E. coli were used at the following concentrations: ampicillin 100 
µg/ml, spectinomycin 100 µg/ml, kanamycin 50 µg/ml, chloramphenicol 30 µg/ml.  
GAS strains, media, and growth conditions 
GAS strains used and constructed in the study are listed in Table 3.1. GAS 
was cultured in Todd-Hewitt medium (Alpha Biosciences) supplemented with 0.2% 
yeast extract (Fisher Scientific) (THY). Growth was assayed by optical density with a 
Klett-Summerson colorimeter (A filter) and expressed in Klett Units. Alternatively, 
GAS were grown on blood agar plates overnight at 37oC with 5% ambient CO2. 
Colonies were scraped off the plate and resuspended in 10 ml of sterile saline. C 
Media was prepared using a previously described method (246). Prior to use, 




(150 mM) were added and the pH of the media was buffered to 7.5 with concentrated 
HCl. Otherwise, a 2x Chemically Defined Media (CDM) (Alpha Biosciences) was 
prepared, as previously described (28). Prior to use, freshly prepared sodium 
bicarbonate (59.51 µM) and L-cysteine (11.68 µM) were added along with a 
carbohydrate and source at a final concentration of either 0.5% (glucose) or 1% (all 





Table 3.1: Bacterial strains and plasmids 
Strain Description Reference 
 
E. coli Strains 
 
  
DH5α hsdR17 recA1 hyrA endA1 relA1 (247) 
C41 [DE3] F- ompT gal dcm hsdSB (rB-mB-)(DE3) (248) 
C43 [DE3] F- ompT gal dcm hsdSB (rB-mB-)(DE3) (248) 
BTH101 F- cya-99 araD139 galE15 galK16 rpsL1 (StrR) hsdR2 
mcaA1 mcrB1 
Gift, D. Kearns 
   
S. pyogenes Strains 
 
  
5448 M1T1 GAS, clinical isolate, SpeB(+) SpeA(-) Sda1(low) (85) 
5448.930 ∆mga mutant in 5448 (insertional inactivation) This study 
5448.930R mga+ 5448, cured strain  This study 
KM16.1 ∆mga mutant in 5448 (transposon) This study 
5448.∆fruR ∆fruR mutant in 5448 (allelic exchange) This study 
5448.∆fruB ∆fruB mutant in 5448 (allelic exchange) This study 
5448.∆fruA ∆fruA mutant in 5448 (allelic exchange) This study 
5448.∆fruRR ∆fruR rescue strain in 5448 This study 
5448.∆fruBR ∆fruB rescue strain in 5448 This study 
5448.∆fruAR ∆fruA rescue strain in 5448 This study 




KSM547 ∆mga mutant in GA40634 (243) 
SF370 M1 GAS (249) 
KSM165L ∆mga mutant in SF370 (229) 
   
Plasmids   
pACYC Vector contaiming CmR gene (250) 
pCRS Temperature-sensitive conditional vector; SpR (15) 
pJRS525 Replicating vector for GAS with SpR (226) 
p5448.∆fruR ∆fruR mutagenic plasmid; nonpolar cat This study 
p5448.∆fruB ∆fruB mutagenic plasmid; nonpolar cat This study 
p5448.∆fruA ∆fruA mutagenic plasmid; nonpolar cat This study 
pKSM201 Broad host range cloning vector, KmR (5) 
pKSM720 GAS replicating plasmid with promoterless firefly luciferase (luc) and ribosomal binding site (5) 
pKSM807 WT mga1 under native Pmga1 (251) 
pKSM808 WT mga4-his6 (GA40634) under native Pmga4 (251) 
pKSM809 WT mga1-his6 under native Pmga1 (251) 
pKSM813  ∆139 mga1-his6 under native Pmga1 (251) 
pKSM871 A/A/A M4 Mga-His6 (251) 
pKSM930 pCRS derivative for insertional inactivation of mga This study 
pKSM934 pUC19 containing Pmga1-mga1 for SDM constructs This study 
pKSM935 GAS replicating plasmid Pmga1-mga1 F430Y This study 
pKSM936 GAS replicating plasmid Pmga1-mga1S432G This study 
pKSM937 GAS replicating plasmid Pmga1-mga1L409F This study 
pKSM938 GAS replicating plasmid Pmga1-mga1D445V This study 
pKSM939 GAS replicating plasmid Pmga1-mga1N453S This study 
pKSM940 GAS replicating plasmid Pmga1-mga1M461I This study 
pKSM941  GAS replicating plasmid Pmga1-mga1K425A This study 




pKSM943 GAS replicating plasmid Pmga1-mga1Y387A This study 
pKSM944 GAS replicating plasmid with full length Pfru driving expression of luc This study 
pKSM945 GAS replicating plasmid with Pfru no FruR consensus driving expression of luc This study 
pKSM948 GAS replicating plasmid with PsloR driving expression of luc This study 
pLZ12-Spec Broad host range cloning vector, SpR (252) 
pMga1-His WT mga1 (SF370) with C-terminal His6 (251) 
pT18N-link N-terminal T18 expressing two-hybrid vector with linker region ApR Gift, D. Kearns 
pT25N-link N-terminal T25 expressing two-hybrid vector with linker region KmR Gift, D. Kearns 
pUC19 ColE1 ori ApR lacZα (253) 
pT25N-F430Y T25 fragment of cya- fused to Mga1-F430Y This study 
pT25N-S432G T25 fragment of cya- fused to Mga1-S432G This study 
pT25N-N453S T25 fragment of cya- fused to Mga1-N435S This study 
pT25N-M461I T25 fragment of cya- fused to Mga1-M461I This study 
pT25N-L409F T25 fragment of cya- fused to Mga1-L409F This study 
pT25N-D445V T25 fragment of cya- fused to Mga1-D455V This study 
   




Modified Diauxic Growth 
GAS strains were cultured on blood agar plates (TSA + 5% sheep blood) 
(Beckton Dickinson) overnight at 37oC with 5% ambient CO2. Colonies were scraped 
off and resuspended in sterile saline. Klett flasks containing 150 ml of CDM + 0.5% 
glucose were inoculated to an OD600 = 0.05. Strains were grown to mid-log (To) then 
pelleted and washed in 10 ml of warm saline. The pellet was then resuspended in 1 ml 
of saline and split into two 500 µl aliquots for inoculation into fresh CDM + 0.5% 
glucose or CDM + 1% fructose (75 ml). A 10 ml sample of culture was harvested 
after T30min, T1h, and T2h of growth for RNA extraction, and growth continued until 




Plasmid DNA was isolated from E. coli by alkaline lysis using the Wizard 
Plus SV Miniprep kit (Promega) or the Midiprep purification system (Qiagen) 
following the manufacture’s instructions. Alternatively, DNA fragments were isolated 
from agarose gels using the Wizard SV Gel and PCR Clean-up kit (Promega). 
Genomic DNA extraction 
GAS genomic DNA (gDNA) was isolated as previously described (254). 
Briefly, 10 ml of an overnight culture grown at 37oC were pelleted by centrifugation 




resuspended in 10 mM Tris pH 8.0 supplemented with fresh lysozyme (100 mg/ml) 
and incubated at 37oC for 2 h with vigorous agitation in a shaking heat block 
(Eppendorf). The proceeding extraction was then carried out following the 
manufacturer’s instructions for gDNA isolation of Gram-positive bacteria using the 
MasterPure Complete DNA and RNA Purification kit (Epicentre).  
Polymerase Chain Reaction (PCR) 
PCR was performed using Phusion (New England Biolabs; NEB) or 
Accuprime pfx (Life Technologies) for cloning and Taq DNA polymerase (NEB) was 
used for diagnostic assays. To use Phusion DNA polymerase, annealing temperatures 
for primers (Table 3.2) were determined using the Tm calculator 
(http://tmcalculator.neb.com) selecting the HF buffer conditions. Amplification was 
carried out by an initial denaturation step at 98oC for 4 min, followed by 30 cycles of 
denaturation at 98oC for 10 s, a 30 s annealing step at the pre-determined temperature, 
and extension step of 72oC for approximately 1 min/kb of DNA. A final extension 
step of 4 min was added for the completion of the reaction. For pfx, the parameters 
were as follows: An initial denaturation at 98oC for 2 min followed by 30 cycles of 
denaturation at 98oC for 30 s, a 30 s annealing step at 55oC, and extension step of 
68oC for approximately 1 min/kb of DNA.  PCR reactions were purified by the 
Wizard SV Gel and PCR Clean-up kit (Promega) according to the manufacturer’s 









Table 3.2: Primers used in this study 
 
Target Primer Name Sequence (5’-3’) Reference 
fruR FruR RevTrans F TATGTCAAACAAACGACCGA This study 
 FruR SP1 TCAGCACCTCCATGAACACG This study 
 FruR SP2 ATGTAGCCGTCCTTCTTGCT This study 
 FruR SP3 CCAACTCTCCTAGATCTCTA This study 
 oAXSpy0660.5 cccGGATCCCAGAGCTAGTTCACGCTAAAG This study 
 oAXSpy0660.2 TATCCAGTGATTTTTTTCTCCATGATTAATTGTTTTCGTTTTGATTTT This study 
 oAXSpy0660.3 CAGGGCGGGGCGTAATTTATACCGTGACCTTAAACCC This study 
 oAXSpy0660.6 cccGGATCCAATTCGGTCTCTTCTTGTGAC This study 
 FruR luc_1 gggGGATCCTTGTGAGCCTAGATTATGAG This study 
 FruR luc_4 gggCTCGAGGATTAATTGTTTTCGTTTTG This study 
fruB FruB RevTrans F TATGAAGAGTCAAAATCCAA This study 
 FruB RevTrans R GGGAAAGCTTAGTTTTCAAA This study 
 oAXSpy0661.1 cccGGATCCATTACTCAACTCCTCTGAGTC This study 
 oAXSpy0661.2 TATCCAGTGATTTTTTTCTCCATAATTCAATCACCTTTGCCTTTTC This study 
 oAXSpy0661.3 GATGAGTGGCAGGGCGGGGCGGCTTTCTCTGATGACTTGGC This study 
 oAXSpy0661.4 cccGGATCCTAGCTACTCCCATTTCTGCAG This study 
fruA FruA RevTrans R ATCATAAAGAAGAGATCCGT This study 
 oAXSpy0662.1 cccGGATCCAAAGGTGATCAAGATACTCG This study 
 oAXSpy0662.2 TATCCAGTGATTTTTTTCTCCATCGTTTTTCTACCTCAACTTTATG This study 
 oAXSpy0662.3 GGCAGGGCGGGGCGTAAAAGGTAAAGAACTTTTTTCTTAC This study 
 oAXSpy0662.4 cccGGATCCAAAATTAGTGAGTTGATACC This study 
mga Mga InIn F cccGGATCCCAGTGGAGAGAACTAAAATT This study 
 Mga InIn R cccGGATCCTAATTCTTCCAAAGAGTTGA This study 
sloR sloR InIn F gggGGATCCATTCTTGTTTTAGCTATTTT This study 
 sloR InIn R gggGGATCCCCCAGCCACAAAACCTGGGA This study 
 sloR luc F gggGGATCCGTCAAACTTCCTATATCTATCTT This study 
 sloR luc R gggCTCGAGATACGAACCTCCTCATTGATAATAT This study 
cat oCatFwd ATGGAGAAAAAAATCACTGGATA This study 
 oCatRev TTACGCCCCGCCCTGCC This study 
 oCatSeq1 TTCCATGAGCAAACTGAAACG This study 
 oCatSeq2 CAGGTTTTCACCGTAACACG This study 
M13 1201 AACAGCTATGACCATGATTACG Genewiz 
 1211 GTTGTAAAACGACGGCCAGT Genewiz 
aad3 SPR1 cccCTCGAGAATAAAGCCCCGCTTCGGCG (15) 
 SPR1 cccACTAGTAAGGACTTAAAAGAGCGTATTG (15) 
 
†Bold type denotes restriction site 
 * Underline segments denote overlap with cat cassette for PCR-SOEing 








Enzymatic DNA Modifications 
Enzymatic DNA modifications were performed using enzymes with 
conditions suggested by the manufacturer (NEB). Restriction digests were performed 
for 2 h at their optimal temperatures. Ligation reactions using T4 DNA ligase were 
set up using a 1:16 vector to insert ratio with overnight incubations at 16oC. Antarctic 
phosphatase was used to dephosphorylate the vector ends for cloning with 
incubations at 37oC for 1 h followed by 10 min inactivation at 80oC. T4 
polynucleotide kinase (PNK) was used to radioactively end-label probes at 25oC for 
10 min.  
  
Bacterial Transformation 
E. coli competent cells 
To prepare DH5α or C43 [DE3] competent cells, 500 ml of LB broth was 
inoculated with a 5 ml overnight culture and grown to an OD600 of 0.5. Cells were 
placed on ice for 30 min prior to centrifugation at 7,000 x g for 30 min at 4oC. After 
pelleting, cells were washed and resuspended three times in ice-cold sterile 10% 
glycerol. After the final wash, cells were resuspended in 1 ml of 10% glycerol and 
split into 75 µl aliquots. Aliquots were stored at -80oC for no more than 1 year. GAS 
competent cells 
To prepare GAS competent cells, 150 ml of THY broth containing 20 mM 
glycine and 85 µg/ml of hyaluronidase was inoculated with 7.5 ml of an overnight 




to centrifugation at 7,000 x g for 30 min. Cells were washed three times in 20 ml of 
10% glycerol and resuspended in a final volume of 1 ml. Cells were split into aliquots 
of 175 µl and stored at -80oC for no more than 6 months.   
Electroporation 
To remove excess salts prior to electroporation of DNA into either E. coli or 
GAS, DNA was drop dialyzed with dH2O on a 0.025 µm membrane filter (Millipore) 
for 30 min for E. coli and 1 h for GAS. Electroporation of both E. coli and GAS was 
performed using a GenePulser Xcell (Bio-Rad). The 75 µl aliquot of E. coli along 
with the drop dialyzed DNA was added to a pre-chilled 2 mm cuvette and 
electroporated using the following settings: 2.5 kV, 200 Ω and 25 µF. Cells were 
immediately transferred to 1 ml of LB broth and outgrown for 1 h at 37oC shaking, 
prior to centrifugation at 6,000 x g. Pelleted cells were resuspended in 100 µl of 
saline and plated on the appropriate antibiotic selection. For electroporation of GAS, 
the parameters were as follows:  1.75 kV, 400 Ω and 25 µF. Cells were transferred to 
10 ml of THY and outgrown statically for 2 h at 37oC. Cells were pelleted at 8,000 x 
g and resuspended in 100 µl of THY broth prior to plating on the appropriate 







Construction of pKSM930 
An internal fragment of mga that began 30 nucleotides downstream of the 
ATG was amplified from 5448 gDNA using primers Mga_InIn_F and Mga_InIn_R 
(Table 3.2). The 300 bp fragment was digested with BamHI and ligated into BamHI-
digested pCRS to create pKSM930 (Table 3.1). 
Construction of Pfru-luc and PsloR-luc vectors, pKSM944, pKSM945, 
and pKSM948 
The wild type Pfru promoter was amplified from 5448 gDNA using primers 
FruR_luc_1 and FruR_luc_4 (Table 3.2). The 163 bp PCR fragment was digested 
with BglII/XhoI and ligated into a BamHI/XhoI-digested pKSM720 (Table 3.1) to 
form pKSM944. 
A truncated PfruR was amplified from 5448 gDNA using primers FruR_luc_2 
and FruR_luc_4 (Table 3.2), deleting the first 60 bp from the promoter region and 
eliminating the putative FruR binding site. The 103 bp promoter PCR fragment was 
digested with BglII/XhoI and ligated into a BamHI/XhoI-digested pKSM720 (Table 
3.1) to form pKSM945.  
Wild type PsloR was amplified from 5448 gDNA using primers sloR_luc_F 
and sloR_luc_R (Table 3.2). The 175 bp promoter PCR fragment was digested with 





Construction of pKSM934 
A wild type Pmga1-mga1 was digested from pKSM807 (Table 3.1) using 
BamHI and XhoI, and ligated into a BamHI/XhoI-digested pUC19 to create 
pKSM934. 
Construction of EIIB mutated complementation vectors, pKSM935-
pKSM943 
Using pKSM934 (Table 3.1) as a template, point mutations were made in the 
EIIB domain of Mga1 using the Quickchange II Site-Directed Mutagenesis kit 
(Stratagene). Briefly, oligonucleotides containing the mutated residue(s), each 
complementary to the opposite strands of the vector, were extended during 16 cycles 
by PfuUltra HF DNA polymerase (Stratagene) with an extension time of 5 min. To 
create point mutations, primer pairs Mga1-xxxx-L and Mga1-xxxx-R (Table 3.2) 
were used to generate the following amino acid replacements: K425A, E394A, 
Y387A, F430Y, S432G, L409F, D445V, N453S, and M461I. Following temperature 
cycling, the PCR product was DpnI treated for 1.5 h, followed by enzyme heat 
inactivation at 80oC for 15 min. Then, 1.5 µl of the reaction was transformed into 
DH5α electrocompetent cells. Up to 14 clones were selected for sequence analysis for 
mutation verification. The confirmed mutants were then digested with BamHI/XhoI, 
gel purified, and the Pmga1-mga1 fragment was moved into pJRS525 digested with 
BamHI/XhoI in a DH5α background. The resulting plasmids were named pKSM935, 
pKSM936, pKSM937, pKSM938, pKSM939, pKSM940, pKSM941, pKSM942, and 






Inactivation of mga in 5448  
The mga gene in the M1T1 strain 5448 (Table 3.1) was inactivated using the 
temperature-sensitive integration method as previously described (223). Briefly, 
plasmid pKSM930 (Table 3.1) was electroporated into 5448, followed by growth at 
30oC with spectinomycin selection. To allow for integration of the plasmid, cells were 
passed twice at 37oC under spectinomycin selection. Integrants were screened for 
plasmid/genomic junctions by PCR using the primers Mga_InIn_F and M13R (Table 
3.2).  
Rescuing of 5448.930 
The strain 5448.930 (Table 3.1) was cured of the plasmid inactivating mga by 
passage in liquid culture four times at 30oC with no drug selection. Cultures were 
then plated, and patched on THY supplemented with spectinomycin and THY alone. 
Patches that showed spectinomycin sensitivity were then screened for loss of the 
spectinomycin gene by PCR using the primer SPR1 and SPR 2 (Table 3.2). 
Transposon mutagenesis of mga in 5448 
A transposon insertion in mga was identified from a pool of Krmit (for 
kanamycin-resistant transposon for massive identification of transposants) transposon 
mutants generated in 5448. Library #16 was screened using AP-PCR (254) followed 
by sequencing and alignment of sequence to the 5448 genome. Transposant #1 was 






RNA extraction and DNase treatment 
RNA was isolated using a Triton X-100 method as previously described (255). 
Briefly, 10 ml of THY broth was inoculated 1:20 from an overnight culture and 
grown to the appropriate Klett unit. Cells were pelleted by centrifugation at 8,000 x g 
for 10 min at 4oC. Cells were then resuspended in TE buffer containing 0.2% Triton 
X-100 (v/v) and boiled for 10 min. A chloroform:isoamyl alcohol (24:1) extraction 
was performed twice, and ethanol was used to precipitate the RNA at -80oC for 30 
min. The reaction was then pelleted at 10,000 x g for 10 min and washed with 1 ml of 
70% ethanol. The RNA was resuspended in DEPC-treated water and quantified using 
a spectrophotometer. The RNA was assessed for quality on formaldehyde gel: 18% 
(v/v) formaldehyde, 1% (w/v) agarose, 72% DEPC-treated water, and 10% (v/v) 10x 
MOPS.  
RNA was then treated with Turbo DNA-free kit (Life Technologies) to 
remove gDNA from the sample. Approximately 20 µg of RNA was incubated with 1 
µl (20 U) of Turbo DNase along with 1 µl of RNase Inhibitor (NEB) at 37oC for 1 h 
as per manufacturer’s recommendations. A 1x volume of the DNase Inactivation 
Reagent was added to the reaction and incubated at room temperature for 2 min with 
occasional mixing. The sample was then pelleted at 10,000 x g for 1.5 min at room 
temperature, and the supernatant containing the DNAsed RNA was transferred to a 
new 1.5 ml tube and stored at -80oC for no more than 1 year. A diagnostic PCR 
reaction was performed on 1.5 µl of the DNased RNA to verify complete degradation 





For RNA sequencing (RNA-Seq), total RNA was extracted using the Direct-
zol RNA MiniPrep kit (Zymo Research) using a modified procedure to improve GAS 
cell disruption. Cells from frozen pellets were resuspended in 700 µl of Trizol 
supplemented with approximately 300 mg of acid-washed glass beads (Sigma Life 
Science) and disrupted by vortexing for 5 min. Beads were collected by brief 
centrifugation and cell lysate was used for RNA purification as recommended by the 
manufacturer. RNA samples were treated with the Turbo DNase-free kit (Life 
Technologies) to avoid gDNA contamination. A total of 5 µg of DNased RNA was 
treated for Ribosomal RNA (rRNA) removal using the Ribo-Zero Magnetic kit 
(Epicentre) for Gram-positive bacteria and rRNA-depleted RNA was then purified 
with the RNAClean XP kit (Agencourt). Sample quality was assessed using a 2100 
Bioanalyzer (Agilent) and sample quantity was determined using a NanoDrop 8000 
spectrophotometer (Thermo Scientific). 
RNA-Seq directional libraries were generated using the ScriptSeq v2 RNA-
Seq Library Preparation kit (Illumina) according to the manufacturer’s 
recommendations. Briefly, 45 ng rRNA-depleted RNA was fragmented and used for 
reverse-transcription with random primers containing a 5’-tagging sequence. The 5’-
tagged cDNA was then modified at its 3’ end by a terminal-tagging reaction to 
generate di-tagged, single-stranded cDNA that was then purified using the AMPure 
System (Agencourt). The purified di-tagged cDNA was used as a template to generate 
second strand cDNA containing Illumina adaptor sequences, to incorporate index 




libraries were purified using the AMPure System (Agencourt) and RNA-Seq library 
quality was verified as described above. A rapid-run 100 bp single-read DNA 
sequencing was then performed at the Institute for Bioscience and Biotechnology 
Research (IBBR) Sequencing Facility at the University of Maryland, College Park 
using the Illumina HiSeq 1500 platform. Data were generated in the standard Sanger 
FastQ format and raw reads were deposited with the Sequence Read Archive (SRA) 
at the National Center for Biotechnology Institute. 
Read quality was measured using FastQC (256), filtered and trimmed using 
trimmomatic (257), and mapped against the MGAS5005 genome (accession 
CP000017) using bowtie (258), bowtie2 (259), and tophat (260) with options to allow 
0,1,2 mismatches and randomly map multihit reads. The resulting alignments were 
converted (261) and counted (262) by coding and intergenic region. Initial 
visualizations of the sequencing mapping were performed using the Integrative 
Genomics Viewer (IGV) (263). Differential expression analyses were performed after 
library quantification, normalization, and batch effect estimation using limma (264) 
and/or DESeq (265). The resulting metrics of expression were visualized using 
KEGG (266) and circos (267) as well as tested for ontology enrichment using goseq 
(268, clusterProfiler {Yu, 2012 #1997), GOstat (269), and topGO (270). 
Quantitative Real-time PCR 
The quantitative real-time PCR (qRT-PCR) experiments were performed as 
follows: 25 ng of DNase-treated RNA was added to a SYBR green master mix (Life 
Technologies) with 0.25 µl of of each gene-specific real-time primer from a 20 nM 




Technologies) using the one-step protocol on a Light Cycler 480 (Roche). The 
reaction conditions were as follows: 48oC for 30 min, 95oC for 10 min, and 40 cycles 
of 95oC for 15 s followed by 60oC for 1 min. 
Alternatively, for any RNA-Seq validation, cDNA was generated using a two-
step protocol in order to mimic the strand-specificity of the RNA-Seq results. Briefly, 
100 ng of DNase-treated total RNA was incubated with a gene-specific primer using 
the manufacturers recommendations (Quanta Biosciences). 25 ng of cDNA was then 
added to a SYBR green master mix (Quanta Biosciences) with 0.25 µl of gene-
specific primers from a 20 nM stock. The reaction conditions were as follows: an 
initial denaturation at 95oC for 3 min, 40 cycles of 95oC for 15 s followed by 60oC for 
45 s. Correlation coefficients for RNA-Seq were determined by plotting the log value 
of the array on the X-axis to the log value of the quantitative real-time RT-PCR 
(qPCR) on the Y-axis. Linear regression was used to determine the line of best fit, 
and the resulting R2 value was calculated, which represented the fitness of the data.  
For all experiments, standard error was calculated from three biological 
replicates, and differences over 2-fold in expression were considered significant. 
Transcript levels presented represent ratios of wild type/experimental relative to the 
level of gyrA transcript as an internal control. All real-time primers were designed 
using the interactive tool Primer3 




Table 3.3: Real-time qPCR primers 
Target Primer Sequence (5’-3’) Reference 
adh.2 adh.2 M1T1 RT L ATGGACTCGGTCACTCAGC This study 
 adh.2 M1T1 RT R ATTCCAGATGACGCGGATA This study 
amyA amyA  M1T1 RT R TGGGTGATGTTTTTGAGATGG (5) 
 amyA M1T1 RT L GTTTGGGTACTTGGCAATGG (5) 
emm emm1 RT-L ACTCCAGCTGTTGCCATAACAG (233) 
 emm1 RT-R GAGACAGTTACCATCAACAGGTGAA (233) 
fruA fruA M1 RT L ACCGGGCTTAGTAGCTGGT This study 
 fruA M1 RT R ACTTCTCCTCCTGCTGCAA This study 
fruB fruB M1 RT L GTTCAGCGCCAGCTAATCT This study 
 fruB M1 RT R TCACAAACCACCTGAGCAC This study 
fruR fruR M1 RT L GTCAAACAAACGACCGATC This study 
 fruR M1 RT R TCCAAGAAATGCCTTGTCA This study 
glnH glnH M1T1 RT L TGAGGGCATTTCTACTGGTG This study 
 glnH M1T1 RT R GCAGCTAAGCCATTGTTGAA This study 
gyrA gyrA M1 RT-L CGACTTGTCTGAACGCCAAAGTC (233) 
 gyrA M1 RT-R ATCACGTTCCAAACCAGTCAAAC (233) 
lacD.2 lacD.2 M1 RT-L GCTGCTTGTGGTCCTTCTTC (160) 
 lacD.2 M1 RT-R TTGGTGTTTGCAGCAGAATC (160) 
mac mac M1T1 RT L ACGGCTACCGCCTTAGTCT This study 
 mac M1T1 RT R ACGGCGTCAAAATACCAC This study 
malX malX  M1T1 RT R TTTGCTTTTGCCTCTGAACC (5) 
 malX M1T1 RT L CCATAACCGGCAATTAAACC (5) 
mga mga M1 RT-L CGCTGAGTTGAGCCTGATTTC (160) 
 mga M1 RT-R AGACTCACCAACGGGCTGTC (160) 
nagB nagB M1T1 RT L TGTTTTGGCACATCCTCAAT This study 
 nagB M1T1 RT R AAGAAGAAACGCATGTGGTG This study 
opuAA opuAA M1 RT-L TGATTTGCAAGACAGCATGA (160) 
 opuAA M1 RT-R CATCAAAGCAATCCGATCAC (160) 
ptsA ptsA  M1T1 RT R TTCATTACAGCGGTTACCATTTTC (5) 
 ptsA M1T1 RT L TGAGCAGGGCCTTATTTTTACTG (5) 
sagC sagC M1T1 RT L TGCTGATGCTTGAGGATGAC (5) 
 sagC M1T1 RT R GCGCCATAAAACGGAAATTA (5) 
salB salB M1T1 RT L TGGTGTTTTAGCAGCATTTT This study 
 salB M1T1 RT R AATCTCCGCCTGAAACAAT This study 
sclA sclA M1 RT-L TGCTGACAAAGAAGCTAACCAAAC (233) 
 sclA M1 RT-R CGTCTGTGGTTGTTGGCTACAG (233) 
sdaD2 sdaD2 M1T1 RT L AGCAAACCAGAGCCAAGTG This study 
 sdaD2 M1T1 RT R CACATTTTTGGGGCTATGC This study 
sdhA sdhA M1T1 RT L TGCAGGAGCTTTTGGTCTT This study 
 sdhA M1T1 RT R GCAGCTGCAGAACCAACTT This study 
sic sic M1 RT-L GGTAAAGTAGGCGGACATGCC (233) 
 sic M1 RT-R CCTCGTGTGCCAGAAAAACC (233) 
ska ska M1T1 RT L TGCAAACGGCAAGGTCTAC This study 
 ska M1T1 RT R GCGCACATGTCCCTTTAAC This study 
slo slo M1 RT-L AAAACAAACCAGACGCGGTAGT (233) 
 slo M1 RT-R TTGTCTCCCATACCTGGTAAATCA (233) 
sloR sloR M1T1 RT L GTGAAGTAGGCGGAGCAAA This study 
 sloR M1T1 RT R CGGCATAACCTGGAGACAC This study 
speB speB M1T1 RT L GGTAAAGTAGGCGGACATGCC (160) 
 speB M1T1 RT R CACCCCAACCCCAGTTAACA (160) 
spxA.2 spxA.2 M1T1 RT L ATGCCAAAGCTCTCGATTG This study 





Reverse Transcriptase PCR (RT-PCR) 
Reverse transcriptase PCR (RT-PCR) was carried out on 500 ng of total RNA 
with M-MuLV reverse transcriptase (NEB) according to the manufacturer’s protocol, 
using primers complementary to the RNA. Reverse transcription was performed for 1 
h at 42°C using 1 µl of cDNA as a template in reaction, followed by enzyme 
inactivation at 90oC for 10 min. The subsequent PCR was done with the following 
parameters: 5 min at 95°C (initial activation); 30 cycles of 30 s at 95°C, 30 s at 55°C, 
and 1.5 min at 72oC (PCR); and a final extension step of 5 min at 72oC. PCR 
reactions were performed on the RT+ and the RT- cDNA samples, as well as on 
gDNA, using Taq polymerase. The following primer pairs were used to amplify 
intergenic regions with the fruRBA operon: fruR-fruA (FruR_RevTrans_F and 
FruA_RevTrans_R); fruB-fruA (FruB_RevTrans_F and FruA_RevTrans_R); fruR-
fruB (FruR_RevTrans_F and FruB_RevTrans_R) (Table 3.1).   
5’ RACE 
The 5’/3’ Rapid Amplification of cDNA Ends (RACE) kit (Roche) was used 
according to the supplier’s instructions. A 500 ng aliquot of total DNase-treated RNA 
was used to obtain the cDNA by primer extension with primer complementary to the 
sequence (fruR_SP1; Table 3.1). Following the 3’ tailing reaction with dATPs, the 
cDNA was amplified by PCR using the reverse primer (fruR_SP2; Table 3.1) and 
oligo(dT)-anchor (forward primer; supplied with the kit). The 5’ end of the transcript 







Mga-1 purification and expression 
GAS Mga1-His6 was purified as previously described (251). Briefly, E. coli 
containing the plasmid pMga1-His was grown in ZYP auto-induction media for ~50 h 
at 37oC. Cells were harvested by centrifugation at 4oC. Pellets were then resuspended 
in Lysis Buffer A (20 mM NaPi, 500 mM NaCl, 20 mM imidazole, pH 7.4) and 1x 
EDTA-free cOmplete protease inhibitor (Roche), and incubated on ice with lysozyme 
for 30 min followed by sonication using a Branson Sonifier 450 with a tapered 
microtip (setting 6, 50% duty cycle) pulsing 3 x 1 min with 3 min breaks on ice 
between cycles. The lysate was spun for clarification at 20,000 x g for 30 min at 4oC 
3-4 times. The lysate was loaded on a 5 ml NiNTA agarose resin (Qiagen) and rotated 
at 4oC for 1 h. The column was then washed twice with NiNTA Wash Buffer (50 mM 
NaH2PO4, 300 mM NaCl, 20mM imidazole, pH 8.0). Protein was eluted with 10 ml 
of NiNTA elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 
8.0) and chosen fractions were stored at -20oC. Protein concentration was analyzed 
using the Bio-Rad protein assay kit, reading the absorbance at 595 nm on a 
spectrophotometer.  
GAS whole cell lysates 
Soluble GAS protein extractions were performed using the bacteriophage 
lysine, PlyC (kindly provided by D. Nelson) as previously described (251). Briefly, 
GAS cells were inoculated 1:20 into 12 ml of THY or C media (246), grown to late-




in 200 µl of Buffer D (30 mM Tris pH 7.5, 0.1 mM dithiothreitol [DTT], 40% (v/v) 
glycerol), 1x cOmplete EDTA-free protease inhibitor (Roche), 10 µl (20 U) of Turbo 
DNase (Life Technologies), and 5 µl (250 U) of PlyC. The cells were mixed by 
flicking and incubated on ice for 20 min, followed by centrifugation at 13,000 x g for 
10 min at 4oC. Clarified supernatants containing soluble proteins were extracted and 
boiled with 3x cracking buffer (0.15% [w/v] Bromophenol Blue, 0.6% [w/v] SDS, 3 
ml glycerol, 3.9 ml Tris-HCl [500 mM, pH 6.8], 1.5 ml β-mercaptoethanol, and 4 ml 
dH2O) at 95oC for 5 min, and stored at -20oC. Protein concentration was assayed 
using the Bio-Rad protein assay kit, reading the absorbance at 595 nm on a 
spectrophotometer.  
SDS-PAGE Analysis 
SDS-polyacrylamide gels were made as follows: a 10% resolving gel was 
mixed and poured followed by a 6% stacking gel using the reagents found in Table 
3.4.  Protein samples were mixed with 1x cracking buffer, boiled at 95°C, and loaded 
into the wells.  SDS-PAGE was run at 180V for 1 h. 
Western Blots 
Selected protein samples were run on a 10% SDS-PAGE, with 6% stacking 
gel, for 1 h at 180V. The gels were then transferred to nitrocellulose membranes using 
the Mini-Protean apparatus (Bio-Rad) in 1x transfer buffer (25 mM Tris base, 0.2 M 
glycine, 20% methanol). Membranes were blocked overnight at 4°C in blocking 
solution (5% (w/v) dried milk in PBS-tween). Primary antibodies were incubated at a 




at a 1:1,000 dilution: α-His antibody (Roche), α-Mga4, α-Mga1-HRP, and α-Sda1. 
Blots were then washed three times for 5 min in PBS-tween. The primary antibody 
Hsp60 (Enzo Life Sciences) was used at a 1:2,500 dilution. Blots were then incubated 
with secondary antibodies: α-rabbit-HRP (1:5,000) or α-mouse-HRP (1:20,000) for 1 
h. The blots were then washed with PBS-tween three times for 5 min, and visualized 






Table 3.4: SDS-PAGE buffer 
10- 15% Resolving gel 6% Stacking gel 
26% (v/v) Lower gel stock 25% (v/v) Upper gel stock 
25-37.5% (v/v) 40% Acrylamide/ bis sol. 15% (v/v) 40% Acrylamide/ bis sol. 
0.5% (v/v) 10% ammonium persulfate 0.5% (v/v) 10% ammonium persulfate 
0.1% (v/v) tetramehylethylene diamine 0.1% (v/v) tetramehylethylene diamine 
Brought up with H2O Brought up with H2O 
  
Lower gel stock Upper gel stock 
1.5M Tris HCl pH 8.8 0.5M Tris-HCl pH 8.8 
0.4% (w/v) SDS 0.4% (w/v) SDS 
Brought up with H2O Brought up with H2O 
  
SDS running buffer Transfer buffer 
25mM Tris 25mM Tris base 
190mM Glycine 0.2M glycine 
0.1% (w/v) SDS Brought up with 20% methanol 
Brought up with H2O  
   
5x Cracking buffer PBS-Tween 
0.3M Tris pH 6.8 0.01M PBS pH 7.4 
25% (v/v) 2-mercaptoethanol 0.5% Tween-20 
51% (v/v) glycerol Brought up with H2O 
10% (w/v) SDS 
0.01% (w/v) bromophenol blue 
Brought up with H2O 
Heated at 55ºC 




Phos-tag phosphate affinity gel 
The Phos-tag gel system was used to visualize the phosphorylation state of 
Mga. Briefly, GAS whole cell lysates were run on a Mn2+-Phos-tag 10% SDS-PAGE 
gel (WAKO), with 6% stacking gel. The resolving gel was made as follows: 1.75 ml 
of 1.5 M Tris-HCl, 1.75 ml of 40% bis-acrylamide, 140 µl of 10 mM MnCl, 140 µl of 
phos-tag solution, 3.1 ml of dH2O, 100 µl of 10% ammonium persulfate, and 20 µl of 
TEMED (Bio-Rad). Protein samples were run for 2 h at room temperature and 1 h on 
ice, for a total of 3 h at 180 V. 
 
Transcriptional Reporter Assay 
Luciferase Assay 
For strains containing the Pfru-luc or the PsloR-luc constructs, luciferase 
assays were performed as follows: 5448 (WT), 5448.∆fruR (fruR mutant) were 
transformed with pKSM944 and pKSM948 and grown static in 12.5 ml CDM 
supplemented with the appropriate carbon source under spectinomycin selection at 
37ºC. The construct pKSM944 is a Pfru-luc reporter plasmids, and pKSM948 is a 
PsloR-luc (Table 3.1) reporter plasmid that are both capable of replicating in GAS. 
500 µl samples were taken at mid-logarithmic (Klett 50) and late-logarithmic (Klett 
80) phase, centrifuged, and pellets were placed at -20ºC overnight. The luciferase 
assay was performed using the Luciferase Assay system (Promega). Pellets were 
resuspended in various amounts of 1x Lysis buffer to normalize for cell unit 




using a Centro XS3 LB 960 luminometer (Berthold Technologies) after 50 µl of 
Luciferin-D reagent was directly injected. 
 
Virulence Assays 
Lancefield bactericidal assay 
The ability of GAS strains to survive in whole human blood was tested as 
previously described (271). Briefly, GAS were grown to early mid-exponential phase 
(OD600 ~ 0.15) and serially diluted in saline. Blood donation is approved by the 
University of Maryland Institutional Review Board (IRB) (protocol 10-0735) with 
approved consent from donors; records have been archived. A 50 µl volume of a 10-4 
dilution (ca. 50 to 200 CFU) was added to 500 µl of fresh heparinized whole human 
blood and rotated for 3 h at 37°C.  
A murine blood bactericidal assay was performed as follows: Whole blood 
was obtained from 8- to 10-week old female CD1 mice (weight > 25g; Charles River 
Laboratories). The mice were anesthetized with ketamine, then a blood volume ≥ 
500µl was withdrawn by terminal cardiac puncture and the blood was immediately 
transferred to a heparinized vacutainer (Beckton Dickinson). Cervical dislocation was 
performed as a secondary method of euthanasia to ensure animals were deceased 
following cardiac puncture. A 30-µl volume of a 10−4 dilution (ca. 50 to 200 CFU) 
was added to 300 µl of fresh whole mouse blood and rotated for 3 h at 37°C.  
The multiplication factor (MF) was calculated for both assays by dividing the 
CFU obtained after blood challenge by the initial CFU inoculated. Data are presented 




of the wild type (WT) × 100. The human bactericidal assay MF of each strain was 
calculated from 6 biological replicates, whereas the murine bactericidal assay 
obtained blood from multiple mice (n= 4-6) in duplicate. Significance (p-value) was 
determined using a unpaired Student t test. 
Opsonophagocytic killing assays 
 Isolated PMNs or differentiated HL60 cells were seeded at a density of 106 
cells/ml in 24-well plates with RPMI 1640 cell culture medium supplemented with 
2.05 mM L-Glutamine. GAS was grown overnight, and cultures were diluted into 
fresh THY and grown to mid-log phase (OD600 ~ 0.4). Bacteria were opsonized prior 
to neutrophil challenge by re-suspension in donor plasma (PMN assays) or FBS 
(HL60 assays) for 30 min at 37˚C. GAS were then added to seeded neutrophils to 
desired multiplicity of infection (MOI = 0.1 unless otherwise indicated) in a final 
volume of 1 ml RPMI 1640 cell culture medium (HyClone) + 2.05 mM L-Glutamine, 
20% plasma or FBS. Neutrophil-challenged bacteria were incubated at 37˚C in 5% 
CO2 for 2 h. GAS were also incubated in RPMI 1640 + 2.05 mM L-Glutamine, 20% 
plasma or FBS in the absence of PMNs, monocytes or differentiated HL60 cells for 
the purpose of survival comparison. 
 Following incubation, surviving GAS were harvested by collecting 
supernatants and neutrophils. Neutrophils were immediately lysed by re-suspension in 
sterile H2O and the intracellular contents pelleted and recombined with corresponding 
well supernatants for plating on THY agar to obtain total viable bacterial counts after 
overnight incubation at 37˚C; 5% CO2. Resistance of GAS to opsonophagocytic 




from plating of viable bacteria isolated from killing assays to CFUs obtained from 
GAS incubation in cell culture media in the absence of neutrophils 
(!"# !!"#$%&'( !!"!!"#$!"# !!"#$%&'( !!"! "#$% !×!100)!1! . All survival indices are normalized to survival of wild 
type 5448 (100%) in the condition tested. Data presented is the result of at least 3 
biological replicates, each performed in triplicate with p values determined by 
unpaired t test.  
Murine intraperitoneal model of infection 
All animal work was performed in   AAALAC-accredited ABSL-2 facilities at 
the University of Maryland following IACUC-approved protocols (R12-112) for 
humane treatment of animal subjects in accordance with guidelines set up by the 
Office of Laboratory Animal Welfare (OLAW) at NIH, Public Health Service, and 
the Guide for the Care and Use of Laboratory Animals. Every effort to limit distress 
and pain to animals were taken.  
An overnight culture (10 ml) was used to inoculate 80 ml of THY and 
incubated static at 37°C until late-logarithmic phase (Klett 100). Briefly, 6- to 7-
week-old female CD-1 mice   (Charles   River   Laboratories) were injected in the 
peritoneal cavity with 100 µl of 4 x 109 CFU/ml dilution (4 x 108 CFU). Mice were 
monitored three times daily for a period not exceeding 72 h and were euthanized 
using CO2 asphyxiation consistent with the recommendations of the Panel on 
Euthanasia of the American Veterinary Medical Association upon signs of systemic 
morbidity (hunching, lethargy, hind leg paralysis). Survival data were assessed by 
Kaplan-Meier survival analysis and tested for significance by log rank test. Data 







Chapter 4: The fruRBA operon is necessary for Group A 
Streptococcal growth in fructose and for resistance to neutrophil 
killing during growth in whole human blood 
 






Bacterial pathogenesis is intimately linked to the availability of nutrients that 
a pathogen encounters in the host, such as preferred carbohydrate sources for carbon 
and energy. This paradigm holds true for Gram-positive pathogens in the phylum 
Firmicutes, and is discussed extensively in Chapter 2. The main system responsible 
for the appropriate coordination of virulence gene expression in response to available 
sugars is the phosphoenolpyruvate (PEP)-phosphotransferase system (PTS) (detailed 
in Chapter 2). The Group A Streptococcus (GAS) utilizes the PTS as an 
environmental sensor in order to coordinate the expression of virulence factors. 
Examples of such synchronization include: the stand-alone regulator Mga (19), 
LacD.1 (4), and CcpA and PtsI (5-8). Taken together, these findings point to the 
direct link between GAS carbohydrate metabolism and virulence factor production.  
Several PTS EIIs have been implicated in the pathogenesis of low-G+C 




pathogenic species of Streptococci. In the oral pathogen S. gordonii, the fructose 
EIIABC (fruA) has been linked to biofilm formation (272). In the zoonotic pathogen 
S. iniae, fruA was found in the genomes of five virulent strains, but was absent in 
non-virulent strains (273). In GAS, a transposon-site hybridization (TraSH) screen 
found fruA as a gene critical for the survival of GAS in whole human blood (15). 
Transcription of fruA was also induced in an analysis of global heme stress in GAS 
(274), a condition likely encountered during bloodstream infection.  
Despite clear links to pathogenesis, the exact role of FruA and fructose 
utilization in the physiology and virulence of GAS has yet to be examined.  fruA 
encodes one of the 14 EII PTS sugar-transporters found in the GAS M1T1 genome 
(197), and is predicted to be located within a three-gene fruRBA operon (fruRBA) 
conserved across low G+C Gram-positive bacteria. In the model organism 
Lactococcus lactis, the fruRKA operon is composed of fruR, encoding a DeoR family 
transcriptional repressor; fruK (fruB), a 1-phosphofructokinase; and fruA, an EIIABC 
PTS sugar transporter (275). 
In this study, we have characterized the fruRBA operon in the M1T1 strain 
5448, a representative of one of the most prevalent serotypes of GAS isolated from 
invasive forms of infections worldwide. We found that expression of the fruRBA 
genes are highly induced as an operon in the presence of fructose, and FruR acted as a 
repressor of the operon likely in conjunction with CcpA (CCR). Growth and 
metabolism studies demonstrated that FruA was the likely primary transporter of 
fructose for GAS and that all three fru genes were important for growth in fructose. 




and for evasion of human neutrophils whereas the FruA EII transporter was not. 
Surprisingly, neither growth in whole mouse blood nor intraperitoneal (i.p.) infection 
in mice was attenuated by mutations in the fruRBA operon. These data strongly 
suggest FruB, and its regulation by FruR, affect a human-specific mechanism for 






Transcriptome of M1T1 5448 growing with fructose as the sole carbon 
source  
Our previous genome-wide screen to identify genes required for GAS 5448 
fitness in whole human blood identified the putative PTS fructose EII gene fruA (15), 
suggesting a role for fructose utilization in host survival. To determine the effect of 
fructose on GAS gene expression, we conducted RNA-sequencing (RNA-Seq) in 
order to assess how fructose affects global transcription. Total RNA was isolated 
from the wild type 5448 grown in either chemically defined media (CDM) 
supplemented with 0.5% glucose or 1% fructose to late logarithmic phase in two 
biological replicates and processed for RNA-Seq. Data obtained from fructose-grown 
cells was compared to glucose-grown cells (WT-glu/WT-fru) with changes in gene 
expression over two-fold (log2 ≤ -1.0 or ≥ 1.0) with a p value ≤ 0.05 were considered 



















Table 4.1: Genes in 5448 differentially expressed in CDM-glu compared to CDM-fru 
 
Spy # Annotation Gene name Log2 FCa 
Induced by Fructose 
 
M5005_Spy_0039 alcohol dehydrogenase/acetaldehyde dehydrogenase adh.2 -2.10 
M5005_Spy_0123 translation initiation inhibitor  -1.82 
M5005_Spy_0124 serine catabolism regulator; FruA-like EIIC domain protein sloR -2.32 
M5005_Spy_0125 hypothetical protein  -1.09 
M5005_Spy_0126 V-type sodium ATP synthase subunit I ntpI -2.01 
M5005_Spy_0127 V-type sodium ATP synthase subunit K ntpK -1.97 
M5005_Spy_0128 V-type sodium ATP synthase subunit E ntpE -2.22 
M5005_Spy_0129 V-type sodium ATP synthase subunit C ntpC -1.79 
M5005_Spy_0130 V-type sodium ATP synthase subunit F ntpF -1.22 
M5005_Spy_0131 V-type sodium ATP synthase subunit A ntpA -1.24 
M5005_Spy_0132 V-type sodium ATP synthase subunit B ntpB -0.96 
M5005_Spy_0133 V-type sodium ATP synthase subunit D ntpD -1.21 
M5005_Spy_0150 PTS system, 3-keto-L-gulonate specific IIA  ptxA -0.99 
M5005_Spy_0474 transcription antiterminator, BglG family licT -1.36 
M5005_Spy_0476 6-phospho-beta-glucosidase bglA -1.22 
M5005_Spy_0521 PTS system, N-acetylgalactosamine-specific IIB  agaV -1.75 
M5005_Spy_0660 fructose repressor fruR -1.95 
M5005_Spy_0661 1-phosphofructokinase fruB -2.52 
M5005_Spy_0662 PTS system, Fructose-specific IIABC  fruA -3.33 
M5005_Spy_0798 IFN-response binding factor 1  -1.01 
M5005_Spy_1062 maltodextrose utilization protein malA -1.12 
M5005_Spy_1063 ABC Cyclomaltodextrin permease protein malD -1.17 
M5005_Spy_1081 PTS system, Cellobiose-specific IIA component  -0.98 
M5005_Spy_1307 hypothetical membrane spanning protein  -1.02 
M5005_Spy_1308 ABC unknown sugar-binding protein  -1.16 
M5005_Spy_1309 ABC unknown sugar permease protein  -1.82 
M5005_Spy_1310 ABC unknown sugar permease protein  -1.40 
M5005_Spy_1395 tagatose-bisphosphate aldolase; SpeB regulator lacD.1 -1.01 
M5005_Spy_1396 tagatose-6-phosphate kinase; regulatory lacC.1 -1.35 
M5005_Spy_1397 galactose-6-phosphate isomerase lacB subunit; regulatory lacB.1 -1.54 
M5005_Spy_1400 PTS system, Galactose-specific IIB component  -1.45 
M5005_Spy_1401 PTS system, Galactose-specific IIA component  -1.14 
M5005_Spy_1509 pyruvate, phosphate dikinase  -1.36 
M5005_Spy_1510 pyruvate, phosphate dikinase  -1.26 
M5005_Spy_1629 lantibiotic transport ATP-binding protein salX -1.89 
M5005_Spy_1631 lantibiotic salivaricin A salA -1.67 
M5005_Spy_1632 6-phospho-beta-galactosidase lacG -1.66 
M5005_Spy_1633 PTS system, Lactose-specific IIBC component lacE -2.73 
M5005_Spy_1634 PTS system, Lactose-specific IIA component lacF -2.22 
M5005_Spy_1635 tagatose-bisphosphate aldolase lacD.2 -2.18 
M5005_Spy_1636 tagatose-6-phosphate kinase lacC.2 -1.49 
M5005_Spy_1637 galactose-6-phosphate isomerase lacB subunit lacB.2 -1.67 
M5005_Spy_1638 galactose-6-phosphate isomerase lacA subunit lacA.2 -1.50 
M5005_Spy_1663 PTS system, Mannitol-specific IIB component  -1.69 
M5005_Spy_1744 PTS system, Cellobiose-specific IIC component celC -1.34 
M5005_Spy_1745 PTS system, Cellobiose-specific IIB component celB -0.95 
M5005_Spy_1841 L-serine dehydratase sdhB -1.06 
M5005_Spy_1842 L-serine dehydratase sdhA -1.27 
 
Repressed by Fructose 
 
M5005_Spy_0667 exotoxin type C precursor  2.07 
M5005_Spy_1139 glucosamine-6-phosphate isomerase nagB 0.98 
M5005_Spy_1388 N-acetylglucosamine-6-phosphate deacetylase nagA 0.97 
M5005_Spy_1574 universal stress protein family  2.05 
M5005_Spy_1575 quinolone resistance protein norA 2.33 
M5005_Spy_1746 PTS system, Cellobiose-specific IIA component celA 1.02 















Figure 4.1. Transcriptomic landscape of GAS 5448 during growth in fructose.  
Circos plot of wild type GAS 5448 gene global expression altered under growth in 
CDM + 0.5% glucose versus CDM + 1% fructose. The outer most ring represents a 
size ruler. The next two rings represent the GAS open reading frames on the (+) and 
(-) strand of the genome, respectively. The fourth ring shows transcript levels of 
genes, where the height of the bars represent the log2 fold change in differential 
expression in glucose vs. fructose (inside is induced, outside is repressed). The 






A total of 195 genes (103 non-phage genes; 5.5% of genome) were altered by 
the presence of fructose in comparison to glucose as the sole carbon source (Table 
4.1 and Fig. 4.1). Several predicted and established sugar metabolism operons were 
highly induced during growth in fructose (Table 4.1, shaded gray), including the 
lacD.1 and lacD.2 β-glucoside-specific PTS operons, the maltose-specific ABC 
transport system (malADC), and the predicted fructose operon (fruRBA). Of these, the 
putative fruRBA operon was the most highly induced by fructose with over a 5-fold 
increase in expression (Table 4.1). In addition, several members of the SerR regulon 
involved in serine metabolism were induced by fructose (276), including genes 
encoding the putative regulator SloR, the V-type sodium ATP synthase (ntp) operon 
and the serine dehydratase (sdhAB) operon. Interestingly, sloR is predicted to encode 
a transmembrane protein that exhibits homology to the EIIC domain of the putative 
FruA PTS transporter. Notably, only six genes, including nagB and nagA involved 
with N-acetylglucosamine metabolism, appeared to be repressed in the presence of 
fructose. Overall, the two highest gene ontology categories found to be induced by 
fructose were carbohydrate transport and metabolism (33 genes; 32%) and energy 
production conversion (9 genes; 9%). Therefore, the presence of fructose influences 
the expression of a subset of sugar metabolism genes, particularly the predicted 
fruRBA fructose utilization operon.   
In order to validate the RNA-Seq results, seven genes were selected for 
analysis by qPCR (Fig. 4.2A). Overall, the qPCR results confirmed the RNA-Seq 













































Figure 4.2. Validation of RNA-Seq results using qPCR.  
(A) Transcript levels were determined using qPCR on RNA taken from GAS grown 
in fructose compared to glucose as the sole carbon source.  Error bars represent the 
standard error from three biological replicates. Differences greater than 2-fold in 
expression for fructose grown cells compared to glucose grown cells (denoted by a 
dashed line) are considered significant. (B) Coefficient of correlation between the 
RNA-Seq and RT-qPCR results. Generated a confidence in the data with an R2 =83%. 





fruRBA represents an operon in M1T1 GAS  
In the 5448 genome, the fru locus is comprised of three contiguous genes 
(Fig. 4.3A and Table 4.1): fruR, encoding a predicted transcriptional repressor; fruB, 
encoding the enzyme 1-phosphofructokinase; and fruA, encoding a predicted 
fructose-specific EIIIABC component of the sugar phosphotransferase system (PTS). 
Each of the three genes slightly overlaps, where the start codon of the gene 
downstream is found in the upstream gene, suggesting they might form an operon. 
RT-PCR of transcripts from 5448 grown in CDM + 1% fructose showed 
transcriptional linkage between fruB/fruA and fruR/fruB, as well as a 1.5 kb full-
length transcript detected between fruR/fruA (Fig. 4.3AB). These data demonstrate 
that fruRBA are expressed as an operon during inducing growth in fructose as the sole 





-35 -10 cre site FruR site +1 
A. fruR fruB fruA 
B. 
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Figure 4.3. fruRBA is an operon in GAS M1T1 5448.  
(A) Genetic organization of fruR (encoding a transcriptional regulator), fruB 
(encoding 1-phosphofructokinase), and fruA (encoding PTS fructose-specific 
EIIABC) is shown. Magnified region indicates promoter sequences, including 
putative FruR and CcpA (cre) binding sites (underlined). Solid lines indicate 
transcription linkage found by RT-PCR. Dashed lines indicate location of qPCR 
amplification target. The transcriptional start site is indicated by an arrow along with 
the -10 and -35 shown in (A). (B) RT-PCR on RNA isolated from 5448 grown in 
CDM + 1% fructose demonstrating transcriptional linkage between fruR/fruB, 
fruB/fruA, and fruR/fruA.  Reactions were run using specific primers (Table 3.2) 
either with reverse transcriptase (+RT), without reverse transcriptase (-RT) as a 
negative control, and using genomic DNA (gDNA) as a positive control.  Expected 
sizes of bands are indicated. (C) The transcriptional start site (+1) was determined by 
5’-RACE and subsequent DNA sequencing (gray bar) from 5448 grown in THY and 






To determine the transcriptional start site (TSS) of the fruRBA operon, 5’-
rapid amplification of cDNA ends (5’-RACE) was used in conjunction with a primer 
complementary to fruR (fruR_SP1; Table 3.2). A TSS was identified 56 bp upstream 
of the start codon for fruR (Fig. 4.3AC) that possessed classical  -10 (TATAAT) and 
-35 (TTGACT) promoter hexamers upstream. A predicted CcpA- (cre site, (7)) and a 
putative FruR-binding site (275) were also identified overlapping and upstream of the 
promoter, respectively (Fig. 4.3A). Finally, a putative rho-independent terminator 
was detected downstream of fruA consistent with the generation of the full-length 
fruRBA transcript (Fig. 4.3A). Thus, the promoter of the fruRBA operon appears to be 
under CcpA-mediated catabolite repression by glucose and FruR-mediated induction 
by fructose. 
Non-polar deletion mutants of genes in the fruRBA operon 
To interrogate each gene in the fruRBA operon for its role in fructose 
metabolism and virulence, we generated non-polar deletions for fruR, fruB, and fruA 
by allelic exchange in the 5448 genome with an in-frame chloramphenicol (cat) 
cassette (250), generating the mutant strains 5448.∆fruR, 5448.∆fruB, and 
5448.∆fruA, respectively (Table 3.1). These mutations were subsequently verified by 
PCR (data not shown). Both 5448.∆fruR and 5448.∆fruA showed growth kinetics 
comparable to the parental 5448 in THY (Fig. 4.4B). 5448.∆fruB had a slightly 
slower growth rate than the WT, but reached the same yield after overnight growth 
(Fig. 4.4B). When the mutants were streaked on TSA supplemented with 5% sheep 





















































































































































∆fruB 5448 ∆fruR ∆fruA 
C. 
∆fruB 5448 ∆fruR ∆fruA 
 
 
Figure 4.4. Growth and expression of fruRBA genes in individual fru mutants 
and their rescue strains.  
(A) Shown are real-time qPCR analyses of relative transcript levels for each gene in 
the fruRBA operon in individual mutants and their respective rescue strains in fruR, 
fruB, and fruA compared to wild type 5448 grown in THY to late log. Error bars 
represent the standard error from three biological replicates. Dashed lines indicate 2-
fold significance. Significance was determined using relative transcript level 
comparisons to the gene gyrA. (B) Each fru mutant was grown in THY with their 
respective revertant strain and the parental 5448. (C) Colony morphology of each fru 
mutant was streaked on blood agar (TSA + 5% sheep blood) plates, cultured 
overnight at 37oC + 5% CO2 and imaged. Shown are the parental 5448, ∆fruR, ∆fruB, 





Due to the translational overlap between the genes in the fruRBA operon, we 
wanted to further validate that the mutations generated for each individual gene did 
not influence expression of the gene downstream. qPCR for each individual mutant 
was utilized to assess this using probes centered on each gene as shown in Fig. 4.3A 
with RNA isolated during late logarithmic phase in THY. The data for ∆fruR, ∆fruB, 
and ∆fruA show that the transcript levels for each mutant, respectively, was 
significantly reduced (Fig. 4.4A). Revertant strains for each mutant restored the 
transcript levels of that gene. Importantly, the transcript levels of the other genes in 
the operon were unaffected by other individual mutations as expected due to the 
operon being under CCR in THY. Thus, the mutations made in the fruRBA operon 
genes were non-polar and their transcript levels could be restored via reversion. 
fruA is required for optimal growth and utilization of fructose in GAS 
5448 
FruA is predicted to be a fusion of the EIIA, EIIB, and EIIC enzyme subunits 
of a fructose-specific PTS Enzyme II (EII) involved in import and concomitant 
phosphorylation of fructose. To confirm the role of FruA in the utilization of fructose, 
5448.∆fruA was grown on a panel of PTS sugars and compared to the parental GAS 
5448.  In order to establish what PTS sugars are amenable for 5448 growth, growth 
curves in CDM supplemented with 1% (0.5% for glucose) of 11 readily available PTS 
sugars were determined (Fig. 4.5A). The wild type 5448 was able to grow in 9 of the 
11 PTS sugars tested; however, mannitol and cellobiose were not conducive for 
significant growth of 5448 and were eliminated from further analysis. When 




reduced growth (Fig. 4.5BC and 4.6C). Importantly, reversion of the ∆fruA mutation 
(5448.fruAR) restored growth in fructose back to wild type levels (Fig. 4.5BC and 
4.6C). Both 5448.∆fruB and 5448.∆fruR also displayed significant growth defects in 
CDM supplemented with 1% fructose that was restored in the revertant (Fig. 4.6AB).  
These data suggest that FruA is the primary EII transporter of fructose in GAS 5448 



























































































































































Figure 4.5. Growth analysis of 5448 and fruRBA operon mutants in PTS sugars.  
(A) Total yield was calculated for GAS 5448 grown for 26 h at 37°C, 5% CO2 in 
various PTS sugars as the sole carbon source. (B) Growth rates were determined for 
5448 (black bars) and 5448.∆fruA (white bars) in 9 PTS sugars (p value < 0.05). 
Growth of the fruAR revertant (gray bar) was assessed for fructose only. Error bars 
represent standard error of the mean from three biological replicates. Statistical 
analysis was performed using an unpaired t test. Data is representative of three 
independent experiments. (C) Klett unit relative to 5448 at each time point was 
calculated by taking the percent WT of each individual time point, and plotting the 
median percent WT along with the interquartile range (25-75% of the data set). Black 
bars represent sugars in which 5448.∆fruA grows similarly to the parental 5448. Gray 
bars indicate sugars in which 5448.∆fruA grows poorly compared to 5448. Black 
square represents growth comparison of 5448.fruAR to wildtype. Dashed lines 







Due to the growth defect that was exhibited by a ∆fruA mutant, we also 
wanted to ascertain if fruA affects the utilization of other carbon sources. We used 
Biolog PM1 and PM2A Phenotype Microarrays (PMs) to monitor the metabolism of 
190 different carbon sources by the ∆fruA strain. The parental GAS 5448 and 
5448.∆fruA were different in their utilization of 72 carbon sources (data not shown), 3 
of which are designated as PTS sugars (N-acetyl-D-galactosamine, cellobiose, and 
mannitol) (Table 4.2). Surprisingly, fructose was not identified in the Biolog assay as 
having a defect in metabolism (Table 4.2). This suggests that there is another PTS 
transporter that is able to transport fructose, although at levels that do not sustain wild 
type growth (Fig. 4.5B and 4.6C). To confirm this observation, wild type 5448 and 
5448.∆fruA were also tested using a Biomérieux API50® strip that tests utilization of 
a subset of 50 carbohydrates (Fig. 4.7). As seen with BIOLOG, 5448.∆fruA was able 
to utilize fructose similarly to 5448 in this assay; however, the fructose utilization is 
insufficient to support growth.  We also tested 5448.∆fruB and 5448.∆fruR using the 
API50 strips. Like 5448.∆fruA, both the ∆fruR and ∆fruB mutants were able to utilize 
fructose, even though neither was able to grow on fructose as the sole carbon source 
(Fig. 4.7). Taken together, these data suggest that fruA is required for optimal growth 
on fructose, and that FruA is the main fructose transporter for GAS. Since a PTS-
defective mutant (∆ptsI) of M1T1 GAS is defective for utilization of fructose in the 
BIOLOG assay (8), there appears to be another PTS EII that is able to transport 
fructose to be metabolized, albeit not at the levels necessary to support GAS growth 




however this is unsurprising as a ∆ptsI also affects utilization of non-PTS carbon 
sources through currently unknown mechanisms. 
 
 























































Figure 4.6. Growth curves of individual fruRBA operon mutants in minimal 
media.  
Growth curves for (A) 5448.∆fruR mutant and its fruRR revertant, (B) 5448.∆fruB 
mutant and its fruBR revertant, and (C) 5448.∆fruA and 5448.fruAR in chemically-
defined media (CDM) supplemented with 1% fructose was measured by absorbance 
using a Klett-Summerson colorimeter (Klett units) and compared to wild type 5448. 












Table 4.2: Carbon sources with altered utilization 
 
Carbon Source 5448 5448.∆fruA 
N-Acetyl-D-Galactosamine + +/− 
D-Cellobiose + +/− 
D-Mannitol + +/− 
D-Galactose + + 
D-Fructose + + 
α-D-Glucose + + 
D-Mannose + + 
Sucrose + + 
α-D-Lactose + + 
Maltose + + 
Salicin + + 
D-Trehalose + + 
β-Methyl-D-Glucoside + + 
Maltotriose + + 
 
*Listed are only PTS carbon sources. 
** +, Omnilog Value (OV) >200; +/-, 125<OV<200; -, OV<125. 
































        
        
        
        
        
        
        
        
        
        
      
        
        











        
        
        
        
        
        
        
        
        
        
      
        
        






































Figure 4.7. Limited carbohydrate metabolism profile of 5448 and the fruRBA 
operon mutants.  
Wild type 5448 and the 5448.∆fruA, 5448.∆fruB, and 5448.∆fruR mutants were 
assayed using an API® 50 CH results after incubation at 37°C for 24 h and 48 h. 
Listed are select carbon sources from a panel of 50 carbohydrate sources: complete 
utilization (white boxes); partial utilization (gray boxes), and no utilization (black 









The effect of fructose on sloR  
The RNA-Seq data (Table 4.1) showed that several members of the SerR 
regulon (276) were up regulated in fructose, including sloR, the putative Streptolysin 
O regulator (277). In silico analysis of sloR showed nine transmembrane domains that 
exhibited a high degree of homology to a fructose-specific EIIC. Given that a ∆fruA 
mutant could still utilize fructose (Table 4.2, Fig. 4.5B, Fig. 4.6C, Fig. 4.7), we 
wanted to explore the role of SloR in fructose utilization and transport in addition to 
confirming its regulation in fructose.  
An insertional inactivation mutant in sloR (5448.∆sloR; Table 3.1) was 
generated using a temperature sensitive replicating plasmid. Growth of 5448.∆sloR in 
CDM + 1% fructose was found to be comparable to the wild type 5448 (Fig. 4.8B), 
suggesting that SloR likely does not play a role in fructose uptake. We also tested the 
effect SloR had on the metabolism of other sugar sources using the API50 assay, and 
saw no observable difference between a ∆sloR strain and wild type 5448 (data not 
shown). However, the effect of fructose on the induction of sloR was confirmed using 
qPCR (Fig. 4.2, blue bar). Additionally, an expression reporter plasmid was 
constructed by cloning the promoter of sloR (PsloR) upstream of the firefly luciferase 
gene (luc) and activity was determined through quantification of relative luciferase 
units (LU). A significant increase in PsloR-luciferase activity was observed when 
cells were grown in fructose in comparison to sucrose (Fig. 4.8A). To rule out that 
FruR regulates sloR, we also tested sloR transcript levels in a ∆fruR strain grown in 
fructose and glucose using qPCR and saw no observable difference (data not shown). 




however this induction is independent of FruR. We also show that that sloR is most 
likely not an alternative transporter of fructose, but this cannot be ruled out until a 









































































































































































































































































Figure 4.8. The effect of fructose on sloR.  
(A) PsloR promoter activity in WT 5448 containing the PsloR-luc luciferase reporter 
plasmid was grown in CDM containing either 1% fructose (solid bars) or sucrose 
(diagonal bars). Samples were taken at three time points in logarithmic phase of 
growth (early: white bars; mid: light gray bars; late: dark gray bars) and assayed for 
luciferase production, expressed in relative luciferase units. Error bars for represent 
mean ± SD of the results from three biological replicates performed in triplicate. 
Significance for (A) was determined using a Student t test (p ≤ 0.01). (B) Growth of 







FruR is a repressor of the fruRBA operon 
In other streptococci, fruR encodes a putative DeoR-like repressor in the 
family of carbohydrate regulatory proteins (272, 275, 278). To confirm that FruR is a 
repressor of the fruRBA operon, we grew wild type 5448 and the 5448.∆fruR mutant 
in both catabolite repressing (glucose) and inducing (fructose) conditions in order to 
isolate RNA for qPCR. Growth in CDM + 0.5% glucose (Fig. 4.9A) was successful, 
however, when fructose was the sole carbon source available, the ∆fruR strain failed 
to grow (Fig. 4.6A and 4.9A). In order to generate appropriate cell density to extract 
RNA, we applied a “diauxic growth” condition.  Both the WT and the ∆fruR strains 
were grown in CDM + 0.5% glucose to late logarithmic phase, washed twice, and 
transferred for growth in either CDM + 1% fructose or CDM + 0.5% glucose for one 
hour. qPCR was used to determine the effect of the 5448.∆fruR mutant on the 
transcription of fruB and fruA using RNA from cells grown in either fructose or 
glucose. When comparing WT 5448 grown in glucose then fructose, we saw an 
increase in transcript levels across the entire operon (Fig. 4.9B, black bars), mirroring 
what we saw in the RNA-Seq results (Table 4.1). Comparing WT 5448 grown in 
fructose to 5448.∆fruR grown in fructose, an increase in fruB and fruA transcript 
levels is observed, indicating that FruR is acting as a repressor of this operon (Fig. 
4.9B, checkered bars). Furthermore, an even larger increase in transcript levels for 
fruB and fruA in the 5448.∆fruR mutant was observed when grown in glucose 
compared to fructose, indicating that the operon is also under carbon catabolite 












































































































































































Figure 4.9. FruR represses expression of the fruRBA operon. 
 (A) Growth of 5448 (black) or the 5448.∆fruR mutant (gray) strain under modified 
diauxic conditions. Cells were grown in CDM + 0.5% glucose (solid line) to late log 
(To), washed and transferred into CDM with either 0.5% glucose (solid line) or 1% 
fructose (dashed line). Cells were outgrown for 1hr (T1hr) in either sugar for RNA 
extraction. (B) Transcript levels of fruRBA operon genes were measured by RT-qPCR 
with respect to growth condition. 5448 grown in fructose compared to glucose (black 
bars), the 5448.∆fruR mutant grown in fructose compared to glucose (diagonal bars), 
and the 5448.∆fruR mutant grown in fructose compared to the WT 5448 grown in 
fructose (checkered bars) are shown. Error bars represent the standard error from two 
biological replicates. Differences greater than 2-fold in expression for the mutant 
compared with wild type (denoted by a dashed line) are considered significant. 
Significance was determined using relative transcript level comparisons to the gene 
gyrA. (C) PfruR promoter activity in WT 5448 containing the PfruR-luc luciferase 
reporter plasmid was grown in CDM containing 0.5% glucose or 1% fructose, 
mannose, or sucrose. Samples were taken at mid logarithmic phase of growth and 
assayed for luciferase production, expressed in relative luciferase units. Error bars for 
represent mean ± SD of the results from three biological replicates performed in 
triplicate. Significance for (C) was determined in comparison to glucose using a 







To confirm the role of FruR on repression of the fruRBA operon, a luciferase 
reporter assay was performed using the mapped promoter region of the operon 
(PfruR). A significant increase in luciferase activity was observed only when the WT 
5448 containing the PfruR-luc construct was grown in CDM + 1% fructose as 
opposed to 0.5% glucose, or 1% sucrose or mannose (Fig. 4.9C) indicating induction 
of the operon is fructose-dependent. When the same assay was performed in the 




tested (Fig. 4.9C). Therefore, both FruR and CcpA negatively control the expression 
of the fruRBA operon, and fructose (after conversion to fructose-1-phosphate) likely 
acts as an inducer of the operon through inactivation of FruR. 
fruB and fruR, but not fruA, are important for 5448 survival in whole 
human blood 
The fruA gene was identified as important for GAS survival in whole human 
blood during a genome-wide competitive TraSH (15). To determine the step in 
fructose utilization that might be involved in GAS survival in blood, we performed 
Lancefield bactericidal assays on each of the non-polar fruRBA operon mutants and 
their respective revertant strains. Interestingly, both 5448.∆fruR and 5448.∆fruB 
exhibited decreased survival in whole human blood relative to the parental GAS 5448 
(Fig. 4.10A). Surprisingly, the 5448.∆fruA did not show a significant decrease in 
survival in human blood, although it trended downward and was variable. The 
revertant strains for all three mutants showed a restoration of growth comparable to 
wild type 5448 (Fig. 4.10A). Thus, although our TraSH screen had indicated that fruA 
was needed for GAS survival in human blood, (15), our data using defined non-polar 
















































































































































































Figure 4.10. fruR and fruB are important for survival in human blood and 
phagocytic cells.  
In all assays, wild type 5448 (black bars) was compared to 5448.∆fruR (white bars), 
5448.∆fruB (light gray bars) and 5448.∆fruA (dark gray bars) for growth and survival. 
Respective rescued mutant strains were indicated with diagonal lines. (A) Lancefield 
bactericidal assay was performed by monitoring growth in whole human blood with 
rotation at 37°C for 3 h.  Data is presented as percent growth in blood corresponding 
to the multiplication factor (MF) of the mutant divided by the MF of the wild type × 
100. Error bars represent mean ± SD of the results of six independent experiments. 
(B) Survival in neutrophil-like HL60 cells. GAS (1×105 cfu/well) and HL60 cells 
(1×106 cfu/well) were incubated for 2 h at 37˚C. Cells were lysed and percentage of 
surviving GAS was determined relative to survival of 5448. (C) Survival in human 
neutrophils (PMNs). GAS (1×105 cfu/well) and neutrophils (1×106 cfu/well) were 
incubated for 2h at 37˚C. Neutrophils were then lysed and the percentage of surviving 
GAS was determined and shown as relative survival to the WT (5448). (D) Survival 
in human monocytes. GAS (1×105 cfu/well) and human monocytic cells (1×106 
cfu/well) were incubated for 2 h at 37˚C. Cells were lysed and percentage of 
surviving GAS was determined relative to survival of 5448.Error bars for (B-D) 
represent mean ± SD of the results from three biological replicates performed in 
triplicate. Significance for (A) was determined using a Student t test (p ≤ 0.0015), 
while significance for (B-D) was determined by unpaired t test (p < 0.05). 





fruR and fruB are important for GAS 5448 survival in neutrophils and 
monocytes 
The phenotype exhibited by 5448.∆fruR and 5448.∆fruB in whole human 
blood can be attributed to defects in metabolic processes or in immune evasion. To 
clarify this question, we subjected 5448.∆fruR and 5448.∆fruB to opsonophagocytic 
killing assays using the human-derived promyelocytic leukemia cell line HL60 
differentiated into neutrophil-like cells (Fig. 4.10B) and in freshly isolated human 
polymorphonuclear leukocytes (PMNs) (Fig. 4.10C). Neutrophils are the 
predominant cell type that act as a first line of defense at the site of infection, and can 
kill pathogens through multiple extra- or intra-cellular means such as antimicrobial 
peptides, phagocytosis, and DNA neutrophil extracellular traps (NETs) (279). Both 
neutrophil-like HL60 cells and human-isolated PMNs were infected using an MOI of 
0.1, and strains were plated for survival and compared to the parental 5448. When 
either 5448.∆fruR or 5448.∆fruB was incubated with HL60 cells, each showed a 
significant decrease in survival compared to 5448 (Fig. 4.10B). However, 5448.∆fruA 
survived comparable to the wild type GAS. Importantly, revertant strains 5448.fruRR 
and 5448.fruBR either partially or completely restored the phenotype to wild type 
levels (Fig. 4.10B). These phenotypes were recapitulated with freshly isolated human 
PMNs (Fig. 4.10C), supporting a requirement for FruB and FruR, but not FruA, for 
survival in human neutrophils. There was also a survival defect observed for 
5448.∆fruR or 5448.∆fruB, but not 5448.∆fruA, in human monocytes, suggesting a 




types (Fig. 4.10D). To eliminate the possibility that any of the fruRBA operon 
mutants had a reduced ability to grow on cell culture media and artificially cause the 
phenotypes we observed, we also grew each strain in RPMI + 20% plasma, and saw 
no growth defect in comparison to the parental 5448 (Fig. 4.11). Thus, fruR and fruB, 
but not fruA, are important for GAS resistance to killing by human neutrophils and 










































































































Figure 4.11. 5448 and ΔfruRBA Growth in RPMI+ 20% Plasma.  
Each fru mutant was grown along with the parental strain 5448 in RPMI + 20% 
plasma. Data from 6 independent experiments, with at least three replicates for each 
fruRBA operon mutant in comparison to WT 5448 are shown in (A). The cumulative 









fruR and fruB phenotypes are not observed in murine models of infection  
Murine models of infection have long been used as the gold standard for 
simulating disease of human pathogens, with GAS being no exception. The 
significant reduction in survival of both 5448.∆fruR and 5448.∆fruB in human blood 
and phagocytic cells led us to hypothesize that both mutants would show attenuated 
virulence in mouse models. We first subjected 5448.∆fruR and 5448.∆fruB to a 
modified Lancefield bactericidal assay using whole murine blood. Unexpectedly, we 
found that both 5448.∆fruR and 5448.∆fruB mutants did not show a defect for growth 
in mouse blood as seen in human blood (Fig. 4.12A). To test the impact of the 
fruRBA operon mutants in vivo, an intraperitoneal (i.p.) murine model of systemic 
GAS infection was used. Mice were infected i.p. with 4 x 108 CFU/ml of 5448, 
5448.∆fruR and 5448.∆fruB, and monitored three times daily during a 72 h period. 
Similar to the murine Lancefield bactericidal assay, we did not see a decrease in 
survival for the 5448.∆fruR or the 5448.∆fruB mutants when compared to the parental 
5448 (Fig. 4.12B). Thus, while fruR and fruB appear to be important for survival 
against neutrophil and monocyte killing in human blood, they do not affect GAS 
pathogenesis during murine models of infection. This strongly suggests a species-



















































Figure 4.12. Loss of fruR and fruB does not affect survival in murine models of 
infection.  
The 5448.∆fruR and 5448.∆fruB mutants were compared to the wild type 5448 in the 
following two assays; (A) Survival in a modified Lancefield bactericidal assay using 
whole mouse blood. The data are presented as percent growth in blood corresponding 
to the multiplication factor (MF) of the mutant divided by the MF of the wild type × 
100. Data represents GAS survival in blood obtained from multiple mice (n=4-6). 
Error bars represent mean ± SD of the results of two independent experiments. 
Significance was determined using a Student t test (p ≤ 0.0015) (B) Survival in a 
murine intraperitoneal (i.p.) model of infection. GAS (~4×108 Cfu/mouse) were 
injected i.p into mice (n=10/strain) and monitored for morbidity over the course of 72 
h. Significance was determined using Kaplan–Meier survival analysis and log rank 





The current study was undertaken to assess the importance of fructose 
utilization in GAS pathogenesis. Our results reveal a fructose-induced operon 
(fruRBA) that was found to be required for growth of GAS in fructose and implicate 
the PTS-transporter, FruA, as the primary transporter of fructose in GAS. FruR acts 
as a repressor at the fruRBA operon promoter, likely along with CcpA, to allow for 
fructose induction of the system. Mutants lacking fruR and fruB, but not fruA, were 
found to be sensitive to survival in whole human blood and phagocytic killing by 
neutrophils and monocytes. Interestingly, neither mutant was found to be required for 
survival in murine blood or for virulence in a murine model of systemic infection. 
Thus, the fruRBA operon plays a key role in both GAS metabolism and pathogenesis, 
revealing a mechanism by which this human pathogen can sense its nutritional 
environment during infection and directly linking this operon to innate immune 
evasion in the host. 
Fructose-induced regulon of GAS  
Metabolic genes for utilization of alternative (non-glucose) sugars are 
typically induced only during times of low glucose (carbon catabolite repression, 
CCR) and in the presence of the inducing sugar itself. For pathogenic streptococci 
and related low G+C Gram-positive bacteria, a genome-wide fructose-induced 
regulon has previously been determined only for Streptococcus mutans and the 
probiotic Lactobacillus acidophilus (280, 281). In S. mutans, microarray analysis 




in fructose compared to glucose, whereas a similar analysis in L. acidophilus found 
that 110 genes (6% of genome) were regulated. Our RNA-Seq analysis discovered 
that growth of GAS in CDM with fructose affected transcription of roughly 5.5% of 
the non-prophage genome (102 genes) compared to glucose (Tables 4.1). This is in 
line with what was observed in both L. acidophilus and S. mutans, highlighting a 
fairly focused fructose-specific response in these cells. The most highly fructose-
induced genes in GAS were fruRBA, followed by several other sugar-specific PTS 
operons such as lacD.1 and lacD.2. The comparable L. acidophilus fruRBA genes 
were also highly induced by fructose (281). In contrast, the S. mutans genes for 
fruRBA (Smu.0870-72) were constitutively expressed and a separate 
mannose/fructose family PTS system was found to be inducible (280).  
We also observed an increase in expression of genes in the serine catabolism 
regulon including sloR, sdhAB, and ntpA-K (276). We further validated the fructose 
induction of sloR expression via qPCR (Fig. 4.2A) and through promoter-luciferase 
fusions (Fig. 4.8A).  SloR was initially implicated in streptolysin O expression (277), 
but more recently was shown to be involved in serine acquisition (276). Interestingly, 
in silico analysis (282) of SloR shows significant homology to a fructose EIIC 
transporter, suggesting that it might play a role in the transport of fructose, and 
potentially aid in signal transduction to coordinate gene expression. However, a sloR 
mutant did not show any significant effect on utilization of fructose or any other PTS 




Role of the fruRBA operon in fructose metabolism 
(i)FruA  
The GAS M1T1 genome is predicted to encode 14 sugar-specific Enzyme II 
(EII) translocation components of the phosphoenolpyruvate-phosphotransferase 
system (PTS). This is the first study in GAS characterizing fructose utilization and the 
contribution of the fruRBA operon, confirming its annotated role in fructose 
metabolism. We found that an in-frame mutant in fruA (5448.∆fruA), encoding the 
putative PTS EIIABC, exhibited a significant growth defect in comparison to WT 
(5448), but did show some residual growth on fructose (Fig. 4.5BC and 4.6C). Non-
polar mutants in fruB (5448.∆fruB), encoding 1-phosphofructokinase, and fruR 
(5448.∆fruR), a putative repressor, also showed a comparable defect in growth on 
fructose, confirming that the entire fruRBA operon is necessary for fructose utilization 
in GAS. As mentioned above, the residual growth and utilization of fructose may 
involve other PTS EII pathways as other PTS-transporters were up regulated in a 
fructose-specific manner (Fig. 4.7 and Table 4.2).  
(ii) FruR 
The DeoR-family transcriptional regulator, FruR, is directly involved in 
repression of the fruRBA operon in L. lactis (275) and other Gram-positive bacteria 
(272, 278, 283). Through transcriptional analysis of the 5448.∆fruR mutant and its 
rescue strain (5448.∆fruRR), we demonstrated that FruR represses transcription of the 
fruRBA operon through its promoter (Pfru) and that this promoter is required for 
fructose-induction (Fig.4.9).  Furthermore, expression of the operon exhibits evidence 




fruRBA promoter region identified the presence of a putative FruR binding site (275) 
upstream of the -35 hexamer and a catabolite response element (cre) site for CcpA 
binding (5-7) overlapping with the start of transcription (Fig. 4.3A). The 
physiological inducer of FruR de-repression is fructose-1-phosphate (F1P) and only 1 
mM of F1P is sufficient to disrupt FruR binding to its operator in P. putida (284, 
285). Fructose-1-phosphate is also the inducer of the fruRBA operon in other Gram-
positive species such as L. lactis (275).  This correlates with FruR being a member of 
the DeoR-family of repressors, which are typically induced by sugar-phosphates 
produced by the regulatory pathway they control (180, 272, 275).  
The fruR mutant also exhibited a significant growth defect when grown in 
fructose alone, similar to loss of fruA and fruB (Fig. 2 and Fig S5). Given that the 
fruRBA operon is up regulated in this mutant, it would be expected to metabolize 
fructose at wild type levels. One explanation might be that, in a ∆fruR strain increased 
fruA and fruB transcripts leads to an increase in the intracellular levels of F1P that is 
converted to fructose-1,6-bisphosphate (FBP) by FruB.  This mechanistic conversion 
of fructose into FBP directly feeds into gluconeogenesis and glycolysis. High levels 
of FBP have been shown to be important for signal transduction in Gram-positive 
bacteria as it stimulates activity of HprK, a serine/threonine kinase involved in 
catabolite repression through phosphorylation of Hpr(Ser~P), which can then interact 
with CcpA and trigger CCR (181, 286). Therefore, high levels of FBP can mimic 
high levels of glucose and elicit CCR conditions (glucose), which then shuts down 
transcription of CcpA regulated operons such as fruRBA, and this then would lead to 




high levels of the fruB and fruA transcript in the qPCR results (Fig 4.9B) observed in 
the ∆fruR mutant, and there were high levels of activity exhibited in the Pfru-luc 
reporter assays (Fig. 4.9C). 
(iii) FruB  
1-phosphofructokinase (fruB) converts imported fructose-1-phosphate to 
fructose-1,6-bisphosphate and our data shows that it is also necessary for GAS 
growth on fructose (Fig. 4.4B). The fruB mutant (5448.∆fruB) also exhibited a small 
colony phenotype when plated on blood agar (Fig. 4.4C) and showed a slightly 
longer doubling time when compared to the parental 5448 and its revertant 
(5448.∆fruBR) in rich media implicating this enzyme in playing role outside of the 
conversion of F1P to FBP (discussed below). Although other alternate PTS EII 
pathways exist in GAS that allow for the transport of fructose (enters the cell as 
fructose-6-phosphate; F6P), as demonstrated by both the RNA-Seq and Biolog/API 
CH50® metabolic data (Tables 4.1, and 4.2; Fig. 4.7), the efficiency of transport is 
not able to support growth. In addition, when fructose is transported by alternative 
PTS systems, a 6-phosphofructokinase (pfkA) enzyme to convert F6P to FBP would 
need to be present (287). However, pfkA was not up regulated when GAS was grown 
in fructose as the sole carbon source (Table 4.1). Therefore, while the data presented 
in this study demonstrates that the fruRBA operon is the main operon responsible for 
the uptake and growth in fructose for the GAS, there are other PTS transporters that 




Role of FruR and FruB in innate immune evasion 
A phenotype for fruA in either whole human blood or in phagocytic killing 
was not observed, which is surprising as fruA was originally observed to be important 
for survival of GAS in whole human blood using a genome-wide TraSH screen (15). 
However, the TraSH screen is a competitive assay, therefore it is possible that fruA is 
important in competition. Regardless, since a fruB mutant (5448.∆fruB) is defective 
for survival in whole blood and human-derived phagocytic cells (Fig. 4.10A), it 
would appear that 1-phosphofructokinase enzymatic activity (F1P conversion to FBP) 
is crucial for GAS to evade the innate immune response through an undefined 
mechanism. It could simply be that the buildup of F1P triggers a downstream 
regulatory cascade that influences genes important for resistance to phagocytic 
killing.  However, FruB may be playing a more direct role, such as the LacD 
tagatose-1,6-bisphosphate aldolase, which controls expression of the SpeB exotoxin 
through interacting with the transcriptional regulator RopB (4). 
FruR, which also exhibits decreased survival in whole human blood and 
phagocytic killing, is likely contributing to this phenotype through its regulation of 
fruB. Although there is an increase in fruB transcript levels (Fig. 4.9B), and 
presumably FruB protein levels, in a ∆fruR mutant, it is still sensitive to phagocytic 
killing (Fig. 4.10). These data suggest that there is a stoichiometry effect of the levels 
of 1-phosphofructokinase in the cell leads to a similar defect in immune evasion. In 
silico analysis of the MGAS5005 genome shows that a consensus FruR binding site 
(275) only occurs once in the genome, upstream of FruR. Therefore, it is unlikely that 




this hypothesis cannot be ruled out, and a transcriptional analysis of a fruR mutant 
could be performed to answer this question.  
fruRB-mediated immune evasion is specific to the human host 
environment 
  Although fruR and fruB mutants were defective for survival in human blood 
and phagocytes (Fig. 4.10), we saw no growth defects in whole mouse blood or any 
attenuation in a mouse model of systemic GAS infection (Fig. 4.12). This strongly 
suggests that the fruRB-mediated mechanism of innate immune evasion is highly 
adapted to its human host. This is most likely attributed to the composition of the 
neutrophils present in human blood versus mouse blood, which is further addressed in 
Chapter 7. While mice have been used extensively for studying GAS pathogenesis, 
there are aspects related to species specificity that have been problematic for disease 
modeling. GAS is able to produce a wide range of disease severities in different 
mouse strains, causing different strains of mice to be either better or worse models for 
simulating GAS infections (288). It would appear that coevolution between the 
human immune system and GAS has resulted in adaptation to its natural host 
environment. Whether 1-phosphofructokinase (FruB) is directly sensing a human-
specific environmental stimulus leading to downstream virulence gene regulation, or 
whether it merely results in the signal remains to be determined. However we 
hypothesize that it is not the ability for GAS to transport fructose into the cell, but the 
metabolic byproducts and activity of FruB itself that contributes to the virulence 




between fructose metabolism and regulation of immune evasion molecules that are 
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Chapter 5: Glucose differentially phosphorylates Mga and alters 




Coordination of the timely expression of virulence factors is key for bacterial 
pathogens in order to successfully colonize the host and elicit an infection. For Gram-
positive bacteria, expression of virulence genes is often linked to the availability of 
essential nutrients, specifically carbohydrates (186). Therefore, it is not surprising 
that these bacteria have tied their main system for carbohydrate uptake, the 
phosphoenolpyruvate (PEP)-phosphotransferase system (PTS), (180, 186) to 
coordinate the expression of carbohydrate metabolism genes (14, 19, 289-293) (9).  
The Group A Streptococcus (GAS) or Streptococcus pyogenes is a Gram-
positive pathogen that can colonize a variety of tissues in the human host, resulting in 
a wide range of invasive or non-invasive diseases. GAS can successfully colonize and 
adapt to a variety of niches in the human host through coordination of environmental 
cues and nutritional status with global transcriptional networks, as has been shown in 
several studies (12, 14, 157, 228, 294). Since GAS does not encode for alternate 
sigma factors to coordinately regulate expression of genes, GAS utilizes global 
transcriptional regulators to synchronize transcriptomic changes. GAS encodes for 13 
two-component systems (TCS) and several “stand-alone” regulators (e.g., RofA-like 
proteins [RALPs], Rgg, and Mga) that control virulence gene expression in response 




The multiple gene regulator of GAS, or Mga, is ubiquitous in all sequenced 
strains thus far (11). A microarray study found Mga to regulate approximately 10% of 
the GAS genome during exponential phase of growth under nutrient rich conditions 
(THY) (229). The core Mga regulon consists of genes important for colonization and 
immune evasion. Recently, the PTS of GAS has been shown to directly phosphorylate 
Mga on conserved histidines located on the two PTS regulatory domains (PRDs) both 
in vitro (19) and in vivo (20). The PTS acts antagonistically on the phosphorylation of 
the PRDs, which has been shown to affect the activity of Mga in vivo (19). Taken 
together, Mga is a PRD-containing virulence regulator (PCVR) that is critical for 
GAS pathogenicity, and its activity is intimately linked to carbohydrate utilization. 
Although it is known that Mga activity is modulated by the PTS, how specific 
carbohydrates affect Mga-dependent gene regulation has not been investigated. In this 
study, we characterized the effects of limited glucose availability on GAS physiology. 
Particularly, we were interested in the effects this may have on Mga and the 
expression of its regulon. We observed that Mga was differentially phosphorylated in 
THY in comparison to C media, which led to a high degree of plasticity of the 
regulon that is directly correlated to glucose availability. Thus, we were able to 
correlate activation of the Mga regulon, through glucose, to differential 






Transcriptome analysis of M1T1 5448 growing in a low-glucose 
environment.  
When GAS colonizes the host, it must adapt to both the hosts’ immune 
response and to altered availability of nutrients. Often, this signal for global 
transcriptional change within the cell is critical for pathogen survival. When GAS 
invades deep tissue niches in the host, it encounters a limited carbohydrate (ie. 
carbon) source supply, where specifically, the preferred carbohydrate, glucose, is not 
readily available. Previous work by Loughman et al. has shown that C media acts as 
an accurate representation of the environment encountered by GAS during a deep-
tissue infection due to its low glucose, high peptide composition (88), and because it 







































































Figure 5.1. Global gene expression profiles of the WT 5448 at late logarithmic 
growth in different medias.   
A principal component analysis (PCA) plot is shown for the transcriptome of the WT 
5448 grown in either THY (high glucose) or C media (low glucose) at late 
logarithmic growth phase prior to normalization for batch effects. The PCA plots 
show the first two principal components on the X and Y axes, respectively, and the 
percentage of total variance specific to that principle component is indicated. Each 
biological replicate is represented as a single point with color corresponding to the 
media condition (THY, brown; C media, purple) and shapes represent different 







This study focuses on identifying whether a low-glucose versus a high-
glucose environment has any effect on the global transcriptome of the M1T1 strain 
5448. Thus, as representatives of these two conditions, we used the rich media THY 
as a representative of a high-glucose environment, and C media as a representative of 
a low-glucose environment. Total RNA was isolated from the WT 5448 grown in 
either THY (0.5% glucose (w/v)) or C media (0.05% glucose (w/v)) to late 
logarithmic phase in four biological replicates and processed for RNA-Seq. Data 
obtained from THY-grown cells was compared to C media-grown cells (WT-
THY/WT-C media) with changes in gene expression over 1.9-fold (log2 ≤ -0.95 or ≥ 
0.95) and a p value of ≤ 0.05 was considered significant (Appendix 2). 
We used a principal component analysis (PCA) plot in order to visualize the 
correlation between the two media conditions (Fig. 5.1). The plot showed a strong 
simialrities between the replicates generated from the same media, which 
demonstrates that reproducibility of the datasets (Fig 5.1; y axis). In addition, a stray 
batch effect was also observed. It also demonstrated that the transcriptional profile 
between WT 5448 grown in THY, is different from 5448 grown in C media, as 
demonstrated by PC1 (Fig 5.1; x axis). 
 CcpA controls the expression of genes for carbon catabolite repression (CCR) 
through directly binding to catabolite response elements (cre sites). Thus, during 
favorable growth conditions (high glucose), CCR occurs. Since C media contains low 
amounts of glucose (0.05% w/v), we hypothesize that repression of genes that are 
normally under CCR to be relieved in C media. A total of 510 genes (476 non-phage 




media compared to THY (Fig. 5.2; Appendix 2). 75 of those genes (~15%), were 
also found to regulated by CcpA using microarrays, and are likely under direct CCR, 
(5, 6). Additionally, 28 cre sites were observed upstream of genes that were activated 
and repressed in C media, further supporting that genes that are activated in C media 
are most likely directly regulated through CcpA. Thus, the data presented here shows 
that growth of the WT 5448 in C media mimics a CcpA regulon (5, 6), although there 
are media specific phenotypes as well, and confirms that C media can act a good 
representative for a low glucose environment.  
Alternative methods of sugar uptake are usually necessary for carbon 
acquisition during times of low glucose, thus metabolic genes involved in utilization 
and transport of alternative (non-glucose) sugars were induced during growth in C 
media. We observed that most of the alternative PTS carbohydrate EII transporters 
such as 3-keto-L-gulonate (ptxABC), mannitol (spy_1664), galactose (spy_1399), 
both cellobiose operons (spy_1079-1083 and celB), and trehalose (treCB) were all up 
regulated in C media. The ABC transporters for sialic acid (spy_0213-0215), 
cyclomaltodextrin (malADC), and an unknown sugar permease (spy_1308-1310) 
were also up regulated. Interestingly, the β-glucoside-specific EIIABC and both 
mannose operons ptsABCD and manLMNO were repressed in C media (Appendix 2). 
This indicates, that these two operons are potentially not important for sugar uptake 
under this condition.  
We also found several virulence-related genes to be activated in C media, 
including the has operon (capsule synthesis) and the sag operon (Streptolysin S), both 




regulon and a CcpA regulon, there were also media-specific regulatory phenotypes. 
Interestingly, we found that an additional 25 genes found in this study have been 
previously shown to be regulated by CcpA (5, 6), but were regulated in a different 
direction. Interestingly, we observed a significant increase in the expression of both 
the lacD.1 operon and rgg/ropB, both of which are regulators of the secreted cysteine 
protease and virulence factor gene speB. As mentioned above, C media is an inducer 
of speB expression (88); however, we did not see speB being differentially expressed 



























































































































































































































Figure 5.2. Transcriptomic landscape of 5448 during growth in C Media.  
Circos plot of wild-type GAS 5448 gene global expression altered under 
growth in C media versus THY. The outer most ring represents a size ruler. The next 
two rings represent the GAS open reading frames on the (+) and (-) strand of the 
genome, respectively. The fourth ring shows transcript levels of genes, where the 
height of the bars in the fourth ring represent the log2 fold-change in deferential 
expression in C media vs. THY (inside is repressed, outside is induced). The mga 





We also found the majority of the core Mga regulon to be down regulated in C 
media (Table 5.1) in comparison to THY. Interestingly, we did not find the transcript 
levels of emm and mga to be affected. We further confirmed this observation by real-
time qPCR using the same RNA from the original RNA-Seq experiments, where mga 
and emm transcript levels continued to be unaffected by growth in C media and the 
genes encoding the fibronectin binding protein (fba) and the C5A peptidase precursor 
(scpA) were down regulated. Interestingly, we were unable to observe a phenotype for 
the secreted inhibitor of complement gene sic using qPCR (Table 5.1).   
 
 
Table 5.1: Repression of the Mga locus in C media 
 





M5005_Spy1714 cell surface protein; Mga-regulated fba 2.51 1.32 ± 0.17  
M5005_Spy1715 C5A peptidase precursor; Mga-regulated scpA 2.20 1.26 ± 0.33 
M5005_Spy1716 transposase  -1.66 -- 
M5005_Spy1717 transposase  -2.47 -- 
M5005_Spy1718 
streptococcal inhibitor of complement; 
Mga-regulated sic1.0 2.32 
 
0.49 ± 0.14 
M5005_Spy1719 M protein; Mga-regulated emm1 0.74 0.84 ± 0.21 
M5005_Spy1720 Multi-virulence gene regulator Mga mga 0.67 0.32 ± 0.11 
M5005_Spy1721 hypothetical protein  -2.86 -- 
 
 
Analysis of gene ontology categories found to be the most affected by growth 
in C media revealed that amino acid transport and metabolism (51 genes; 10.7% of 
total genes differentially expressed), carbohydrate transport and metabolism (59 
genes; 12.4% of total genes differentially expressed), and translation, ribosomal 
structure and biogenesis (61 genes; 12.8% total genes differentially expressed) were 
the top three COG categories. These three categories correlate with the composition 




synthesis of metabolites is necessary for GAS growth on this media. Overall, 25.5% 
of the genome is differentially regulated in C media in comparison THY. Taken 
together, the transcriptome of 5448 in C media in comparison to THY exhibits 
similarity to a CcpA regulon likely due to the low glucose conditions present in C 
media. Additionally, expression of some of the Mga regulon is activated in THY in 
comparison to C media during late logarithmic phase of growth. 
Mga is differentially phosphorylated in C Media. 
As mentioned in the previous section, we observed some of the core Mga 
regulon genes to be activated in THY (high glucose), but Mga itself was not 
differentially expressed (Table 5.1). Because it is know that Mga activity is 
dependent on phosphorylation by the PTS of GAS, and there was a global 
transcriptional change in the WT 5448 response to limited glucose availability, we 
wanted to see if the phosphorylation of Mga was altered between these two mediums. 
To test this, we used a Phos-tag SDS-PAGE gel matrix. The Phos-tag compound 
specifically forms a complex with phosphorylated amino acid residues present on the 
protein of interest and retards its movement through the gel matrix, as opposed to 
their unphosphorylated counterparts which run quicker. We hypothesized that under 
favorable growth conditions, such as high glucose (THY), we would observe an 
abundance of unphosphorylated Mga than phosphorylated Mga. Under low glucose 
conditions, the converse would be true, where there would be more phosphorylated 
than unphosphorylated Mga. To test whether Mga was differentially phosphorylated 
in vivo under these conditions, we attempted to grow a M1T1 strain containing a 




Pmga1-mga-his6 (pKSM809) (Table 3.1) in either THY or C media. However, we 
never saw sufficient expression of Mga1 by western blot and SDS-PAGE analysis 
(data not shown) in the conditions tested.  
As an alternative, we used an existing plasmid expressing an M4 mga 
construct, Pmga4-mga4-his6, (pKSM808, WT M4) in the strain KSM547 
(GA40634.∆mga4) (Table 3.1) that has been successfully expressed in GAS for PTS 
analysis previously (19). The phosphoablative construct, pKSM871, which substitutes 
all three PTS-phosphorylatable histidines with alanines (A/A/A M4 Mga construct) 
was also used. The two strains were grown in either THY or C media to late 
logarithmic growth and whole cell lysates were isolated. Phos-tag gel analysis of the 
lysates followed by a western blot with anti-Mga4 antibodies revealed two distinct 
bands corresponding to WT Mga, a slow-migrating band arising from phosphorylated 
Mga and a fast-migrating band corresponding to non-phosphorylated Mga for the 
THY grown strain. When the strain expressing the WT Mga4 was grown in C media, 
only a single band corresponding to the unphosphorylated A/A/A protein was present 
(Fig 5.3A). As expected, the A/A/A M4 Mga control mutant showed the 
unphosphorylated species regardless of the media (Fig 5.3A).  
As a control for equal loading, cell lysates were separated by SDS-PAGE and 
subjected to a western blot revealing only one Mga-specific band (Fig. 5.3B). Thus, 
the retarded migration of Mga occurs only on the Phos-tag gel and likely results from 
alternative phosphorylation status of Mga. Interestingly, while an equal amount of 
protein was detected for all strains in the Western blot, there was consistently less 




by Phos-tag gel. Together, these data provide the first evidence that Mga can be 
alternatively phosphorylated between high and low glucose conditions, and that 
phosphorylation is most likely occurring on the PRD1/2 phosphohistidines. Overall, 
these data provide the first evidence that Mga can be alternatively phosphorylated 
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Figure 5.3. Mga is differentially phosphorylated based on glucose availability.  
The isogenic M4 mga mutant strain KSM547 complemented in trans with the His6-
tagged WT strain (pKSM808) or phosphoablative (A/A/A) mga mutant (pKSM871) 
was grown in THY or C medium to the late exponential growth phase, pictured is a 
representative image of multiple replicates. Cells were lysed using PlyC. (A) Equal 
concentrations of cell lysates of the WT and A/A/A strain were resolved on a Phos-
tag-MnSO4 gel and probed using a polycolonal α-Mga4 antibody. Bands 
corresponding to non-phosphorylated Mga and phosphorylated Mga are labeled and 
indicated by arrows. (B) Protein levels in cell lysates of the mga strains were 





The M1T1 Mga regulon in THY versus C media.  
Since we observed differential phosphorylation patterns for a WT Mga strain 
under different glucose availability and media conditions, we hypothesized that the 
Mga regulon in these two medias would vary. A previous study (229) characterized 
the Mga regulon in THY at late logarithmic growth across three serotypes (M4, M6, 
and a lower virulence M1) using a microarray. Due to the in-depth resolution of 
RNA-Seq over microarrays, the clinical relevance of the M1T1 clinical isolate 5448, 
and the need for comparison to C media, determination of the THY Mga regulon 
again was warranted. We constructed an insertional inactivation of mga in 5448 using 
a temperature sensitive replicating plasmid to generate the mga mutant, 5448.930 
(Table 3.1). Growth kinetics of 5448.930 were found to be comparable to parental 
5448 in both THY and C media (data not shown). Total RNA was isolated from the 
WT 5448 and the ∆mga strain grown in either THY or C media to late logarithmic 
phase in two biological replicates and processed for RNA-Seq. Data obtained from 
the parental 5448 was compared to the ∆mga grown cells in either media (WT/∆mga) 
with changes in gene expression over 1.8-fold (log2 ≤ -0.85 or ≥ 0.85) and a p value 
























































































































































































































Figure 5.4. Transcriptomic landscape of ∆mga mutant during growth under 
varying glucose conditions.  
Circos plot of the differentially expressed (DE) genes between wild-type GAS 5448 
versus a ∆mga mutant under growth in either C media or THY at late logarithmic 
growth. The outer most ring represents a size ruler. The next two rings represent the 
GAS open reading frames on the (+) and (-) strand of the genome, respectively. The 
fourth ring shows transcript levels of genes, where the height of the bars in the fourth 
ring represent the log2 fold-change in deferential expression in THY (blue) vs. C 





As expected for both medias, the most activated genes were those of the core 
regulon (emm, sic, scpA, etc.), which all showed between an 18- and 7-fold reduction 
in transcript levels (Table 5.2; Appendix 3 and 4). Interestingly, we did not observe 
a Mga-specific phenotype for sclA in either RNA-Seq datasets. sclA is a gene 
consider to be apart of the core Mga regulon that contains a category B promoter (see 
Chapter 2, Mga DNA binding section) and is directly regulated by Mga (20, 111, 229, 
243). Lack of finding slcA in our data could indicate that sclA is under the control of a 
different regulatory mechanism in the M1T1 5448, is not expressed in this 
background, or it could signify that the computational analysis had difficulty mapping 
this gene. Thus, we performed real-time qPCR on both the WT 5448 and 5448.930 
∆mga strain using the same RNA that was used in the RNA-Seq for both conditions. 
We observed hat sclA was still regulated by Mga via real-time qPCR, and could be 
complemented (Fig 5.5AB and Fig. 5.6AB), therefore it appears that there was some 
issue with read alignment or calculations of differential expression for this gene. 
There are two scl genes (sclA and scl2) encoded in M1 GAS strains, the second of 
which is not regulated by Mga. However, because of their homology and the 
restrictions of mapping reads with Bowtie (258, 259) this second gene may artificially 
add reads to the Mga-regulated sclA gene that would otherwise correspond to scl2. 
This could help explain the abnormal phenotype of sclA regulation in the RNA-Seq 
data, which was not recapitulated in the qPCR results.  
(i) M1T1 Mga regulon in THY 
A total of 155 genes (including 7 tRNA genes) were found to be significantly 




(80) genes (Appendix 3; Fig. 5.4, blue ring). The chromosomally encoded DNase 
spd, was also shown to be activated by Mga; transcript levels were reduced by 4-fold 
in comparison to WT 5448. As opposed to what was seen from the microarray study 
(229), speB is repressed by Mga in a M1T1 background (Appendix 3; Fig 5.5A). 
Mga also repressed spi, an inhibitor of speB, to similar levels (Appendix 3), 
indicating that proper expression of SpeB may be critical for GAS under this 
condition. The microarray study also showed Mga to indirectly regulate operons 
involved in sugar metabolism, this phenotype was recapitulated in our RNA-Seq 
experiment as well; however, here, the majority of sugar-related operons were 
activated by Mga and not repressed as was previously observed (229).  
In order to validate the RNA-Seq results generated from THY, a total of 8 
genes were chosen for analysis via qPCR; 6 genes which are activated, 2 which are 
repressed (Fig. 5.5A). In addition, 5448.930 was passaged at the permissive 
temperature in order to generate the rescue strain, 5448.930R, which was used to 
complement the phenotypes seen in both the RNA-Seq and qPCR data (Fig. 5.5B). 
The real time qPCR results confirmed the RNA-Seq data with a correlation 
coefficient of 87% (Fig. 5.5C). Overall, a total of 8.3% (7.9% without tRNA genes) 
of the genome was regulated by Mga in THY at late logarithmic phase in an M1T1 
background. While there appears to be similarities between the broad categories of 
genes regulated by Mga in our study with those observed by Ribardo et al. in the 
microarray experiment, there were several differences on both the individual gene 




show a Mga regulon that is specific to the M1T1 GAS in THY (high glucose) at late 













































































































































Figure 5.5. Validation of THY RNA-Seq results using qPCR.  
(A) Transcript levels were determined using qPCR on RNA taken from WT GAS 
5448 grown in THY at late-log compared to 5448.930 grown under the same 
conditions. Error bars represent the standard error from three biological replicates. 
Differences greater than 2-fold in expression for fructose grown cells compared to 
glucose grown cells (denoted by a dashed line) are considered significant. (B) 
Complementation of the ∆mga mutant using the rescue strain 5448.930R restores the 
transcriptional phenotypes observed in THY. (C) Coefficient of correlation between 






 (ii) M1T1 Mga regulon in C media 
For C media, a total of 148 genes (including 13 tRNA genes) were regulated 
by Mga (57 repressed, 91 activated) in C media, representing 7.9% (7.2% without 
tRNA genes) of the genome (Fig. 5.4; purple ring). We also observed novel virulence 
factors and metabolic genes to be regulated in C media that were not observed in 
THY. For example, both hemolysin operons Streptolysin S (sagA-H) and Streptolysin 
O (slo), Streptokinase (ska), Streptococcal secreted esterase (sse), the heme utilization 
operon (hupYZ), and the osmotic stress operon (opuAA/opuABC) were regulated by 
Mga in C media. In addition, Mga did not regulate speB in this condition (Fig 5.6, 
light blue bar), indicating that speB is Mga regulated in potentially a glucose-specific 
manner. We also observed grm to be Mga regulated in a C media-specific manner. 
grm encodes for a 78 amino acid hypothetical cytosolic protein that was directly 
regulated by Mga at its Category B promoter (Pgrm), and was suggested to be a part 
of the core Mga regulon (229), however its role in GAS physiology has never been 
identified.  
A total of 9 genes were chosen for validation via qPCR. We also used the 
rescue strain, 5448.930R, to complement the phenotypes seen in both the RNA-Seq 
and qPCR data (Fig. 5.6B). The real time qPCR results confirmed the RNA-Seq data 
with a correlation coefficient of 95% (Fig. 5.6C). Overall, we observed a broader 
induction of known virulence factors in a ∆mga background in C media. Taken 
together, these data indicates that there is a glucose-specific effect on the Mga 
regulon in the M1T1 GAS that occurs most likely due to the altered phosphorylation 



































































































































Figure 5.6. Validation of C media RNA-Seq results using qPCR.  
(A) Transcript levels were determined using qPCR on RNA taken from WT GAS 
5448 grown in C media at late-log compared to 5448.930 grown under the same 
conditions. Error bars represent the standard error from three biological replicates. 
Differences greater than 2-fold in expression for fructose grown cells compared to 
glucose grown cells (denoted by a dashed line) are considered significant. (B) 
Complementation of the ∆mga mutant using the rescue strain 5448.930R (hashed bars) 
restores the transcriptional phenotypes observed in C media. (C) Coefficient of 
correlation between the RNA-Seq and RT-qPCR results. Generated a confidence in 




Comparison of the Mga regulon under varying glucose availability. 
Analysis of the Mga regulon in either THY or C media revealed a significant 
difference between the two data sets. Not only were the genes that are regulated by 
Mga in either condition different, but also the number of genes that are 
activated/repressed in these conditions were also different; THY had equal numbers 
whereas C media had more activated genes. Furthermore, while we expected a 
difference in gene regulation between the high and low glucose conditions, we did not 
expect to see the so little in common between the two data sets. In total, only 19 
genes, 3 of which encode for tRNAs, were shown to be in common between the two 
Mga regulons (Fig.5.7; Table 5.2). The majority of genes that were consistently 
regulated between both medias were the core regulon genes (Table 5.2; bold, shaded 
grey). In addition, glnH and glnQ.2 (bicarbonate transporter), mac (IgG-degrading 
protease), spd (chromosomally encoded streptodornase), M5005_spy0522 (sugar 
hydrolase), M5005_ spy0143 (hypothetical protein), and spxA.2 (a transcriptional 







Figure 5.7.  Genes in common between the Mga regulons in medias.  
Venn diagram showing the numbers of Mga-regulated genes by either THY (left) or 
C media (right), and their overlap with each other. A total of 16 genes were in 
common between the two data sets (shaded grey). In parenthesis is the number of 
tRNA genes found in each dataset. Percentage of regulation was calculated by 









Albeit the stark difference in genes that are regulated by Mga in a high 
glucose versus a low glucose condition, the COG categories that were most affected 
were not different. In THY, the top three COGs regulated by Mga were “unknown 
function” (23 total; 8/15) “carbohydrate utilization” (32 total; 31/2) “defense 
mechanism” (18 total; 12/6) (activated/repressed) (Fig. 5.8). In C media, the  
“unknown function” COG still had the highest representation (32 total; 13/19), this 
was followed by “defense mechanism” (19 total; 18/1), and “energy production and 
conservation” (17 total; 3/14) (activated/repressed) (Fig. 5.8). Taken together, while 




conditions, the broad categories that these genes belong to do not vary. This confirms 
that Mga is a master regulator for genes involved in virulence factor production and 











Table 5.2: Genes regulated by Mga in both THY and C Media (WT 5448/∆mga)  
 





M5005_Spy0113 transposase   1.47 1.32 
M5005_Spy0143 hypothetical protein 
 
2.54 3.35 
M5005_Spy0522 unsaturated glucuronyl hydrolase 
 
1.45 0.98 




pyrophosphokinase folK -1.00 -0.87 
M5005_Spy1076 Putative Bicarbonate transporter glnH -1.31 -0.85 
M5005_Spy1077 Putative Bicarbonate transporter glnQ.2 -1.04 -1.04 
M5005_Spy1714 cell surface protein; Mga-regulated fba 3.20 4.79 
M5005_Spy1715 C5A peptidase precursor; Mga-regulated scpA 3.43 5.04 
M5005_Spy1718 
streptococcal inhibitor of complement; Mga-
regulated sic1.0 4.63 5.53 
M5005_Spy1719 M protein; Mga-regulated emm1 9.08 10.06 
M5005_Spy1720 Multi-virulence gene regulator Mga mga 4.60 5.84 
M5005_Spy1721 hypothetical protein 
 
-2.78 -5.00 
M5005_Spy1733 hypothetical protein 
 
-2.54 1.45 
M5005_Spy1738 phage-associated deoxyribonuclease spd 0.98 1.03 
















Importantly, in addition to complementation, we were also able to control for 
Mga regulation of the genes identified in these two datasets by using an alternative, 
independent ∆mga mutant. The stable transposon mutant, KM16.1 (Table 3.1), was 
used for real time qPCR on selected targets in either C media or THY. KSM16.1 
contains a KRMIT (295) insertion at the 5’-end of mga. Four genes originally chosen 
for validation in THY (Fig. 5.9A) and nine genes that were identified in C media 
(Fig. 5.9B) were tested using this mutant. We observed an identical phenotype in 
gene regulation for KM16.1 in both medias in comparison to WT 5448 (Fig. 5.5A 
and 5.6A). Therefore, the regulon observed in either THY or C media is consistent in 
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Figure 5.8. Comparison of the COG categories observed in THY and C media 
for a ∆mga strain.  
A comparison of the differentially expressed (DE) genes in various cluster of 
orthologous genes (COG) categories from THY versus C media of a ∆mga mutant at 
late logarithmic growth when compared to the WT 5448. Bar length depicts the 
number of DE genes either down regulated (red) or up regulated (green) at p value of 
≤0.05 with the total number of down and up regulated genes shown. Plain (THY) or 

































Figure 5.9. Transcriptional regulation of genes by Mga is recapitulated in an 
alternative ∆mga mutant.  
Transcript levels were determined using qPCR on RNA taken from WT GAS 5448 
grown in THY (A) or C media (B) at late-log compared to KM16.1 grown under the 
same conditions. Error bars represent the standard error from three biological 
replicates. Differences greater than 2-fold in expression for fructose grown cells 






Supplementation of glucose in C media restores some phenotypes. 
 Mga has an altered regulon in C media (low glucose) in comparison to THY 
(high glucose) that is likely to due to the phosphorylation status of the protein (Fig. 
5.3A). We were interested in testing whether supplementing C media, which has 
0.05% (w/v) of glucose to a final concentration of 0.5% (w/v) (the amount that is 
present in THY), would mimic the THY regulon. RNA was isolated for real-time 
qPCR from 5448.930 and the parental 5448 grown in C media supplemented to 0.5% 
glucose. We chose a total of 5 of differentially-regulated genes that were exclusive to 
the C media RNA-Seq dataset (Appendix 4; Fig. 5.6A and 5.9B) including speB, 
which was only found to be regulated in THY (Fig. 5.5A, 5.6A, 5.9; Appendix 3 and 
4) and emm which was observed in both datasets. We saw that 4 out of the 5 
differentially regulated genes specific to C Media were no longer regulated by Mga 
when glucose was supplemented back to levels present in THY, which includes the 
phage-encoded DNase sdaD2 (Fig. 5.10; green bar). Interestingly, opuAA (Fig.5.10; 
pink bar) was the only gene that was not complemented by glucose, which potentially 
indicates that growth in C media causes osmotic stress and is likely regulated, 




























Figure 5.10. Supplementation of C media with glucose mimics some phenotypes 
observed for a ∆mga strain in THY.  
Transcript levels were determined using qPCR on RNA taken from WT GAS 5448 
grown in C media supplemented to 0.5% glucose at late-log compared to 5448.930 
grown under the same conditions. Error bars represent the standard error from three 
biological replicates. Differences greater than 2-fold in expression for fructose grown 











Interestingly, Mga was shown to activate the transcription of speB in THY at 
late log phase (Fig. 5.5A and Fig. 5.9A; light blue bar) and this regulation phenotype 
was abolished in C media (Fig. 5.6A and Fig 5.9B; light blue bar). Therefore, we 
wanted to test whether speB regulation could be restored when glucose was 
supplemented back into C media. Indeed, upon the addition of glucose to 0.5% (w/v), 
speB was regulated by Mga once again (Fig 5.10; light blue bar). Therefore, while the 
mechanism by which Mga regulates speB is most likely indirect, there is a direct 




appears to be two causes to the changes observed between THY and C media: 1) the 
majority of the changes are specific to glucose availability, and therefore are probably 
directly related to the phosphorylation status of Mga. 2) A minor subset of changes in 
the regulon dynamics are due to C media-specific differences.  
Phage-encoded DNase, Sda1, is subject to C media-specific Mga 
regulation. 
In C media, Mga transcriptionally activates all three phage-associated DNases 
or streptodornases, including the M1T1 distinguishing phage, sdaD2 (encoding 
Sda1). The RNA-Seq data showed that there was over a 5-fold reduction in transcript 
of sdaD2 in a ∆mga mutant (~8-fold qPCR; Fig. 5.6A and Fig 5.9B; green bar) in a 
low glucose environment. Interestingly, regulation of sdaD2 by Mga (Fig. 5.10; green 
bar) was complemented upon glucose supplementation, confirming that regulation of 
this streptodornase occurs in a glucose-dependent manner. Sda1 is encoded on 
Φ5448.3, one of the mobile genetic elements that is responsible for the emergence of 
the M1T1 serotype (145, 296). Due to the reduction of transcript level observed in a 
low glucose environment (C media), we wanted to test if this would be reflected at 
the protein level. We grew WT 5448 and the two independently constructed ∆mga 
mutants (5448.930 and KM16.1) in C Media in the presence of E-64 protease 
inhibitor, and observed expression of Sda1 in culture supernatants. There was 
significant decrease in protein production of Sda1 in both ∆mga mutants in 
comparison to WT 5448 in several independent replicates (Fig. 5.11). We also 
attempted correlate this phenotype to a functional defect in a ∆mga mutant to degrade 




we were unable to see a significant decrease in the ability for a ∆mga mutant to 
degrade DNA. However, while Mga does activate all three streptodornases in 5448 in 
C media, the amount of DNase produced from a ∆mga background may be sufficient 
enough to not observe a difference between the two strains. Regardless, Mga clearly 
regulates this serotype-specific virulence determinant in a glucose-dependent manner 






Figure 5.11. Sda1 expression is reduced in a ∆mga background in M1T1 GAS.  
Western blot analysis of the expression Sda1 (encoded by sdaD2) (44 kDa), the 
Φ5448.3 phage-encoded streptodornase in culture supernatants grown to late-log 
phase (Klett ~70) in the WT 5448 compared to two independent ∆mga mutants 
(5448.930 and KM16.1). Culture supernatants were concentrated using methanol-
chloroform precipitation, and equal amounts were run on a 10% SDS-page gel and 








The current study was undertaken to assess how glucose availability affects 
global transcriptional changes in the cell; in particular how it affects Mga activity. 
Our results reveal that some of the Mga regulon is up regulated in THY, a high 
glucose environment. In addition, there was a strong correlation between the genes 
activated in the C media dataset and those previously shown to be repressed by CcpA, 
indicating that C media can relieve CCR. We show that the difference in Mga activity 
in THY is likely due to alternative phosphorylation patterns of Mga in comparison to 
C media through its PRD domains. We then tested the differences of the Mga regulon 
under these two glucose levels and found that while a similar percentage of the 
genome was regulated under both THY and C media, there was very little overlap. 
Importantly, we show that a high percentage of the differences in the Mga regulons 
are directly attributed to glucose. Thus, this is the first time that Mga and its regulon 
are influenced by glucose, revealing an in vivo link between glucose availability and 
activation of a global transcriptional network that plays a key role in virulence gene 
regulation.  
The C media-mediated regulon of M1T1 GAS.  
For low G+C Gram-positive bacteria, carbon catabolite repression (CCR) is 
controlled by the master regulator, CcpA through direct binding of catabolite 
response elements (cre) sites. Metabolic genes for utilization of alternative (non-
glucose) sugars are typically induced during lack of the preferred carbohydrate 




have been determined (5, 6). Both studies found that ~8% of the GAS genome is 
regulated by CcpA in THY. We found that 15.8% of the total number of genes 
differentially expressed in C media overlapped with the CcpA regulon (5, 6), 
indicating that the low glucose environment encountered by GAS in C media is 
capable of relieving CCR and stimulating the transcription of alternative carbohydrate 
uptake systems. Although there is clear overlap between these two dataset, our data 
also showed that GAS undergoes a much more broader global transcriptomic change 
during growth in C media (low glucose) as 25.5% of the entire non-prophage GAS 
genome (476 genes) were differentially expressed when compared to THY (high 
glucose) (Appendix 2). Thus, there is a media specific regulon that encompasses 
some of the CcpA regulon, which indicates that growth in C media can mimic a 
limited glucose environment, but it also creates other changes in the cell that are most 
likely attributed to its high levels of peptides.  
The C media-induced regulon has been established for the M5 strain, HSC5, 
using altered buffered and osmotic conditions at early stationary growth phase (88). 
However, this is the first study to investigate the global regulatory changes that occur 
when GAS is grown in THY compared to C media using RNA-Seq in an M1T1 
strain. As mentioned previously, C media is a low in glucose but is also peptide rich. 
This media has been shown to be a representative of conditions encountered by GAS 
during deep tissue infection due to up regulation of the virulence factor and cysteine 
protease, speB, to levels comparable to those observed during in vivo infection (88). 
Thus, C media has been used in several studies as an inducer of speB expression. 




media as expected. However, this study was conducted in late logarithmic phase, and 
not stationary phase, where speB is known to be most highly expressed. However, we 
did observe an increase in expression both the lacD.1 and rgg/ropB, which have been 
shown to interact and together stimulate speB activity (297). Therefore, due to the 
growth phase constraint of our data set, the conditions tested here may not be optimal 
for the induction of speB expression. To answer this questions, we could conduct 
qPCR on RNA isolated a various stages in growth, including stationary phase to 
assess speB expression. Another possibility of the lack of observable speB expression 
is that since C media acts as a growth media that mimics deep tissues infection (88), it 
is possible that speB is not being expressed in the WT 5448. A study found that in 
vivo/environmental signals suppress the expression of speB, and induce the 
expression of speA (298). While C media can induce the expression of speB in other 
serotypes, it is possible that it cannot function in the same for the M1T1 serotype. 
However, there was no observable change in transcript level for speA in our RNA-
Seq results of the WT 5448 grown in either THY or C media. Therefore, it is likely 
that the first scenario is what is occurring.  
Plasticity of the M1T1 Mga virulence regulon under varying glucose 
availability. 
The multiple gene regulator of GAS, or Mga, has a well-characterized regulon 
encompassing both virulence and carbohydrate metabolism genes (229). However, 
questions remain with regards to how Mga, through activation of its regulon, may 
differ due to availability of a preferred carbohydrate source (glucose). To date, a 




(C media) to a rich glucose (THY) environment has not been undertaken. In this 
study, we used RNA-Seq in order to identify differences in the Mga regulon under 
different nutrient conditions.  
(i) The M1 versus the M1T1 Mga regulon in THY  
It was previously reported that 10% of the genome was regulated by Mga at 
late-logarithmic growth in THY; however, this study was conducted across 3 
serotypes (M1, M6, and M4) using a microarray (229). Our RNA-Seq experiments 
revealed that the Mga regulon in an M1T1 GAS strain under similar growth 
conditions regulated 7.9% of the genome. While RNA-Seq is a much more sensitive 
technique than a microarray, we performed our analysis on only a single serotype 
(M1T1) as, opposed to three serotypes (M1, M6 and M4). Therefore, it is possible 
that the regulon is smaller when only one genome is under consideration. Although 
the M1 and M1T1 serotypes only have a 7% difference between their core genomes, 
and the majority of these differences lie in their prophage content (299), comparison 
of the Mga regulon datasets revealed very little overlap. Only 8 genes were regulated 
by Mga in the same direction, with the majority (5 genes) being the core regulon 
(Table 5.3). The other three genes were lacG (6-phospho-beta-galactosidase), lctO 
(lactate oxidase), and M5005_spy0143 (hypothetical protein). Interestingly, 
M5005_spy0143 was also found to be regulated in the C media dataset (Fig. 5.7 and 
Table 5.2), therefore further experimentation should be done to characterize this 
small hypothetical protein as it is the only gene in common across the three different 
experiments besides the core regulon. Both lacG and lctO are involved in lactose 




production of hydrogen peroxide (H2O2) in a growth phase- and glucose-dependent 
manner through direct repression by CcpA (7). In S. pneumoniae, increase of H2O2 
production acts as a virulence trait that aids in colonization by slowing the clearance 
of bacteria through the inhibition of ciliary beating in the upper respiratory tract and 
by promoting bacteriocidal activity to kill other competing with other naturally 
occurring microflora (300-302). Therefore it’s possible that Mga activates the 
transcription of lctO in order to up regulate hydrogen peroxide production just enough 
to aid in colonization, which is the stage of infection that correlates with the highest 






Table 5.3. Comparison between the M1 and M1T1 Mga regulon in THY at late-log 
MGAS5005 Gene 
name 
Annotation Log2 FC - 
RNA-Seq 
SF370 Log2 FC - 
Microarray 
M5005_spy0143  hypothetical protein 2.54 SPy0169 1.95 
M5005_spy0340 lctO L-lactate oxidase 2.47 SPy0414 1.30 
M5005_spy1632 lacG 6-phospho-beta-galactosidase 2.06 SPy1916 1.59 
M5005_spy1714 fba cell surface protein 3.20 SPy2009 5.59 
M5005_spy1715 scpA C5A peptidase precursor 3.43 SPy2010 5.67 
M5005_spy1718 sic1.0 streptococcal inhibitor of complement 4.63 SPy2016 6.13 
M5005_spy1719 emm1 M protein; Mga-regulated 9.08 SPy2018 6.13 









The THY Mga regulon showed several sugar-specific operons to be activated 
by Mga, which was in contrast to what was observed previously, where all metabolic 
operons were repressed (229). However, for this invasive clinical isolate M1T1 strain, 
it appears that Mga regulates carbon metabolism genes in a manner that mimics what 
was observed for MafR, a recently characterized Mga-homolog and PRD-containing 
virulence regulator (PCVR) that has also been implicated in the pathogenesis of E. 
faecalis (218). Thus, this could present a much more accurate representation of the 
Mga regulon in invasive GAS strains. Regardless of the difference that were observed 
between the microarray and our RNA-Seq results, it is apparent that Mga still 
regulates a variety of genes that are important for adhesion and initial colonization 
and plays as a role, albeit indirect, in regulation of metabolic operons under high 
glucose conditions. As expected, under both media conditions, the genes that showed 
the strongest levels of regulation corresponded to the “core” Mga regulon genes 
(Table 5.2). These genes are defined as those that are directly regulated by Mga (235, 
243) and are located in the Mga locus (emm, sic, scpA, and fba).  
Of note, the cysteine protease, speB, and the SpeB inhibitor (speI) were both 
observed as being repressed by Mga (Appendix 3; Fig 5.4A, light blue bar). It is 
curious, that both the protease and its inhibitor are simultaneously repressed, and may 
point to a feedback loop between these two genes in M1T1 GAS that keeps 
expression levels this virulence factor in under tight control. speB was previously 
observed as being activated by Mga in a serotype specific manner (229), however 
here we observe speB to be repressed. Interestingly, no change in the transcript of 




expression (4). In addition, Mga only activates one gene in the regulatory lacD.1 
operon, lacB.1, in THY at late log. Interestingly, regulation of speB by Mga was 
restored when glucose was added back to C media (Fig 5.10). Taken together, this 
demonstrates that there is a Mga-dependent, glucose-dependent regulation of speB 
within the M1T1 strain 5448. Furthermore, there appears to be several serotype 
specificities for a Mga regulon even amongst closely related strains.  
 (ii) Comparison between THY and C media Mga regulons 
In both THY and C media at logarithmic growth, ~8%  (155 genes, THY; 148 
genes, C media) of the non-prophage genome was regulated by Mga (Fig. 5.4 and 
5.7). Interestingly Mga also affects the same COG categories in both of these medias 
as well (Fig. 5.8); however, there was a stark contrast in the genes represented 
between the two datasets. A total of 16 genes overlapped between THY and C media, 
half of which are a part of the core Mga regulon (Table 5.2, Fig. 5.4 and 5.7). The 
remaining genes, were not previously identified as a part of the Mga regulon (229), 
and therefore could be unique to the M1T1 core Mga regulon. Interestingly, Mga 
repressed both genes (glnH and glnQ) that encode for the putative bicarbonate 
transporter in both medias. Mga has been shown to be activated under elevated CO2 
conditions (238), and this environmental signal may act independent of other 
activation signals, as is seen in other Mga homologs, such as the B. anthracis PCVR 
regulator AtxA and the group G Streptococcus (GBS) DmgB (11). Therefore, a 
potential link between bicarbonate transport and Mga gene regulation may exist. 
Experiments that elucidate bicarbonate transport in a ∆mga mutant may shed more 




also found in both data sets. Since Mga is intimately tied to sugar status of the cell via 
the PTS is would not be surprising that if it directly regulates a sugar hydrolase. Since 
the number of genes that overlap between the THY and C media regulon datasets are 
so few, we propose that this set of these novel 9 genes may also be a part of the core 
M1T1 Mga regulon. Further DNA binding assays need to be performed in order to 
determine if Mga can directly regulate these genes via binding to their promoter 
regions.  
 (iii) Regulation of the M1T1 Streptodornases by Mga.  
Of note, all three phage encoded DNases (spd, sda1/sdaD.2, and spd3) were 
activated by Mga in C media (Appendix 4); however, the chromosomally encoded 
spd was activated in both conditions (Table 5.2). This is not the first instance 
demonstrating that a stand-alone regulator can play a role in regulation of a phage-
encoded streptodornase.  In the M49 strain, NZ131, Rgg was found to bind directly to 
the upstream region of spd3, and directly represses the transcription of this phage-
encoded nuclease (303) (167). Further studies need to be conducted in order to 
determine if Mga can directly bind to this gene and activate its transcription.  
In addition, we also demonstrated that Mga regulates expression of sdaD2 in a 
glucose-dependent manner (Fig. 5.6A, 5.9B, and 5.10). sdaD2 is one of two 
horizontally transferred genes that distinguishes the invasive M1T1 serotype (304). 
This horizontally acquired streptodornase has been attributed to provide selective 
pressure for the switch to the hypervirulent covS- mutant in the M1T1 strain 5448 
(covS+) in vivo (85, 144). However, introduction of the sdaD2-encoding prophage 




(146). There has also been evidence in an alternative covS+ M1T1 train, MGAS2221, 
that the Mga regulon, not Sda1, plays a much more important role in the covS switch 
in vivo (305). Taken together, we hypothesize that during invasive infection with 
covS+ M1T1 strains, where a low glucose environment is encountered, there is an 
alternative activation of the Mga regulon, where there is an increase in sdaD2 
expression (along with other streptodornases) that plays a role in stimulating and 
favoring the switch to a covS- mutant. 
Glucose availability affects Mga phosphorylation and subsequent 
activation of its regulon. 
We observed a 4- to 5-fold repression of some core Mga regulon genes (fba, 
scpA, sic, etc.) in C Media (Table 5.1); however, a significant change in transcription 
of emm was not observed. Since emm is one of the most highly expressed genes in the 
GAS genome, the potential modest levels of reduction that occur in C media are 
above the limit of detection for differential gene expression calculations. There are 
two different possibilities that can contribute to the reduction in expression of the 
Mga regulon in C media when compared to THY: (1) CcpA has been shown to bind 
directly to a cre site located upstream of the P1 promoter region of mga (Pmga P1) 
and stimulate transcription (17). The low-glucose environment in C media relieves 
CCR, as seen by the large overlap between the data generated from our RNA-Seq 
experiments and microarray generated from a ∆ccpA mutant. Therefore, under these 
conditions it is possible that CcpA is released from the cre site upstream of the P1 
promoter region of mga, causing a decrease in mga transcript, and therefore causing a 




possibility for this phenotype is that (2) Mga activity is modulated by the PTS of 
GAS through phosphorylation events on the PRD domains, which directly affects its 
activity and ability to regulate core regulon genes (19, 20). Furthermore, 
phosphorylation of Mga is hypothesized to be connected to availability of a preferred 
carbohydrate source. We believe that the latter scenario is the most probable, as the 
transcript levels of mga were not significantly different between THY and C media, 
indicating that the changes in the regulon exhibited in C media is most likely due to a 
posttranslational modification.  
To test this hypothesis we looked for differential phosphorylation patterns of 
Mga using Phos-tag gel. Phosphorylation is hypothesized to affect the transcription of 
the regulon genes in one of three ways: 1) no phosphorylation produces an active 
Mga, 2) phosphorylation on only PRD2 can cause an increase in activity, and 3) 
phosphorylation on PRD1 inhibits Mga activity, and is dominant over PRD2 
phosphorylation (19) (Fig 5.12). Therefore, we hypothesized that the low glucose 
environment encountered in C media would likely cause phosphorylation on PRD1, 
causing a reduction in Mga activity and regulon expression. In contrast, growth in 
THY (high glucose) would result in an unphosphorylated Mga and remain active. 
Hence this would help explain the activation of the regulon in THY over C media 
(Table 5.1). Furthermore, if this phosphorylation were a direct result of the PTS, we 
would predict that the phosphohistidines would be the target of modification(s), and 
using a phosphoablative construct would eliminate the phosphorylation phenotype 









Figure 5.12. Graphical representation of the hypothesized role of PTS-mediated 
Mga phosphorylation on activity based on the presence of glucose. 
In the absence of glucose, Mga would be inactivated through phosphorylation of 
PRD1, regardless of the presence of an inducer. However, when glucose and inducer 
are present, Mga is not phosphorylated at either PRD and is active. In the presence of 
glucose only phosphorylation of Mga PRD2 leads a more dramatic increase in 







 Surprisingly, under the conditions tested in this study, when the WT M4 Mga 
was grown in THY, two bands were observed on a Phos-tag gel, corresponding to a 
phosphorylated and unphosphorylated species. In C media, only an unphosphorylated 
Mga was observed; the same pattern was seen for the phosphoablative (A/A/A) 
construct under both media conditions (Fig 5.3). Therefore, we now hypothesize that 
in C media, Mga still may be in its “active” form (condition 1), and THY represents a 
“hyper active” form of Mga (condition 2). This would be in line with the model that 
was previously proposed by Hondorp et al. (19), since glucose is present in both THY 
and C media. Therefore, it may not only be the level of glucose that is important for 
Mga activity, but the mere presence of it. Furthermore, since we observed only a 
nonphosphorylated band for the A/A/A construct in both C media and THY, this 
indicates that the phosphorylation is occurring at the phosphohistidines. However, 
this experiment does not verify which phosphohistidine(s) this is occurring at, 
although we hypothesize that it is located on PRD2 (H324). In order to confirm this, a 
Phos-tag gel would need to be performed on a Mga mutant that changed both 
histidines on PRD1 to alanines (A/A construct). If the banding pattern is identical for 
this strain when grown in THY as the WT grown in C media, it would implicate that 
the phosphate on PRD2 is responsible for the banding pattern observed in this study. 
Taken together, this is the first study that identifies that glucose is the sugar that 
dictates the activity of Mga, and the phosphorylation by the PTS occurs at the 
phosphohistidines on the PRD domains of Mga.  
As discussed above, Mga has very different regulons in high versus low 




regulating genes is dependent on the level of glucose, we hypothesized that C media 
supplemented to 0.5% glucose should show a reversion to the phenotypes observed in 
THY. Indeed, out of the 6 genes that were specific to the C media regulon, 5 that 
were tested via qPCR showed a glucose specific phenotype (Fig. 5.10). However, we 
also saw differences in the regulon (Fig. 5.10; opuAA) that are most likely due to 
broader attributes of C media itself. In order to further confirm that glucose is the 
inducer of the effect observed here, it would be important to conduct a Phos-tag gel 
comparing the WT Mga in THY, C media, and C media-0.5% glucose. Based on our 
data, we would expect the lack of phosphorylation on the WT that was observed in C 
media would now have a phosphate(s)-specific band, and mirror what was seen in 
THY.  
Taken together, this work shows that glucose directly affects Mga activity and 
the composition of the Mga regulon. Furthermore, the differences between the 
regulons at varying glucose levels is most likely attributed to a phosphorylation event 
that occurs on the phosphohistidines located on the PRD domains of Mga. While it is 
unclear which phosphohistdine(s) are affected and the mechanism by which Mga is 
able to regulate genes alternatively, it is clear that in the presence of glucose, the PTS 
plays an important role in activating this global transcriptional regulator and virulence 
genes downstream.  
 
 
**Author contributions: K.M.V. performed the research for all the sections. A.T.B. aided in RNA-Seq 





Chapter 6: Identification of critical amino acids necessary for 
Mga dimerization and transcriptional activation 
Introduction 
The group A streptococcus (GAS) relies on the timely expression of a wide 
range of virulence factors in order to successfully evade the host immune system and 
cause infection (3). Expression of virulence determinants are under tight control by 
multiple regulatory networks, which include two-component signal transduction 
systems (TCS) and “stand-alone” regulators, in order to produce adaptive responses 
to the host environment (10). The multiple gene activator of the group A 
streptococcus, or Mga, is a highly conserved stand-alone regulator that is ubiquitous 
in GAS (219, 220). It activates the transcription of a variety of virulence factors 
important for immune evasion and adhesion, including the M and M-like proteins, 
during exponential phase growth. Expression of the Mga regulon is also dependent on 
different environmental signals such as increased CO2 levels, body temperature, and 
exponential-phase growth (238, 239). Mga activity is also dictated by the sugar 
utilization status of the cell via its PEP-phosphotransferase system (PTS) regulation 
domains (PRDs), demonstrating that virulence factor production is intimately linked 
to carbohydrate utilization in GAS. Thus, Mga has been categorized as a PRD-
containing virulence regulator, PCVR, which is part of a broad family of Gram-
positive virulence regulators whose activity is dictated by carbohydrates (19).  
GAS strains have been divided into two classes; Class I strains contain the 




serotype) (306). The two different mga alleles share approximately 88% sequence 
identity and can complement each other across serotypes, indicating functional 
similarity (307). Mga is a 530 amino acid protein with a molecular weight of 62 kDa 
comprised of six domains. The amino-terminus contains a three domains (CMD, 
HTH-3, wHTH-4) that are all important for DNA binding (235, 308). Mga also 
contains PRD-1 and PRD-2, which directly phosphorylated by the PTS to modulate 
functional activity (19). The carboxy-terminus was originally suggested to have 
structural similarity to a CheY-like receiver domain (223). However, in silico (282) 
analysis later determined that this region shared close homology to an EIIBGat-like 
domain (Fig 6.1). (251). Interestingly, while Mga is highly homologous across all 







Figure 6.1. Mga EIIB domain is necessary for full activation.  
Schematic representation of Mga, shown are the N-terminal regions implicated in 
DNA binding (CMD-1, HTH-3 and HTH-4) and the central two domains have 
structural homology to PTS regulatory domains (PRD-1 and PRD-2). The C-terminal 
region with structural homology to an EIIB domain is depicted. Lines representing 
the different C-terminal truncation mutants and their effect on Mga activity; only the 






Hondorp et al. utilized different truncations in the C-terminus of a M4 Mga to 
establish its effect on Mga activity. Two mutants that deleted either the last 29 or 47 
amino acid residues, removing the non-conserved region of the protein, showed no 
functional difference in activation of arp and sof, two genes that are a part of the 
Class II Mga regulon. However, a mutation that deleted the last 139 amino acids 
(∆139-Mga4), which eliminates the putative EIIBGat-like domain, led to a significant 
decrease in Mga activity and also loss of oligomerization. This truncation did not 
affect the ability for Mga to bind DNA. Importantly, this phenotype was recapitulated 
in an M1 serotype as well (237). Therefore, while Mga needs its helix-turn-helix 
DNA binding domains in order to bind to its core regulon genes, this activity is not 
sufficient for full Mga activity, and oligomerization is critical for full activation of the 
Mga regulon in vivo across all serotypes.   
The E. faecalis protein MafR, a Mga homolog with unknown functional 
activity, has a readily available crystal structure deposited in the Protein Databank 
(PDB 3SQN) (217); however, a crystal structure for Mga is not available. Therefore, 
using the information concurrently available from both Hondorp et al. and the MafR 
protein structure, a modified bacterial two-hybrid screen (311) was undertaken using 
an M1 Mga in conjunction with low-frequency random mutagenesis of the carboxy-
terminal region, which aimed at identifying amino acid residues that were critical for 
Mga oligomerization and activity (310). Subsequent to the two-hybrid study, a crystal 
structure for the established Mga homolog and PCVR AtxA from B. anthracis was 
published (PDB 4R6I) (216). In this study, we used the results generated from the 




characterized the amino acid residues that were shown to abrogate Mga dimerization 







Expression of the Mga1 EIIB-mutants shown to abrogate Mga 
oligomerization in E. coli.  
A bacterial two-hybrid screen revealed 20 different mutations that showed a 
loss of interaction with the wild type Mga. Out of 20, 17 contained single amino acid 
substitutions, and 3 contained a frameshift insertion. Given they would likely not 
produce a full-length Mga, the 3 frame-shift mutants were disregarded in our analysis. 
We also identified two amino acid residues that were found more than once in the 
screen (T458 and M461). Interestingly, the mutations that were identified appeared to 
cluster within two distinct regions in the EIIB domain (Fig 6.2; red triangles). We 
also identified single amino acid substitutions that generated a positive interaction 
phenotype (Fig 6.2; green triangles), which were subsequently used as a positive 















Figure 6.2. Localization of mutants identified in a bacterial two-hybrid screen.  
A random mutagenesis approach was used to generate a low-frequency mutation rate 
in the EIIB region of Mga. These mutants were then screened in a two-hybrid system, 
and mutants showing lack of interaction (white colonies) were mapped. A total of 17 
individual amino acid substitutions (red triangles) were identified, mutations that 
generated positive interactions were also found (green triangles). Residues that were 







 One explanation for a negative interaction phenotype would be the inability to 
produce Mga; therefore, mutants were verified for production of a functional protein. 
Attempts were made to express the proteins in their original strains used in the 2-
hybrid screen (contains both bait and prey plasmids). However, due to the similarity 
in size between the two adenylate cyclase fragments (T25N, ~88kDa; T18N; 
~84kDa), we could not resolve the two bands by SDS-PAGE for comparison by 
western blot. We next attempted to resolve the two plasmids from the original 
background by using a limited dilution approach. Plasmids (pT25N-xxxx) were 




the E. coli cya- strain BTH101 (D. Kearns, gift) or C43 [DE3] (248) with appropriate 
antibiotic selection. Strains were grown, induced and whole cell lysates were then 
analyzed for Mga expression by western blot. Despite several attempts, we were 
unable to observe expression of full-length Mga for any of the original mutants 
generated in the EIIB screen or positive controls in either background (data not 
shown). 
Expression of select Mga mutants in GAS.  
Due to the expression issues encountered with the 2-hybrid constructs in E. 
coli, we generated a representative group of mutants that were found in the screen via 
site directed mutagenesis (SDM) in a native M1 mga background. A total of 7 
different EIIB mutants were constructed (K425A, F430Y, S432G, N435S, and 
M461I), two of which were dimerization controls (L409F and D445V), generating 
plasmids pKSM935-941 (Table 3.1, and Fig. 6.2). The EIIB mutant plasmids were 
expressed from their native promoter (Pmga1), and transformed in a M1 ∆mga 
background strain, KSM165L. Using this approach, we were able to express 5 out of 
the 7 EIIB mutants, including the two dimerization controls (K425A, F430Y, S432G, 
L409F and D445V). Interestingly, one of our dimerization controls, D445V, runs at a 
slightly smaller protein, however a similar phenotype was observed before, when 
other mutations in Mga were generated (19).  Importantly, each of these mutants 















































Figure 6.3. Expression of site-directed EIIB mutants of M1 Mga in GAS.  
Western blot of whole cell lysates of the EIIB and PRD mutants compared to WT 
Mga1 and ∆139-Mga1 expressing using α-Mga1. Predicted size for ∆139-Mga1 is 









Mapping of Mga4 onto the crystal structure of AtxA. 
The B. anthracis master regulator, AtxA, controls the expression of a variety 
of virulence genes including toxin and capsule production (213). AtxA is a functional 
homolog of Mga and a member of the PCVR family of transcriptional regulators. The 
crystal structure of AtxA was recently resolved by Hammerstrom et al. to 2.4-3.1 
angstrom (Å) resolution (PDB accession number 4R6I) (216). Contrary to what was 
observed with E. faecalis MafR, where both EIIB domains on each monomer act as 
the dimer interface, the AtxA dimer utilizes the EIIB domain of one monomer and the 

























Figure 6.4. Alignment of Mga1 and Mga4.  
Mga homologues are found in all serotypes of GAS and are highly conserved, 
however the C-terminus of the protein seems to exhibit a high degree or variability. A 
pBLAST alignment of the Mga1 and Mg4 protein demonstrates differences between 
these two strains (red letters), with conserved residues indicated as a dot.  Highlighted 






In collaboration with Dr. Osnat Herzberg (IBBR), we were able to thread an 
M4 Mga amino acid sequence onto this newly available crystal structure. The 
programs, Raptor (312), I-tasser (313), and Robetta (314) were each used to 
determine the best structure of Mga4. As stated earlier, Mga1 and Mga4 posses 88% 
sequence identity (307) (Fig. 6.4), and M4 Mga was initially chosen for comparison 




I-tasser computed the model with a high degree of probability, and both shared a 
significant similarities between the outputs, and were therefore chosen for further 
analysis (Figure 6.5). 
Interestingly, while the N-terminus of the protein mapped perfectly to the 
AtxA crystal structure, the segment of the protein immediately after PRD2 (aa 391-
530) was very hard to map and remains relatively unstructured. This is attributed to a 
large insertion that Mga possesses between the last helix of PRD2 and the EIIB 
domain. This indicates that Mga has a unique tertiary structure in the C-terminal of 












Figure 6.5. AtxA-based structure of C-terminal Mga interactions.  
Shown is a modular 3-dimensional structure of the Mga dimer as deduced from the 
crystal structure of AtxA. Mga was threaded onto the AtxA crystal structure using the 
Raptor and I-tasser protein modeling programs. Two Mga monomers are shown in 
dimer conformation. The N-terminals are depicted in cyan (dimer 1) or pink (dimer 2) 
and the PRD and EIIB domains are shown in green (dimer 1) or yellow (dimer 2). 





Identification of PRD2 interaction residues.  
Since the original region targeted in the bacterial two-hybrid screen was based 
on the MafR crystal structure, which shows the EIIB domain as the sole interaction 
region for dimerization, PRD2 was never interrogated. However, given the new 
information provided by the AtxA crystal structure, it was possible that both the 
PRD2 and the EIIB domains of Mga are critical for dimerization. Therefore, the 
predicted Mga4 crystal structure (using both Raptor and I-Tasser) was used to 
identify several residues in PRD2 that were putative interaction partners with the 
EIIB domain. Raptor identified residues I381, Y387, or E394, whereas I-tasser 
identified: Y387, I391, F397, E394 as putative residues critical for dimerization. 
Since they were found in both models, we chose to modify both Y387 and E394 via 
alanine substitutions (Table 3.1; pKSM942 and pKSM943). In addition, both 
residues putatively interact with residue K425 on the EIIB domain (Figure 6.6), a 
residue that was identified in the two-hybrid screen, and expressed in western blot 
assays (Fig 6.3). After creation of the site-directed mutants, Y387A and E394A, we 
tested their expression in the M1 ∆mga GAS background KSM165L using western 
blot with α-Mga1 antibodies; both showed expression comparable to WT Mga1 levels 













Figure 6.6. Interactions of Mga-PRD2 with residue K425 during dimerization.  
Two PRD2 residues, Y387 (yellow; A) and E394 (green; B) show putative 
interactions with residue K425 (orange) located on the EIIB domain. *Performed by 




Functional activity of Mga EIIB mutants.  
To determine the in vivo effects of the EIIB mutants on Mga activity, RNA 
was isolated from strains grown in THY to late exponential phase. Mga activity was 
then assayed by real-time qPCR using the Mga-regulated virulence gene encoding for 
the M protein (emm). Changes in transcript levels for the EIIB mutant strains that 




Mga1 were considered significant (Figure 6.7, dotted line). The F430Y, N435S, and 
M461I showed a significant decrease in transcript levels for emm compared to the 
wild type strain. Interestingly, one of our dimer interface positive controls, D445V, 



































































Figure 6.7. In vivo activity of putative residues critical for dimerization.  
Mga activity was assayed in vivo by real-time qPCR analysis of the Mga-regulated 
gene emm. Positive dimerization controls are shown in green, the PRD2 mutant is 
shown in dark red, and the EIIB mutants are shown in red. The ∆139-mga1 (light 
grey) and empty vector ∆mga (dark grey; pJRS525) results are shown alongside for 
comparison. Relative transcript levels for each strain compared to the wild type are 
presented. Error bars represent the standard error from at least three biological 
replicates. Differences greater than two-fold in expression were considered significant 
(dashed line). Mutants bolded and red are those that were expressed and showed a 
functional defect in emm activation, and only bolded indicates those mutants that are 






Although M461I and N435S showed a decrease in transcript levels of emm, 
with M461I showing a decrease comparable to both the ∆139 and the empty vector 
strain, this is most likely due to the lack of expression of a full-sized protein (Fig. 
6.3). Unfortunately, the mutation in residue K425, which was predicted based on the 
mapped crystal structure to be critical for interaction with PRD2, showed no 
significant effect on Mga activity. Therefore, out of the 9 site-directed mutants that 
were constructed, 6 showed expression in GAS, and only two showed a significant 
decrease in Mga transcriptional activation, albeit not to the levels of either the ∆139-





While it has recently been established by our laboratory that the C-terminus 
plays an important role in both Class I and Class II Mga dimerization and activation 
(251), the exact residues that are important for this interaction have yet to be 
established. This study is the first to look at individual residues within the C-terminus 
of M1 Mga in order to characterize their functional importance. Furthermore, while 
Mga has been modeled to the AtxA crystal structure previously using I-Tasser (20), 
this is the first time that Mga was modeled using multiple structure prediction 
programs in order to help predict residues involved in the interactions between the 
EIIB domain that are important for dimerization.  
 
General mutability and protein stability of Mga’s C-terminus. 
Interestingly, while there were 17 mutations that were found to abrogate Mga1 
dimerization using the two-hybrid screen, we experienced difficulty in obtaining full-
length expression of these Mga mutants in E. coli. We attribute this to the potential 
stability of the adenylate cyclase fragment (T25N) when fused to Mga, since we 
observed degradation products but never a full-length (~84 kDa) protein (data not 
shown). The two adenylate cyclase fragments, T25 and T18, may aid in stabilizing 
protein expression in order to have a functional two-hybrid system. However, when 
one fragment is removed, induction and expression of a single fragment fused to the 
protein of interest may result in a protein that is susceptible to degradation.  
To overcome this issue, we generated 7 representative site-directed mutants 




were experiencing in E. coli, it did not resolve the issue of protein expression for 
some of the mutants. We were only able to express a full-length Mga in 5 out of the 7 
constructed mutants; N435S and M461I were never observed by western blot of GAS 
whole cell lysates. In addition, when expressing PRD mutations predicted as 
interaction partners with K425, both Y387A and E394A were expressed. In 2006, 
Vahling et al. conducted a screen using a Pemm-gusA reporter that aimed to identify 
domains critical for Mga activity. While the study identified 272 C-terminal mutants 
that showed little to no functional Mga activity, western blot analysis revealed that 
none produced wild type levels of protein (308). Taken together with our results, this 
suggests that the C-terminus of Mga is extremely sensitive to mutagenesis, and the 
majority of mutations result in the inability to produce a full-length protein in GAS. 
These results support the importance of the C-terminus and EIIB domain in Mga 
structure and function, but further study of this region will be very difficult and 
another method of identifying amino acid residues critical for Mga dimerization may 
be required. This could be potentially accomplished using chemical cross-linking 
assays, as was done originally for the Mga homolog, AtxA, prior to the availably of 
its crystal structure (215). 
 
Amino acids important for full activity of Mga. 
(i) F430 and D445 play a role in Mga1 dimerization and activation 
Out of the original 7 residues that were interrogated by mutagenesis, only two 
(F430 and D445) were able to express full-length Mga at levels comparable to wild 




of the Mga-regulated gene emm (Fig. 6.7, bold and red). Based on the modeled 
crystal structure of the M4 Mga, it appears that both F430 and D445 face away from 
the dimer interface (Fig. 6.8AB). However, the exact positioning and interaction that 
these key residues in Mga may be altered in the AtxA-modeled Mga. As mentioned 
above, the threading of the C-terminus of Mga was extremely difficult due to a large 
insertion between the last helix of PRD2 and the EIIB domain in Mga that is not 
present in AtxA. This insertion may alter the exact positions of both F430 and D445 
in Mga, and these residues may actually be closer to the dimer interface than 
predicted by the model.  
Surprisingly, one of the original amino acid substitutions that was chosen as a 
control that would not effect dimerization based on its 2-hybrid phenotype, actually 
showed a decrease in transcriptional activation of emm. We attribute this finding to 
two possibilities: (1) it was a false positive in the original bacterial two-hybrid screen. 
Since none of the residues found were screened in the opposite direction, where EIIB 
mutants were cloned into the T18 containing vector and screened against the wild 
type T25-Mga1, it is possible that this mutation could have been missed as an actual 
negative interaction. (2) It has no affect on Mga dimerization, but does affect Mga 
activity. We believe that the latter is most likely outcome since it showed a positive 
interaction in on iteration of the two-hybrid screen. Regardless, it is clear that a 
mutation in either F430 or D445 results in a decrease in Mga activity, and potentially 
disrupt dimerization. Of interest, neither F430 nor D445 showed a decrease in activity 
to the levels of either the ∆139-mga or ∆mga strains. Therefore, a single mutation 




implicated in these types of interactions. In order to further confirm these two mutants 
















Figure 6.8. Localization of residues important for Mga dimerization and activity.  
Shown are F430 (cyan, A), D445 (orange, B) and M461 (green, C) on one monomer 






(ii) M461 plays an important role in the conformation of Mga. 
A mutation in residue M461 was identified twice (M461I and M461K) in the 
two-hybrid screen as potentially abrogating Mga-Mga interaction (Fig. 6.2). Further 
analysis of this residue showed that it exhibited over a 100-fold decrease in 
transcriptional activity (Fig. 6.7). However, when this residue was tested for 
expression of Mga using Western blot analysis (Fig. 6.3), it was not shown to express 
a full-length protein. Upon alignment of primary amino acid sequences for Mga from 
multiple GAS strains, it was noted that the methionine residue at position 461 was 
conserved among all Mga proteins.  
A previous study compared two Class II mga alleles found in M50 and M4 
GAS that are nearly identical at the amino acid level, yet the M50 strain is defective 
in activating downstream Mga-regulated genes (309, 315, 316). Vahling et al. found 
only three non-conserved amino acid between these two mga alleles. Interestingly, 
one of the residues containing an amino acid substitution was residue 461, where the 
methionine was changed to an arginine in the M50 strain (316). This study also 
showed that the levels of Mga produced by the wild type M50 strain was not 
equivalent to either the M4 Mga or a M50 Mga R461M mutant. In addition, a reporter 
assay using the promoter of the Mga regulated gene mrp (Pmrp-gusA) showed the 
M50 strain had a 52% decrease in transcriptional activation in comparison to M4 and 
to an M50 strain that was restored the amino acid residue to a methionine (R461M) 
(316). Of particular interest, this study also tested the importance of this residue in the 
Class I M6 strain JRS4, and no significant difference was seen either protein 




that JRS4 is a lab-adapted strain that exhibits an altered Mga regulon from other GAS 
strains (229). This could therefore attribute the differences seen from this study.  
 Taken together, residue M461 is of great importance to the stability of Mga as 
demonstrated both here and in other studies (315, 316). This is can be attributed to 
position 461 being essential for correct protein conformation, and any amino acid 
substitution could lead to a protein that is sensitive to degradation. This also points to 
the importance of the correct conformation of the EIIB domain for overall protein 
stability, since very few mutations generated a fully functional protein in several 
studies. Therefore, it is possible that Mga may need to exist in a dimer within the cell 
in order to be fully functional and not be susceptible to degradation. In order to test 
this hypothesis, further work is needed. In vivo dimerization assays, such as a native 
gel can be used to answer this question.  
While, it is yet unclear the physiological implications these amino acid 
mutations studies here cause on Mga dimerization, it is clear that several affect Mga 
activity. Overall, this study has elucidated two potential residues, F430 and D445, 
located in the EIIB domain that have implication on Mga activation, and thus could 
have effects in dimer formation. In addition, a mutation in residue M461 has been 
proven in multiple studies to cause a general destabilization of Mga, and thus 
generates a complete loss of protein expression and down-stream gene activation. 
 
 
**Author contributions: A.M.K. performed the two-hybrid assay. A.M.K. and K.M.V. performed the 
research on expression of the EIIB mutants in E. coli. O.H. performed threading of Mga crystal 




Chapter 7: Conclusions and Recommendations 
 
 
The Group A Streptococcus (GAS) is a strict human pathogen that is capable 
of causing a wide range of diseases in diverse niches in the host. In order to adapt to 
these locations, GAS utilizes environmental cues, such as carbohydrates, to act as a 
signal to coordinate the expression of virulence factors. Research efforts to date have 
focused on identifying how either components of the phosphoenolpyruvate-
phosphotransferase system (PTS) or global transcriptional networks affect the 
regulation of virulence factors, but not the synergistic relationship between the two. 
In this dissertation, the role of putative PTS-fructose sugar transport operon in GAS 
pathogenesis and sugar utilization was investigated. In addition, while it is known that 
the PTS can affect activity of the Mga virulence regulator, further characterization of 
the mechanism by which sugars and its protein domains affect its activity have not 
been studied. Here, two aspects of Mga activity were investigated: (1) how glucose 
availability affects Mga activity and changes the dynamics of its regulon, and (2) how 
amino acid interactions aid in the formation of Mga homodimers, a target of PTS 
regulation, and activate transcription of regulon genes. Overall, this dissertation 
sought to shed light on how external environmental cues, specifically carbohydrates, 
control complex regulatory networks used by GAS to adapt to various nutrient 




Fructose metabolism by the M1T1 GAS 
The PTS is the main system that is utilized by bacteria for the uptake of sugar 
and sugar derivatives as well as for signal transduction (180). The GAS genome 
encodes for 14 putative sugar-specific EII proteins (197), whereas EI and Hpr are 
common for metabolism of all the carbohydrates imported in the cell. In this 
dissertation, the fruRBA operon, its role in fructose metabolism and utilization in the 
physiology of the M1T1 GAS was characterized. The clinical isolate, 5448 was 
utilized as a representative of the M1T1 serotype, which is the most common serotype 
associated with invasive infection worldwide.   
The global transcriptional changes of wild type 5448 grown in chemically 
defined media supplemented with either glucose or fructose showed that the fruRBA 
operon was the most highly induced followed by several other sugar-specific PTS 
operons. There are three potential mechanisms by which fructose could enter GAS: 
(i) the predominant pathway in Gram-positive bacteria involves the canonical PTSfru 
EIIABC (fruA/fruI), a 1-phosphofructokinase (fruB/fruK), and a fructose-responsive 
regulator (fruR); (ii) an alternate PTS that recognizes and translocates fructose as 
fructose-6-phosphate (F6P) with lower affinities than (i), and; (iii) facilitated 
diffusion transport using a membrane spanning permease that would esterify free 
fructose at position-6 using ATP (287). The induction of fruRBA by fructose in GAS 
suggests (i) is the main pathway; however, induction of other PTS systems (e.g., 
lacD.1, lacD.2) suggests that mechanism (ii) may also play a role in fructose 
utilization. Thus this raises the question of the role other PTS operons play in the 




characterize of all 14 EII sugar-specific transporters and their specificity for 
transporting sugars. Interestingly, current data indicates that several PTS EII’s are 
redundant in their ability to transport a single sugar. However, the reason behind this 
redundancy is not understood and will need to be explored further. Furthermore, 
questions remain in regards to the EII transporters, such as, 1) how the does the 
chemical structure of the sugar affect its ability to be transported by certain EIIs? 2) 
Does the specificity for the sugar(s) the EII transports come from the structure of the 
protein itself or another mechanism? 
sloR and its regulon were also activated in fructose. SloR was initially 
implicated in streptolysin O expression (277), but more recently was shown to be 
involved in serine acquisition (276). This gene shows significant homology to a 
fructose EIIC transporter based on in silico analysis (282), thus suggesting that it 
might play a role in the transport of fructose (ii, intake as F6P) and potentially aid in 
signal transduction to coordinate gene expression. However, a sloR mutant did not 
show any significant effect on utilization of fructose or any other PTS sugar by GAS. 
In other Streptococcus and Listeria species, orphan EIICs have been suggested to act 
as environmental sensors that interact with other regulatory proteins to influence gene 
expression (317, 318). It is possible that SloR serves a similar sensory role in GAS, 
and this hypothesis still needs to be investigated.  
Prior to this study, functional characterization of only one of the putative PTS 
EIIs encoded in the GAS genome has been carried out so far. This resulted in a 
discrepancy between the predicted function of the EII and the experimentally 




annotation does not necessarily follow functionality. fruA (encoded in the fruRBA 
operon) encodes one of the 13 other uncharacterized EII PTS sugar-transporters 
found in the M1T1 GAS genome. Interestingly, deletion of fruA showed a defect in 
the utilization of 3 other PTS sugars (N-Acetyl-D-Galactosamine, Cellobiose, and 
Mannitol) using two carbon utilization assays. Although a fruA mutant could utilize 
fructose, it exhibited a significant growth defect when this sugar was the sole carbon 
source available. Residual growth was observed for a fruA mutant, and this can be 
potentially attributed to the activation of other EII PTS transporters that were 
observed in the RNA-Seq data, however the exact role of these alternative fructose 
transporters need to be confirmed. In addition, questions still remain on why FruA 
affects the utilization of the three alternative PTS sugars, and how the metabolism of 
those sugars feed into gluconeogenesis through FruA. In addition, a definitive 
experiment confirming the transport of fructose into the cell is necessary to 
conclusively state that FruA is the main transporter of fructose. 
FruR was demonstrated to be the fructose repressor through transcriptional 
assays, and is necessary for growth in fructose. However, demonstration that FruR 
can directly bind to its recognized sequence has not been shown and will need to be 
explored further. The physiological inducer of FruR de-repression is fructose-1-
phosphate (F1P) and only 1 mM of F1P is sufficient to disrupt FruR binding to its 
operator in P. putida (284, 285). Fructose-1-phosphate is also the inducer of the 
fruRBA operon in other Gram-positive species, such as L. lactis (275).  This correlates 
with FruR being a member of the DeoR-family of repressors, which are typically 




272, 275). However, the role of F1P in derepression of the fructose operon in GAS 
has yet to be explored. The question still remains if FruR is able to bind F1P and 
subsequently relieve repression of the fruRBA operon. 
FruB encodes for 1-phosphofructokinase, the enzyme that converts F1P to 
FBP. Surprisingly, a fruB mutant exhibited a significant growth defect in fructose. 
This is likely due to the fact that the fruB mutant (5448.∆fruB) would be expected to 
build up F1P due to an inability to convert it to FBP following transport by FruA. 
Since the majority of intracellular fructose cannot be further metabolized, 
gluconeogenesis of FBP for glycolysis would be blocked thus resulting in growth 
arrest. 
Results presented in this dissertation demonstrates that not only FruA, but also 
FruB (1-phosphofructokinase) and FruR (DeoR-family repressor) are necessary for 
metabolism and growth on fructose, and the fruRBA operon is the primary transporter 
of fructose in M1T1 GAS. This is further supported given that fruRBA is the only 
operon that encodes a 1-phosphofructokinase (M5005_Spy_0061; fruB) in the 5448 
genome (i, above) (319). Additionally, this operon has been confirmed as the primary 
transporter of fructose in several other Gram-positive bacterial species (272, 275, 278, 
283). However, several questions are left unanswered about the complex metabolism 
and transport of sugars in GAS. In particular, studies will be necessary to determine 




fruR and fruB contribute to GAS pathogenesis in a human-specific 
manner. 
Several PTS EIIs have been implicated in the pathogenesis of low-G+C 
Gram-positive bacteria, including the fructose-specific PTS system in other 
pathogenic species of Streptococci (272, 273). The putative fructose-specific EII 
(fruA) was originally identified as important for GAS fitness during growth in whole 
human blood in a TraSH screen performed in our lab (15), however this study showed 
that a fruA mutant did not exhibit a virulence defect. However, in the current study, 
non-polar defined GAS mutants in fruR and fruB, but not fruA, exhibited a significant 
survival defect in whole human blood as well as within neutrophil-like HL60 cells, 
human neutrophils, and peripheral blood monocytic cells or peripheral blood 
monocytic cells (PBMCs). One possible explanation for the lack of a fruA phenotype 
here is that TraSH screens are based on large libraries of mutants that must compete 
to survive. Therefore, fruA may only show a defect in blood survival and killing by 
phagocytes in a competitive environment, and a competition assay in whole human 
blood or PBMCs may elucidate this further. Furthermore, fruR and fruB may have not 
been identified in the original TraSH screen because it relied on a GAS 
oligonucleotide microarray that was found to miss almost 40% of the genome due to 
technical limitations of hybridization and array probes (15). Regardless, because fruA 
was not found to be important for GAS survival in human blood or neutrophils, this 





The virulence defect exhibited in either whole human blood or neutrophils by 
a fruB mutant is hypothesized to be attributed to its enzymatic activity (F1P 
conversion to FBP). This is not the first study in GAS demonstrating PTS-related 
enzymes having an effect on virulence outcomes. The GAS tagatose-1,6-bisphosphate 
aldolase (LacD.1) enzyme has been adapted to play a regulatory role in controlling 
expression of the SpeB exotoxin through interacting with the transcriptional regulator 
RopB (4). LacD.1 still functions as an aldolase, although it is not the preferred 
aldolase used in galactose metabolism in GAS (297). Therefore, a metabolically 
functional enzyme can play a regulatory role via indirect interaction with regulatory 
proteins. However, the question remains as to the mechanism by which FruB is 
impacting immune evasion. Thus the following questions remain: Does FruB directly 
interact with a transcriptional regulator? If the virulence defect is attributed to a build 
up of F1P, and therefore a direct result of a lack of enzymatic activity through FruB, 
how does this act as a signal for the cell? In turn, this raises the question if FBP acts 
as more than an intermediate for gluconeogenesis and can actually be a regulatory 
signal for GAS and affect pathogenesis? Making a mutation in the catalytic domain of 
FruB, which presumably will cause a build up of F1P, and observing the effect of this 
mutation on GAS pathogenesis can help answer these questions. Additionally, if it is 
not the build up of F1P but an interaction of FruB with another regulator, this 
catalytically inactive mutant may be able to complement the virulence defect 
observed in a ∆fruB strain.  
FruR also exhibits decreased survival in either whole human blood or 




of fruB, which suggests that there is a stoichiometry effect during the buildup of 1-
phosphofructokinase in the cell that leads to a defect in immune evasion. It is unlikely 
that FruR is regulating other virulence factors as a canonical FruR binding site (275) 
only occurs once in the genome, upstream of FruR. However, this cannot currently be 
ruled out and needs to be investigated further as GAS may have an alternative 
consensus for FruR binding. In addition, although RNA-Seq would provide 
information with regards to whether FruR is capable of regulating virulence genes, it 
would be difficult to perform this experiment due to the growth phenotype FruR 
exhibits in fructose. As an alternative, RNA-seq could be performed in glucose as an 
alternative, however if fructose is the primary signal for this gene and the fru operon, 
it is possible that a phenotype would not be observed under these conditions. 
Although the fruB and fruR phenotypes observed in this study are most likely 
not due to a fructose-specific signal, the RNA-Seq results of the WT 5448 in fructose 
did reveal three virulence related genes to be up regulated during growth on fructose. 
These genes and the proteins that they encode for are as follows: M5005_spy_0798 
(IFN-response binding factor 1), M5005_spy_1629 (Lantibiotic transport ATP-
binding protein salX), and M5005_spy_1631 (Lantibiotic salivaricin A). However, it 
is important to consider for further studies the environment to conduct these 
experiments in. The neutrophil/whole blood environment is different from CDM + 
fructose/glucose, therefore, the transcriptome results generated in CDM are not 
necessarily representative of the ex vivo environments. While the regulation of these 
genes is fructose-dependent, they are not necessarily fruR/B-dependent, and this 




hypothesis that the virulence defect is attributed to a signaling effect due to feedback 
of fruB/R. 
Surprisingly, we were unable to observe a virulence phenotype for either fruR 
or fruB during an intraperitoneal (i.p.) model of infection or during growth in whole 
mouse blood. Recapitulation of human disease in a susceptible laboratory animal has 
been the gold standard for pathogenesis since the inception of Koch’s postulates. 
Host-pathogen research has favored mouse models due to reduced cost, 
reproducibility, and availability of reagents, amongst others. However, this poses a 
challenge with testing human-restricted pathogens in mice, where striking differences 
in the immune system between these two species can lead to varied disease 
progression. Immune system differences can cause misleading results as has been 
seen with using mouse models to identify protective antigens for a S. aureus vaccine, 
where identified targets in mice have not been a good predictor of outcomes in human 
clinical trails (320). Of particular note, the composition of blood between the two 
species is quite different; human blood is neutrophil rich (50-70% of blood), whereas 
mouse blood has more circulating lymphocytes and fewer neutrophils (10-25% of 
blood) (321). Therefore it is necessary to investigate what component(s) of whole 
human blood, which are not present in murine blood, are necessary for clearly GAS 
infections. This leads to the question whether or not the mere difference in neutrophil 
composition between these two species blood is enough to cause a difference in 
virulence? Or if it is a difference in recognition of the pathogen itself, and a host-





Furthermore, to elicit disease in a mouse, the inoculums of GAS required are 
often several times higher than what would be needed in humans (5, 8, 160, 322, 
323). It can also be difficult to reiterate certain GAS diseases in mice. Mice do not 
elicit symptoms of GAS pharyngitis (strep throat) when infected intranasally or in the 
pharynx directly. An in vivo model of streptococcal impetigo, one of the most 
prevalent forms of non-invasive disease (1), required the grafting of human foreskin 
onto huSCID mice (324). Known GAS virulence factors, such as streptokinase (325, 
326) and protein H (327) (328), were not testable until the development of humanized 
mice expressing either human plasminogen (329) or human C4BP/Factor H (330), 
respectively. Additionally, murine T cells appear not to proliferate and respond to 
GAS superantigens such as SMEZ, SpeG, or SpeC, while human T cells do (331). 
Taken together, it would appear that coevolution between the human immune system 
and GAS has resulted in adaptation to its natural host environment.   
It cannot be ruled out, nevertheless, that the i.p model of infection was not the 
appropriate environment to exhibit a virulence phenotype for either fruB or fruR. 
Virulence genes and their transcriptional regulators are often implicated in specific 
stages of infection and growth. It would be important to attempt virulence studies 
using several different models of infection, for example the subcutaneous model of 
infection since it was shown that a mutant in EI of the PTS (ptsI) causes a 
hypervirulent phenotype in this model of infection through its altered temporal 
regulation of streptolysin S (SLS) (8). In addition, perhaps using huSCID mice may 
be more appropriate for these studies since the results presented in this dissertation 




 Overall, this dissertation has shown that FruB and FruR, through its regulation 
of fruB, are necessary for full virulence of GAS in a host-specific manner. It is 
hypothesized that FruB is directly stimulating downstream virulence gene regulation 
through a currently unknown signaling mechanism. Nonetheless, there is a clear link 
between fructose metabolism and regulation of immune evasion-related genes that are 
important for GAS during human infection.  
The effect of glucose on Mga phosphorylation and activity. 
The stand-alone regulator, Mga, possesses homology to PRD domains found 
in sugar-specific regulators, suggesting that Mga may be linked to the PTS (11). 
Thus, global virulence gene regulation can be directly influenced by carbohydrate 
metabolism. Work conducted by Hondorp et al. demonstrated that the PTS, through 
EI/Hpr, can modulate Mga in vitro by phosphorylating histidines located on the PRD 
domains of the protein; thus affecting activity in vivo through expression of its 
regulon (19). PRD regulators are also often phosphorylated by an EIIBsugar and can 
affect protein activity; however, this phosphodonor(s) has yet to be identified for 
Mga. Furthermore, while it is hypothesized that glucose is the main inducer of Mga 
regulon expression, it has never been conclusively demonstrated. This dissertation 
characterizes the effect of glucose on Mga phosphorylation and the subsequent effect 
it has on the expression of the Mga regulon in M1T1 GAS.  
Transcription of several of the core Mga-regulated genes were repressed 
during growth in C media (low glucose) as opposed to THY (high glucose). Phos-tag 
gel analysis revealed that in the presence of high glucose (THY), Mga exhibited a 




exhibited only an unphosphorylated species. For PRD-containing regulators, 
phosphorylation often creates antagonistic effects on activity depending on which 
domain is targeted (332). Hondorp et al. was able to demonstrate, using real-time 
qPCR and a phosphomimetic construct of the two phosphohistidine located on PRD1, 
that a there was a complete loss of activity regardless of the phosphorylation status of 
PRD2, indicating that PRD1-inactivation of Mga by phosphorylation is dominant 
(19). In addition, this condition is meant to mimic growth conditions in the absence of 
glucose. Importantly, the aforementioned study also suggested that phosphorylation 
of residue H324 (PRD2) enhances Mga activity, as a 2- to 3-fold loss of activity was 
observed for a complete phosphoablative mutant (PRD1/PRD2; A/A/A) compared to 
a construct that prevents phosphorylation on just PRD1 (A/A); the former occurring 
in the presence of both glucose and an inducing sugar, and the latter occurring solely 
in the presence of glucose. Interestingly, qPCR results from a H324A mutant (PRD2) 
alone showed no difference in regulon activity in comparison to the WT, which was 
attributed to the high level of protein produced due to the use of the multi-copy 
plasmid-based system used, causing a compensation for loss of regulon activity. 
Thus, based on the results of this study in combination with the model presented by 
Hondorp et al., we propose that Mga is phosphorylated on PRD2 during high levels 
of glucose (growth on THY), causing a hyperactive phenotype. This is validated by 
what was seen previously, where loss of phosphorylation on all three PRDs (A/A/A) 
shows a more dramatic loss in activation of regulon genes when compared to the wild 
type because in theory the WT is in the “hyperactive state” due to high glucose in 




present at low levels, Mga is still in an active state albeit to a lesser extent than 
observed in THY. Based on this model, C media must also have the hypothetical 
EIIBsugar active to import and inducing sugar, and shunt the flow of phosphates to the 
phosphohistidine on PRD2 of Mga.  
The PTS is not the primary system for GAS glucose uptake based on the 
finding that a ∆ptsI mutant was defective on growth and utilization of the majority of 
PTS sugars, but not growth and utilization of glucose (8), indicating an alternative 
uptake system for glucose. Other species of low G+C Gram-positive bacteria encode 
for either a PTS-independent active transport system called the multiple sugar 
metabolism (MSM) system, or a non-PTS glucose uptake system called GlcU (333-
335). However, genes encoding for a homologous MSM system are not found in the 
genome of GAS, but glcU is encoded for by GAS. Thus, since glucose plays a key 
role in not only the metabolism of GAS, but also the regulation of Mga, the search for 
the alternative glucose transport system(s) is currently under investigation in our lab. 
Interestingly, preliminary studies show that GlcU is not the only alternative non-PTS 
transport system in GAS because mutagenesis of glcU in a ∆ptsI background revealed 
that it can still grow on glucose. Therefore, it appears that GlcU may not be the sole 
glucose transport system encoded in GAS, and is not the preferred route of glucose 
uptake, which points to yet a third unknown method for glucose to be transported into 
the cell.  
This currently unknown primary glucose transport system would be the 
predominant pathway for glucose uptake, and it would most likely be sufficient for 




on low glucose, such as in C media, sole utilization of this primary transport system 
may not be efficient for growth, and activation of the EII PTS transporters that are 
specific for glucose may occur. This can be seen in the RNA-Seq data presented here, 
where the PTS transporters for mannitol, cellobiose (both), trehalose, galactose, sialic 
acid, and the 3-keto-L-gulonate were all activated in C media. Therefore, this may 
provide the first evidence of a PTS EII(s) that is able to transport glucose into the cell. 
However, this raises the question as to which one(s) are actually transporting 
glucose? Additionally, do any of these EIIs act as a phosphodonor for Mga 
activation? In order to determine which PTS EII is directly interacting with Mga, a 
bacterial two-hybrid screen between Mga and all 14 EIIs could be used. In addition, if 
glucose is being transported in to the cell via an alternate PTS transport system it 
would mean that glucose itself could act as an inducing sugar. Thus the interplay 
between glucose, the PTS, and Mga activations would be more nuanced than 
previously thought.  
It is also possible that the model proposed by Hondorp et al. is incorrect, and 
an alternative mechanism is used to regulate Mga activity in a high versus a low 
glucose environment. Phosphorylation is often a transient property of proteins, and so 
the current bimodal view of Mga phosphorylation and activity may not be an accurate 
representation of what is happening within the cell. It was originally hypothesized 
that C media, with its low glucose composition, would be a condition where Mga 
would be phosphorylated (on PRD1) and less active than in THY; however, only a 
band corresponding to an unphosphorylated protein was observed in C media. A 




affects the Mga regulon expression, presumably through posttranslational 
modification of Mga (336). Thus, although no phosphorylation of Mga in C media 
was observed, it is possible that this phosphatase may be playing a role in the 
observed phosphorylation status of Mga in C media and masking alternative 
phosphorylation in these conditions. However, it is important to note that this 
phosphatase was not found to be differentially regulated in the wild type 5448 RNA-
Seq in THY versus C media. Still, questions still remain as to whether this 
phosphatase affects Mga activity directly? It is possible that other regulatory proteins 
may be interacting with Mga and causing a change in activity. Questions regarding 
these interactions can be addressed using Tn-Seq in both THY and C media and to 
identify genetic interaction of mga. Tn-Seq allows for epistatic relationships between 
genes to be elucidated and thus, this could provide a clearer picture to not only what 
Mga is interacting with downstream but also upstream.  
Regardless of the physical mechanism by which glucose is affecting the 
phosphorylation of Mga, it is clear that glucose is crucial for activation of the protein 
and the types of genes it regulates. The Mga virulence regulon was highly variable 
under different glucose levels. While 7.9% of the genome was regulated in both THY 
and C media, the genes within these two datasets were different. Only 16 genes were 
found in common, most of which were the core regulon genes (emm, sic, scpA, and 
fba). From the data generated here, several questions remain: How does 
phosphorylation of Mga enable the protein to differentially regulate genes based on 
glucose availability? Does the phosphorylation (hypothesized to occur on PRD2) 




differentially than when it is completely unphosphorylated? Or, does the variation in 
the regulon demonstrate a change in the cell on a much more global level; does 
removal of Mga in C media signal for a sort of stress response for GAS, which causes 
a Mga-independent transcriptional change that allows for compensation for loss of 
this stand-alone regulator? In order to answer this question, ChIP-Seq will need to be 
performed on Mga when grown in either THY or C media in order to detect direct 
DNA binding differences on a genome level.  
Interestingly, when comparing the microarray study with the RNA-Seq data 
generated in THY, only 8 genes overlapped and 5 of these were part of the core 
regulon. Importantly, analysis of this dataset revealed that the only other gene that 
was in common in the microarray, THY RNA-Seq and the C media RNA-Seq was the 
gene spy_0143. This gene encodes for a 78 amino acid hypothetical protein, with 
unknown function. This small protein is reminiscent of the gene grm, which was 
previously shown to be directly regulated by Mga, but the function of this gene has 
never been identified (229), and no role in virulence was ever determined (Gold, 
unpublished data). Intriguingly, grm was found to be regulated in C media by Mga 
but not in THY in an M1T1 background, potentially indicating a low glucose-specific 
role for this gene. Therefore, there are questions that remain concerning why Mga 
regulates these two small peptides. For example, why does Mga regulate several of 
these smaller proteins? What are the roles of these peptides in GAS physiology and 
could they act as a signaling mechanism for peptide-mediated quorum sensing? In 
addition, why are some of these small peptides, such as grm, regulated in a glucose-




Finally, the regulon in C media contained a number of novel genes that were 
involved in adhesion and immune evasion, such as all three phage-associated 
nucleases. Interestingly, it was demonstrated that much of the genes that were 
differentially-regulated in C media were due to the low glucose availability, and 
supplementation of C media with glucose restored the regulon to what was observed 
in THY. This further supports the conclusion that glucose is the inducer of Mga 
activity. Importantly, C media also acts a representative media condition for a deep 
tissue infection, including cellulitis and necrotizing fasciitis (88). Therefore, it would 
be interesting to analyze the Mga regulon in a subcutaneous model of skin infection 
to confirm that the profile of gene regulation that was observed in vitro  (C media) 
mimics what is occurring in vivo.  
Overall, this dissertation has shown that Mga is differentially phosphorylated 
due to glucose availability, which correlates with a change in the genes within the 
Mga regulon. It is hypothesized that THY acts as a condition where Mga is in a 
“hyperactive” condition, and phosphorylated on PRD2. In contrast, C media would 
act as a more physiologically-relevant condition that limits the source of glucose. 
However, since some glucose is still present in the media, it maintains Mga in an 
unphosphorylated and active form. While the location of the phosphorylation event 
on Mga can be directly attributed to the phosphohistdines, the residue(s) that are 
affected were not determined. How this affects the conformation of the protein in vivo 
has yet to be studied. Nonetheless, it is clear that glucose is a main inducer of Mga 




Importance of the C-terminus of Mga for activity. 
 Through previous work, it is known that the key components for Mga activity 
are DNA-binding, dimerization, and PTS phosphorylation (19, 236, 251). 
Specifically, the N-terminus of Mga is important for binding to the promoters of 
target virulence genes, but is not sufficient for Mga activity in vivo. The C-terminus, 
specifically the EIIB domain, is necessary for dimerization and full activation of Mga 
(251). It is hypothesized that Mga forms homodimers using multiple amino acid 
residues on the EIIB domain based on the crystal structures of Mga homologs. A 
bacterial two-hybrid screen was used to identify residues that could play a role in 
dimerization of Mga. In this dissertation, we characterized nine different single amino 
acid mutants in the EIIB domain of Mga for their effect on transcriptional activation 
of known regulon genes. In addition, we modeled Mga onto its homolog, AtxA, from 
B. anthracis (PDB 4R6I) (216).  
The two-hybrid screen was originally conducted based on the crystal structure 
of the Mga homolog, MafR (formally known as EF3013) from E. faecalis (PDB 
3SQN) (217, 218). MafR was demonstrated to form homodimers based on 
interactions between its EIIB domains. Therefore, using targeted random 
mutagenesis, the EIIB domain of Mga was probed for putative interaction residues. A 
total of 20 putative interaction residues were identified in the screen as abolishing 
interaction of Mga1-Mga1. In each case, the mutation identified led to a change in 
amino acid polarity or size. Therefore, it is possible that such chemical changes may 
have altered local hydrogen bonding or intermolecular interactions of the protein fold 




validated by confirming protein expression levels and transcriptional activation of the 
Mga-regulated gene, emm, as an indirect method of measuring dimerization. Out of 
the nine residues, two (F430Y and D445V) were found to be expressed at levels 
comparable to wild type M1 Mga, and also affect the expression of emm. Thus, the 
data presented in this dissertation suggests that C-terminal Mga1 residues F430 and 
D445 normally function to mediate Mga homodimerization. However, based on the 
AtxA crystal structure, both of these residues exist outside of the putative dimer 
interface. Therefore, the question remains whether these residues are affecting 
dimerization in vivo, or if they are just affecting protein activity? This question can 
only be addressed by determining the dimerization state of the resulting Mga proteins, 
using techniques such as gel filtration or native gel analysis. However, if loss of emm 
activation is solely due to protein activity, how do these residues play a regulatory 
role in Mga activation?  
In addition, since the two-hybrid study was conducted, a crystal structure of B. 
anthracis AtxA has revealed that this PRD-containing regulator forms dimers using 
both its EIIB and PRD2 domains (216). Based on this new information, and the 
modeling of Mga to the AtxA crystal structure, two putative residues were identified 
on PRD2 (E349 and Y387) as potential interaction partners; however, no defect in 
activation of emm was observed for either of the residues. A number of questions 
regarding Mga’s ability to dimerize still remain and need to be explored. For 
example, does Mga form dimers similar to MafR (EIIB-EIIB) or like AtxA (PRD2-
EIIB)? Further comprehensive mutational analysis of PRD2 may help answer this 




to make accurate predictions pertaining to the quaternary structure of Mga and the 
tertiary effects of individual amino acids in the EIIB region.  
This study used the Mga homolog and transcriptional regulator, AtxA from B. 
anthracis (PDB 4R6I) (216) as a model for Mga dimerization. Interestingly, the C-
terminal tail was extremely unstructured in all three predicted protein structures, 
while the rest of the protein was mapped with a high degree of precision. In addition, 
it was extremely difficult to produce mutations in Mga in this study and in others 
(308). Taken together, Mga possesses unique properties in its C-terminus, and 
therefore it crucial for future studies involving interrogation of this region to have a 
precise Mga crystal structure. However, due to difficulties in the quantity of Mga 
generated from protein purification, it has been impossible to produce a crystal 
structure thus far.  
Interestingly, while mutational analysis revealed that complete removal of the 
EIIB domain abolished dimer formation in solution, and consequently loss of 
activation of regulon genes, it was still able to bind cognate DNA in vitro. This points 
to a much more complex mechanism by which Mga is able to activate transcription of 
its regulon genes, and multimerization plays a key role in this activation. Thus, it 
would be important to test the mutants identified in this study for their effect on DNA 
binding. Based on previous studies it is hypothesized that they would maintain their 
ability to bind to target DNA.   
Historically, dimerization is not the only important attribute of EIIB domains 
on PRD-containing regulators. Many possess a conserved regulatory amino acid on 




example, the B. subtilis PRD regulator MtlR contains a cysteine in its EIIBGat-like 
domain that can modulate its activity (337) through phosphorylation by a PTS EIIA 
(211). Mga does not have the conserved catalytic cysteine residue, and instead a 
glutamate (E413) exists in its place. Therefore, it was hypothesized that this 
glutamate may serve as a phosphomimetic and further play a role in Mga activity 
(251). However, in a study conducted by Kruszewski et al., mutational analysis of the 
glutamate to an alanine (E413A) revealed that this residue was not important for Mga 
activity (310). However, this study was conducted using a multi-copy plasmid 
system, and therefore it may alter the phenotypes that were observed. Therefore, this 
residue may still play a role in Mga activity, and further investigation of E413 should 
be conducted in single-copy using ectopic integration on the chromosome. 
Identification of a putative “activation switch amino acid residue(s)” would have 
potentially not been identified by the two-hybrid screen, as they may not affect 
dimerization. Therefore, if this residue or another is phosphorylated, it would be 
important to 1) determine if activity is affected by loss of dimerization, and 2) 
identify what EIIA is responsible for the phosphorylation of this putative residue. In 
order to answer this question alanine scanning on the EIIB domain and subsequent 
analysis of activation of Mga may answer this question. However, this may prove to 
be difficult due to the general issues with generating mutation in this region stated 
above.  
Since Mga also relies on phosphorylation events on its PRD domains for 
activation, phosphorylation on PRD1 may play antagonistic effect on Mga activity 




causing a conformational change that occludes interaction residues on the EIIB 
domain. Conversely, dimerization may hinder phosphorylation of PRD1 by occluding 
the phosphohistidine and prolong activation of the Mga regulon. A similar scenario 
was demonstrated in the archetype PRD-containing anti-terminator, LicT. The 
phosphohistidines of LicT are buried deep within the dimer interface, and therefore 
are inaccessible to phosphorylating enzymes (205). In silico models predicted that 
phosphorylation of the histidines on PRD1 lead to strong electrostatic repulsions, 
whereas phosphorylation of PRD2 leads to increased electrostatic complementarity 
between the homodimer (208). Thus, it would be interesting to investigate the 
dynamics of Mga phosphorylation, not only in the context of activation of its regulon, 
but also in the context of dimer formation.  
Overall, this study demonstrated that two amino acid (F430 and D445) 
substitutions within the EIIB domain affect Mga activity, and potentially mediate 
Mga dimerization. Furthermore, while Mga homologs have played a useful role in 
characterizing potential interaction residues for Mga dimerization, future work would 
greatly benefit from a direct Mga crystal structure.  
Summary 
In conclusion, the results of this work have characterized the role of a PTS-
fructose operon in both fructose metabolism and its role in GAS pathogenesis. FruA 
was identified as the main transporter of fructose in the M1T1 GAS, and all three 
operon genes (fruRBA) were necessary for growth in fructose. In addition, FruB and 
FruR, through its regulation of fruB, were found to be are necessary for full virulence 




that are necessary for full Mga activation. Glucose was found to be the inducing sugar 
that promotes Mga activity and causes differential phosphorylation patterns of the 
protein on its PTS-regulatory domains (PRD), which subsequently alter activation of 
the Mga regulon. Mga activity was also affected by individual amino acid residues 
located in the EIIB domain, and implicate these residues in dimer formation. Overall, 
the results provided within this dissertation have established the functional 
characterization of the role of sugars as major contributors to virulence factor 
production through either directly eliciting genome-wide transcriptional changes or 






Appendix 1: Genes in 5448 differentially expressed in CDM-glucose compared to 
CDM-fructose 
 
Spy # Annotation Gene Name Log2 FC a 
M5005_Spy_0039 
alcohol dehydrogenase/acetaldehyde dehydrogenase 
(acetylating) adh2 -2.10 
M5005_Spy_0086 comG operon protein 1 comYA -0.99 
M5005_Spy_0089 comG operon protein 4  1.72 
M5005_Spy_0120 acetate CoA-transferase alpha subunit atoD.2 1.76 
M5005_Spy_0123 translation initiation inhibitor  -1.82 
M5005_Spy_0124 serine catabolism regulator sloR -2.32 
M5005_Spy_0125 hypothetical protein  -1.09 
M5005_Spy_0126 V-type sodium ATP synthase subunit I ntpI -2.01 
M5005_Spy_0127 V-type sodium ATP synthase subunit K ntpK -1.97 
M5005_Spy_0128 V-type sodium ATP synthase subunit E ntpE -2.22 
M5005_Spy_0129 V-type ATP synthase subunit C ntpC -1.79 
M5005_Spy_0130 V-type sodium ATP synthase subunit F ntpF -1.22 
M5005_Spy_0131 V-type sodium ATP synthase subunit A ntpA -1.24 
M5005_Spy_0132 V-type sodium ATP synthase subunit B ntpB -0.96 
M5005_Spy_0133 V-type sodium ATP synthase subunit D ntpD -1.21 
M5005_Spy_0145 hypothetical protein  -1.31 
M5005_Spy_0150 PTS system, 3-keto-L-gulonate specific IIA  ptxA -0.99 
M5005_Spy_0152 L-xylulose 5-phosphate 3-epimerase  1.37 
M5005_Spy_0154 hypothetical protein  1.57 
M5005_Spy_0166 transposase  -1.32 
M5005_Spy_0167 transposase  -1.15 
M5005_Spy_0168 transposase  -1.70 
M5005_Spy_0170 nicotinate-nucleotide pyrophosphorylase (carboxylating) nadC -1.95 
M5005_Spy_0184 hypothetical cytosolic protein  -1.28 
M5005_Spy_0189 hypothetical protein  -1.66 
M5005_Spy_0256 competence-specific sigma factor  -1.68 
M5005_Spy_0297 transposase  -1.12 
M5005_Spy_0395 transposase  -1.39 
M5005_Spy_0451 transcriptional regulator  -1.07 
M5005_Spy_0460 hypothetical protein  1.13 
M5005_Spy_0474 transcription antiterminator, BglG family licT -1.36 
M5005_Spy_0476 6-phospho-beta-glucosidase bglA -1.22 
M5005_Spy_0479 hypothetical membrane spanning protein  -1.80 
M5005_Spy_0518 oligohyaluronate lyase  1.35 
M5005_Spy_0521 PTS system, N-acetylgalactosamine-specific IIB  agaV -1.75 
M5005_Spy_0616 ferredoxin  -1.02 
M5005_Spy_0650 hypothetical protein  -1.95 
M5005_Spy_0659 2-dehydropantoate 2-reductase apbA -0.95 
M5005_Spy_0660 fructose repressor fruR -1.95 
M5005_Spy_0661 1-phosphofructokinase fruB -2.52 
M5005_Spy_0662 PTS system, Fructose-specific IIABC  fruA -3.33 
M5005_Spy_0666 hypothetical protein  -1.70 
M5005_Spy_0667 exotoxin type C precursor  2.07 
M5005_Spy_0773 hypothetical protein  0.99 




M5005_Spy_0800 DNA-cytosine methyltransferase  -1.38 
M5005_Spy_0853 short chain dehydrogenase  -1.25 
M5005_Spy_0912 hypothetical protein  -1.41 
M5005_Spy_0997 phage protein   1.20 
M5005_Spy_0998 phage protein   -1.40 
M5005_Spy_0999 phage protein   1.92 
M5005_Spy_1000 phage protein   2.52 
M5005_Spy_1010 phage protein   1.56 
M5005_Spy_1013 antigen B   2.32 
M5005_Spy_1017 phage protein   2.65 
M5005_Spy_1023 terminase large subunit   1.52 
M5005_Spy_1025 phage encoded transcriptional regulator, ArpU family   0.96 
M5005_Spy_1026 phage protein   2.04 
M5005_Spy_1027 phage protein   1.00 
M5005_Spy_1028 phage protein   1.12 
M5005_Spy_1029 phage protein   1.92 
M5005_Spy_1030 phage protein   1.38 
M5005_Spy_1032 phage protein   1.84 
M5005_Spy_1033 phage protein   1.69 
M5005_Spy_1034 phage protein   1.48 
M5005_Spy_1035 phage protein   1.41 
M5005_Spy_1036 phage single-strand DNA binding protein ssb2 1.48 
M5005_Spy_1037 phage single-strand DNA binding protein ssb1 2.07 
M5005_Spy_1038 phage protein   1.87 
M5005_Spy_1039 phage protein   2.09 
M5005_Spy_1040 phage protein   1.71 
M5005_Spy_1041 phage protein   2.76 
M5005_Spy_1042 phage replication protein   2.03 
M5005_Spy_1043 phage protein   1.88 
M5005_Spy_1045 transcriptional regulator   1.80 
M5005_Spy_1062 maltodextrose utilization protein malA -1.12 
M5005_Spy_1063 ABC Cyclomaltodextrin permease protein malD -1.17 
M5005_Spy_1078 hypothetical protein  -1.53 
M5005_Spy_1081 PTS system, Cellobiose-specific IIA component   -0.98 
M5005_Spy_1089 hypothetical protein  -1.19 
M5005_Spy_1090 transposase  -1.58 
M5005_Spy_1139 glucosamine-6-phosphate isomerase nagB 0.98 
M5005_Spy_1172 holin   0.99 
M5005_Spy_1173 phage protein   -1.33 
M5005_Spy_1174 phage protein   2.37 
M5005_Spy_1175 phage protein   1.47 
M5005_Spy_1176 phage infection protein   1.34 
M5005_Spy_1187 phage structural protein   1.05 
M5005_Spy_1190 phage protein   -1.19 
M5005_Spy_1200 phage protein   1.14 
M5005_Spy_1201 phage protein   1.94 
M5005_Spy_1203 phage protein   2.16 
M5005_Spy_1204 recT protein   1.59 
M5005_Spy_1205 phage protein   1.75 
M5005_Spy_1206 phage protein   1.91 
M5005_Spy_1208 phage protein   2.23 
M5005_Spy_1209 DNA replication protein   1.82 
M5005_Spy_1210 phage replication protein   1.45 
M5005_Spy_1211 phage protein   1.42 
M5005_Spy_1213 phage protein   1.72 




M5005_Spy_1217 phage antirepressor protein   1.20 
M5005_Spy_1218 phage protein   1.79 
M5005_Spy_1307 hypothetical membrane spanning protein  -1.02 
M5005_Spy_1308 ABC unknown sugar-binding protein   -1.16 
M5005_Spy_1309 ABC unknown sugar permease protein   -1.82 
M5005_Spy_1310 ABC unknown sugar permease protein   -1.40 
M5005_Spy_1388 N-acetylglucosamine-6-phosphate deacetylase nagA 0.97 
M5005_Spy_1395 tagatose-bisphosphate aldolase; SpeB regulator lacD.1 -1.01 
M5005_Spy_1396 tagatose-6-phosphate kinase lacC.1 -1.35 
M5005_Spy_1397 galactose-6-phosphate isomerase lacB subunit lacB.1 -1.54 
M5005_Spy_1400 PTS system, Galactose-specific IIB component   -1.45 
M5005_Spy_1401 PTS system, Galactose-specific IIA component   -1.14 
M5005_Spy_1414 phage protein  1.42 
M5005_Spy_1416 phage-associated cell wall hydrolase   1.90 
M5005_Spy_1417 phage protein   1.44 
M5005_Spy_1418 phage protein   2.34 
M5005_Spy_1419 phage protein   2.03 
M5005_Spy_1420 phage protein   1.67 
M5005_Spy_1421 phage infection protein   1.81 
M5005_Spy_1422 phage protein   1.48 
M5005_Spy_1423 hyaluronoglucosaminidase   1.95 
M5005_Spy_1424 phage endopeptidase   1.89 
M5005_Spy_1425 phage protein   2.07 
M5005_Spy_1426 phage protein   2.49 
M5005_Spy_1427 phage protein   2.18 
M5005_Spy_1428 phage protein   2.41 
M5005_Spy_1429 phage protein   2.27 
M5005_Spy_1430 phage protein   1.99 
M5005_Spy_1431 phage protein   1.95 
M5005_Spy_1432 phage protein   2.30 
M5005_Spy_1433 phage protein   2.00 
M5005_Spy_1434 phage protein   2.38 
M5005_Spy_1435 phage scaffold protein   2.40 
M5005_Spy_1436 phage protein   2.18 
M5005_Spy_1437 hypothetical protein   2.26 
M5005_Spy_1438 phage protein   1.81 
M5005_Spy_1439 portal protein   2.14 
M5005_Spy_1440 terminase large subunit   1.79 
M5005_Spy_1441 phage terminase small subunit   1.83 
M5005_Spy_1442 phage transcriptional activator   2.50 
M5005_Spy_1444 adenine-specific methyltransferase   1.89 
M5005_Spy_1446 phage protein   1.20 
M5005_Spy_1447 phage-related DNA helicase   1.49 
M5005_Spy_1448 hypothetical protein   1.22 
M5005_Spy_1449 DNA primase   2.37 
M5005_Spy_1450 phage-encoded DNA polymerase   1.80 
M5005_Spy_1451 phage protein   1.69 
M5005_Spy_1452 phage protein   1.74 
M5005_Spy_1453 phage protein   1.60 
M5005_Spy_1454 phage protein   2.02 
M5005_Spy_1455 phage protein   1.82 
M5005_Spy_1457 phage protein   2.66 
M5005_Spy_1458 phage protein   1.70 
M5005_Spy_1459 phage protein   1.57 
M5005_Spy_1460 phage protein   1.35 




M5005_Spy_1463 phage protein   1.79 
M5005_Spy_1509 pyruvate, phosphate dikinase  -1.36 
M5005_Spy_1510 pyruvate, phosphate dikinase  -1.26 
M5005_Spy_1536 transposase  -1.17 
M5005_Spy_1541 hypothetical protein  -1.10 
M5005_Spy_1574 universal stress protein family  2.05 
M5005_Spy_1575 quinolone resistance protein norA 2.33 
M5005_Spy_1629 lantibiotic transport ATP-binding protein salX -1.89 
M5005_Spy_1631 lantibiotic salivaricin A salA -1.67 
M5005_Spy_1632 6-phospho-beta-galactosidase lacG -1.66 
M5005_Spy_1633 PTS system, Lactose-specific IIBC component lacE -2.73 
M5005_Spy_1634 PTS system, Lactose-specific IIA component lacF -2.22 
M5005_Spy_1635 tagatose-bisphosphate aldolase lacD.2 -2.18 
M5005_Spy_1636 tagatose-6-phosphate kinase lacC.2 -1.49 
M5005_Spy_1637 galactose-6-phosphate isomerase lacB subunit lacB.2 -1.67 
M5005_Spy_1638 galactose-6-phosphate isomerase lacA subunit lacA.2 -1.50 
M5005_Spy_1643 hypothetical protein  0.99 
M5005_Spy_1663 PTS system, Mannitol-specific IIB component   -1.69 
M5005_Spy_1689 hypothetical protein  1.42 
M5005_Spy_1744 PTS system, Cellobiose-specific IIC component celC -1.34 
M5005_Spy_1745 PTS system, Cellobiose-specific IIB component celB -0.95 
M5005_Spy_1746 PTS system, Cellobiose-specific IIA component celA 1.02 
M5005_Spy_1786 transcriptional regulator, MarR family  1.04 
M5005_Spy_1832 hypothetical protein  -1.15 
M5005_Spy_1841 L-serine dehydratase sdhB -1.06 
M5005_Spy_1842 L-serine dehydratase sdhA -1.27 
M5005_SpyR0011 large subunit 23S ribosomal RNA  -1.05 
M5005_SpyT0020 tRNA-Pro  -1.84 
M5005_SpyT0030 tRNA-Val  1.00 
M5005_SpyT0031 tRNA-Gly  -1.80 
M5005_SpyT0032 tRNA-Ile  -1.52 
M5005_SpyT0033 tRNA-Glu  -1.35 
M5005_SpyT0036 tRNA-Phe  -1.13 
M5005_SpyT0040 tRNA-Gln  -2.59 
M5005_SpyT0041 tRNA-Leu  -1.13 
M5005_SpyT0046 tRNA-Tyr  -1.02 
M5005_SpyT0052 tRNA-Thr  -1.00 
M5005_SpyT0065 tRNA-Asn  -0.97 
 
 






Appendix 2: Genes in 5448 differentially expressed in THY compared to C Media 
 
Spy #              Annotation Gene Log2 FC a p value b 
M5005_Spy0011 tRNA(Ile)-lysidine synthetase tilS -1.45 3E-04 
M5005_Spy0017 
CHAP-domain-containing cell wall hydrolase; 
pcsB/sibA homolog cdhA 2.34 7E-07 
M5005_Spy0019 DNA repair protein recO -1.05 1E-03 
M5005_Spy0022 
phosphoribosylaminoimidazole-
succinocarboxamide synthase  2.45 1E-04 
M5005_Spy0023 phosphoribosylformylglycinamidine synthase  1.97 3E-04 
M5005_Spy0024 amidophosphoribosyltransferase purF 2.76 2E-06 
M5005_ Spy0025 
phosphoribosylformylglycinamidine cyclo-
ligase purM 2.38 1E-04 
M5005_Spy0026 phosphoribosylglycinamide formyltransferase purN 2.05 1E-04 
M5005_Spy0027 
phosphoribosylaminoimidazolecarboxamide 
formyltransferase/IMP cyclohydrolase  2.00 3E-05 
M5005_Spy0029 phosphoribosylamine--glycine ligase purD 2.21 7E-04 
M5005_Spy0030 
phosphoribosylaminoimidazole carboxylase 
catalytic subunit purE 1.63 8E-03 
M5005_Spy0031 
phosphoribosylaminoimidazole carboxylase 
ATPase subunit purK 1.27 5E-03 
M5005_Spy0032 hypothetical protein  1.06 9E-03 
M5005_Spy0034 transcriptional regulator  1.24 3E-03 
M5005_Spy0035 holliday junction DNA helicase ruvB 1.46 2E-04 
M5005_Spy0039 
alcohol dehydrogenase/acetaldehyde 
dehydrogenase (acetylating) adh2 -2.07 7E-03 
M5005_Spy0040 alcohol dehydrogenase adhA -1.94 2E-02 
M5005_Spy0041 Na+ driven multidrug efflux pump  -1.03 9E-03 
M5005_Spy0043 SSU ribosomal protein S10P rpsJ 1.15 2E-02 
M5005_Spy0044 LSU ribosomal protein L3P rplC 1.04 1E-02 
M5005_Spy0052 LSU ribosomal protein L29P rpmC 1.54 1E-02 
M5005_Spy0064 protein translocase subunit secY 1.22 8E-03 
M5005_Spy0065 adenylate kinase adk 1.97 4E-04 
M5005_Spy0066 bacterial protein translation initiation factor 1 infA 1.54 4E-04 
M5005_Spy0068 SSU ribosomal protein S13P rpsM 1.25 2E-03 
M5005_Spy0070 DNA-directed RNA polymerase alpha chain rpoA 1.49 9E-04 
M5005_Spy0071 LSU ribosomal protein L17P rplQ 1.70 3E-04 
M5005_Spy0073 hypothetical protein  2.57 5E-03 
M5005_Spy0076 
4-diphosphocytidyl-2-C-methyl-D-erythritol 
kinase  1.16 2E-02 
M5005_Spy0077 transcriptional regulator, MarR family adcR 1.09 9E-05 
M5005_Spy0078 
high-affinity zinc uptake system ATP-binding 
protein adcC 1.10 1E-03 
M5005_Spy0085 putative DNA binding protein  2.62 9E-06 
M5005_Spy0086 comG operon protein 1 comYA 2.00 5E-03 
M5005_Spy0088 comG operon protein 3 comYC 1.76 2E-03 
M5005_Spy0094 acetate kinase ackA 1.21 2E-03 
M5005_Spy0095 hypothetical protein  2.59 2E-04 
M5005_Spy0106 transcriptional regulator; Regulator of protein F rofA -1.39 8E-04 
M5005_Spy0107 fibronectin-binding protein; FCT Pilus Region cpa 2.50 4E-07 
M5005_Spy0108 signal peptidase I; FCT Pilus Region sipA1 2.52 3E-06 
M5005_Spy0109 fibronectin-binding protein; FCT Pilus Region  2.37 1E-04 
M5005_Spy0110 hypothetical protein srtC2 2.61 8E-06 
M5005_Spy0111 hypothetical protein  1.63 2E-03 




M5005_Spy0114 sortase; FCT Pilus Region srtB 2.59 3E-04 
M5005_Spy0115 hypothetical protein  -1.26 4E-04 
M5005_Spy0134 tellurite resistance protein  -1.33 1E-05 
M5005_Spy0137 nucleoside-binding protein  1.39 2E-05 
M5005_Spy0142 hypothetical protein  2.34 2E-03 
M5005_Spy0143 hypothetical protein  3.97 2E-03 
M5005_Spy0148 PTS system, 3-keto-L-gulonate specific IIC  ptxC -2.37 6E-03 
M5005_Spy0149 PTS system, 3-keto-L-gulonate specific IIB  ptxB -4.53 2E-05 
M5005_Spy0150 PTS system, 3-keto-L-gulonate specific IIA  ptxA -4.61 3E-04 
M5005_Spy0151 3-keto-L-gulonate-6-phosphate decarboxylase  -3.52 4E-03 
M5005_Spy0152 L-xylulose 5-phosphate 3-epimerase  -3.57 7E-04 
M5005_Spy0153 L-ribulose-5-phosphate 4-epimerase araD -5.77 3E-06 
M5005_Spy0154 hypothetical protein  -3.95 6E-05 
M5005_Spy0156 metal-dependent hydrolase  -2.14 4E-04 
M5005_Spy0157 glycine betaine transport ATP-binding protein opuAA 2.11 2E-07 
M5005_Spy0158 
glycine betaine transport system permease 
protein opuABC 2.01 2E-06 
M5005_Spy0174 hypothetical protein  1.96 1E-02 
M5005_Spy0175 queuine tRNA-ribosyltransferase tgt 1.06 2E-03 
M5005_Spy0177 bioY protein  1.21 2E-02 
M5005_Spy0185 glucose-6-phosphate isomerase pgi 1.09 4E-02 
M5005_Spy0192 UTP--glucose-1-phosphate uridylyltransferase hasC.2 -1.19 1E-03 
M5005_Spy0194 glycerol-3-phosphate dehydrogenase; GAPDH gapA -1.27 2E-04 
M5005_Spy0195 
Heme-sensitive transcriptional repressor, MarR-
family pefR 1.17 1E-02 
M5005_Spy0204 TCS-1 histidine kinase FasB  fasB 1.10 1E-03 
M5005_Spy0206 TCS-1 response regulator FasA  fasA 1.13 1E-02 
M5005_Spy0211 LSU ribosomal protein L34P rpmH 1.64 2E-03 
M5005_Spy0213 
ABC Sialic Acid; N-acetylneuraminate-binding 
protein  -1.98 2E-03 
M5005_Spy0214 
ABC Sialic Acid; N-acetylneuraminate 
permease protein  -2.11 6E-04 
M5005_Spy0215 
ABC Sialic Acid; N-acetylneuraminate 
permease protein  -1.83 3E-03 
M5005_Spy0216 hypothetical membrane spanning protein  -2.87 1E-04 
M5005_Spy0217 N-acetylneuraminate lyase nanH -1.94 3E-03 
M5005_Spy0218 N-acetylmannosamine kinase  -1.95 3E-03 
M5005_Spy0221 ribonuclease M5  1.31 2E-03 
M5005_Spy0224 ribulose-phosphate 3-epimerase rpe -1.36 1E-04 
M5005_Spy0230 SSU ribosomal protein S12P rpsL 1.71 4E-04 
M5005_Spy0231 SSU ribosomal protein S7P rpsG 1.32 4E-03 
M5005_Spy0238 putative undecaprenol kinase bacA -1.20 2E-03 
M5005_Spy0241 hypothetical cytosolic protein rgpG 1.62 3E-02 
M5005_Spy0247 D-alanyl-D-alanine carboxypeptidase  1.79 1E-05 
M5005_Spy0273 ABC transporter permease protein  1.32 4E-02 
M5005_Spy0274 
branched-chain amino acid transport system 
carrier protein braB 4.77 6E-07 
M5005_Spy0275 serine/threonine sodium symporter  3.26 2E-07 
M5005_Spy0295 60 kDa inner membrane protein YIDC  -1.20 2E-03 
M5005_Spy0296 acylphosphatase  -1.23 2E-03 
M5005_Spy0307 
DNA integration/recombination/invertion 
protein  -1.22 2E-04 
M5005_Spy0318 pyruvate formate-lyase activating enzyme pflC 1.35 4E-04 
M5005_Spy0321 ferrichrome transport system permease protein fhuG 1.34 5E-04 
M5005_Spy0323 ferrichrome-binding protein fhuD 1.13 8E-03 




M5005_Spy0329 hypothetical cytosolic protein  -1.11 5E-05 
M5005_Spy0333 signal peptidase-like protein  -1.23 5E-04 
M5005_Spy0335 corrin/porphyrin methyltransferase  -0.97 2E-04 
M5005_Spy0336 hypothetical membrane associated protein  -1.13 1E-02 
M5005_Spy0338 arsenate reductase family protein  1.24 1E-03 
M5005_Spy0341 lactocepin; SpyCEP; IL-8 protease spyCEP -1.78 1E-04 
M5005_Spy0346 hypothetical protein  -1.41 3E-02 
M5005_Spy0347 ribonucleoside-diphosphate reductase beta chain nrdF.1 -1.25 2E-03 
M5005_Spy0348 hypothetical protein nrdI -1.49 5E-03 
M5005_Spy0349 
ribonucleoside-diphosphate reductase alpha 
chain nrdE.1 -1.56 4E-03 
M5005_Spy0361 phosphoglycerate transporter protein  -1.05 3E-02 
M5005_Spy0374 LSU ribosomal protein L11P rplK 1.84 5E-03 
M5005_Spy0375 LSU ribosomal protein L1P rplA 1.86 3E-03 
M5005_Spy0385 67 kDa Myosin-crossreactive antigen  -1.23 5E-03 
M5005_Spy0387 uracil DNA glycosylase superfamily protein  -0.98 1E-02 
M5005_Spy0398 bacteriocin  1.53 4E-02 
M5005_Spy0421 lactoylglutathione lyase gloA -1.70 1E-05 
M5005_Spy0422 NAD(P)H-dependent quinone reductase  -1.94 4E-06 
M5005_Spy0423 Xaa-Pro dipeptidase pepQ -1.61 2E-04 
M5005_Spy0425 glycosyltransferase  -1.29 2E-04 
M5005_Spy0426 1,2-diacylglycerol 3-glucosyltransferase  -1.52 3E-04 
M5005_Spy0457 plasmid stabilization system protein  -1.08 2E-02 
M5005_Spy0461 hypothetical cytosolic protein  -1.67 2E-04 
M5005_Spy0462 hypothetical protein  -1.50 7E-03 
M5005_Spy0463 hypothetical cytosolic protein  -1.13 5E-03 
M5005_Spy0464 microcin C7 self-immunity protein mccF -1.14 1E-03 
M5005_Spy0465 hypothetical protein  -0.95 2E-02 
M5005_Spy0466 hypothetical protein  -1.43 3E-05 
M5005_Spy0467 transposase  -1.09 3E-02 
M5005_Spy0469 hypothetical protein  -1.74 9E-04 
M5005_Spy0473 multidrug resistance protein B  1.46 1E-03 
M5005_Spy0474 transcription antiterminator, BglG family licT 2.43 8E-05 
M5005_Spy0475 PTS system, b-Glucoside-specific IIABC   3.78 3E-08 
M5005_Spy0476 6-phospho-beta-glucosidase bglA 2.94 4E-06 
M5005_Spy0477 hypothetical membrane spanning protein  -1.67 4E-05 
M5005_Spy0478 hypothetical membrane spanning protein  -1.65 4E-04 
M5005_Spy0479 hypothetical membrane spanning protein  -3.11 5E-02 
M5005_Spy0483 stress-responsive transcriptional regulator  -2.31 4E-08 
M5005_Spy0485 prolipoprotein diacylglyceryl transferase lgt -0.96 6E-04 
M5005_Spy0486 hypothetical protein  -1.21 3E-03 
M5005_Spy0496 hydrolase, HAD superfamily  1.90 5E-06 
M5005_Spy0503 glutathione peroxidase  -1.45 1E-04 
M5005_Spy0504 oligoendopeptidase F pepF -1.70 1E-05 
M5005_Spy0512 hydrolase, HAD superfamily  -1.02 9E-05 
M5005_Spy0523 hypothetical protein  -1.63 2E-02 
M5005_Spy0528 
beta-phosphoglucomutase/glucose-1-phosphate 
phosphodismutase  -1.13 1E-03 
M5005_Spy0539 ATP-binding protein  -1.30 2E-05 
M5005_Spy0540 transporter  -1.27 4E-04 
M5005_Spy0541 hypothetical cytosolic protein  -1.50 6E-05 
M5005_Spy0542 dipeptidase pepD -1.77 9E-05 
M5005_Spy0543 
high-affinity zinc uptake system protein znuA 
precursor  1.49 3E-03 
M5005_Spy0545 
galactosamine-6-phosphate deaminase 




M5005_Spy0546 LSU ribosomal protein L31P rpmE 1.77 5E-06 
M5005_Spy0549 chorismate mutase  1.13 1E-02 
M5005_Spy0551 LSU ribosomal protein L19P rplS 2.14 5E-05 
M5005_Spy0555 hypothetical cytosolic protein  -1.40 8E-04 
M5005_Spy0558 transposase  -1.01 5E-02 
M5005_Spy0562 streptolysin S precursor sagA -2.37 2E-04 
M5005_Spy0563 streptolysin S biosynthesis protein sagB -1.86 2E-04 
M5005_Spy0564 streptolysin S biosynthesis protein sagC -1.87 1E-04 
M5005_Spy0565 streptolysin S biosynthesis protein sagD -1.25 2E-03 
M5005_Spy0566 streptolysin S putative self-immunity protein sagE -2.32 6E-05 
M5005_Spy0567 streptolysin S biosynthesis protein sagF -1.82 1E-03 
M5005_Spy0568 streptolysin S export ATP-binding protein sagG -1.88 8E-05 
M5005_Spy0569 streptolysin S export transmembrane protein sagH -1.76 2E-04 
M5005_Spy0570 streptolysin S export transmembrane protein sagI -1.14 3E-02 
M5005_Spy0575 ATP synthase C chain atpE 1.60 1E-04 
M5005_Spy0576 ATP synthase A chain atpB 1.26 2E-03 
M5005_Spy0579 ATP synthase alpha chain atpA 1.43 2E-02 
M5005_Spy0593 neutral zinc metallopeptidase family  -1.35 8E-05 
M5005_Spy0594 ATP-dependent nuclease subunit B rexB -1.18 7E-04 
M5005_Spy0595 ATP-dependent nuclease subunit A rexA -1.26 4E-04 
M5005_Spy0597 SSU ribosomal protein S21P  1.39 1E-03 
M5005_Spy0611 Group A Carbohydrate; Membrane protein gacJ -1.02 9E-03 
M5005_Spy0615 pore forming protein ebsA -1.66 4E-04 
M5005_Spy0616 ferredoxin  -1.78 5E-02 
M5005_Spy0618 cytidylate kinase cmk -1.08 4E-04 
M5005_Spy0619 bacterial protein translation initiation factor 3 infC 2.03 4E-04 
M5005_Spy0620 LSU ribosomal protein L35P rpl36 1.93 2E-03 
M5005_Spy0621 LSU ribosomal protein L20P rplT 2.34 1E-05 
M5005_Spy0624 3-dehydroquinate dehydratase aroD 1.25 4E-04 
M5005_Spy0625 chorismate synthase aroF 1.20 5E-03 
M5005_Spy0628 
folylpolyglutamate synthase/dihydrofolate 
synthase folC.2 -1.18 2E-04 
M5005_Spy0633 LSU ribosomal protein L21P rplU 1.84 4E-05 
M5005_Spy0634 hypothetical ribosome-associated protein  1.05 1E-03 
M5005_Spy0635 LSU ribosomal protein L27P rpmA 2.05 3E-05 
M5005_Spy0636 transcriptional regulator, LysR family  -1.36 2E-05 
M5005_Spy0637 lipoprotein signal peptidase lsp -1.45 5E-05 
M5005_Spy0638 
ribosomal large subunit pseudouridine synthase 
D  -1.21 1E-05 
M5005_Spy0639 pyrR bifunctional protein pyrR 1.57 2E-03 
M5005_Spy0640 uracil permease pyrP 1.30 5E-03 
M5005_Spy0641 aspartate carbamoyltransferase pyrB 2.18 2E-05 
M5005_Spy0642 carbamoyl-phosphate synthase small chain carA 1.73 4E-04 
M5005_Spy0643 carbamoyl-phosphate synthase large chain carB 1.62 2E-03 
M5005_Spy0648 SSU ribosomal protein S16P rpsP 1.74 4E-04 
M5005_Spy0649 RNA binding protein  1.59 7E-05 
M5005_Spy0651 Heme-utilization cell surface protein hupY 1.11 1E-02 
M5005_Spy0652 Heme-oxygenase cytosolic protein hupZ 1.76 5E-04 
M5005_Spy0653 cobalt-zinc-cadmium resistance protein czcD -3.16 3E-05 
M5005_Spy0655 16S rRNA processing protein rimM 1.25 6E-04 
M5005_Spy0668 IgG-degrading protease mac 1.82 4E-03 
M5005_Spy0669 phage protein  1.84 3E-02 
M5005_Spy0676 hypothetical protein  1.25 2E-02 
M5005_Spy0686 
3-hydroxy-3-methylglutaryl-coenzyme A 
reductase  -1.29 5E-04 




M5005_Spy0696 phosphopentomutase deoB -1.00 7E-03 
M5005_Spy0698 purine nucleoside phosphorylase punA -1.01 2E-02 
M5005_Spy0703 orotidine 5'-phosphate decarboxylase pyrF 1.62 6E-03 
M5005_Spy0704 orotate phosphoribosyltransferase pyrE 2.61 1E-03 
M5005_Spy0706 cystine-binding protein  1.67 5E-05 
M5005_Spy0707 cystine transport system permease protein  1.07 8E-03 
M5005_Spy0717 rhodanese-related sulfurtransferases  1.23 7E-04 
M5005_Spy0718 hypothetical protein  1.11 7E-03 
M5005_Spy0719 glutathione S-transferase  2.40 2E-06 
M5005_Spy0721 hypothetical protein  -0.99 3E-02 
M5005_Spy0732 NIF3-related protein  1.24 2E-02 
M5005_Spy0735 dTDP-4-dehydrorhamnose 3,5-epimerase cpsFP -1.04 8E-04 
M5005_Spy0737 
mutator mutT protein/7,8-dihydro-8-
oxoguanine-triphosphatase  -1.48 6E-05 
M5005_Spy0738 hypothetical membrane spanning protein  -1.64 2E-06 
M5005_Spy0739 tetratricopeptide repeat family protein  -1.19 1E-03 
M5005_Spy0751 
pyruvate dehydrogenase E1 component alpha 
subunit acoA 1.95 5E-03 
M5005_Spy0752 
pyruvate dehydrogenase E1 component beta 
subunit acoB 1.85 9E-04 
M5005_Spy0753 
dihydrolipoamide acetyltransferase component 
of pyruvate dehydrogenase complex acoC 1.02 5E-03 
M5005_Spy0774 nucleoside diphosphate kinase  2.02 5E-03 
M5005_Spy0775 nucleoside diphosphate kinase  1.61 6E-04 
M5005_Spy0780 
PTS system, Mannose/Fructose family IIA 
component ptsA 1.51 8E-03 
M5005_Spy0781 
PTS system, Mannose/Fructose family IIB 
component ptsB 1.33 1E-03 
M5005_Spy0783 
PTS system, Mannose/Fructose family IID 
component ptsD 1.12 1E-02 
M5005_Spy0790 succinate-semialdehyde dehydrogenase gabD -1.23 1E-02 
M5005_Spy0791 excinuclease ABC subunit C uvrC -1.98 5E-04 
M5005_Spy0792 NAD(P)H-dependent quinone reductase  -2.64 1E-04 
M5005_Spy0793 Xaa-His dipeptidase  -1.74 2E-02 
M5005_Spy0794 
tRNA (5-carboxymethylaminomethyl-2-
thiouridylate) synthase thdF 2.16 5E-06 
M5005_Spy0795 LSU ribosomal protein L10P rplJ 1.52 9E-03 
M5005_Spy0796 LSU ribosomal protein L12P rplL 2.69 1E-03 
M5005_Spy0804 TCS-6 response regulator;  Streptin biosynthesis  srtR -0.94 4E-04 
M5005_Spy0806 lantibiotic precursor srtA -1.24 2E-03 
M5005_Spy0807 
ABC transporter (ATP binding)-lantibiotic 
associated srtT -1.63 6E-06 
M5005_Spy0808 lantibiotic transport ATP-binding protein srtF -0.95 3E-03 
M5005_Spy0809 lantibiotic transport permease protein srtE -1.98 4E-05 
M5005_Spy0810 lantibiotic transport permease protein srtG -1.62 1E-04 
M5005_Spy0811 transcriptional regulator, Cro/CI family  -1.29 5E-02 
M5005_Spy0820 
folylpolyglutamate synthase/dihydrofolate 
synthase folC.1 -2.04 6E-08 
M5005_Spy0821 GTP cyclohydrolase I folE -1.20 4E-04 
M5005_Spy0822 dihydropteroate synthase folP -1.11 2E-02 




pyrophosphokinase folK -1.51 1E-04 
M5005_Spy0825 
UDP-N-acetylenolpyruvoylglucosamine 





spermidine/putrescine transport system ATP-
binding protein potA 2.58 4E-05 
M5005_Spy0827 
spermidine/putrescine transport system 
permease protein potB 1.36 8E-04 
M5005_Spy0828 
spermidine/putrescine transport system 
permease protein potC 1.52 4E-03 
M5005_Spy0829 spermidine/putrescine-binding protein  2.29 3E-04 
M5005_Spy0835 class B acid phosphatase  -1.26 2E-03 
M5005_Spy0841 glutamine amidotransferase, class I  -1.06 3E-03 
M5005_Spy0843 hypothetical cytosolic protein  -1.46 8E-05 
M5005_Spy0845 ribose-phosphate pyrophosphokinase  -1.00 2E-03 
M5005_Spy0852 short chain dehydrogenase  2.02 2E-06 
M5005_Spy0853 short chain dehydrogenase  2.86 4E-07 
M5005_Spy0858 xanthine phosphoribosyltransferase xpt 4.52 2E-06 
M5005_Spy0859 xanthine permease  4.41 2E-09 
M5005_Spy0873 L-lactate dehydrogenase ldh 1.60 1E-03 
M5005_Spy0879 hypothetical protein  -2.03 3E-04 
M5005_Spy0880 conserved membrane protein  -5.13 1E-06 
M5005_Spy0881 hypothetical cytosolic protein  -5.63 7E-09 
M5005_Spy0883 ribonuclease HII  1.06 4E-05 
M5005_Spy0884 hypothetical protein smf 2.51 1E-08 
M5005_Spy0890 D-lactate dehydrogenase ddh 1.57 7E-03 
M5005_Spy0911 hypothetical protein  -1.01 8E-03 
M5005_Spy0914 phage transcriptional repressor  1.30 5E-03 
M5005_Spy0943 cytidine deaminase cdd 1.42 5E-04 
M5005_Spy0945 pantothenate kinase coaA -1.61 4E-04 
M5005_Spy0965 ABC transporter permease protein  -1.09 6E-04 
M5005_Spy0982 histidine-binding protein  1.14 1E-03 
M5005_Spy1017 phage protein  3.15 6E-03 
M5005_Spy1023 terminase large subunit  1.45 4E-02 
M5005_Spy1028 phage protein  3.67 2E-03 
M5005_Spy1046 phage protein  -1.28 5E-03 
M5005_Spy1062 maltodextrose utilization protein malA -1.96 4E-02 
M5005_Spy1063 ABC Cyclomaltodextrin permease protein malD -1.85 4E-02 
M5005_Spy1064 ABC Cyclomaltodextrin permease protein malC -1.57 5E-02 
M5005_Spy1065 alpha-amylase amyA -1.70 3E-02 
M5005_Spy1066 
neopullulanase/cyclomaltodextrinase/maltogenic 
alpha-amylase amyB -1.65 5E-02 
M5005_Spy1069 esterase  -0.99 3E-03 
M5005_Spy1070 protein precursor dltD -0.92 1E-02 
M5005_Spy1072 protein DltB dltB -1.47 7E-05 
M5005_Spy1073 D-alanine-activating enzyme dltA -1.43 1E-06 
M5005_Spy1074 hypothetical protein  -1.79 3E-04 
M5005_Spy1075 excinuclease ABC subunit B uvrB -1.57 6E-07 
M5005_Spy1079 PTS system, Cellobiose-specific IIC component  -2.09 3E-03 
M5005_Spy1080 hypothetical protein  -1.43 7E-03 
M5005_Spy1081 PTS system, Cellobiose-specific IIA component  -1.76 8E-03 
M5005_Spy1082 PTS system, Cellobiose-specific IIB component  -1.99 4E-03 
M5005_Spy1083 PTS system, Cellobiose-specific IIA component  -1.83 6E-04 
M5005_Spy1084 outer surface protein  -1.25 2E-02 
M5005_Spy1085 beta-glucosidase bglA.2 -1.61 7E-03 
M5005_Spy1093 hypothetical protein  -3.31 2E-06 
M5005_Spy1096 thioesterase superfamily protein  1.85 8E-03 
M5005_Spy1097 phosphorylase, Pnp/Udp family  -0.97 2E-02 
M5005_Spy1100 shikimate kinase aroK -1.23 5E-03 




M5005_Spy1106 protein G-related alpha 2M-binding protein grab 1.90 7E-05 
M5005_Spy1107 
UDP-N-acetylglucosamine 1-carboxyvinyl 
transferase murZ 1.34 7E-03 
M5005_Spy1109 internalin protein inlA 1.27 1E-03 
M5005_Spy1114 hypothetical membrane spanning protein  -1.93 9E-04 
M5005_Spy1117 ATP-dependent RNA helicase deaD2 -1.00 4E-03 
M5005_Spy1120 
phosphoenolpyruvate-protein 
phosphotransferase pstI 1.55 6E-04 
M5005_Spy1122 glutaredoxin nrdH -1.87 5E-05 
M5005_Spy1123 
ribonucleoside-diphosphate reductase alpha 
chain nrdE.2 -1.62 1E-03 
M5005_Spy1124 ribonucleoside-diphosphate reductase beta chain nrdF.2 -1.07 5E-03 
M5005_Spy1125 chloride channel protein  -1.59 3E-06 
M5005_Spy1131 transcriptional regulator, Cro/CI family  2.11 4E-05 
M5005_Spy1132 alanyl-tRNA synthetase alaS 2.46 9E-06 
M5005_Spy1137 putative competence protein/transcription factor  1.62 2E-03 
M5005_Spy1139 glucosamine-6-phosphate isomerase nagB 1.24 3E-03 
M5005_Spy1142 hypothetical protein  -2.17 9E-03 
M5005_Spy1143 hypothetical protein  -2.16 2E-02 
M5005_Spy1144 hypothetical protein  -2.26 1E-03 
M5005_Spy1149 1-acyl-sn-glycerol-3-phosphate acyltransferase  1.23 3E-02 
M5005_Spy1152 kup system potassium uptake protein  1.56 3E-04 
M5005_Spy1167 
lead, cadmium, zinc and mercury transporting 
ATPase; MtsR, PerR regulated pmtA 1.43 2E-03 
M5005_Spy1199 phage protein  2.11 3E-02 
M5005_Spy1205 phage protein  1.51 1E-02 
M5005_Spy1227 hypothetical protein  1.08 3E-03 
M5005_Spy1229 arginine repressor argR1 1.72 7E-03 
M5005_Spy1230 hemolysin  1.18 5E-02 
M5005_Spy1231 dimethylallyltransferase/geranyltranstransferase fps 1.55 2E-02 
M5005_Spy1232 exodeoxyribonuclease VII small subunit xseB 2.43 1E-03 
M5005_Spy1237 arginine transport ATP-binding protein artP 2.19 8E-05 
M5005_Spy1238 arginine transport system permease protein artQ 1.52 1E-03 
M5005_Spy1241 
mutator protein (7,8-dihydro-8-oxoguanine-
triphosphatase) mutT -0.95 2E-03 
M5005_Spy1256 rhodanese-related sulfurtransferases  1.12 8E-03 
M5005_Spy1257 glucokinase/Xylose repressor glcK 1.98 3E-04 
M5005_Spy1258 hypothetical cytosolic protein  2.50 3E-06 
M5005_Spy1263 hypothetical protein  -1.65 3E-03 
M5005_Spy1270 carbamate kinase arcC -3.88 3E-05 
M5005_Spy1271 Xaa-His dipeptidase  -4.11 6E-09 
M5005_Spy1272 arginine/ornithine antiporter  -4.09 2E-07 
M5005_Spy1273 ornithine carbamoyltransferase arcB -4.04 4E-06 
M5005_Spy1274 acetyltransferase  -3.79 2E-07 
M5005_Spy1275 arginine deiminase arcA -3.22 2E-04 
M5005_Spy1281 TCS-9 response regulator yesN-like tcs9R -0.99 2E-02 
M5005_Spy1297 phospho-2-dehydro-3-deoxyheptonate aldolase  1.91 7E-04 
M5005_Spy1298 3-dehydroquinate synthase aroB 2.02 8E-03 
M5005_Spy1299 hypothetical protein  -1.91 4E-02 
M5005_Spy1305 TCS-10 response regulator; TCS-X; YesN-like  trxR -1.20 1E-02 
M5005_Spy1308 ABC unknown sugar-binding protein  -1.79 9E-03 
M5005_Spy1309 ABC unknown sugar permease protein  -2.78 7E-03 
M5005_Spy1310 ABC unknown sugar permease protein  -2.82 6E-03 
M5005_Spy1311 glucokinase  -1.95 2E-03 
M5005_Spy1312 hypothetical protein  -3.23 3E-03 




M5005_Spy1323 transposase  -1.12 2E-02 
M5005_Spy1329 cysteine synthase cysM 3.54 1E-05 
M5005_Spy1334 transporter yvqF -1.13 1E-02 
M5005_Spy1340 DNA-directed RNA polymerase omega chain  2.04 2E-05 
M5005_Spy1341 guanylate kinase gmk 1.23 4E-03 
M5005_Spy1342 hydrolase, HAD superfamily  1.30 4E-04 
M5005_Spy1344 acetyl-CoA acetyltransferase atoB -1.16 5E-04 
M5005_Spy1346 acetate CoA-transferase beta subunit atoA -1.44 7E-04 
M5005_Spy1347 D-beta-hydroxybutyrate dehydrogenase  -1.76 1E-03 
M5005_Spy1348 D-beta-hydroxybutyrate permease  -2.18 6E-08 
M5005_Spy1354 recombination protein recU -1.14 3E-03 
M5005_Spy1356 aminopeptidase C pepC -1.25 2E-02 
M5005_Spy1359 amino acid permease  1.36 2E-04 
M5005_Spy1362 transporter  1.78 4E-06 
M5005_Spy1363 amino acid ABC transporter permease protein  1.17 2E-03 
M5005_Spy1374 hypothetical protein  1.17 1E-02 
M5005_Spy1376 transaldolase  -2.82 1E-04 
M5005_Spy1377 trans-acting positive regulator  -2.26 3E-03 
M5005_Spy1378 NADH peroxidase  -1.90 2E-02 
M5005_Spy1379 glycerol uptake facilitator protein glpF -4.84 1E-05 
M5005_Spy1380 alpha-glycerophosphate oxidase glpO -4.44 2E-07 
M5005_Spy1381 glycerol kinase glpK -4.13 5E-08 
M5005_Spy1391 degV family protein  -1.76 8E-06 
M5005_Spy1393 hydrolase, HAD superfamily  -1.17 5E-05 
M5005_Spy1395 tagatose-bisphosphate aldolase; SpeB regulator lacD.1 -2.93 3E-04 
M5005_Spy1396 tagatose-6-phosphate kinase lacC.1 -2.29 6E-03 
M5005_Spy1397 galactose-6-phosphate isomerase lacB subunit lacB.1 -2.54 8E-04 
M5005_Spy1398 galactose-6-phosphate isomerase lacA subunit lacA.1 -2.63 4E-03 
M5005_Spy1399 PTS system, Galactose-specific IIC component  -2.16 2E-02 
M5005_Spy1408 ribosome-binding factor A rbfA 1.44 2E-03 
M5005_Spy1409 bacterial protein translation initiation factor 2 infB 1.69 2E-04 
M5005_Spy1410 LSU ribosomal protein L7AE  1.47 3E-04 
M5005_Spy1412 N utilization substance protein A nusA 1.09 4E-03 
M5005_Spy1420 phage protein  1.52 3E-03 
M5005_Spy1428 phage protein  1.79 3E-03 
M5005_Spy1432 phage protein  1.08 3E-02 
M5005_Spy1441 phage terminase small subunit  1.52 1E-02 
M5005_Spy1442 phage transcriptional activator  2.16 3E-04 
M5005_Spy1444 adenine-specific methyltransferase  2.09 6E-03 
M5005_Spy1445 phage protein  2.05 5E-03 
M5005_Spy1447 phage-related DNA helicase  1.20 2E-02 
M5005_Spy1448 hypothetical protein  1.52 4E-02 
M5005_Spy1449 DNA primase  1.45 2E-02 
M5005_Spy1450 phage-encoded DNA polymerase  1.45 8E-03 
M5005_Spy1454 phage protein  1.20 1E-02 
M5005_Spy1455 phage protein  1.60 2E-02 
M5005_Spy1459 phage protein  2.58 1E-03 
M5005_Spy1466 phage protein  1.29 3E-02 
M5005_Spy1472 
bis(5'-nucleosyl)-tetraphosphatase 
(asymmetrical) hit -1.32 2E-03 
M5005_Spy1476 ATP/GTP hydrolase  1.16 2E-04 
M5005_Spy1477 guanine-hypoxanthine permease  2.27 2E-05 
M5005_Spy1479 
PTS system, Mannose-specific IIAB; Primary 
Glucose PTS manL 2.99 7E-05 
M5005_Spy1480 
PTS system, Mannose-specific IIC; Primary 





PTS system, Mannose-specific IID; Primary 
Glucose PTS manN 2.78 4E-05 
M5005_Spy1482 hypothetical cytosolic protein manO -0.97 3E-02 
M5005_Spy1493 acyl carrier protein acpP 1.39 2E-02 
M5005_Spy1497 chaperone protein dnaJ 1.27 3E-03 
M5005_Spy1504 hypothetical membrane spanning protein  1.14 2E-02 
M5005_Spy1508 
glutamyl-tRNA(Gln) amidotransferase subunit 
C gatC 1.04 4E-04 
M5005_Spy1511 pyrazinamidase/nicotinamidase  1.01 3E-02 
M5005_Spy1518 transporter  1.52 4E-03 
M5005_Spy1519 ATP-dependent DNA helicase recG -1.14 5E-04 
M5005_Spy1520 hypothetical protein  -4.09 7E-04 
M5005_Spy1523 ABC transporter, ATP-binding protein siaF -1.09 7E-04 
M5005_Spy1533 holo-[acyl-carrier protein] synthase alr 1.13 8E-03 
M5005_Spy1538 mannose-6-phosphate isomerase pmi -1.39 8E-04 
M5005_Spy1539 fructokinase scrK 1.59 5E-04 
M5005_Spy1553 SSU ribosomal protein S18P rpsR 1.93 1E-03 
M5005_Spy1559 thioredoxin trx -1.26 3E-03 
M5005_Spy1569 formate acetyltransferase pfl 2.57 4E-07 
M5005_Spy1574 universal stress protein family  8.91 2E-10 
M5005_Spy1575 quinolone resistance protein norA 9.81 1E-12 
M5005_Spy1581 transcriptional regulator, MerR family  1.32 8E-03 
M5005_Spy1582 DNA polymerase III, epsilon chain dnaQ 1.26 7E-03 
M5005_Spy1598 hypothetical protein  -1.38 2E-04 
M5005_Spy1606 LSU ribosomal protein L28P rpmB 2.04 2E-05 
M5005_Spy1610 CTP synthase pyrG 2.63 8E-06 
M5005_Spy1611 DNA-directed RNA polymerase delta chain rpoE 1.33 1E-04 
M5005_Spy1627 ABC transporter permease protein salY -1.16 5E-04 
M5005_Spy1644 
DNA integration/recombination/invertion 
protein  2.93 3E-02 
M5005_Spy1646 SSU ribosomal protein S9P rpsI 1.92 4E-04 
M5005_Spy1647 LSU ribosomal protein L13P rplM 1.51 1E-03 
M5005_Spy1661 transaldolase  -1.72 2E-03 
M5005_Spy1662 putative transport protein  -1.70 1E-03 
M5005_Spy1664 PTS system, Mannitol-specific IIA component  -1.17 3E-02 
M5005_Spy1666 SSU ribosomal protein S15P  1.83 4E-04 
M5005_Spy1667 hypothetical protein  1.58 1E-03 
M5005_Spy1671 transcriptional regulator, MarR family  -1.00 8E-03 
M5005_Spy1675 phosphatidate cytidylyltransferase cdsA -1.21 5E-04 
M5005_Spy1691 exodeoxyribonuclease III  -1.63 2E-04 
M5005_Spy1697 
para-aminobenzoate synthetase component I/4-
amino-4-deoxychorismate lyase  -1.09 3E-04 
M5005_Spy1698 
anthranilate synthase component II/para-
aminobenzoate synthase glutamine 
amidotransferase component II trpG -1.45 1E-04 
M5005_Spy1699 ATPase, AAA family  -1.70 9E-06 
M5005_Spy1710 streptococcal histidine triad protein  3.01 4E-08 
M5005_Spy1711 
laminin binding lipoprotein; virulence assoc; 
AdcR- repressed lsp 2.25 3E-05 
M5005_Spy1714 cell surface protein; Mga-regulated fba 2.51 2E-03 
M5005_Spy1715 C5A peptidase precursor; Mga-regulated scpA 2.20 3E-03 
M5005_Spy1716 transposase  -1.66 9E-05 
M5005_Spy1717 transposase  -2.47 1E-03 
M5005_Spy1718 
streptococcal inhibitor of complement; Mga-
regulated sic1.0 2.32 2E-03 




M5005_Spy1730 hypothetical protein  -1.45 1E-04 
M5005_Spy1736 hypothetical protein  -2.04 2E-02 
M5005_Spy1737 Stand-alone transcriptional regulator Rgg, RopB 
rgg, 
ropB -1.43 1E-02 
M5005_Spy1738 phage-associated deoxyribonuclease spd 1.45 8E-04 
M5005_Spy1741 glycerol dehydrogenase gldA -1.50 1E-04 
M5005_Spy1742 transaldolase mipB -1.35 9E-04 
M5005_Spy1743 formate acetyltransferase pflD -1.35 2E-05 
M5005_Spy1745 PTS system, Cellobiose-specific IIB component celB -1.64 3E-02 
M5005_Spy1747 sorbitol operon regulator  1.07 3E-02 
M5005_Spy1765 cold shock protein csp 1.67 8E-03 
M5005_Spy1768 peroxiredoxin reductase (NAD(P)H) ahpC -1.07 6E-03 
M5005_Spy1769 peroxiredoxin reductase (NAD(P)H) ahpF -1.24 6E-03 
M5005_Spy1770 imidazolonepropionase hutI -5.24 1E-03 
M5005_Spy1771 urocanate hydratase hutU -5.28 1E-02 
M5005_Spy1773 formiminotetrahydrofolate cyclodeaminase  -7.25 3E-03 
M5005_Spy1774 formate--tetrahydrofolate ligase fhs.2 -7.37 2E-03 
M5005_Spy1775 hypothetical cytosolic protein  -6.67 9E-03 
M5005_Spy1776 amino acid permease  -7.13 4E-03 
M5005_Spy1777 histidine ammonia-lyase hutH -6.67 2E-03 
M5005_Spy1778 formiminoglutamase hutG -1.82 6E-03 
M5005_Spy1780 SSU ribosomal protein S2P rpsB 1.79 3E-04 
M5005_Spy1781 protein translation elongation factor Ts  1.72 6E-04 
M5005_Spy1782 neutral endopeptidase pepO -1.38 2E-04 
M5005_Spy1783 trehalose-6-phosphate hydrolase treC -1.55 3E-04 
M5005_Spy1784 
PTS system, Trehalose-specific IIBC 
component treB -0.95 4E-02 
M5005_Spy1786 transcriptional regulator, MarR family  2.52 3E-04 
M5005_Spy1787 glyoxalase family protein  -1.05 8E-03 
M5005_Spy1789 
anaerobic ribonucleoside-triphosphate reductase 
activating protein nrdG 1.44 2E-03 
M5005_Spy1790 acetyltransferase  2.23 1E-02 
M5005_Spy1792 hypothetical protein  1.02 2E-03 
M5005_Spy1797 hypothetical cytosolic protein  -1.38 1E-04 
M5005_Spy1798 suppressor of clpP & X SpxA homolog, allele 2 spxA2 -2.61 2E-04 
M5005_Spy1802 holliday junction DNA helicase ruvA -1.19 6E-04 
M5005_Spy1803 multidrug resistance protein B lmrP -1.12 2E-03 
M5005_Spy1806 hypothetical cytosolic protein  1.45 4E-03 
M5005_Spy1810 hypothetical membrane spanning protein  1.47 6E-03 
M5005_Spy1811 hypothetical membrane spanning protein  2.32 1E-02 
M5005_Spy1812 hypothetical membrane spanning protein  1.18 1E-02 
M5005_Spy1815 LSU ribosomal protein L32P rpmF 2.49 1E-03 
M5005_Spy1821 hypothetical protein  1.20 3E-03 
M5005_Spy1823 integral membrane protein  -1.65 1E-05 
M5005_Spy1830 transcriptional regulator, TetR family  1.12 7E-03 
M5005_Spy1831 SSU ribosomal protein S4P rpsD 1.43 2E-03 
M5005_Spy1834 hypothetical protein  1.49 1E-03 
M5005_Spy1840 
tRNA (5-methylaminomethyl-2-thiouridylate)-
methyltransferase trmU 1.32 2E-02 
M5005_Spy1841 L-serine dehydratase sdhB 3.26 1E-03 
M5005_Spy1842 L-serine dehydratase sdhA 3.50 6E-04 
M5005_Spy1843 transglycosylase SLT domain family protein  2.76 1E-04 
M5005_Spy1847 
CDP-diacylglycerol--glycerol-3-phosphate 3-
phosphatidyltransferase  -0.96 1E-02 
M5005_Spy1849 zinc protease  -0.93 9E-03 




M5005_Spy1853 UTP--glucose-1-phosphate uridylyltransferase hasC 1.24 2E-03 
M5005_Spy1862 ABC transporter, permease protein  -1.42 5E-05 
M5005_SpyT0010 tRNA-Pro  2.48 3E-04 
M5005_SpyT0021 tRNA-Met  1.91 3E-02 
M5005_SpyT0027 tRNA-Ile  2.55 4E-02 
M5005_SpyT0028 tRNA-Ser  2.46 4E-04 
M5005_SpyT0030 tRNA-Val  3.10 1E-02 
M5005_SpyT0038 tRNA-Tyr  2.01 1E-02 
M5005_SpyT0041 tRNA-Leu  1.71 5E-02 
M5005_SpyT0048 tRNA-Arg  -1.43 2E-02 
M5005_SpyT0051 tRNA-Ile  4.60 4E-05 
M5005_SpyT0052 tRNA-Thr  2.23 2E-03 
M5005_SpyT0059 tRNA-Leu  2.56 5E-03 
M5005_SpyT0065 tRNA-Asp  1.45 4E-02 




a Both Limma & DESeq analyses exhibited Log2 fold-change  of –0.95 ≤ or ≥ 095. Limma data only 
shown. 





Appendix 3: RNA-Seq results of a mga mutant in THY (WT/∆mga) 
 












M5005_Spy0040 alcohol dehydrogenase adhA 1.21 5.05E-02 











M5005_Spy0115 hypothetical protein 
 
1.21 2.16E-05 
M5005_Spy0117 transcriptional regulator, LysR family 
 
2.06 1.59E-04 
M5005_Spy0118 transcriptional regulator, LysR family 
 
1.32 2.67E-02 
M5005_Spy0143 hypothetical protein 
 
2.54 5.24E-03 
M5005_Spy0156 metal-dependent hydrolase 
 
1.16 9.06E-03 













M5005_Spy0260 putative lipase 
 
-1.04 1.51E-03 






M5005_Spy0313 riboflavin transporter 
 
-1.20 1.40E-04 
M5005_Spy0318 pyruvate formate-lyase activating enzyme pflC 1.52 8.23E-07 
M5005_Spy0319 
manganese-dependent inorganic 
pyrophosphatase ppaC 0.90 4.79E-05 
M5005_Spy0340 L-lactate oxidase lctO 2.47 2.56E-04 
M5005_Spy0341 lactocepin; SpyCEP; IL-8 protease 
spyCE




M5005_Spy0361 phosphoglycerate transporter protein 
 
1.01 7.77E-03 
M5005_Spy0383 D-alanyl-D-alanine carboxypeptidase 
 
-1.04 2.70E-03 
M5005_Spy0432 acetyl-CoA acetyltransferase 
 
-1.22 4.35E-04 
M5005_Spy0456 plasmid stabilization system antitoxin protein 
 
-1.13 1.13E-02 
M5005_Spy0469 hypothetical protein 
 
-1.04 3.96E-03 
M5005_Spy0471 hydrolase, HAD superfamily 
 
-1.09 3.40E-03 
M5005_Spy0494 hypothetical protein 
 
-1.19 4.26E-03 




PTS system, N-acetylgalactosamine-specific 
IID  agaD 1.02 3.58E-02 
M5005_Spy0520 
PTS system, N-acetylgalactosamine-specific 
IIC  agaS 1.89 4.88E-05 
M5005_Spy0522 unsaturated glucuronyl hydrolase 
 
1.45 8.61E-04 
M5005_Spy0549 chorismate mutase 
 
-1.15 3.80E-04 
M5005_Spy0585 epuA protein epuA -1.20 6.36E-03 
M5005_Spy0660 fructose repressor fruR 1.06 1.84E-02 
M5005_Spy0667 exotoxin type C precursor 
 
2.07 7.07E-03 
M5005_Spy0668 IgG-degrading protease mac 1.62 6.08E-04 
M5005_Spy0714 hypothetical cytosolic protein 
 
-1.24 2.46E-04 






M5005_Spy0743 ABC transporter substrate-binding protein 
 
-1.59 1.83E-05 
M5005_Spy0744 hypothetical protein 
 
-1.55 2.63E-04 
M5005_Spy0745 ABC transporter permease protein 
 
-1.26 3.78E-05 




PTS system, Mannose/Fructose family IIA 
component ptsA 1.50 6.80E-04 
M5005_Spy0781 
PTS system, Mannose/Fructose family IIB 
component ptsB 1.30 7.22E-05 
M5005_Spy0782 
PTS system, Mannose/Fructose family IIC 
component ptsC 1.03 1.35E-03 
M5005_Spy0786 iron(III)-binding protein 
 
0.89 1.97E-03 
M5005_Spy0793 Xaa-His dipeptidase 
 
-1.04 4.77E-02 
M5005_Spy0797 hypothetical protein 
 
-2.85 1.38E-02 






pyrophosphokinase folK -1.00 3.83E-04 
M5005_Spy0834 




M5005_Spy0853 short chain dehydrogenase 
 
0.96 7.07E-03 
M5005_Spy0858 xanthine phosphoribosyltransferase xpt -2.16 7.40E-05 
M5005_Spy0859 xanthine permease 
 
-1.81 6.01E-06 








M5005_Spy0921 ABC transporter ATP-binding protein 
 
-1.54 8.39E-05 








M5005_Spy0934 lipoate-protein ligase A 
 
1.07 5.14E-04 
M5005_Spy0978 hypothetical protein 
 
-1.17 6.29E-04 





aminotransferase (isomerizing) glmS -1.02 4.97E-04 
M5005_Spy1059 ABC Maltodextrin permease protein malF 0.94 2.81E-04 
M5005_Spy1062 maltodextrose utilization protein malA 1.49 4.11E-02 
M5005_Spy1063 ABC Cyclomaltodextrin permease protein malD 1.54 2.66E-02 
M5005_Spy1064 ABC Cyclomaltodextrin permease protein malC 1.38 2.28E-02 
M5005_Spy1065 alpha-amylase amyA 1.46 1.05E-02 
M5005_Spy1066 
neopullulanase/cyclomaltodextrinase/maltoge
nic alpha-amylase amyB 1.74 7.27E-03 
M5005_Spy1067 ABC Cyclomaltodextrin -binding protein malX 2.52 1.94E-05 
M5005_Spy1076 Putative Bicarbonate transporter glnH -1.31 2.34E-03 
M5005_Spy1077 Putative Bicarbonate transporter glnQ.2 -1.04 1.32E-02 
M5005_Spy1082 









M5005_Spy1084 outer surface protein 
 
1.02 1.76E-02 
M5005_Spy1085 beta-glucosidase bglA.2 1.46 2.32E-03 
M5005_Spy1093 hypothetical protein 
 
1.15 1.48E-02 
M5005_Spy1135 oxalate/formate antiporter 
 
-1.16 3.94E-06 
M5005_Spy1148 COME operon protein 1 
 
-1.32 2.04E-02 
















M5005_Spy1275 arginine deiminase arcA 1.75 4.22E-03 
M5005_Spy1284 cytochrome c-type biogenesis protein ccdA 1.31 2.87E-02 
M5005_Spy1299 hypothetical protein 
 
-2.03 3.07E-03 
M5005_Spy1314 hyaluronoglucosaminidase hyl 0.85 1.02E-02 
M5005_Spy1315 transcriptional regulator, GntR family 
 
1.18 3.01E-04 






M5005_Spy1340 DNA-directed RNA polymerase omega chain 
 
-1.50 1.71E-05 






M5005_Spy1377 trans-acting positive regulator 
 
1.09 5.66E-02 
M5005_Spy1387 aldo/keto reductase family 
 
1.35 2.37E-05 
M5005_Spy1397 galactose-6-phosphate isomerase lacB subunit lacB.1 1.10 5.00E-02 
M5005_Spy1477 guanine-hypoxanthine permease 
 
-1.29 2.08E-04 
M5005_Spy1488 biotin carboxyl carrier protein of acetyl-CoA  accB -1.20 1.61E-02 
M5005_Spy1489 3-oxoacyl-[acyl-carrier-protein] synthase fabF -1.11 2.96E-02 
M5005_Spy1491 
malonyl-CoA-[acyl-carrier-protein] 
transacylase fabD -1.21 4.90E-03 
M5005_Spy1492 
enoyl-[acyl-carrier protein] reductase 
(NADH) fabK -1.13 1.78E-02 
M5005_Spy1569 formate acetyltransferase pfl 1.06 8.55E-04 
M5005_Spy1572 hypothetical membrane spanning protein 
 
-1.36 1.35E-04 
M5005_Spy1587 uridine phosphorylase udp 1.12 3.29E-05 
M5005_Spy1589 
transcriptional regulator, Cathelicidin 
resistance crgR -1.13 7.00E-03 
M5005_Spy1618 competence-specific sigma factor 
comX.
2 -2.41 2.07E-02 
M5005_Spy1628 ABC transporter ATP-binding protein 
 
1.40 3.76E-03 
M5005_Spy1629 lantibiotic transport ATP-binding protein salX 1.53 4.27E-03 
M5005_Spy1630 serine (threonine) dehydratase salB 2.13 6.52E-06 
M5005_Spy1631 lantibiotic salivaricin A salA 1.81 3.35E-02 
M5005_Spy1632 6-phospho-beta-galactosidase lacG 2.06 2.70E-03 
M5005_Spy1633 
PTS system, Lactose-specific IIBC 
component lacE 2.12 4.34E-03 
M5005_Spy1634 PTS system, Lactose-specific IIA component lacF 2.06 1.43E-02 
M5005_Spy1635 tagatose-bisphosphate aldolase lacD.2 2.11 5.38E-03 
M5005_Spy1636 tagatose-6-phosphate kinase lacC.2 2.52 1.48E-03 
M5005_Spy1637 galactose-6-phosphate isomerase lacB subunit lacB.2 2.24 4.25E-03 






M5005_Spy1649 hypothetical membrane spanning protein 
 
-1.00 2.85E-03 
M5005_Spy1682 multiple sugar transport ATP-binding protein msmK 1.01 1.18E-03 
M5005_Spy1702 mitogenic exotoxin Z smeZ -1.15 1.79E-04 
M5005_Spy1705 dipeptide transport system permease protein dppB -1.09 6.94E-03 
M5005_Spy1709 hypothetical protein 
 
-1.47 7.88E-04 
M5005_Spy1714 cell surface protein; Mga-regulated fba 3.20 4.52E-06 









M5005_Spy1719 M protein; Mga-regulated emm1 9.08 8.56E-16 
M5005_Spy1720 Multi-virulence gene regulator Mga mga 4.60 2.76E-15 
M5005_Spy1721 hypothetical protein 
 
-2.78 6.42E-04 
M5005_Spy1733 hypothetical protein 
 
-2.54 4.21E-03 
M5005_Spy1734 streptopain SpeB inhibitor speI -2.94 3.09E-03 
M5005_Spy1735 streptococcal pyrogenic exotoxin B speB -2.73 2.05E-04 
M5005_Spy1738 phage-associated deoxyribonuclease spd 0.98 2.19E-03 
M5005_Spy1750 hypothetical protein 
 
-1.14 2.46E-04 
M5005_Spy1758 probable dipeptidase B 
 
1.09 5.27E-04 
M5005_Spy1759 transcriptional regulator, MutR family 
 
-1.10 6.96E-03 
M5005_Spy1762 10 kDa chaperonin groES -1.04 7.08E-03 




suppressor of clpP & X SpxA homolog, allele 
2 spxA2 -1.86 2.98E-04 
M5005_Spy1809 bacteriocin uviB -1.13 1.46E-03 
M5005_Spy1812 hypothetical membrane spanning protein 
 
-1.01 2.96E-03 

























a Both Limma & DESeq analyses exhibited Log2 fold-change  of –0.85 ≤ or ≥ 0.85. Limma data only 
shown. 





Appendix 4: RNA-Seq results of the mga mutant in C Media (WT/∆mga) 
 
Spy #  Annotation Gene Log2 FCa p valueb 





catalytic subunit purE 1.09 2.88E-02 
M5005_Spy0036 protein tyrosine phosphatase 
 
-0.93 3.99E-03 
M5005_Spy0091 comG operon protein 6 comYD 1.45 1.39E-02 
M5005_Spy0106 transcriptional regulator; Regulator of protein F rofA -1.09 1.79E-04 
M5005_Spy0113 transposase   1.32 1.76E-02 
M5005_Spy0129 V-type ATP synthase subunit C ntpC -1.78 6.66E-03 
M5005_Spy0130 V-type sodium ATP synthase subunit F ntpF -1.44 8.76E-03 
M5005_Spy0131 V-type sodium ATP synthase subunit A ntpA -1.30 1.38E-02 
M5005_Spy0132 V-type sodium ATP synthase subunit B ntpB -1.50 1.15E-02 
M5005_Spy0133 V-type sodium ATP synthase subunit D ntpD -1.57 8.51E-03 
M5005_Spy0136 adenylosuccinate synthetase purA -1.11 2.90E-05 
M5005_Spy0139 NAD glycohydrolase 
nga/ 
spn 1.04 4.63E-02 
M5005_Spy0140 NAD glycohydrolase inhibitor ifs 1.14 4.89E-02 
M5005_Spy0141 streptolysin O slo 1.12 2.94E-02 
M5005_Spy0143 hypothetical protein 
 
3.35 2.11E-03 




M5005_Spy0183 hypothetical membrane associated protein 
 
0.91 5.42E-03 
M5005_Spy0202 hypothetical protein 
 
-1.34 6.89E-05 










M5005_Spy0385 67 kDa Myosin-crossreactive antigen 
 
-1.32 6.12E-05 
M5005_Spy0403 hypothetical protein 
 
0.92 4.61E-02 
M5005_Spy0422 NAD(P)H-dependent quinone reductase 
 
-1.11 4.80E-05 
M5005_Spy0423 Xaa-Pro dipeptidase pepQ -1.23 4.72E-05 
M5005_Spy0477 hypothetical membrane spanning protein 
 
-0.97 2.83E-04 
M5005_Spy0478 hypothetical membrane spanning protein 
 
-1.08 5.98E-04 
M5005_Spy0486 hypothetical protein 
 
-1.08 2.60E-04 





3-deoxyphosphogluconate aldolase kgdA 1.03 5.35E-04 
M5005_Spy0555 hypothetical cytosolic protein 
 
-1.09 2.67E-04 
M5005_Spy0560 transcriptional regulator 
 
-0.94 1.36E-02 
M5005_Spy0562 streptolysin S precursor sagA 1.33 7.39E-04 
M5005_Spy0564 streptolysin S biosynthesis protein sagC 0.99 6.77E-04 
M5005_Spy0565 streptolysin S biosynthesis protein sagD 1.09 1.51E-04 
M5005_Spy0567 streptolysin S biosynthesis protein sagF 1.46 1.07E-04 
M5005_Spy0568 streptolysin S export ATP-binding protein sagG 1.30 2.50E-05 
M5005_Spy0569 streptolysin S export transmembrane protein sagH 1.09 3.36E-04 






M5005_Spy0598 large-conductance mechanosensitive channel mscL -0.88 2.64E-02 







M5005_Spy0641 aspartate carbamoyltransferase pyrB 0.90 5.65E-03 
M5005_Spy0651 Heme-utilization cell surface protein hupY 2.28 4.55E-09 
M5005_Spy0652 Heme-oxygenase cytosolic protein hupZ 2.16 5.20E-08 
M5005_Spy0668 IgG-degrading protease mac 1.37 1.24E-02 
M5005_Spy0679 GTP pyrophosphokinase 
 
-1.01 3.03E-04 
M5005_Spy0703 orotidine 5'-phosphate decarboxylase pyrF 1.15 9.19E-03 
M5005_Spy0708 uracil-DNA glycosylase ung -0.86 4.09E-02 
M5005_Spy0715 SSU ribosomal protein S1P 
 
1.28 9.43E-04 




dihydrolipoamide acetyltransferase component 
of pyruvate dehydrogenase complex acoC -0.85 8.15E-04 
M5005_Spy0754 hypothetical protein 
 
-1.50 5.80E-02 
M5005_Spy0755 dihydrolipoamide dehydrogenase acoL -1.16 2.91E-05 
M5005_Spy0794 
tRNA (5-carboxymethylaminomethyl-2-
thiouridylate) synthase thdF 1.10 2.70E-04 
M5005_Spy0820 
folylpolyglutamate synthase/dihydrofolate 
synthase folC.1 -0.98 1.95E-05 
M5005_Spy0821 GTP cyclohydrolase I folE -0.95 6.65E-05 




pyrophosphokinase folK -0.87 1.42E-3 
M5005_Spy0879 hypothetical protein 
 
-1.52 7.92E-05 
M5005_Spy0880 conserved membrane protein 
 
-2.45 2.47E-05 
M5005_Spy0881 hypothetical cytosolic protein 
 
-1.93 5.24E-05 






M5005_Spy1005 phage protein   -1.47 2.11E-02 
M5005_Spy1035 phage protein   1.44 6.01E-02 
M5005_Spy1076 Putative Bicarbonate transporter glnH -0.85 3.52E-02 
M5005_Spy1077 Putative Bicarbonate transporter glnQ.2 -1.04 1.02E-02 
M5005_Spy1093 hypothetical protein 
 
-1.16 1.95E-04 
M5005_Spy1145 superoxide dismutase sodA -0.93 5.73E-03 
M5005_Spy1169 streptodornase spd3 2.35 1.01E-06 
M5005_Spy1170 hypothetical membrane associated protein   2.39 6.14E-07 
M5005_Spy1199 phage protein   -1.87 9.59E-03 
M5005_Spy1211 phage protein   1.19 4.99E-02 
M5005_Spy1213 phage protein   1.28 7.48E-03 
M5005_Spy1227 hypothetical protein 
 
1.06 6.16E-05 
M5005_Spy1228 DNA repair protein recN 0.99 6.69E-03 




M5005_Spy1237 arginine transport ATP-binding protein artP 1.36 7.76E-04 
M5005_Spy1238 arginine transport system permease protein artQ 1.40 2.08E-04 
M5005_Spy1239 hypothetical cytosolic protein 
 
1.14 1.48E-02 
M5005_Spy1285 CRISPR2-associated protein Cas2 cas2 1.11 4.91E-04 
M5005_Spy1287 CRISPR2-associated protein Cas4 cas4 1.08 2.63E-04 
M5005_Spy1289 CRISPR2-associated protein Cds1 cds1 1.06 4.01E-07 
M5005_Spy1297 phospho-2-dehydro-3-deoxyheptonate aldolase 
 
1.18 3.04E-03 




M5005_Spy1325 ribosome-associated factor Y 
 
-1.16 5.79E-04 






M5005_Spy1372 ABC transporter permease protein proB 1.11 2.21E-04 
M5005_Spy1382 hypothetical membrane associated protein 
 
-1.40 1.37E-03 
M5005_Spy1400 PTS system, Galactose-specific IIB component   -2.47 2.38E-03 
M5005_Spy1401 PTS system, Galactose-specific IIA component   -2.66 2.89E-04 
M5005_Spy1407 streptococcal secreted esterase Sse sse 1.81 6.49E-04 
M5005_Spy1415 phage-encoded streptodornase sdaD2 2.22 8.65E-06 
M5005_Spy1440 terminase large subunit   1.23 1.17E-02 
M5005_Spy1441 phage terminase small subunit   1.12 3.41E-02 
M5005_Spy1514 universal stress protein family 
 
-1.22 1.16E-03 
M5005_Spy1525 conserved hypothetical protein siaD 1.09 2.23E-03 
M5005_Spy1526 
ABC transporter, ATP-binding protein, 
putative siaC 1.33 7.51E-07 
M5005_Spy1527 
ABC transporter, ATP-binding protein, 
putative siaB 1.39 1.21E-03 
M5005_Spy1528 
iron compound ABC transporter, ATP-binding 
protein siaA 1.44 9.46E-04 
M5005_Spy1529 
iron compound ABC transporter, permease 
protein shp 1.22 6.56E-05 
M5005_Spy1530 
iron compound ABC transporter, substrate-
binding protein shr 1.27 4.35E-07 
M5005_Spy1559 thioredoxin trx -0.96 9.74E-04 
M5005_Spy1590 SSU ribosomal protein S14P rpsN2 -1.22 7.50E-03 
M5005_Spy1622 
type I restriction-modification system 
specificity subunit hsdS 1.20 9.40E-07 
M5005_Spy1714 cell surface protein; Mga-regulated fba 4.79 8.72E-08 
M5005_Spy1715 C5A peptidase precursor; Mga-regulated scpA 5.04 2.90E-10 
M5005_Spy1716 transposase   -1.07 1.26E-04 
M5005_Spy1718 
streptococcal inhibitor of complement; Mga-
regulated sic1.0 5.53 2.06E-09 
M5005_Spy1719 M protein; Mga-regulated emm1 10.06 8.06E-17 
M5005_Spy1720 Multi-virulence gene regulator Mga mga 5.84 4.18E-17 
M5005_Spy1721 hypothetical protein 
 
-5.00 2.44E-08 
M5005_Spy1727 ABC transporter ATP-binding protein 
 
0.99 1.00E-02 
M5005_Spy1731 gene regulated by Mga;; Mga-regulated grm 3.85 7.69E-05 
M5005_Spy1733 hypothetical protein 
 
1.45 5.22E-02 
M5005_Spy1736 hypothetical protein 
 
-1.31 2.98E-02 
M5005_Spy1738 phage-associated deoxyribonuclease spd 1.03 3.17E-04 
M5005_Spy1739 hypothetical protein 
 
-3.02 3.24E-05 
M5005_Spy1754 translation initiation inhibitor 
 
-0.98 4.57E-02 
M5005_Spy1768 peroxiredoxin reductase (NAD(P)H) ahpC -0.92 1.06E-03 
M5005_Spy1774 formate--tetrahydrofolate ligase fhs.2 1.84 2.49E-02 
M5005_Spy1775 hypothetical cytosolic protein 
 
1.59 5.02E-02 
M5005_Spy1776 amino acid permease 
 
1.83 2.75E-02 
M5005_Spy1777 histidine ammonia-lyase hutH 2.16 9.13E-03 
M5005_Spy1778 formiminoglutamase hutG 1.01 9.55E-03 
M5005_Spy1798 suppressor of clpP & X SpxA homolog, allele 2 spxA2 -1.07 1.68E-02 
M5005_Spy1823 integral membrane protein 
 
-0.88 3.46E-04 
M5005_Spy1843 transglycosylase SLT domain family protein 
 
1.33 4.54E-03 
M5005_SpyT0010 tRNA-Pro 1.33 4.54E-03 
M5005_SpyT0021 tRNA-Met  1.07 1.87E-02 
M5005_SpyT0028 tRNA-Ser  1.68 2.07E-02 
M5005_SpyT0038 tRNA-Tyr  1.43 4.17E-03 
M5005_SpyT0039 tRNA-His  2.21 7.82E-04 




M5005_SpyT0046 tRNA-Tyr  2.38 2.22E-03 
M5005_SpyT0047 tRNA-Gln  1.48 1.47E-02 
M5005_SpyT0051 tRNA-Ile  2.04 4.62E-04 
M5005_SpyT0052 tRNA-Thr  1.78 3.51E-02 
M5005_SpyT0058 tRNA-Ser  1.29 3.34E-02 
M5005_SpyT0064 tRNA-Cys  1.37 8.30E-03 
M5005_SpyT0065 tRNA-Asn  1.27 3.24E-02 
     
a Both Limma & DESeq analyses exhibited Log2 fold-change  of –0.85 ≤ or ≥ 0.85. Limma data only 
shown. 





Appendix 5: Differential Expression of intergenic region in WT 5448 in CDM-
glucose compared to CDM-fructose at late log (CDM-glu/CDM-fru) 
 
Spy #a Gene Name Log2 FCb p valuec 
M5005_Spy0040 adhA -1.89 1.04E-02 
M5005_Spy0154  2.43 2.10E-02 
M5005_Spy0170 nadC -1.34 7.19E-04 
M5005_Spy0207 fasX -1.37 1.52E-05 
M5005_Spy0216  1.40 7.63E-03 
M5005_Spy0660 fruR -1.12 8.86E-03 
M5005_Spy0661 fruB -2.47 9.49E-03 
M5005_Spy0662 fruA -2.60 2.21E-03 
M5005_Spy0663 mur1.1 -2.37 1.55E-07 
M5005_Spy0968  1.37 1.32E-02 
M5005_Spy1005  2.69 1.57E-03 
M5005_Spy1010  3.45 9.78E-04 
M5005_Spy1011  2.14 2.83E-02 
M5005_Spy1012  2.91 1.03E-03 
M5005_Spy1017  2.16 1.30E-02 
M5005_Spy1021  2.76 2.08E-03 
M5005_Spy1022  2.89 2.43E-03 
M5005_Spy1026  1.69 2.89E-03 
M5005_Spy1027  2.06 9.45E-04 
M5005_Spy1029  2.32 1.66E-03 
M5005_Spy1030  3.04 5.72E-04 
M5005_Spy1031  2.04 7.79E-03 
M5005_Spy1032  3.56 1.47E-05 
M5005_Spy1034  2.26 2.07E-05 
M5005_Spy1035  2.73 4.20E-05 
M5005_Spy1036 ssb2 2.39 1.01E-03 
M5005_Spy1038  3.00 1.46E-06 
M5005_Spy1039  2.98 2.39E-06 
M5005_Spy1040  2.73 1.18E-04 
M5005_Spy1041  2.16 3.14E-03 
M5005_Spy1042  2.30 9.72E-05 
M5005_Spy1043  2.59 1.26E-05 
M5005_Spy1044  2.27 2.76E-06 
M5005_Spy1049  1.46 4.41E-04 
M5005_Spy1139 nagB 1.33 1.22E-03 
M5005_Spy1154 deaD -1.18 1.77E-02 
M5005_Spy1185  2.59 6.44E-03 
M5005_Spy1186  2.20 1.15E-02 
M5005_Spy1188  3.15 1.48E-03 
M5005_Spy1198  1.80 8.37E-05 
M5005_Spy1200  2.66 2.42E-04 
M5005_Spy1201  3.02 2.66E-04 
M5005_Spy1202  2.03 4.92E-04 
M5005_Spy1203  2.11 6.27E-03 
M5005_Spy1204  2.48 1.23E-04 
M5005_Spy1205  2.38 3.53E-03 
M5005_Spy1206  3.04 5.57E-05 
M5005_Spy1207  2.54 3.67E-04 
M5005_Spy1209  2.67 1.57E-03 
M5005_Spy1210  2.75 1.52E-04 
M5005_Spy1211  3.56 3.53E-05 




M5005_Spy1217  1.76 2.81E-04 
M5005_Spy1218  1.72 4.43E-04 
M5005_Spy1307  -1.87 2.77E-02 
M5005_Spy1415 sdaD2 1.93 3.73E-04 
M5005_Spy1416  1.61 8.70E-03 
M5005_Spy1417  2.53 6.97E-07 
M5005_Spy1418  2.79 9.09E-06 
M5005_Spy1419  3.41 9.83E-07 
M5005_Spy1420  3.06 1.37E-06 
M5005_Spy1421  2.50 2.19E-06 
M5005_Spy1422  2.02 4.90E-05 
M5005_Spy1423  2.45 4.87E-07 
M5005_Spy1424  2.27 5.27E-04 
M5005_Spy1425  2.80 7.23E-07 
M5005_Spy1426  2.84 5.46E-06 
M5005_Spy1427  2.68 2.51E-07 
M5005_Spy1428  3.11 4.14E-07 
M5005_Spy1429  2.66 1.47E-07 
M5005_Spy1430  2.77 1.05E-07 
M5005_Spy1431  2.53 8.65E-09 
M5005_Spy1432  2.59 2.36E-08 
M5005_Spy1433  2.88 1.96E-06 
M5005_Spy1434  2.77 1.63E-08 
M5005_Spy1435  2.68 2.04E-08 
M5005_Spy1436  2.89 1.23E-08 
M5005_Spy1437  2.66 3.40E-09 
M5005_Spy1438  2.35 8.25E-04 
M5005_Spy1439  2.61 2.39E-07 
M5005_Spy1440  2.13 4.07E-05 
M5005_Spy1441  2.34 5.74E-05 
M5005_Spy1442  2.44 1.90E-03 
M5005_Spy1444  1.79 3.88E-03 
M5005_Spy1446  1.98 1.05E-02 
M5005_Spy1447  2.19 8.63E-04 
M5005_Spy1448  3.41 7.60E-08 
M5005_Spy1449  2.17 2.44E-04 
M5005_Spy1451  2.25 2.46E-07 
M5005_Spy1452  3.15 9.52E-09 
M5005_Spy1453  1.92 1.57E-03 
M5005_Spy1454  2.52 9.63E-04 
M5005_Spy1455  2.44 4.07E-05 
M5005_Spy1456  2.63 9.01E-05 
M5005_Spy1457  2.62 3.06E-05 
M5005_Spy1458  1.90 2.04E-04 
M5005_Spy1459  2.19 2.38E-05 
M5005_Spy1460  1.71 1.21E-03 
M5005_Spy1461  2.49 1.48E-06 
M5005_Spy1462  1.72 7.27E-05 
M5005_Spy1575 norA 2.69 2.53E-06 
M5005_Spy1746  2.77 1.08E-02 
M5005_Spy1779  2.50 1.33E-02 
M5005_Spy1838 gidA 1.63 9.30E-04 
 
a Analysis conducted on intergenic region 5’ to spy number listed 
b Both Limma & DESeq analyses exhibited Log2 fold-change  of –1 ≤ or ≥ 1. Limma data only shown. 




Appendix 6: Differential Expression WT 5448 in C media compared to THY at late 
log (WT C media/ WT THY) 
 
Spy #a Gene Name Log2 FCb p valuec 
M5005_Spy0012  1.60 9.79E-04 
M5005_Spy0013 ftsH 1.16 7.43E-03 
M5005_Spy0014  1.93 3.97E-04 
M5005_Spy0022  2.37 3.43E-03 
M5005_Spy0023  -2.32 1.57E-02 
M5005_Spy0024 purF -1.38 1.69E-02 
M5005_Spy0025 purM -2.15 1.78E-02 
M5005_Spy0026 purN -2.23 1.63E-03 
M5005_Spy0027  -2.94 2.05E-06 
M5005_Spy0028  -2.35 4.11E-04 
M5005_Spy0029 purD -2.99 2.13E-05 
M5005_Spy0030 purE -2.31 2.13E-03 
M5005_Spy0031 purK -1.92 9.53E-03 
M5005_Spy0032  -1.55 1.02E-03 
M5005_Spy0033 purB -1.90 8.23E-04 
M5005_Spy0034  -1.67 9.58E-05 
M5005_Spy0039 adh2 1.44 4.03E-02 
M5005_Spy0040 adhA 2.34 3.06E-03 
M5005_Spy0041  2.56 3.01E-03 
M5005_Spy0043 rpsJ -1.77 9.07E-04 
M5005_Spy0069 rpsK -2.10 2.20E-04 
M5005_Spy0070 rpoA -1.60 1.33E-03 
M5005_Spy0071 rplQ -2.04 6.24E-05 
M5005_Spy0073  -1.92 9.29E-05 
M5005_Spy0074  -1.19 1.39E-02 
M5005_Spy0076  -1.79 2.25E-03 
M5005_Spy0085  -2.66 4.03E-06 
M5005_Spy0089  -2.03 1.48E-02 
M5005_Spy0095  -1.86 5.30E-03 
M5005_Spy0103  -1.45 9.43E-03 
M5005_Spy0104  -1.32 4.15E-03 
M5005_Spy0108  -1.85 4.13E-03 
M5005_Spy0109  -2.82 7.35E-06 
M5005_Spy0110 eftLSL.B -2.14 1.38E-03 
M5005_Spy0111  -3.26 7.33E-07 
M5005_Spy0112  -2.22 2.49E-05 
M5005_Spy0114  -1.44 3.84E-03 
M5005_Spy0116 atoE 3.12 1.62E-03 
M5005_Spy0144  -3.16 2.16E-03 
M5005_Spy0149  2.94 3.44E-04 
M5005_Spy0150  2.80 3.39E-03 
M5005_Spy0151  3.37 5.66E-03 
M5005_Spy0152  3.08 5.45E-03 
M5005_Spy0153 araD 3.55 8.84E-04 
M5005_Spy0154  3.88 4.43E-04 
M5005_Spy0157 opuAA -1.18 6.43E-03 
M5005_Spy0158 opuABC -2.72 3.10E-07 
M5005_Spy0159 polA -3.04 2.17E-07 
M5005_Spy0165  -1.88 9.89E-03 
M5005_Spy0166  -2.21 5.74E-03 




M5005_Spy0185 pgi -1.51 6.33E-03 
M5005_Spy0195  1.61 1.91E-03 
M5005_Spy0211 rpmH -2.19 4.38E-05 
M5005_Spy0214  1.86 6.86E-03 
M5005_Spy0215  2.04 1.13E-02 
M5005_Spy0217 nanH 1.77 1.34E-02 
M5005_Spy0222 ksgA -1.69 3.43E-04 
M5005_Spy0226  1.37 1.36E-02 
M5005_Spy0230 rpsL -1.68 3.92E-04 
M5005_Spy0231 rpsG -2.29 5.41E-05 
M5005_Spy0232 fus -1.53 1.19E-03 
M5005_Spy0236  -1.74 4.40E-05 
M5005_Spy0273  -1.70 2.76E-02 
M5005_Spy0274 braB -2.76 7.25E-03 
M5005_Spy0275  -1.61 4.18E-02 
M5005_Spy0285 dnaB 1.55 3.23E-04 
M5005_Spy0296  1.43 1.39E-03 
M5005_Spy0306  1.06 8.70E-03 
M5005_Spy0307  1.73 3.80E-04 
M5005_Spy0308  1.74 1.96E-03 
M5005_Spy0324 fhuA -2.38 2.53E-04 
M5005_Spy0334  1.03 1.26E-02 
M5005_Spy0337 cutC 1.81 4.46E-02 
M5005_Spy0341  1.50 3.55E-02 
M5005_Spy0348 nrdI 3.18 8.13E-04 
M5005_Spy0350  2.49 1.14E-03 
M5005_Spy0353  2.96 1.57E-02 
M5005_Spy0362 gcaD 1.25 1.85E-02 
M5005_Spy0375 rplA -1.96 1.54E-03 
M5005_Spy0386 phoH 1.68 7.76E-04 
M5005_Spy0399  -2.46 1.38E-03 
M5005_Spy0423 pepQ 1.72 4.77E-05 
M5005_Spy0426  1.10 3.14E-02 
M5005_Spy0436 vicK 1.61 1.14E-03 
M5005_Spy0450 mefE 2.00 1.91E-03 
M5005_Spy0466  1.39 4.43E-05 
M5005_Spy0467  1.81 3.04E-04 
M5005_Spy0468  1.32 3.05E-03 
M5005_Spy0469  1.74 4.98E-04 
M5005_Spy0471  1.38 5.57E-03 
M5005_Spy0476 bglA -2.17 1.66E-05 
M5005_Spy0477  1.66 7.95E-04 
M5005_Spy0478  1.50 8.82E-03 
M5005_Spy0479  1.55 2.92E-04 
M5005_Spy0483  2.60 2.78E-06 
M5005_Spy0484 ptsK 2.01 5.40E-04 
M5005_Spy0486  1.16 1.43E-02 
M5005_Spy0492  1.21 3.94E-02 
M5005_Spy0495 lysS 1.23 3.82E-04 
M5005_Spy0497  -1.50 4.14E-03 
M5005_Spy0504 pepF 2.64 2.76E-05 
M5005_Spy0511 murM 1.11 1.00E-02 
M5005_Spy0529  1.03 2.63E-03 
M5005_Spy0540  1.38 1.23E-02 
M5005_Spy0542 pepD 1.34 1.95E-02 




M5005_Spy0551 rplS -1.78 1.80E-02 
M5005_Spy0562 sagA 3.54 1.60E-06 
M5005_Spy0563 sagB 2.55 4.95E-05 
M5005_Spy0564 sagC 1.27 3.80E-02 
M5005_Spy0565 sagD 1.69 3.87E-03 
M5005_Spy0566 sagE 3.00 1.33E-07 
M5005_Spy0567 sagF 3.02 4.68E-04 
M5005_Spy0569 sagH 2.03 4.59E-04 
M5005_Spy0570 sagI 1.50 2.01E-02 
M5005_Spy0576 atpB -1.50 1.16E-03 
M5005_Spy0577 atpF -1.72 1.72E-03 
M5005_Spy0596  1.38 4.80E-04 
M5005_Spy0599 dnaG -1.73 3.79E-03 
M5005_Spy0600 rpoD -1.61 4.16E-05 
M5005_Spy0615 ebsA 1.90 1.76E-05 
M5005_Spy0616  1.28 1.02E-02 
M5005_Spy0619 infC -2.02 5.05E-05 
M5005_Spy0620 rpl36 -2.05 1.01E-03 
M5005_Spy0621 rplT -2.61 6.60E-07 
M5005_Spy0622  -2.12 1.04E-03 
M5005_Spy0629  1.21 4.33E-02 
M5005_Spy0633 rplU -1.71 4.84E-04 
M5005_Spy0635 rpmA -1.63 2.38E-04 
M5005_Spy0637 lsp 2.19 4.52E-05 
M5005_Spy0640 pyrP -1.68 3.28E-03 
M5005_Spy0641 pyrB -1.48 2.08E-03 
M5005_Spy0642 carA -2.79 2.14E-06 
M5005_Spy0643 carB -1.95 1.30E-03 
M5005_Spy0645  -2.20 1.26E-04 
M5005_Spy0648 rpsP -1.47 2.92E-02 
M5005_Spy0649  -1.57 1.99E-03 
M5005_Spy0653 czcD 1.19 3.06E-02 
M5005_Spy0664 mur1.2 1.29 4.83E-03 
M5005_Spy0677 fms -1.20 2.26E-02 
M5005_Spy0693  1.61 1.64E-04 
M5005_Spy0694 clpL 1.21 1.75E-02 
M5005_Spy0696 deoB 1.14 2.01E-03 
M5005_Spy0699 deoD2 1.06 3.13E-02 
M5005_Spy0700 cpsX 1.13 2.93E-02 
M5005_Spy0702  1.50 1.24E-03 
M5005_Spy0704 pyrE -2.32 3.00E-03 
M5005_Spy0705 amiC -1.72 2.59E-02 
M5005_Spy0717  -1.16 1.78E-02 
M5005_Spy0719  -1.86 2.64E-05 
M5005_Spy0722 miaA 1.29 1.14E-02 
M5005_Spy0731  -1.34 2.70E-02 
M5005_Spy0735 cpsFP 1.29 1.91E-02 
M5005_Spy0738  1.68 2.83E-05 
M5005_Spy0740 fbp 1.62 4.48E-02 
M5005_Spy0751 acoA -2.37 9.72E-03 
M5005_Spy0752 acoB -2.16 4.65E-03 
M5005_Spy0753 acoC -1.62 1.02E-03 
M5005_Spy0759  1.82 1.30E-03 
M5005_Spy0774  -2.54 2.06E-04 
M5005_Spy0776 lepA -1.45 1.55E-03 




M5005_Spy0780  -1.80 4.63E-03 
M5005_Spy0781 ptsB -1.81 1.72E-03 
M5005_Spy0790 gabD 1.39 6.85E-03 
M5005_Spy0791 uvrC 2.22 4.62E-05 
M5005_Spy0792  2.35 1.70E-04 
M5005_Spy0793  1.70 4.05E-02 
M5005_Spy0797  -1.87 1.46E-03 
M5005_Spy0805 srtK 1.52 1.02E-03 
M5005_Spy0807 srtT 1.59 2.56E-03 
M5005_Spy0808 srtF 2.10 4.34E-06 
M5005_Spy0810 srtG 1.92 4.03E-03 
M5005_Spy0811  2.73 1.15E-03 
M5005_Spy0820 folC.1 1.85 3.38E-05 
M5005_Spy0823 folQ 1.70 6.80E-05 
M5005_Spy0824 folK 1.34 1.24E-03 
M5005_Spy0826 potA -2.22 7.37E-05 
M5005_Spy0828 potC -1.65 1.39E-03 
M5005_Spy0829  -1.51 2.77E-02 
M5005_Spy0835  3.90 1.80E-03 
M5005_Spy0841  1.94 2.36E-04 
M5005_Spy0845  1.22 3.25E-03 
M5005_Spy0853  -2.33 1.66E-04 
M5005_Spy0854  -2.98 4.45E-09 
M5005_Spy0858 xpt -2.06 1.65E-03 
M5005_Spy0859  -3.79 5.06E-05 
M5005_Spy0869  1.19 7.93E-03 
M5005_Spy0879  -1.55 9.12E-03 
M5005_Spy0880  2.30 1.40E-04 
M5005_Spy0881  3.93 4.58E-06 
M5005_Spy0884 smf -2.83 7.27E-05 
M5005_Spy0893 gid 1.19 1.28E-02 
M5005_Spy0899 citG 1.69 2.19E-02 
M5005_Spy0900  2.42 3.99E-02 
M5005_Spy0913 xerD 1.68 3.30E-02 
M5005_Spy0917  1.50 2.14E-03 
M5005_Spy0918  1.66 5.90E-03 
M5005_Spy0931  1.84 4.41E-04 
M5005_Spy0940  1.39 1.27E-03 
M5005_Spy0948 ciaR 1.81 3.94E-03 
M5005_Spy0950 phoU 1.44 9.02E-04 
M5005_Spy0956  1.12 2.21E-02 
M5005_Spy0972  -1.65 7.94E-03 
M5005_Spy0978  -1.49 2.28E-02 
M5005_Spy0983  -1.47 1.76E-03 
M5005_Spy0984  -1.83 2.71E-05 
M5005_Spy0994  2.06 1.18E-03 
M5005_Spy1001  -2.27 7.41E-03 
M5005_Spy1035  -1.91 8.86E-03 
M5005_Spy1038  -1.95 6.46E-03 
M5005_Spy1057 malR 1.76 3.10E-02 
M5005_Spy1060 malG 2.63 3.73E-03 
M5005_Spy1064 malC 2.95 1.33E-03 
M5005_Spy1067 malX 1.52 2.53E-02 
M5005_Spy1071  1.86 1.26E-02 
M5005_Spy1072  1.59 2.05E-04 




M5005_Spy1074  1.06 7.55E-03 
M5005_Spy1075 uvrB 2.33 6.30E-06 
M5005_Spy1076 glnH 1.31 1.98E-02 
M5005_Spy1080  1.28 2.50E-02 
M5005_Spy1081  2.00 1.09E-02 
M5005_Spy1082  1.61 3.87E-02 
M5005_Spy1083  3.29 1.81E-04 
M5005_Spy1084  1.62 7.59E-03 
M5005_Spy1085 bglA.2 2.78 1.30E-02 
M5005_Spy1103 map 1.07 1.94E-02 
M5005_Spy1107 murZ -1.97 6.31E-04 
M5005_Spy1112  2.56 8.14E-07 
M5005_Spy1121 ptsH -1.50 1.30E-03 
M5005_Spy1124 nrdF.2 1.13 4.71E-02 
M5005_Spy1131  -2.22 8.31E-07 
M5005_Spy1132 alaS -1.54 2.15E-03 
M5005_Spy1137  -1.77 7.12E-04 
M5005_Spy1143  2.73 2.39E-03 
M5005_Spy1144  2.18 1.10E-02 
M5005_Spy1145 sodA 1.23 1.61E-02 
M5005_Spy1197  -1.79 1.66E-02 
M5005_Spy1206  -2.25 4.92E-03 
M5005_Spy1217  -1.59 6.89E-03 
M5005_Spy1218  -2.27 3.87E-04 
M5005_Spy1226  1.17 1.89E-03 
M5005_Spy1230  -1.41 1.69E-02 
M5005_Spy1232 xseB -2.40 3.70E-03 
M5005_Spy1233  -1.49 9.87E-03 
M5005_Spy1238 artQ -1.79 1.44E-03 
M5005_Spy1240 clpE 1.70 1.38E-03 
M5005_Spy1250 ftsA -1.56 1.59E-02 
M5005_Spy1257 glcK -1.55 6.87E-04 
M5005_Spy1258  -3.04 5.56E-06 
M5005_Spy1270 arcC 3.06 4.08E-04 
M5005_Spy1271  4.19 2.69E-05 
M5005_Spy1272  5.05 1.69E-06 
M5005_Spy1273 arcB 4.51 2.45E-06 
M5005_Spy1274  2.98 1.16E-04 
M5005_Spy1275 arcA 3.71 4.03E-06 
M5005_Spy1276  2.61 1.82E-02 
M5005_Spy1282 msrA 1.83 1.73E-03 
M5005_Spy1291  -1.35 1.18E-02 
M5005_Spy1298 aroB -1.59 4.77E-03 
M5005_Spy1299  -2.05 8.42E-03 
M5005_Spy1310  2.75 3.73E-02 
M5005_Spy1311  2.31 1.46E-02 
M5005_Spy1320 recX -2.78 1.57E-03 
M5005_Spy1323  1.31 1.71E-02 
M5005_Spy1324  -1.65 2.74E-04 
M5005_Spy1330  -1.66 9.04E-03 
M5005_Spy1331  1.64 5.53E-05 
M5005_Spy1342  -1.87 7.39E-04 
M5005_Spy1357  1.72 2.37E-02 
M5005_Spy1363  -2.21 2.21E-05 
M5005_Spy1376  1.59 8.22E-03 




M5005_Spy1379 glpF 3.95 4.72E-04 
M5005_Spy1380 glpO 4.93 1.37E-06 
M5005_Spy1381 glpK 3.37 6.85E-04 
M5005_Spy1382  2.16 7.97E-05 
M5005_Spy1390  1.14 1.60E-02 
M5005_Spy1392  2.06 2.41E-05 
M5005_Spy1395 lacD.1 2.39 3.14E-05 
M5005_Spy1396  2.86 1.90E-04 
M5005_Spy1397 lacB.1 2.92 3.80E-03 
M5005_Spy1398 lacA.1 3.08 5.23E-04 
M5005_Spy1399  2.20 3.92E-03 
M5005_Spy1408 rbfA -2.21 8.50E-04 
M5005_Spy1409 infB -1.23 1.47E-02 
M5005_Spy1410  -2.02 3.43E-04 
M5005_Spy1412 nusA -1.52 1.77E-03 
M5005_Spy1418  -2.40 6.42E-04 
M5005_Spy1420  -3.10 4.71E-05 
M5005_Spy1422  -1.34 2.82E-02 
M5005_Spy1424  -2.08 6.83E-03 
M5005_Spy1440  -2.07 1.78E-03 
M5005_Spy1444  -1.48 3.30E-02 
M5005_Spy1445  -2.16 3.82E-02 
M5005_Spy1447  -1.73 2.35E-02 
M5005_Spy1451  -1.74 3.32E-04 
M5005_Spy1452  -1.52 3.78E-03 
M5005_Spy1455  -1.45 2.47E-02 
M5005_Spy1456  -1.69 2.40E-02 
M5005_Spy1462  -1.35 9.47E-03 
M5005_Spy1469  -1.58 6.34E-03 
M5005_Spy1477  -1.28 1.54E-02 
M5005_Spy1479 manL -1.55 2.46E-03 
M5005_Spy1480 manM -2.50 1.53E-03 
M5005_Spy1481 manN -4.09 6.81E-07 
M5005_Spy1482 manO 1.03 2.78E-02 
M5005_Spy1494 fabH -1.31 3.17E-02 
M5005_Spy1495  -1.70 2.27E-03 
M5005_Spy1505  -1.89 2.54E-04 
M5005_Spy1521  1.26 1.67E-03 
M5005_Spy1523  2.14 1.79E-04 
M5005_Spy1524  1.28 1.15E-03 
M5005_Spy1537  1.63 2.02E-02 
M5005_Spy1538 pmi 1.49 1.75E-02 
M5005_Spy1553 rpsR -1.31 8.46E-03 
M5005_Spy1555 rpsF -1.55 3.44E-03 
M5005_Spy1560  1.27 1.02E-02 
M5005_Spy1566 recD 1.06 2.45E-02 
M5005_Spy1569 pfl -2.43 1.24E-03 
M5005_Spy1574  -1.73 4.53E-03 
M5005_Spy1575 norA -9.04 5.80E-13 
M5005_Spy1582 dnaQ -2.20 1.48E-04 
M5005_Spy1592  -1.48 1.00E-03 
M5005_Spy1607 fba -1.84 3.34E-05 
M5005_Spy1610 pyrG -2.54 5.62E-03 
M5005_Spy1611 rpoE -1.55 2.51E-04 
M5005_Spy1613  1.09 2.04E-02 




M5005_Spy1645  -4.02 1.06E-04 
M5005_Spy1647 rplM -2.45 4.26E-05 
M5005_Spy1648  -1.68 4.89E-03 
M5005_Spy1667  -1.86 5.24E-05 
M5005_Spy1668  -1.52 2.27E-03 
M5005_Spy1674  1.16 9.97E-03 
M5005_Spy1692  1.82 2.90E-03 
M5005_Spy1698 trpG 2.11 4.70E-05 
M5005_Spy1699  1.54 2.94E-04 
M5005_Spy1708 dppE 1.28 6.20E-03 
M5005_Spy1711 lmb -2.35 1.01E-03 
M5005_Spy1718 sic1.01 -2.01 2.63E-03 
M5005_Spy1722  1.70 4.74E-03 
M5005_Spy1730  1.73 1.65E-04 
M5005_Spy1743 pflD 1.10 1.33E-02 
M5005_Spy1744  1.06 3.54E-02 
M5005_Spy1745  2.83 7.05E-03 
M5005_Spy1754  1.51 4.05E-03 
M5005_Spy1757  -1.42 1.57E-03 
M5005_Spy1769 ahpF 1.19 2.95E-02 
M5005_Spy1771 hutU 4.32 1.36E-03 
M5005_Spy1772  5.39 1.07E-02 
M5005_Spy1773  8.04 7.67E-07 
M5005_Spy1774 fhs.2 5.03 4.50E-02 
M5005_Spy1775  7.58 2.57E-03 
M5005_Spy1776  6.35 2.81E-03 
M5005_Spy1777 hutH 5.76 1.92E-02 
M5005_Spy1778 hutG 4.69 5.64E-03 
M5005_Spy1780 rpsB -2.03 7.56E-04 
M5005_Spy1781  -2.09 5.40E-05 
M5005_Spy1783 dexS 1.76 3.00E-04 
M5005_Spy1786  -1.68 2.82E-03 
M5005_Spy1787  -2.56 1.48E-04 
M5005_Spy1789 nrdG -1.34 1.31E-03 
M5005_Spy1790  -2.37 1.05E-02 
M5005_Spy1797  1.93 6.97E-06 
M5005_Spy1799 recA 3.32 1.38E-05 
M5005_Spy1802 ruvA 1.09 2.08E-02 
M5005_Spy1811  -2.16 7.67E-04 
M5005_Spy1812  -1.69 4.74E-03 
M5005_Spy1815 rpmF -2.76 1.72E-03 
M5005_Spy1816 rpmG -2.69 3.41E-05 
M5005_Spy1830  -2.89 1.23E-02 
M5005_Spy1835 holB -2.57 2.20E-06 
M5005_Spy1842 sdhA -3.69 9.02E-04 
M5005_Spy1843  -2.79 7.55E-04 
M5005_Spy1848  1.15 3.44E-02 
M5005_Spy1850  1.53 2.74E-02 
M5005_Spy1852 hasB -1.45 3.26E-03 
M5005_Spy1860  -1.69 1.13E-02 
M5005_Spy1863  1.10 6.10E-03 








a Analysis conducted on intergenic region 5’ to spy number listed 
b Both Limma and DESeq analyses exhibited Log2 fold-change  of –1 ≤ or ≥ 1. Limma data only 
shown. 





Appendix 7: Differential Expression of Mga regulated intergenic region in THY at 
late log (∆mga/wt 5448) 
 
Spy #a Gene Name Log2 FCb p valuec 
M5005_Spy0028  -2.48 5.46E-06 
M5005_Spy0029 purD -2.56 1.93E-06 
M5005_Spy0034  -2.33 3.09E-09 
M5005_Spy0065 adk 1.21 5.57E-03 
M5005_Spy0115  -2.89 7.49E-07 
M5005_Spy0140  -2.88 3.39E-04 
M5005_Spy0144  -3.85 1.48E-05 
M5005_Spy0157 opuAA -1.24 2.30E-04 
M5005_Spy0158 opuABC -1.60 1.30E-05 
M5005_Spy0159 polA -3.15 4.48E-10 
M5005_Spy0160  -1.07 5.31E-04 
M5005_Spy0213  -1.37 1.32E-03 
M5005_Spy0623  -1.43 1.52E-03 
M5005_Spy0719  -1.19 1.80E-04 
M5005_Spy0776 lepA -1.53 2.47E-05 
M5005_Spy0778 msrB -1.82 2.38E-04 
M5005_Spy0882  -2.13 8.29E-08 
M5005_Spy0884 smf -2.38 1.09E-05 
M5005_Spy0912  -1.51 1.54E-04 
M5005_Spy1139 nagB -1.80 4.30E-06 
M5005_Spy1348  -1.17 1.33E-03 
M5005_Spy1539 scrK -1.19 9.08E-05 
M5005_Spy1540 endoS -1.98 2.45E-05 
M5005_Spy1543 scrB -2.16 1.63E-05 
M5005_Spy1631 salA -2.00 3.43E-04 
M5005_Spy1661  1.19 2.95E-03 
M5005_Spy1668  -2.77 1.03E-08 
M5005_Spy1714  -3.91 1.65E-05 
M5005_Spy1715 scpA -6.27 3.29E-09 
M5005_Spy1716  -4.79 2.32E-09 
M5005_Spy1718 sic1.01 -5.62 7.13E-13 
M5005_Spy1719 emm1.0 -5.59 1.06E-09 
M5005_Spy1720 mga -3.61 1.17E-09 
M5005_Spy1721  -1.65 6.48E-06 
M5005_Spy1729  -1.25 7.03E-04 
M5005_Spy1730  -1.14 6.40E-04 
M5005_Spy1731  -1.46 2.37E-04 
M5005_Spy1733  2.31 2.49E-05 
M5005_Spy1734 spi 4.68 2.91E-06 
M5005_Spy1735 speB 4.94 1.24E-05 
M5005_Spy1736  4.57 7.03E-09 
M5005_Spy1737 rgg 3.00 1.99E-07 
M5005_Spy1787  -3.03 2.60E-07 
M5005_Spy1852 hasB -1.54 7.45E-05 
M5005_Spy1860  -1.52 2.65E-03 
M5005_Spy1864  -1.47 5.86E-06 
 
a Analyses conducted on intergenic region 5’ to spy number listed 
b Both Limma & DESeq analyses exhibited Log2 fold-change  of –1 ≤ or ≥ 1. Limma data only shown. 




Appendix 8: Differential Expression of Mga regulated intergenic region in C media 
at late log (∆mga/wt 5448) 
 
Spy #a Gene Name Log2 FCb p valuec 
M5005_Spy0006 trcF -1.20 7.56E-03 
M5005_Spy0010  -1.27 4.31E-03 
M5005_Spy0018 prsA.2 -1.57 3.63E-04 
M5005_Spy0023  -2.16 4.84E-03 
M5005_Spy0031 purK -1.45 7.10E-03 
M5005_Spy0043 rpsJ -1.47 7.16E-05 
M5005_Spy0073  -2.31 5.70E-09 
M5005_Spy0107  1.70 5.99E-03 
M5005_Spy0115  -1.17 1.36E-02 
M5005_Spy0116 atoE -1.18 2.51E-02 
M5005_Spy0128 ntpE 1.96 4.20E-03 
M5005_Spy0130 ntpF 1.77 4.09E-03 
M5005_Spy0131 ntpA 1.83 3.32E-03 
M5005_Spy0132 ntpB 1.50 1.28E-02 
M5005_Spy0133 ntpD 2.09 2.16E-03 
M5005_Spy0136 purA 1.46 9.68E-05 
M5005_Spy0137  1.34 4.60E-04 
M5005_Spy0140  -3.74 1.35E-05 
M5005_Spy0141 slo -2.93 9.45E-05 
M5005_Spy0142  -3.33 1.04E-04 
M5005_Spy0144  -3.57 7.19E-04 
M5005_Spy0157 opuAA -1.25 8.81E-05 
M5005_Spy0158 opuABC -1.62 3.33E-06 
M5005_Spy0159 polA -1.22 2.76E-03 
M5005_Spy0167  -2.07 2.19E-02 
M5005_Spy0177  -1.34 4.96E-03 
M5005_Spy0191  -1.18 2.64E-03 
M5005_Spy0197  1.66 2.53E-03 
M5005_Spy0202  1.31 4.86E-04 
M5005_Spy0205 fasC -1.30 1.41E-03 
M5005_Spy0207 fasX -1.47 3.38E-06 
M5005_Spy0224 rpe 1.41 7.49E-03 
M5005_Spy0230 rpsL -1.31 7.53E-05 
M5005_Spy0231 rpsG -1.47 1.16E-04 
M5005_Spy0271  1.39 2.19E-03 
M5005_Spy0274 braB -2.97 9.41E-04 
M5005_Spy0276  -1.28 9.29E-03 
M5005_Spy0280  1.03 4.42E-04 
M5005_Spy0296  1.01 9.03E-04 
M5005_Spy0297  1.81 4.26E-03 
M5005_Spy0318 pflC -1.39 3.64E-04 
M5005_Spy0319 ppaC 1.09 6.59E-04 
M5005_Spy0340 lctO 1.94 4.17E-04 
M5005_Spy0352  -1.92 2.81E-03 
M5005_Spy0375 rplA -1.40 9.02E-04 
M5005_Spy0376  -1.60 2.27E-03 
M5005_Spy0385  1.88 5.65E-03 
M5005_Spy0386 phoH 1.05 1.31E-03 
M5005_Spy0404  -2.60 5.79E-05 
M5005_Spy0423 pepQ 1.23 2.84E-05 




M5005_Spy0432  -1.68 8.33E-05 
M5005_Spy0453  1.90 1.34E-02 
M5005_Spy0455  1.74 1.26E-02 
M5005_Spy0477  1.47 1.14E-05 
M5005_Spy0478  1.20 3.04E-03 
M5005_Spy0479  1.03 1.59E-04 
M5005_Spy0504 pepF 1.52 1.14E-04 
M5005_Spy0518  1.38 5.03E-03 
M5005_Spy0520  -1.68 2.21E-05 
M5005_Spy0521 agaV -1.35 2.94E-03 
M5005_Spy0522  -2.14 6.38E-08 
M5005_Spy0523  -1.50 4.37E-04 
M5005_Spy0535  1.04 1.17E-03 
M5005_Spy0563 sagB -1.65 1.65E-04 
M5005_Spy0564 sagC -1.13 1.43E-03 
M5005_Spy0565 sagD -1.28 1.01E-03 
M5005_Spy0566 sagE -1.35 8.19E-06 
M5005_Spy0567 sagF -1.21 9.23E-03 
M5005_Spy0568 sagG -2.23 4.08E-05 
M5005_Spy0569 sagH -1.62 1.31E-05 
M5005_Spy0570 sagI -1.27 3.04E-03 
M5005_Spy0571  -1.51 1.22E-05 
M5005_Spy0572  -1.26 1.71E-05 
M5005_Spy0573 lig -1.87 6.75E-04 
M5005_Spy0592  1.11 3.04E-03 
M5005_Spy0599 dnaG 1.18 4.56E-03 
M5005_Spy0620 rpl36 -1.29 2.05E-03 
M5005_Spy0621 rplT -1.23 1.34E-04 
M5005_Spy0640 pyrP -1.49 2.40E-04 
M5005_Spy0642 carA -1.33 2.74E-04 
M5005_Spy0650  -1.48 4.33E-03 
M5005_Spy0651  -1.94 9.40E-06 
M5005_Spy0652  -2.10 5.52E-07 
M5005_Spy0653 czcD -2.39 1.12E-07 
M5005_Spy0665  -1.81 3.41E-04 
M5005_Spy0666  -1.64 4.56E-03 
M5005_Spy0668 mac -1.39 5.37E-03 
M5005_Spy0694 clpL -1.34 7.20E-04 
M5005_Spy0710  -1.09 4.42E-02 
M5005_Spy0714  -1.43 2.47E-04 
M5005_Spy0715  -2.51 2.39E-07 
M5005_Spy0722 miaA 1.28 4.32E-04 
M5005_Spy0731  -1.41 4.84E-03 
M5005_Spy0734 cpsFO 1.40 2.37E-02 
M5005_Spy0752 acoB 1.04 3.75E-02 
M5005_Spy0753 acoC 1.19 4.50E-04 
M5005_Spy0754  1.31 4.14E-04 
M5005_Spy0755 acoL 1.72 5.13E-04 
M5005_Spy0756  1.22 1.28E-03 
M5005_Spy0791 uvrC 1.47 5.66E-05 
M5005_Spy0803 srtI -2.53 4.69E-03 
M5005_Spy0811  1.19 2.29E-02 
M5005_Spy0820 folC.1 1.31 2.24E-05 
M5005_Spy0826 potA -1.27 7.11E-04 
M5005_Spy0832 malP -3.00 9.19E-03 




M5005_Spy0858 xpt 1.31 5.12E-03 
M5005_Spy0877  1.36 1.57E-02 
M5005_Spy0878  1.66 2.58E-02 
M5005_Spy0880  2.87 1.08E-08 
M5005_Spy0881  2.83 1.18E-07 
M5005_Spy0882  1.20 1.54E-04 
M5005_Spy0898  -1.53 1.22E-02 
M5005_Spy0900  -1.98 1.47E-02 
M5005_Spy0921  -1.74 1.19E-04 
M5005_Spy0922 pdxK -1.66 3.08E-02 
M5005_Spy0924  -1.18 6.13E-04 
M5005_Spy0947 ciaH -1.42 9.70E-04 
M5005_Spy0978  -1.31 5.94E-03 
M5005_Spy0980  -1.53 1.26E-04 
M5005_Spy0998  -1.27 6.19E-03 
M5005_Spy1000  -2.77 2.82E-03 
M5005_Spy1022  -2.49 1.10E-02 
M5005_Spy1027  -2.24 1.67E-03 
M5005_Spy1028  -1.23 3.07E-02 
M5005_Spy1034  -1.16 1.45E-02 
M5005_Spy1040  -1.51 2.03E-02 
M5005_Spy1041  -1.57 3.29E-02 
M5005_Spy1076 glnH 1.50 2.69E-04 
M5005_Spy1077 glnQ.2 1.26 4.16E-04 
M5005_Spy1090  -1.90 1.01E-02 
M5005_Spy1093  1.23 2.80E-03 
M5005_Spy1108 metK2 -1.33 1.82E-02 
M5005_Spy1110 birA -1.38 2.12E-02 
M5005_Spy1114  -1.50 1.30E-04 
M5005_Spy1116 udk -1.49 2.39E-04 
M5005_Spy1124 nrdF.2 1.06 7.41E-03 
M5005_Spy1134  -1.34 2.23E-04 
M5005_Spy1139 nagB -1.37 6.93E-05 
M5005_Spy1146  1.72 1.07E-03 
M5005_Spy1170  -2.38 8.22E-06 
M5005_Spy1171  -2.76 2.26E-06 
M5005_Spy1172  -1.82 1.36E-02 
M5005_Spy1211  -1.40 3.90E-02 
M5005_Spy1227  -1.17 1.01E-03 
M5005_Spy1228 recN -1.27 3.08E-04 
M5005_Spy1229 argR1 -1.51 2.26E-03 
M5005_Spy1231 fps -1.27 1.45E-02 
M5005_Spy1232 xseB -1.24 2.42E-02 
M5005_Spy1238 artQ -2.37 1.07E-06 
M5005_Spy1239  -1.65 1.05E-02 
M5005_Spy1240 clpE 1.05 3.06E-03 
M5005_Spy1241 mutT 1.45 7.61E-05 
M5005_Spy1260  1.43 1.80E-02 
M5005_Spy1261  -1.48 4.54E-03 
M5005_Spy1290  -1.23 6.94E-03 
M5005_Spy1297  -1.33 3.01E-03 
M5005_Spy1298 aroB -1.52 2.50E-04 
M5005_Spy1324  -1.96 9.19E-08 
M5005_Spy1325  1.03 2.70E-03 
M5005_Spy1326 comFC 1.57 4.69E-04 




M5005_Spy1357  1.56 3.30E-03 
M5005_Spy1369  -1.22 1.49E-02 
M5005_Spy1374  -1.28 3.67E-04 
M5005_Spy1379 glpF 1.37 5.62E-03 
M5005_Spy1387  1.11 7.91E-04 
M5005_Spy1389  -1.15 5.17E-04 
M5005_Spy1415 sdaD2 -1.92 3.04E-04 
M5005_Spy1416  -2.50 1.86E-05 
M5005_Spy1422  -1.37 6.97E-03 
M5005_Spy1427  -1.09 3.23E-02 
M5005_Spy1430  -1.01 2.75E-02 
M5005_Spy1432  -1.08 8.77E-03 
M5005_Spy1435  -1.18 5.01E-03 
M5005_Spy1436  -1.06 1.28E-02 
M5005_Spy1439  -1.08 3.75E-02 
M5005_Spy1440  -2.33 2.81E-04 
M5005_Spy1451  -1.63 1.00E-04 
M5005_Spy1453  -2.24 1.74E-03 
M5005_Spy1479 manL -1.20 3.89E-03 
M5005_Spy1483 serS 1.13 2.57E-03 
M5005_Spy1486 accC 1.43 2.45E-02 
M5005_Spy1487 fabZ 1.08 4.24E-02 
M5005_Spy1488 accB 1.12 1.83E-02 
M5005_Spy1489 fabF 1.38 9.68E-03 
M5005_Spy1490  1.05 1.85E-02 
M5005_Spy1514  1.61 1.55E-02 
M5005_Spy1525  -2.40 6.16E-03 
M5005_Spy1526 fhuC -1.99 4.69E-04 
M5005_Spy1528  -1.85 1.33E-03 
M5005_Spy1529 shp -1.96 2.24E-04 
M5005_Spy1530  -1.30 1.46E-03 
M5005_Spy1537  1.25 2.16E-03 
M5005_Spy1562  -1.27 7.43E-05 
M5005_Spy1570  -1.26 1.83E-02 
M5005_Spy1575 norA 1.23 4.85E-02 
M5005_Spy1582 dnaQ -1.79 9.53E-05 
M5005_Spy1606 rpmB -1.21 9.35E-04 
M5005_Spy1607 fba -1.24 3.36E-05 
M5005_Spy1612 ropA -1.95 1.04E-04 
M5005_Spy1628  -2.60 3.86E-03 
M5005_Spy1630 salB -2.93 6.65E-05 
M5005_Spy1631 salA -2.58 4.65E-05 
M5005_Spy1632 lacG -1.61 6.44E-03 
M5005_Spy1633 lacE -1.94 4.61E-03 
M5005_Spy1635 lacD.2 -1.83 1.06E-02 
M5005_Spy1637 lacB.2 -1.62 1.92E-02 
M5005_Spy1642  -3.44 1.81E-03 
M5005_Spy1647 rplM -1.28 9.15E-04 
M5005_Spy1648  -1.40 6.81E-04 
M5005_Spy1649  -1.63 3.53E-05 
M5005_Spy1671  1.07 1.11E-02 
M5005_Spy1685  -1.43 1.81E-03 
M5005_Spy1702 smeZ -1.15 7.51E-03 
M5005_Spy1714  -6.96 4.20E-09 
M5005_Spy1715 scpA -5.79 3.10E-08 




M5005_Spy1718 sic1.01 -5.29 9.87E-13 
M5005_Spy1719 emm1.0 -6.93 9.47E-13 
M5005_Spy1720 mga -4.64 5.18E-13 
M5005_Spy1721  -1.50 1.53E-05 
M5005_Spy1732  -1.35 1.98E-02 
M5005_Spy1733  -1.12 1.37E-02 
M5005_Spy1738 spd -1.59 4.25E-03 
M5005_Spy1754  1.54 2.49E-05 
M5005_Spy1768 ahpC 1.55 1.69E-03 
M5005_Spy1776  -1.69 4.56E-02 
M5005_Spy1780 rpsB -2.10 2.02E-06 
M5005_Spy1781  -1.35 8.98E-05 
M5005_Spy1800 cinA 1.05 5.23E-03 
M5005_Spy1832  -1.23 4.36E-04 
M5005_Spy1865 htrA 1.10 3.07E-02 
 
a Analysis conducted on intergenic region 5’ to the spy number listed. 
b Both Limma and DESeq analyses exhibited Log2 fold-change  of –1 ≤ or ≥ 1. Limma data only 
shown. 













1. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global 
burden of group A streptococcal diseases. Lancet Infectious Disease 5:685-
694. 
2. Bisno AL, Brito MO, Collins CM. 2003. Molecular basis of group A 
streptococcal virulence. Lancet Infectious Disease 3:191-200. 
3. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. 
Clin Microbiol Rev 13:470-511. 
4. Loughman JA, Caparon MG. 2006. A novel adaptation of aldolase regulates 
virulence in Streptococcus pyogenes. EMBO Journal 25:5414-5422. 
5. Kinkel TL, McIver KS. 2008. CcpA-mediated repression of streptolysin S 
expression and virulence in the group A streptococcus. Infection and 
Immunity 76:3451-3463. 
6. Shelburne SA, 3rd, Keith D, Horstmann N, Sumby P, Davenport MT, 
Graviss EA, Brennan RG, Musser JM. 2008. A direct link between 
carbohydrate utilization and virulence in the major human pathogen group A 
Streptococcus. Proceedings of the National Academy of Sciences of the 
United States of America 105:1698-1703. 
7. Kietzman CC, Caparon MG. 2010. CcpA and LacD.1 affect temporal 
regulation of Streptococcus pyogenes virulence genes. Infection and 
Immunity 78:241-252. 
8. Gera K, Le T, Jamin R, Eichenbaum Z, McIver KS. 2014. The 
Phosphoenolpyruvate Phosphotransferase System in Group A Streptococcus 
Acts To Reduce Streptolysin S Activity and Lesion Severity during Soft 
Tissue Infection. Infection and Immunity 82:1192-1204. 
9. Valdes KM, Sundar GS, Vega LA, Belew AT, Islam E, Binet R, El-Sayed 
NM, Le Breton Y, McIver KS. 2016. The fruRBA operon is necessary for 
Group A Streptococcal growth in fructose and for resistance to neutrophil 
killing during growth in whole human blood. Infection and Immunity 
doi:10.1128/IAI.01296-15. 
10. Kreikemeyer B, McIver KS, Podbielski A. 2003. Virulence factor 
regulation and regulatory networks in Streptococcus pyogenes and their 
impact on pathogen-host interactions. Trends in Microbiology 11:224-232. 
11. Hondorp ER, McIver KS. 2007. The Mga virulence regulon: infection where 
the grass is greener. Molecular Microbiology 66:1056-1065. 
12. Graham MR, Virtaneva K, Porcella SF, Barry WT, Gowen BB, Johnson 
CR, Wright FA, Musser JM. 2005. Group A Streptococcus transcriptome 
dynamics during growth in human blood reveals bacterial adaptive and 
survival strategies. American Journal of Pathology 166:455-465. 
13. Kihlberg BM, Cooney J, Caparon MG, Olsén A, Björck L. 1995. 
Biological properties of a Streptococcus pyogenes mutant generated by Tn916 




14. Cho KH, Caparon MG. 2005. Patterns of virulence gene expression differ 
between biofilm and tissue communities of Streptococcus pyogenes. 
Molecular Microbiology 57:1545-1556. 
15. Le Breton Y, Mistry P, Valdes KM, Quigley J, Kumar N, Tettelin H, 
McIver KS. 2013. Genome-wide identification of genes required for fitness 
of group a streptococcus in human blood. Infection and Immunity 81:862-875. 
16. Kizy AE, Neely MN. 2009. First Streptococcus pyogenes signature-tagged 
mutagenesis screen identifies novel virulence determinants. Infection and 
Immunity 77:1854-1865. 
17. Almengor AC, Kinkel TL, Day SJ, McIver KS. 2007. The catabolite control 
protein CcpA binds to Pmga and influences expression of the virulence 
regulator Mga in the group A streptococcus. Journal of Bacteriology 
189:8405-8416. 
18. Pine L, Reeves MW. 1978. Regulation of the synthesis of M protein by 
sugars, Todd Hewitt broth, and horse serum, in growing cells of Streptococcus 
pyogenes. Microbios 21:185-212. 
19. Hondorp ER, Hou SC, Hause LL, Gera K, Lee CE, McIver KS. 2013. 
PTS phosphorylation of Mga modulates regulon expression and virulence in 
the group A streptococcus. Molecular Microbiology 88:1176-1193. 
20. Sanson M, Makthal N, Gavagan M, Cantu C, Olsen RJ, Musser JM, 
Kumaraswami M. 2015. Phosphorylation events in the multiple gene 
regulator of group A Streptococcus significantly influence global gene 
expression and virulence. Infection and Immunity 83:2382-2395. 
21. Denny FW, Jr. 2000. History of hemolytic streptococci and associated 
diseases, p 1-18. In Stevens DL, Kaplan EL (ed), Streptococcal Infections: 
Clinical Aspects, Microbiology, and Molecular Pathogenesis. Oxford 
University Press, New York. 
22. Magner LN. 1992. A History of Medicine. New York Marcel Dekker, Inc. 
23. Lancefield RC. 1933. A serological differentiation of human and other 
groups of hemolytic streptococci. Journal of Experimental Medicine 57:571-
595. 
24. Martin DR. 2000. Laboratory evaluation of streptococci, p 266-279. In 
Stevens DL, Kaplan EL (ed), Streptococcal Infections: Clinical Aspects, 
Microbiology, and Molecular Pathogenesis. Oxford University Press, New 
York. 
25. Todd EW, Hewitt LF. 1932. A new culture medium for the production of 
antigenic streptococcal haemolysin. Journal of Pathology and Bacteriology 
35:973. 
26. Vincent WF, Lisiewski KJ. 1969. Improved growth medium for group A 
streptococci. Applied Microbiology 18:954-955. 
27. Slade HD, Knox GA, Slamp WC. 1951. The amino acid nutrition of group A 
hemolytic streptococci, with reference to the effect of glutathione on the 
cysteine requirement. Journal of Biochemistry 62:669-675. 
28. van de Rijn I, Kessler RE. 1980. Growth characteristics of group A 





29. Gerber MA, Spadaccini LJ, Wright LL, Deutsch L. 1984. Latex 
agglutination tests for rapid identification of group A streptococci directly 
from throat swabs. Journal of Pediatrics 105:702-705. 
30. Lancefield RC. 1928. The antigenic complex of Streptococcus haemolyticus: 
I. Demonstration of a type-specific substance in extracts of Streptococcus 
haemolyticus. Journal of Experimental Medicine 47:91-103. 
31. Lancefield RC. 1928. The antigenic complex of the Streptococcus 
haemolyticus:  II. Chemical and immunological properties of the protein 
fractions. Journal of Experimental Medicine 47:469-480. 
32. Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, 
Henningham A, Sriprakash KS, Sanderson-Smith ML, Nizet V. 2014. 
Disease manifestations and pathogenic mechanisms of group a Streptococcus. 
Clin Microbiol Rev 27:264-301. 
33. McMillan DJ, Dreze PA, Vu T, Bessen DE, Guglielmini J, Steer AC, 
Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR. 2013. 
Updated model of group A Streptococcus M proteins based on a 
comprehensive worldwide study. Clinical Microbiology and Infection 
19:E222-229. 
34. Griffith F. 1934. The Serological Classification of Streptococcus pyogenes. 
Journal of Hygiene 34:542-584. 
35. Beall B, Facklam RR, Elliott JA, Franklin AR, Hoenes T, Jackson D, 
Laclaire L, Thompson T, Viswanathan R. 1998. Streptococcal emm types 
associated with T-agglutination types and the use of conserved emm gene 
restriction fragment patterns for subtyping group A streptococci. J Med 
Microbiol 47:893-898. 
36. Maxted WR, Widdowson JP, Fraser CA, Ball LC, Bassett DC. 1973. The 
use of the serum opacity reaction in the typing of group A streptococci. 
Journal of Medical Microbiology 6:83-90. 
37. Johnson DR, Kaplan EL. 1993. A review of the correlation of T-
agglutination patterns and M-protein typing and opacity factor production in 
the identification of group A streptococci. Journal of Medical Microbiology 
38:311-315. 
38. Wessels MR. 2011. Clinical practice. Streptococcal pharyngitis. New England 
Journal of Medicine 364:648-655. 
39. Choby BA. 2009. Diagnosis and treatment of streptococcal pharyngitis. 
American Family Physician 79:383-390. 
40. Stevens DL. 2000. Life-threatening streptococcal infections: scarlet fever, 
necrotizing fasciitis, myositis, bacteremia, and streptococcal toxic shock 
syndrome, p 163-179. In Stevens DL, Kaplan EL (ed), Streptococcal 
Infections: Clinical Aspects, Microbiology, and Molecular Pathogenesis. 
Oxford University Press, New York. 
41. Bisno AL, Stevens DL. 1996. Streptococcal infections of skin and soft 
tissues. The New England Journal of Medicine 334:240-245. 
42. Anthony BF. 2000. Streptococcal pyoderma, p 144-151. In Stevens DL, 
Kaplan EL (ed), Streptococcal Infections: Clinical Aspects, Microbiology, and 




43. Stevens DL. 2000. Group A beta-hemolytic streptococci: virulence factors, 
pathogenesis, and spectrum of clinical infections, p 37-56. In Stevens DL, 
Kaplan EL (ed), Streptococcal Infections: Clinical Aspects, Microbiology, and 
Molecular Pathogenesis. Oxford University Press, New York. 
44. Stevens DL. 1995. Streptococcal toxic-shock syndrome: spectrum of disease, 
pathogenesis, and new concepts in treatment. Emerging Infectious Diseases 
1:69-78. 
45. Descamps V, Aitken J, Lee MG. 1994. Hippocrates on necrotising fasciitis. 
Lancet 344:556. 
46. Olsen RJ, Musser JM. 2010. Molecular pathogenesis of necrotizing fasciitis. 
Annual Review of Pathology 5:1-31. 
47. Markowitz M, Kaplan EL. 2000. Rheumatic Fever, p 133-143. In Stevens 
DL, Kaplan EL (ed), Streptococcal Infections: Clinical Aspects, 
Microbiology, and Molecular Pathogenesis. Oxford University Press, New 
York. 
48. Ayoub EM, Kotb M, Cunningham MW. 2000. Rheumatic fever 
pathogenesis, p 102-132. In Stevens DL, Kaplan EL (ed), Streptococcal 
Infections: Clinical Aspects, Microbiology, and Molecular Pathogenesis. 
Oxford University Press, New York. 
49. Jones TD. 1944. The diagnosis of rheumatic fever. Journal of the American 
Medical Association 126:481-484. 
50. Tompkins DG, Boxerbaum B, Liebman J. 1972. Long-term prognosis of 
rheumatic fever patients receiving regular intramuscular benzathine penicillin. 
Circulation 45:543-551. 
51. Holm SE, Nordstrand A, Stevens DL, Norgreen M. 2000. Acute 
poststreptococcal glomerulonephritis, p 152-162. In Stevens DL, Kaplan EL 
(ed), Streptococcal Infections: Clinical Aspects, Microbiology, and Molecular 
Pathogenesis. Oxford University Press, New York. 
52. Williams KA, Swedo SE. 2014. Post-infectious autoimmune disorders: 
Sydenham's chorea, PANDAS and beyond. Brain Research 
doi:10.1016/j.brainres.2014.09.071. 
53. Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, 
Lougee L, Dow S, Zamkoff J, Dubbert BK. 1998. Pediatric autoimmune 
neuropsychiatric disorders associated with streptococcal infections: clinical 
description of the first 50 cases. American Journal of Psychiatry 155:264-271. 
54. Leckman JF, King RA, Gilbert DL, Coffey BJ, Singer HS, Dure LSt, 
Grantz H, Katsovich L, Lin H, Lombroso PJ, Kawikova I, Johnson DR, 
Kurlan RM, Kaplan EL. 2011. Streptococcal upper respiratory tract 
infections and exacerbations of tic and obsessive-compulsive symptoms: a 
prospective longitudinal study. Journal of the American Academy of Child 
and Adolescent Psychiatry 50:108-118 e103. 
55. Kurlan R, Johnson D, Kaplan EL. 2008. Streptococcal infection and 
exacerbations of childhood tics and obsessive-compulsive symptoms: a 
prospective blinded cohort study. Pediatrics 121:1188-1197. 
56. Esposito S, Bianchini S, Baggi E, Fattizzo M, Rigante D. 2014. Pediatric 




infections: an overview. European Journal of Clinical Microbiology and 
Infectious Diseases 33:2105-2109. 
57. Carapetis JR, Currie BJ, Kaplan EL. 1999. Epidemiology and prevention 
of group A streptococcal infections: acute respiratory tract infections, skin 
infections, and their sequelae at the close of the twentieth century. Clinical 
Infectious Disease 28:205-210. 
58. Tsoi SK, Smeesters PR, Frost HR, Licciardi P, Steer AC. 2015. Correlates 
of Protection for M Protein-Based Vaccines against Group A Streptococcus. 
Journal of Immunological Research 2015:167089. 
59. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, 
Wasserman SS, Dale JB. 2004. Safety and immunogenicity of a recombinant 
multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. 
Journal of the American Medical Association 292:709-715. 
60. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. 2002. 
Immunogenicity of a 26-valent group A streptococcal vaccine. Infection and 
Immunity 70:2171-2177. 
61. Hirst GK, Lancefield RC. 1939. Antigenic properties of the type-specific 
substance derived from group A hemolytic streptococci. Journal of 
Experimental Medicine 69:425-445. 
62. Dale JB, Beachey EH. 1985. Epitopes of streptococcal M proteins shared 
with cardiac myosin. Journal of Experimental Medicine 162:583-591. 
63. Dale JB, Penfound TA, Chiang EY, Walton WJ. 2011. New 30-valent M 
protein-based vaccine evokes cross-opsonic antibodies against non-vaccine 
serotypes of group A streptococci. Vaccine 29:8175-8178. 
64. Cole JN, Henningham A, Gillen CM, Ramachandran V, Walker MJ. 
2008. Human pathogenic streptococcal proteomics and vaccine development. 
Proteomics Clinical Applicaation 2:387-410. 
65. Henningham A, Gillen CM, Walker MJ. 2013. Group a streptococcal 
vaccine candidates: potential for the development of a human vaccine. Current 
Topics in Microbiology and Immunology 368:207-242. 
66. Steer AC, Dale JB, Carapetis JR. 2013. Progress toward a global group a 
streptococcal vaccine. The Pediatric Infectious Disease Journal 32:180-182. 
67. Michos AG, Bakoula CG, Braoudaki M, Koutouzi FI, Roma ES, Pangalis 
A, Nikolopoulou G, Kirikou E, Syriopoulou VP. 2009. Macrolide resistance 
in Streptococcus pyogenes: prevalence, resistance determinants, and emm 
types. Diagnosis of Microbiology and Infectious Disease 64:295-299. 
68. Åkesson P, Sjöholm AG, Björck L. 1996. Protein SIC, a novel extracellular 
protein of Streptococcus pyogenes interfering with complement function. 
Journal of Biological Chemistry 271:1081-1088. 
69. Fernie-King BA, Seilly DJ, Willers C, Wurzner R, Davies A, Lachmann 
PJ. 2001. Streptococcal inhibitor of complement (SIC) inhibits the membrane 
attack complex by preventing uptake of C567 onto cell membranes. 
Immunology 103:390-398. 
70. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. 2002. Streptococcal 




innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. 
Infection and Immunity 70:4908-4916. 
71. Akesson P, Herwald H, Rasmussen M, Hakansson K, Abrahamson M, 
Hasan AA, Schmaier AH, Muller-Esterl W, Bjorck L. 2010. Streptococcal 
inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence 
determinant. Microbiology 156:3660-3668. 
72. Hoe NP, Ireland RM, DeLeo FR, Gowen BB, Dorward DW, Voyich JM, 
Liu M, Burns EH, Jr., Culnan DM, Bretscher A, Musser JM. 2002. 
Insight into the molecular basis of pathogen abundance: group A 
streptococcus inhibitor of complement inhibits bacterial adherence and 
internalization into human cells. Proceedings of the National Academy of 
Sciences of the United States of America 99:7646-7651. 
73. Fernie-King BA, Seilly DJ, Lachmann PJ. 2004. The interaction of 
streptococcal inhibitor of complement (SIC) and its proteolytic fragments with 
the human beta defensins. Immunology 111:444-452. 
74. Frick IM, Åkesson P, Rasmussen M, Schmidtchen A, Björck L. 2003. 
SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial 
peptides. Journal of Biological Chemistry 278:16561-16566. 
75. Lukomski S, Hoe NP, Abdi I, Rurangirwa J, Kordari P, Liu M, Dou SJ, 
Adams GG, Musser JM. 2000. Nonpolar inactivation of the hypervariable 
streptococcal inhibitor of complement gene (sic) in serotype M1 
Streptococcus pyogenes significantly decreases mouse mucosal colonization. 
Infection and Immunity 68:535-542. 
76. Pence MA, Rooijakkers SH, Cogen AL, Cole JN, Hollands A, Gallo RL, 
Nizet V. 2010. Streptococcal inhibitor of complement promotes innate 
immune resistance phenotypes of invasive M1T1 group A Streptococcus. 
Journal of Innate Immunity 2:587-595. 
77. Frick IM, Shannon O, Akesson P, Morgelin M, Collin M, Schmidtchen A, 
Bjorck L. 2011. Antibacterial activity of the contact and complement systems 
is blocked by SIC, a protein secreted by Streptococcus pyogenes. Journal of 
Biological Chemistry 286:1331-1340. 
78. Bhakdi S, Tranum-Jensen J, Sziegoleit A. 1985. Mechanism of membrane 
damage by streptolysin-O. Infection and Immunity 47:52-60. 
79. Hirsch JG, Bernheimer AW, Weissmann G. 1963. Motion Picture Study of 
the Toxic Action of Streptolysins on Leucocytes. Journal of Experimental 
Medicine 118:223-228. 
80. Launay JM, Alouf JE. 1979. Biochemical and ultrastructural study of the 
disruption of blood platelets by streptolysin O. Biochim Biophys Acta 
556:278-291. 
81. Bricker AL, Cywes C, Ashbaugh CD, Wessels MR. 2002. NAD+-
glycohydrolase acts as an intracellular toxin to enhance the extracellular 
survival of group A streptococci. Molecular Microbiology 44:257-269. 
82. Bastiat-Sempe B, Love JF, Lomayesva N, Wessels MR. 2014. Streptolysin 
O and NAD-glycohydrolase prevent phagolysosome acidification and 





83. Musser JM, Stockbauer K, Kapur V, Rudgers GW. 1996. Substitution of 
cysteine 192 in a highly conserved Streptococcus pyogenes extracellular 
cysteine protease (interleukin 1beta convertase) alters proteolytic activity and 
ablates zymogen processing. Infection and Immunity 64:1913-1917. 
84. Chaussee MS, Liu J, Stevens DL, Ferretti JJ. 1996. Genetic and phenotypic 
diversity among isolates of Streptococcus pyogenes from invasive infections. 
Journal of Infectious Diseases 173:901-908. 
85. Aziz RK, Pabst MJ, Jeng A, Kansal R, Low DE, Nizet V, Kotb M. 2004. 
Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to 
prevent proteolytic degradation of multiple virulence factors by SpeB. 
Molecular Microbiology 51:123-134. 
86. Chaussee MS, Phillips ER, Ferretti JJ. 1997. Temporal production of 
streptococcal erythrogenic toxin B (streptococcal cysteine proteinase) in 
response to nutrient depletion. Infection and Immunity 65:1956-1959. 
87. Kapur V, Majesky MW, Li LL, Black RA, Musser JM. 1993. Cleavage of 
interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a 
conserved extracellular cysteine protease from Streptococcus pyogenes. 
Proceedings of the National Academy of Sciences of the United States of 
America 90:7676-7680. 
88. Loughman JA, Caparon M. 2006. Regulation of SpeB in Streptococcus 
pyogenes by pH and NaCl: a model for in vivo gene expression. Journal of 
Bacteriology 188:399-408. 
89. Lei B, DeLeo FR, Hoe NP, Graham MR, Mackie SM, Cole RL, Liu M, 
Hill HR, Low DE, Federle MJ, Scott JR, Musser JM. 2001. Evasion of 
human innate and acquired immunity by a bacterial homolog of CD11b that 
inhibits opsonophagocytosis. Nature Medicine 7:1298-1305. 
90. Lei B, DeLeo FR, Reid SD, Voyich JM, Magoun L, Liu M, Braughton 
KR, Ricklefs S, Hoe NP, Cole RL, Leong JM, Musser JM. 2002. 
Opsonophagocytosis-inhibiting mac protein of group a streptococcus: 
identification and characteristics of two genetic complexes. Infection and 
Immunity 70:6880-6890. 
91. von Pawel-Rammingen U, Johansson BP, Bjorck L. 2002. IdeS, a novel 
streptococcal cysteine proteinase with unique specificity for immunoglobulin 
G. EMBO Journal 21:1607-1615. 
92. Agniswamy J, Nagiec MJ, Liu M, Schuck P, Musser JM, Sun PD. 2006. 
Crystal structure of group A streptococcus Mac-1: insight into dimer-mediated 
specificity for recognition of human IgG. Structure 14:225-235. 
93. von Pawel-Rammingen U. 2012. Streptococcal IdeS and its impact on 
immune response and inflammation. Journal of Innate Immunity 4:132-140. 
94. Akesson P, Moritz L, Truedsson M, Christensson B, von Pawel-
Rammingen U. 2006. IdeS, a highly specific immunoglobulin G (IgG)-
cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG 
antibodies generated during infection. Infection and Immunity 74:497-503. 
95. Okada N, Pentland AP, Falk P, Caparon MG. 1994. M protein and protein 
F act as important determinants of cell-specific tropism of Streptococcus 




96. Okada N, Liszewski MK, Atkinson JP, Caparon M. 1995. Membrane 
cofactor protein (CD46) is a keratinocyte receptor for the M protein of the 
group A streptococcus. Proceedings of the National Academy of Sciences of 
the United States of America 92:2489-2493. 
97. Bisno AL. 1979. Alternate complement pathway activation by group A 
streptococci: role of M-protein. Infection and Immunity 26:1172-1176. 
98. Johnsson E, Berggard K, Kotarsky H, Hellwage J, Zipfel PF, Sjobring U, 
Lindahl G. 1998. Role of the hypervariable region in streptococcal M 
proteins: binding of a human complement inhibitor. Journal of Immunology 
161:4894-4901. 
99. Whitnack E, Beachey EH. 1985. Inhibition of complement-mediated 
opsonization and phagocytosis of Streptococcus pyogenes by D fragments of 
fibrinogen and fibrin bound to cell surface M protein. Journal of Experimental 
Medicine 162:1983-1997. 
100. Ghosh P. 2011. The Nonideal Coiled Coil of M Protein and Its Multifarious 
Functions in Pathogenesis, p 197-211. In Linke D, Goldman A (ed), Bacterial 
Adhesion vol 715. Springer Dordrecht Heidelberg, New York, London. 
101. Bessen D, Jones KF, Fischetti VA. 1989. Evidence for two distinct classes of 
streptococcal M protein and their relationship to rheumatic fever. Journal of 
Experimental Medicine 169:269-283. 
102. Horstmann RD, Sievertsen HJ, Leippe M, Fischetti VA. 1992. Role of 
fibrinogen in complement inhibition by streptococcal M protein. Infection and 
Immunity 60:5036-5041. 
103. Carlsson F, Berggard K, Stalhammar-Carlemalm M, Lindahl G. 2003. 
Evasion of phagocytosis through cooperation between two ligand-binding 
regions in Streptococcus pyogenes M protein. Journal of Experimental 
Medicine 198:1057-1068. 
104. Pahlman LI, Morgelin M, Eckert J, Johansson L, Russell W, Riesbeck K, 
Soehnlein O, Lindbom L, Norrby-Teglund A, Schumann RR, Bjorck L, 
Herwald H. 2006. Streptococcal M protein: a multipotent and powerful 
inducer of inflammation. Journal of Immunology 177:1221-1228. 
105. Smeesters PR, McMillan DJ, Sriprakash KS. 2010. The streptococcal M 
protein: a highly versatile molecule. Trends in Microbiology 18:275-282. 
106. Pahlman LI, Olin AI, Darenberg J, Morgelin M, Kotb M, Herwald H, 
Norrby-Teglund A. 2008. Soluble M1 protein of Streptococcus pyogenes 
triggers potent T cell activation. Cell Microbiology 10:404-414. 
107. Whatmore AM, Kehoe MA. 1994. Horizontal gene transfer in the evolution 
of group A streptococcal emm-like genes: gene mosaics and variation in Vir 
regulons. Molecular Microbiology 11:363-374. 
108. Ji Y, Schnitzler N, DeMaster E, Cleary P. 1998. Impact of M49, Mrp, Enn, 
and C5a peptidase proteins on colonization of the mouse oral mucosa by 
Streptococcus pyogenes. Infection and Immunity 66:5399-5405. 
109. Podbielski A, Schnitzler N, Beyhs P, Boyle MD. 1996. M-related protein 
(Mrp) contributes to group A streptococcal resistance to phagocytosis by 




110. Lukomski S, Nakashima K, Abdi I, Cipriano VJ, Ireland RM, Reid SD, 
Adams GG, Musser JM. 2000. Identification and characterization of the scl 
gene encoding a group A streptococcus extracellular protein virulence factor 
with similarity to human collagen. Infection and Immunity 68:6542-6553. 
111. Rasmussen R, Eden A, Björck L. 2000. SclA, a novel collagen-like surface 
protein of Streptococcus pyogenes. Infection and Immunity 68:6370-6377. 
112. Caswell CC, Lukomska E, Seo NS, Höök M, Lukomski S. 2007. Scl1-
dependent internalization of group A Streptococcus via direct interactions 
with the α2β(1) integrin enhances pathogen survival and re-emergence. 
Molecular Microbiology 64:1319-1331. 
113. Dohrmann S, Anik S, Olson J, Anderson EL, Etesami N, No H, Snipper J, 
Nizet V, Okumura CY. 2014. Role for streptococcal collagen-like protein 1 
in M1T1 group A Streptococcus resistance to neutrophil extracellular traps. 
Infection and Immunity 82:4011-4020. 
114. Oliver-Kozup H, Martin KH, Schwegler-Berry D, Green BJ, Betts C, 
Shinde AV, Van De Water L, Lukomski S. 2013. The group A 
streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by 
targeting the extra domain A-containing variant of cellular fibronectin 
expressed in wounded tissue. Molecular Microbiology 87:672-689. 
115. Simpson WJ, LaPenta D, Chen C, Cleary PP. 1990. Coregulation of type 
12 M protein and streptococcal C5a peptidase genes in group A streptococci: 
evidence for a virulence regulon controlled by the virR locus. Journal of 
Bacteriology 172:696-700. 
116. Wexler DE, Chenoweth DE, Cleary PP. 1985. Mechanism of action of the 
group A streptococcal C5a inactivator. Proceedings of the National Academy 
of Sciences of the United States of America 82:8144-8148. 
117. Cleary PP, Prahbu U, Dale JB, Wexler DE, Handley J. 1992. Streptococcal 
C5a peptidase is a highly specific endopeptidase. Infection and Immunity 
60:5219-5223. 
118. Kagawa TF, O'Connell MR, Mouat P, Paoli M, O'Toole PW, Cooney JC. 
2009. Model for substrate interactions in C5a peptidase from Streptococcus 
pyogenes: A 1.9 A crystal structure of the active form of ScpA. Journal of 
Molecular Biology 386:754-772. 
119. Ji Y, McLandsborough L, Kondagunta A, Cleary PP. 1996. C5a peptidase 
alters clearance and trafficking of group A streptococci by infected mice. 
Infection and Immunity 64:503-510. 
120. Park HS, Cleary PP. 2005. Active and passive intranasal immunizations with 
streptococcal surface protein C5a peptidase prevent infection of murine nasal 
mucosa-associated lymphoid tissue, a functional homologue of human tonsils. 
Infection and Immunity 73:7878-7886. 
121. Patti JM, Höök M. 1994. Microbial adhesins recognizing extracellular matrix 
macromolecules. Curr Opin Cell Biol 6:752-758. 
122. Kreikemeyer B, Oehmcke S, Nakata M, Hoffrogge R, Podbielski A. 2004. 
Streptococcus pyogenes fibronectin-binding protein F2: expression profile, 
binding characteristics, and impact on eukaryotic cell interactions. Journal of 




123. LaPenta D, Rubens C, Chi E, Cleary PP. 1994. Group A streptococci 
efficiently invade human respiratory epithelial cells. Proceedings of the 
National Academy of Sciences of the United States of America 91:12115-
12119. 
124. Molinari G, Talay SR, Valentin-Weigand P, Rohde M, Chhatwal GS. 
1997. The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is 
involved in the internalization of group A streptococci by epithelial cells. 
Infection and Immunity 65:1357-1363. 
125. Oehmcke S, Podbielski A, Kreikemeyer B. 2004. Function of the 
fibronectin-binding serum opacity factor of Streptococcus pyogenes in 
adherence to epithelial cells. Infection and Immunity 72:4302-4308. 
126. Rakonjac JV, Robbins JC, Fischetti VA. 1995. DNA sequence of the serum 
opacity factor of group A streptococci: identification of a fibronectin-binding 
repeat domain. Infection and Immunity 63:622-631. 
127. Courtney HS, Hasty DL, Li Y, Chiang HC, Thacker JL, Dale JB. 1999. 
Serum opacity factor is a major fibronectin-binding protein and a virulence 
determinant of M type 2 Streptococcus pyogenes. Molecular Microbiology 
32:89-98. 
128. Falaleeva M, Zurek OW, Watkins RL, Reed RW, Ali H, Sumby P, 
Voyich JM, Korotkova N. 2014. Transcription of the Streptococcus 
pyogenes hyaluronic acid capsule biosynthesis operon is regulated by 
previously unknown upstream elements. Infection and Immunity 82:5293-
5307. 
129. Levin JC, Wessels MR. 1998. Identification of csrR/csrS, a genetic locus that 
regulates hyaluronic acid capsule synthesis in group A streptococcus. 
Molecular Microbiology 30:209-219. 
130. Lynskey NN, Goulding D, Gierula M, Turner CE, Dougan G, Edwards 
RJ, Sriskandan S. 2013. RocA truncation underpins hyper-encapsulation, 
carriage longevity and transmissibility of serotype M18 group A streptococci. 
PLoS Pathog 9:e1003842. 
131. Johnson DR, Stevens DL, Kaplan EL. 1992. Epidemiologic analysis of 
group A streptococcal serotypes associated with severe systemic infections, 
rheumatic fever, or uncomplicated pharyngitis. Journal of Infectious Diseases 
166:374-382. 
132. Wessels MR, Bronze MS. 1994. Critical role of the group A streptococcal 
capsule in pharyngeal colonization and infection in mice. Proceedings of the 
National Academy of Sciences of the United States of America 91:12238-
12242. 
133. Schrager HM, Rheinwald JG, Wessels MR. 1996. Hyaluronic acid capsule 
and the role of streptococcal entry into keratinocytes in invasive skin 
infection. Journal of Clinical Investigation 98:1954-1958. 
134. Stollerman GH, Dale JB. 2008. The importance of the group a streptococcus 
capsule in the pathogenesis of human infections: a historical perspective. Clin 
Infectious Disease 46:1038-1045. 
135. Datta V, Myskowski SM, Kwinn LA, Chiem DN, Varki N, Kansal RG, 




operon encoding streptolysin S and its virulence role in invasive infection. 
Molecular Microbiology 56:681-695. 
136. Ginsburg I. 1999. Is streptolysin S of group A streptococci a virulence 
factor? APMIS : Acta Pathologica, Microbiologica et Immunologica 
Scandinavica 107:1051-1059. 
137. Ofek I, Zafriri D, Goldhar J, Eisenstein BI. 1990. Inability of toxin 
inhibitors to neutralize enhanced toxicity caused by bacteria adherent to tissue 
culture cells. Infection and Immunity 58:3737-3742. 
138. Keiser H, Weissmann G, Bernheimer AW. 1964. Studies on Lysosomes. Iv. 
Solubilization of Enzymes During Mitochondrial Swelling and Disruption of 
Lysosomes by Streptolysin S and Other Hemolytic Agents. Journal of Cell 
Biology 22:101-113. 
139. Ginsburg I. 1972. Mechanisms of cell and tissue injury induced by group A 
streptococci: relation to poststreptococcal sequelae. Journal of Infectious 
Diseases 126:294-340. 
140. Taketo Y, Taketo A. 1966. Cytolytic effect of streptolysin S complex on 
Ehrlich ascites tumor cells. Journal of Biochemistry 60:357-362. 
141. Hryniewicz W, Pryjma J. 1977. Effect of streptolysin S on human and 
mouse T and B lymphocytes. Infection and Immunity 16:730-733. 
142. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, 
Feramisco J, Nizet V. 2006. DNase expression allows the pathogen group A 
Streptococcus to escape killing in neutrophil extracellular traps. Current 
Biology 16:396-400. 
143. Aziz RK, Ismail SA, Park HW, Kotb M. 2004. Post-proteomic 
identification of a novel phage-encoded streptodornase, Sda1, in invasive 
M1T1 Streptococcus pyogenes. Molecular Microbiology 54:184-197. 
144. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, 
Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG, Simpson 
AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet V. 2007. DNase Sda1 
provides selection pressure for a switch to invasive group A streptococcal 
infection. Nat Med 13:981-985. 
145. Sumby P, Barbian KD, Gardner DJ, Whitney AR, Welty DM, Long RD, 
Bailey JR, Parnell MJ, Hoe NP, Adams GG, Deleo FR, Musser JM. 2005. 
Extracellular deoxyribonuclease made by group A streptococcus assists 
pathogenesis by enhancing evasion of the innate immune response. 
Proceedings of the National Academy of Sciences of the United States of 
America 102:1679-1684. 
146. Venturini C, Ong CIY, Gillen CM, Ben-Zakour NL, Maamary PG, Nizet 
V, Beatson SA, Walker MJ. 2013. Acquisition of the Sda1-Encoding 
Bacteriophage Does Not Enhance Virulence of the Serotype M1 
Streptococcus pyogenes Strain SF370. Infection and Immunity 81:2062-2069. 
147. Sriskandan S, Faulkner L, Hopkins P. 2007. Streptococcus pyogenes: 
Insight into the function of the streptococcal superantigens. International 
Journal of Biochemistry and Cellular Biology 39:12-19. 
148. Stock AM, Robinson VL, Goudreau PN. 2000. Two-component signal 




149. Federle MJ, McIver KS, Scott JR. 1999. A response regulator that represses 
transcription of several virulence operons in the group A streptococcus. 
Journal of Bacteriology 181:3649-3657. 
150. Heath A, DiRita VJ, Barg NL, Engleberg NC. 1999. A two-component 
regulatory system, CsrR-CsrS, represses expression of three Streptococcus 
pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and 
pyrogenic exotoxin B. Infection and Immunity 67:5298-5305. 
151. Bernish B, van de Rijn I. 1999. Characterization of a two-component system 
in Streptococcus pyogenes which is involved in regulation of hyaluronic acid 
production. J Biol Chem 274:4786-4793. 
152. Dalton TL, Scott JR. 2004. CovS inactivates CovR and is required for 
growth under conditions of general stress in Streptococcus pyogenes. Journal 
of Bacteriology 186:3928-3937. 
153. Velarde JJ, Ashbaugh M, Wessels MR. 2014. The Human Antimicrobial 
Peptide LL-37 Binds Directly to CsrS, a Sensor Histidine Kinase of Group A 
Streptococcus, to Activate Expression of Virulence Factors. Journal of 
Biological Chemistry 289:36315-36324. 
154. Churchward G. 2007. The two faces of Janus: virulence gene regulation by 
CovR/S in group A streptococci. Molecular Microbiology 64:34-41. 
155. Gryllos I, Grifantini R, Colaprico A, Jiang S, Deforce E, Hakansson A, 
Telford JL, Grandi G, Wessels MR. 2007. Mg(2+) signalling defines the 
group A streptococcal CsrRS (CovRS) regulon. Molecular Microbiology 
65:671-683. 
156. Graham MR, Smoot LM, Migliaccio CA, Virtaneva K, Sturdevant DE, 
Porcella SF, Federle MJ, Adams GJ, Scott JR, Musser JM. 2002. 
Virulence control in group A streptococcus by a two-component gene 
regulatory system: global expression profiling and in vivo infection modeling. 
Proceedings of the National Academy of Sciences of the United States of 
America 99:13855-13860. 
157. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. 2006. 
Genome-wide analysis of group a streptococci reveals a mutation that 
modulates global phenotype and disease specificity. PLoS Pathogens 2:e5. 
158. Engleberg NC, Heath A, Miller A, Rivera C, DiRita VJ. 2001. 
Spontaneous mutations in the CsrRS two-component regulatory system of 
Streptococcus pyogenes result in enhanced virulence in a murine model of 
skin and soft tissue infection. Journal of Infectious Diseases 183:1043-1054. 
159. Federle MJ, Scott JR. 2002. Identification of binding sites for the group A 
streptococcal global regulator CovR. Molecular Microbiology 43:1161-1172. 
160. Leday TV, Gold KM, Kinkel TL, Roberts SA, Scott JR, McIver KS. 2008. 
TrxR, a new CovR-repressed response regulator that activates the Mga 
virulence regulon in group A Streptococcus. Infection and Immunity 76:4659-
4668. 
161. Gold KM. 2011. Characterization of the TrxSR two-component signal 
transduction system of Streptococcus pyogenes and its role in virulence 




162. Chaussee MS, Ajdic D, Ferretti JJ. 1999. The rgg gene of Streptococcus 
pyogenes NZ131 positively influences extracellular SPE B production. 
Infection and Immunity 67:1715-1722. 
163. Chaussee MS, Sylva GL, Sturdevant DE, Smoot LM, Graham MR, 
Watson RO, Musser JM. 2002. Rgg influences the expression of multiple 
regulatory loci to coregulate virulence factor expression in Streptococcus 
pyogenes. Infection and Immunity 70:762-770. 
164. Chaussee MS, Somerville GA, Reitzer L, Musser JM. 2003. Rgg 
coordinates virulence factor synthesis and metabolism in Streptococcus 
pyogenes. Journal of Bacteriology 185:6016-6024. 
165. Chaussee MA, Callegari EA, Chaussee MS. 2004. Rgg regulates growth 
phase-dependent expression of proteins associated with secondary metabolism 
and stress in Streptococcus pyogenes. Journal of Bacteriology 186:7091-7099. 
166. Mashburn-Warren L, Morrison DA, Federle MJ. 2010. A novel double-
tryptophan peptide pheromone controls competence in Streptococcus spp. via 
an Rgg regulator. Molecular Microbiology 78:589-606. 
167. Anbalagan S, McShan WM, Dunman PM, Chaussee MS. 2011. 
Identification of Rgg binding sites in the Streptococcus pyogenes 
chromosome. Journal of bacteriology 193:4933-4942. 
168. Fogg GC, Gibson CM, Caparon MG. 1994. The identification of rofA, a 
positive-acting regulatory component of prtF expression: use of an m-gamma-
delta-based shuttle mutagenesis strategy in Streptococcus pyogenes. 
Molecular Microbiology 11:671-684. 
169. Beckert S, Kreikemeyer B, Podbielski A. 2001. Group A streptococcal rofA 
gene is involved in the control of several virulence genes and eukaryotic cell 
attachment and internalization. Infection and Immunity 69:534-537. 
170. Granok AB, Parsonage D, Ross RP, Caparon MG. 2000. The RofA 
binding site in Streptococcus pyogenes is utilized in multiple transcriptional 
pathways. Journal of Bacteriology 182:1529-1540. 
171. Podbielski A, Woischnik M, Leonard BA, Schmidt KH. 1999. 
Characterization of nra, a global negative regulator gene in group A 
streptococci. Molecular Microbiology 31:1051-1064. 
172. Molinari G, Rohde M, Talay SR, Chhatwal GS, Beckert S, Podbielski A. 
2001. The role played by the group A streptococcal negative regulator Nra on 
bacterial interactions with epithelial cells. Molecular Microbiology 40:99-114. 
173. Kreikemeyer B, Nakata M, Koller T, Hildisch H, Kourakos V, Standar K, 
Kawabata S, Glocker MO, Podbielski A. 2007. The Streptococcus pyogenes 
serotype M49 Nra-Ralp3 transcriptional regulatory network and its control of 
virulence factor expression from the novel eno ralp3 epf sagA pathogenicity 
region. Infection and Immunity 75:5698-5710. 
174. Kreikemeyer B, Beckert S, Braun-Kiewnick A, Podbielski A. 2002. Group 
A streptococcal RofA-type global regulators exhibit a strain-specific genomic 
presence and regulation pattern. Microbiology 148:1501-1511. 
175. Luo F, Lizano S, Bessen DE. 2008. Heterogeneity in the Polarity of Nra 
Regulatory Effects on Streptococcal Pilus Gene Transcription and Virulence. 




176. Kwinn LA, Khosravi A, Aziz RK, Timmer AM, Doran KS, Kotb M, Nizet 
V. 2007. Genetic characterization and virulence role of the RALP3/LSA locus 
upstream of the streptolysin s operon in invasive M1T1 Group A 
Streptococcus. Journal of Bacteriology 189:1322-1329. 
177. Roberts SA, Scott JR. 2007. RivR and the small RNA RivX: the missing 
links between the CovR regulatory cascade and the Mga regulon. Molecular 
Microbiology 66:1506-1522. 
178. Roberts SA, Churchward GG, Scott JR. 2007. Unraveling the regulatory 
network in Streptococcus pyogenes: the global response regulator CovR 
represses rivR directly. Journal of Bacteriology 189:1459-1463. 
179. Trevino J, Liu Z, Cao TN, Ramirez-Pena E, Sumby P. 2013. RivR is a 
negative regulator of virulence factor expression in group A Streptococcus. 
Infection and Immunity 81:364-372. 
180. Deutscher J, Francke C, Postma PW. 2006. How phosphotransferase 
system-related protein phosphorylation regulates carbohydrate metabolism in 
bacteria. Microbiology and Molecular Biology Reviews 70:939-1031. 
181. Deutscher J, Herro R, Bourand A, Mijakovic I, Poncet S. 2005. P-Ser-
HPr--a link between carbon metabolism and the virulence of some pathogenic 
bacteria. Biochimica Biophysica Acta 1754:118-125. 
182. Stulke J, Hillen W. 2000. Regulation of carbon catabolism in Bacillus 
species. Annu Rev Microbiol 54:849-880. 
183. Titgemeyer F, Hillen W. 2002. Global control of sugar metabolism: a gram-
positive solution. Antonie Van Leeuwenhoek 82:59-71. 
184. Fujita Y. 2009. Carbon catabolite control of the metabolic network in 
Bacillus subtilis. Bioscience, Biotechnology, and Biochemistry 73:245-259. 
185. Deutscher J. 2008. The mechanisms of carbon catabolite repression in 
bacteria. Current Opinion in Microbiology 11:87-93. 
186. Gorke B, Stulke J. 2008. Carbon catabolite repression in bacteria: many 
ways to make the most out of nutrients. Nature Reviews Microbiology 6:613-
624. 
187. Milenbachs AA, Brown DP, Moors M, Youngman P. 1997. Carbon-source 
regulation of virulence gene expression in Listeria monocytogenes. Molecular 
Microbiology 23:1075-1085. 
188. Behari J, Youngman P. 1998. A homolog of CcpA mediates catabolite 
control in Listeria monocytogenes but not carbon source regulation of 
virulence genes. Journal of Bacteriology 180:6316-6324. 
189. Herro R, Poncet S, Cossart P, Buchrieser C, Gouin E, Glaser P, 
Deutscher J. 2005. How seryl-phosphorylated HPr inhibits PrfA, a 
transcription activator of Listeria monocytogenes virulence genes. Journal of 
Molecular Microbiology and Biotechnology 9:224-234. 
190. Varga J, Stirewalt VL, Melville SB. 2004. The CcpA protein is necessary 
for efficient sporulation and enterotoxin gene (cpe) regulation in Clostridium 
perfringens. Journal of Bacteriology 186:5221-5229. 
191. Giammarinaro P, Paton JC. 2002. Role of RegM, a homologue of the 
catabolite repressor protein CcpA, in the virulence of Streptococcus 




192. Mendez M, Huang IH, Ohtani K, Grau R, Shimizu T, Sarker MR. 2008. 
Carbon catabolite repression of type IV pilus-dependent gliding motility in the 
anaerobic pathogen Clostridium perfringens. Journal of Bacteriology 190:48-
60. 
193. Seidl K, Stucki M, Ruegg M, Goerke C, Wolz C, Harris L, Berger-Bachi 
B, Bischoff M. 2006. Staphylococcus aureus CcpA affects virulence 
determinant production and antibiotic resistance. Antimicrobial Agents and 
Chemotherapy 50:1183-1194. 
194. Iyer R, Baliga NS, Camilli A. 2005. Catabolite control protein A (CcpA) 
contributes to virulence and regulation of sugar metabolism in Streptococcus 
pneumoniae. Journal of Bacteriology 187:8340-8349. 
195. Krzysciak W, Jurczak A, Koscielniak D, Bystrowska B, Skalniak A. 2014. 
The virulence of Streptococcus mutans and the ability to form biofilms. 
European Journal of Clinical Microbiology and Infectious Disease 33:499-
515. 
196. Fujita Y, Miwa Y, Galinier A, Deutscher J. 1995. Specific recognition of 
the Bacillus subtilis gnt cis-acting catabolite-responsive element by a protein 
complex formed between CcpA and seryl-phosphorylated HPr. Molecular 
Microbiology 17:953-960. 
197. Shelburne SA, 3rd, Keith DB, Davenport MT, Horstmann N, Brennan 
RG, Musser JM. 2008. Molecular characterization of group A Streptococcus 
maltodextrin catabolism and its role in pharyngitis. Molecular Microbiology 
69:436-452. 
198. Shelburne SA, 3rd, Sahasrobhajane P, Suber B, Keith DB, Davenport 
MT, Horstmann N, Kumaraswami M, Olsen RJ, Brennan RG, Musser 
JM. 2011. Niche-specific contribution to streptococcal virulence of a MalR-
regulated carbohydrate binding protein. Molecular Microbiology 81:500-514. 
199. Steiner K, Malke H. 2000. Life in protein-rich environments: the relA-
independent response of Streptococcus pyogenes to amino acid starvation. 
Molecular Microbiology 38:1004-1016. 
200. Malke H, Steiner K, McShan WM, Ferretti JJ. 2006. Linking the 
nutritional status of Streptococcus pyogenes to alteration of transcriptional 
gene expression: the action of CodY and RelA. International Journal of 
Medicinal Microbiology 296:259-275. 
201. Malke H, Ferretti JJ. 2007. CodY-affected transcriptional gene expression 
of Streptococcus pyogenes during growth in human blood. Journal of Medical 
Microbiology 56:707-714. 
202. Pine L, Reeves MW. 1972. Correlation of M protein production with those 
factors found to influence growth and substrate utilization of Streptococcus 
pyogenes. Infection and Immunity 5:668-680. 
203. Stulke J, Arnaud M, Rapoport G, Martin-Verstraete I. 1998. PRD--a 
protein domain involved in PTS-dependent induction and carbon catabolite 





204. Schnetz K, Stulke J, Gertz S, Kruger S, Krieg M, Hecker M, Rak B. 1996. 
LicT, a Bacillus subtilis transcriptional antiterminator protein of the BglG 
family. Journal of Bacteriology 178:1971-1979. 
205. van Tilbeurgh H, Le Coq D, Declerck N. 2001. Crystal structure of an 
activated form of the PTS regulation domain from the LicT transcriptional 
antiterminator. EMBO Journal 20:3789-3799. 
206. Lindner C, Galinier A, Hecker M, Deutscher J. 1999. Regulation of the 
activity of the Bacillus subtilis antiterminator LicT by multiple PEP-
dependent, enzyme I- and HPr-catalysed phosphorylation. Molecular 
Microbiology 31:995-1006. 
207. Tortosa P, Declerck N, Dutartre H, Lindner C, Deutscher J, Le Coq D. 
2001. Sites of positive and negative regulation in the Bacillus subtilis 
antiterminators LicT and SacY. Molecular Microbiology 41:1381-1393. 
208. Ben-Zeev E, Fux L, Amster-Choder O, Eisenstein M. 2005. Experimental 
and computational characterization of the dimerization of the PTS-regulation 
domains of BglG from Escherichia coli. Journal of molecular biology 
347:693-706. 
209. Henstra SA, Tuinhof M, Duurkens RH, Robillard GT. 1999. The Bacillus 
stearothermophilus mannitol regulator, MtlR, of the phosphotransferase 
system. A DNA-binding protein, regulated by HPr and iicbmtl-dependent 
phosphorylation. Journal Biology Chemistry 274:4754-4763. 
210. Henstra SA, Duurkens RH, Robillard GT. 2000. Multiple phosphorylation 
events regulate the activity of the mannitol transcriptional regulator MtlR of 
the Bacillus stearothermophilus phosphoenolpyruvate-dependent mannitol 
phosphotransferase system. Journal of Biological Chemistry 275:7037-7044. 
211. Bouraoui H, Ventroux M, Noirot-Gros MF, Deutscher J, Joyet P. 2013. 
Membrane sequestration by the EIIB domain of the mannitol permease MtlA 
activates the Bacillus subtilis mtl operon regulator MtlR. Molecular 
Microbiology 87:789-801. 
212. Mock M, Fouet A. 2001. Anthrax. Annu Rev Microbiol 55:647-671. 
213. Fouet A. 2010. AtxA, a Bacillus anthracis global virulence regulator. 
Research Microbiology 161:735-742. 
214. Tsvetanova B, Wilson AC, Bongiorni C, Chiang C, Hoch JA, Perego M. 
2007. Opposing effects of histidine phosphorylation regulate the AtxA 
virulence transcription factor in Bacillus anthracis. Molecular Microbiology 
63:644-655. 
215. Hammerstrom TG, Roh JH, Nikonowicz EP, Koehler TM. 2011. Bacillus 
anthracis virulence regulator AtxA: oligomeric state, function and CO(2) -
signalling. Molecular Microbiology 82:634-647. 
216. Hammerstrom TG, Horton LB, Swick MC, Joachimiak A, Osipiuk J, 
Koehler TM. 2015. Crystal structure of Bacillus anthracis virulence regulator 
AtxA and effects of phosphorylated histidines on multimerization and activity. 
Molecular Microbiology 95:426-441. 
217. Osipiuk J, Wu R., Jedrzejczak, R., Moy, S., and Joachimiak, A. 2011. 
Structure for the Putative Mga family transcriptional regulator from 




218. Ruiz-Cruz S, Espinosa M, Goldmann O, Bravo A. 2015. Global Regulation 
of Gene Expression by the MafR Protein of Enterococcus faecalis. Frontiers in 
Microbiology 6:1521. 
219. Podbielski A. 1992. Ubiquitous occurrence of virR and scpA genes in group 
A streptococci. Medical Microbiol ogy and Immunology 181:227-240. 
220. Bessen DE, Manoharan A, Luo F, Wertz JE, Robinson DA. 2005. 
Evolution of transcription regulatory genes is linked to niche specialization in 
the bacterial pathogen Streptococcus pyogenes. Journal of Bacteriology 
187:4163-4172. 
221. Spanier JG, Jones SJ, Cleary P. 1984. Small DNA deletions creating 
avirulence in Streptococcus pyogenes. Science 225:935-938. 
222. Caparon MG, Scott JR. 1987. Identification of a gene that regulates 
expression of M protein, the major virulence determinant of group A 
streptococci. Proceedings of the National Academy of Sciences of the United 
States of America 84:8677-8681. 
223. Perez-Casal J, Caparon MG, Scott JR. 1991. Mry, a trans-acting positive 
regulator of the M protein gene of Streptococcus pyogenes with similarity to 
the receptor proteins of two-component regulatory systems. Journal of 
Bacteriology 173:2617-2624. 
224. Scott JR, Cleary P, Caparon MG, Kehoe M, Heden L, Musser JM, 
Hollingshead S, Podbielski A. 1995. New name for the positive regulator of 
the M protein of group A streptococcus. Molecular Microbiology 17:799. 
225. Shelburne SA, 3rd, Granville C, Tokuyama M, Sitkiewicz I, Patel P, 
Musser JM. 2005. Growth characteristics of and virulence factor production 
by group A Streptococcus during cultivation in human saliva. Infection and 
Immunity 73:4723-4731. 
226. McIver KS, Scott JR. 1997. Role of mga in growth phase regulation of 
virulence genes of the group A streptococcus. Journal of Bacteriology 
179:5178-5187. 
227. Unnikrishnan M, Cohen J, Sriskandan S. 1999. Growth-phase-dependent 
expression of virulence factors in an M1T1 clinical isolate of Streptococcus 
pyogenes. Infection and Immunity 67:5495-5499. 
228. Virtaneva K, Porcella SF, Graham MR, Ireland RM, Johnson CA, 
Ricklefs SM, Babar I, Parkins LD, Romero RA, Corn GJ, Gardner DJ, 
Bailey JR, Parnell MJ, Musser JM. 2005. Longitudinal analysis of the 
group A streptococcus transcriptome in experimental pharyngitis in 
cynomolgus macaques. Proceedings of the National Academy of Sciences of 
the United States of America 102:9014-9019. 
229. Ribardo DA, McIver KS. 2006. Defining the Mga regulon: comparative 
transcriptome analysis reveals both direct and indirect regulation by Mga in 
the group A streptococcus. Molecular Microbiology 62:491-508. 
230. Okada N, Geist RT, Caparon MG. 1993. Positive transcriptional control of 





231. McIver KS, Thurman AS, Scott JR. 1999. Regulation of mga transcription 
in the group A streptococcus: specific binding of Mga within its own promoter 
and evidence for a negative regulator. Journal of Bacteriology 181:5373-5383. 
232. Podbielski A, Flosdorff A, Weber-Heynemann J. 1995. The group A 
streptococcal virR49 gene controls expression of four structural vir regulon 
genes. Infection and Immunity 63:9-20. 
233. Ribardo DA, Lambert TJ, McIver KS. 2004. Role of Streptococcus 
pyogenes two-component response regulators in the temporal control of Mga 
and the Mga-regulated virulence gene emm. Infection and Immunity 72:3668-
3673. 
234. Haanes EJ, Heath DG, Cleary PP. 1992. Architecture of the vir regulons of 
group A streptococci parallels opacity factor phenotype and M protein class. 
Journal of Bacteriology 174:4967-4976. 
235. McIver KS, Heath AS, Green BD, Scott JR. 1995. Specific binding of the 
activator Mga to promoter sequences of the emm and scpA genes in the group 
A streptococcus. Journal of Bacteriology 177:6619-6624. 
236. McIver KS, Myles RL. 2002. Two DNA-binding domains of Mga are 
required for virulence gene activation in the group A streptococcus. Molecular 
Microbiology 43:1591-1602. 
237. Hondorp ER, S.C. H, Hempstead AD, Hause LL, Beckett DM, McIver 
KS. 2012. Characterization of the group A streptococcus Mga virulence 
regulator reveals a role for the C-terminal region in oligomerization and 
transcriptional activation. Molecular Microbiology 83:953-967. 
238. McIver KS, Heath AS, Scott JR. 1995. Regulation of virulence by 
environmental signals in group A streptococci: influence of osmolarity, 
temperature, gas exchange, and iron limitation on emm transcription. Infection 
and Immunity 63:4540-4542. 
239. Caparon MG, Geist RT, Perez-Casal J, Scott JR. 1992. Environmental 
regulation of virulence in group A streptococci: transcription of the gene 
encoding M protein is stimulated by carbon dioxide. Journal of Bacteriology 
174:5693-5701. 
240. Ribardo DA, McIver KS. 2003. amrA encodes a putative membrane protein 
necessary for maximal exponential phase expression of the Mga virulence 
regulon in Streptococcus pyogenes. Molecular Microbiology 50:673-685. 
241. Cox KH, Ruiz-Bustos E, Courtney HS, Dale JB, Pence MA, Nizet V, Aziz 
RK, Gerling I, Price SM, Hasty DL. 2009. Inactivation of DltA modulates 
virulence factor expression in Streptococcus pyogenes. PLoS One 4:e5366. 
242. Hause LL, McIver KS. 2012. Nucleotides critical for the interaction of the 
Streptococcus pyogenes Mga virulence regulator with Mga-regulated 
promoter sequences. Journal of Bacteriology 194:4904-4919. 
243. Almengor AC, McIver KS. 2004. Transcriptional activation of sclA by Mga 
requires a distal binding site in Streptococcus pyogenes. Journal of 
Bacteriology 186:7847-7857. 
244. Almengor AC, Walters MS, McIver KS. 2006. Mga is sufficient to activate 
transcription in vitro of sof/sfbX and other Mga-regulated virulence genes in 




245. Studier FW. 2005. Protein production by auto-induction in high density 
shaking cultures. Protein Expression Purification 41:207-234. 
246. Lyon WR, Gibson CM, Caparon MG. 1998. A role for trigger factor and an 
rgg-like regulator in the transcription, secretion and processing of the cysteine 
proteinase of Streptococcus pyogenes. EMBO Journal 17:6263-6275. 
247. Hanahan D, Meselson M. 1983. Plasmid screening at high colony density. 
Methods in Enzymology 100:333-342. 
248. Miroux B, Walker JE. 1996. Over-production of proteins in Escherichia 
coli: mutant hosts that allow synthesis of some membrane proteins and 
globular proteins at high levels. Journal of Molecular Biology 260:289-298. 
249. Ferretti JJ, McShan WM, Ajdic D, Savic DJ, Savic G, Lyon K, Primeaux 
C, Sezate S, Suvorov AN, Kenton S, Lai HS, Lin SP, Qian Y, Jia HG, 
Najar FZ, Ren Q, Zhu H, Song L, White J, Yuan X, Clifton SW, Roe BA, 
McLaughlin R. 2001. Complete genome sequence of an M1 strain of 
Streptococcus pyogenes. Proceedings of the National Academy of Sciences of 
the United States of America 98:4658-4663. 
250. Rose RE. 1988. The nucleotide sequence of pACYC184. Nucleic acids 
research 16:355. 
251. Hondorp ER, Hou SC, Hempstead AD, Hause LL, Beckett DM, McIver 
KS. 2012. Characterization of the Group A Streptococcus Mga virulence 
regulator reveals a role for the C-terminal region in oligomerization and 
transcriptional activation. Molecular Microbiology 83:953-967. 
252. Husmann LK, Scott JR, Lindahl G, Stenberg L. 1995. Expression of the 
Arp protein, a member of the M protein family, is not sufficient to inhibit 
phagocytosis of Streptococcus pyogenes. Infection and Immunity 63:345-348. 
253. Yanisch-Perron C, Vieira J, Messing J. 1985. Improved M13 phage cloning 
vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 
vectors. Gene 33:103-119. 
254. Le Breton Y, McIver KS. 2013. Genetic Manipulation of Streptococcus 
pyogenes (The Group A Streptococcus, GAS). Current Protocols in 
Microbiology. 
255. Sung K, Khan SA, Nawaz MS, Khan AA. 2003. A simple and efficient 
Triton X-100 boiling and chloroform extraction method of RNA isolation 
from Gram-positive and Gram-negative bacteria. FEMS Microbiology Letters 
229:97-101. 
256. Andrews S. 2010.  FASTQC. A quality control tool for high throughput 
sequence data, on Babraham Institute. 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ Accessed  
257. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for 
Illumina sequence data. Bioinformatics 30:2114-2120. 
258. Langmead B. 2010. Aligning short sequencing reads with Bowtie. Current 
Protocols in Bioinformatics 11. 
259. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. 
Nature methods 9:357-359. 
260. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, 




expression analysis of RNA-seq experiments with TopHat and Cufflinks. 
Nature protocols 7:562-578. 
261. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, 
Abecasis G, Durbin R, Subgroup GPDP. 2009. The Sequence 
Alignment/Map format and SAMtools. Bioinformatics 25:2078-2079. 
262. Anders S, Pyl PT, Huber W. 2015. HTSeq--a Python framework to work 
with high-throughput sequencing data. Bioinformatics 31:166-169. 
263. Thorvaldsdóttir H, Robinson JT, Mesirov JP. 2013. Integrative Genomics 
Viewer (IGV): high-performance genomics data visualization and exploration. 
Briefings in Bioinformatics 14:178-192. 
264. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. 
limma powers differential expression analyses for RNA-sequencing and 
microarray studies. Nucleic acids research 43:e47. 
265. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change 
and dispersion for RNA-Seq data with DESeq2. 
. bioRxiv doi:doi:10.1101/002832. 
266. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. 1999. 
KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic acids research 
27:29-34. 
267. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, 
Jones SJ, Marra MA. 2009. Circos: an information aesthetic for comparative 
genomics. Genome Research 19:1639-1645. 
268. Young MD, Wakefield MJ, Smyth GK, Oshlack A. 2010. Gene ontology 
analysis for RNA-seq: accounting for selection bias. Genome Biology 
11:R14. 
269. Beissbarth T, Speed TP. 2004. GOstat: find statistically overrepresented 
Gene Ontologies within a group of genes. Bioinformatics 20:1464-1465. 
270. Alexa A, Rahnenfuhrer J, Lengauer T. 2006. Improved scoring of 
functional groups from gene expression data by decorrelating GO graph 
structure. Bioinformatics 22:1600-1607. 
271. Lancefield RC. 1957. Differentiation of group A streptococci with a common 
R antigen into three serological types, with special reference to the 
bactericidal test. Journal of Experimental Medicine 106:525-544. 
272. Loo CY, Mitrakul K, Voss IB, Hughes CV, Ganeshkumar N. 2003. 
Involvement of an inducible fructose phosphotransferase operon in 
Streptococcus gordonii biofilm formation. Journal of Bacteriology 185:6241-
6254. 
273. Pridgeon JW, Li Y, Yildirim-Aksoy M, Song L, Klesius PH, Srivastava 
KK, Reddy PG. 2013. Fitness cost, gyrB mutation, and absence of 
phosphotransferase system fructose specific IIABC component in novobiocin-
resistant Streptococcus iniae vaccine strain ISNO. Veterinary Microbiology 
165:384-391. 
274. Sachla AJ, Le Breton Y, Akhter F, McIver KS, Eichenbaum Z. 2014. The 
crimson conundrum: heme toxicity and tolerance in GAS. Frontiers in 




275. Barriere C, Veiga-da-Cunha M, Pons N, Guedon E, van Hijum SA, Kok 
J, Kuipers OP, Ehrlich DS, Renault P. 2005. Fructose utilization in 
Lactococcus lactis as a model for low-GC gram-positive bacteria: its 
regulator, signal, and DNA-binding site. Journal of Bacteriology 187:3752-
3761. 
276. LaSarre B, Federle MJ. 2011. Regulation and consequence of serine 
catabolism in Streptococcus pyogenes. Journal of Bacteriology 193:2002-
2012. 
277. Savic DJ, McShan WM, Ferretti JJ. 2002. Autonomous expression of the 
slo gene of the bicistronic nga-slo operon of Streptococcus pyogenes. 
Infection and Immunity 70:2730-2733. 
278. Wen ZT, Browngardt C, Burne RA. 2001. Characterization of two operons 
that encode components of fructose-specific enzyme II of the 
sugar:phosphotransferase system of Streptococcus mutans. FEMS 
Microbiology Letters 205:337-342. 
279. Kolaczkowska E, Kubes P. 2013. Neutrophil recruitment and function in 
health and inflammation. Nature reviews Immunology 13:159-175. 
280. Ajdic D, Pham VT. 2007. Global transcriptional analysis of Streptococcus 
mutans sugar transporters using microarrays. Journal of Bacteriology 
189:5049-5059. 
281. Barrangou R, Azcarate-Peril MA, Duong T, Conners SB, Kelly RM, 
Klaenhammer TR. 2006. Global analysis of carbohydrate utilization by 
Lactobacillus acidophilus using cDNA microarrays. Proceedings of the 
National Academy of Sciences of the United States of America 103:3816-
3821. 
282. Kelley LA, Sternberg MJ. 2009. Protein structure prediction on the Web: a 
case study using the Phyre server. Nature Protocols 4:363-371. 
283. Voigt C, Bahl H, Fischer RJ. 2014. Identification of PTS(Fru) as the major 
fructose uptake system of Clostridium acetobutylicum. Applied Microbiology 
and Biotechnology 98:7161-7172. 
284. Chavarria M, Durante-Rodriguez G, Krell T, Santiago C, Brezovsky J, 
Damborsky J, de Lorenzo V. 2014. Fructose 1-phosphate is the one and only 
physiological effector of the Cra (FruR) regulator of Pseudomonas putida. 
FEBS Open Bio 4:377-386. 
285. Chavarria M, Santiago C, Platero R, Krell T, Casasnovas JM, de Lorenzo 
V. 2011. Fructose 1-phosphate is the preferred effector of the metabolic 
regulator Cra of Pseudomonas putida. Journal of Biological Chemistry 
286:9351-9359. 
286. Reizer J, Hoischen C, Titgemeyer F, Rivolta C, Rabus R, Stulke J, 
Karamata D, Saier MH, Jr., Hillen W. 1998. A novel protein kinase that 
controls carbon catabolite repression in bacteria. Molecular Microbiology 
27:1157-1169. 
287. Kornberg HL. 2001. Routes for fructose utilization by Escherichia coli. 




288. Medina E, Lengeling A. 2005. Genetic regulation of host responses to group 
A streptococcus in mice. Briefings in Functional Genomics and Proteomics 
4:248-257. 
289. Munoz-Elias EJ, McKinney JD. 2005. Mycobacterium tuberculosis 
isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. 
Nature Medicine 11:638-644. 
290. Iyer R, Camilli A. 2007. Sucrose metabolism contributes to in vivo fitness of 
Streptococcus pneumoniae. Molecular Microbiology 66:1-13. 
291. Son MS, Matthews WJ, Jr., Kang Y, Nguyen DT, Hoang TT. 2007. In 
vivo evidence of Pseudomonas aeruginosa nutrient acquisition and 
pathogenesis in the lungs of cystic fibrosis patients. Infection and Immunity 
75:5313-5324. 
292. Rollenhagen C, Bumann D. 2006. Salmonella enterica highly expressed 
genes are disease specific. Infection and Immunity 74:1649-1660. 
293. Moyrand F, Fontaine T, Janbon G. 2007. Systematic capsule gene 
disruption reveals the central role of galactose metabolism on Cryptococcus 
neoformans virulence. Molecular Microbiology 64:771-781. 
294. Graham MR, Virtaneva K, Porcella SF, Gardner DJ, Long RD, Welty 
DM, Barry WT, Johnson CA, Parkins LD, Wright FA, Musser JM. 2006. 
Analysis of the transcriptome of group A Streptococcus in mouse soft tissue 
infection. American Journal of Pathology 169:927-942. 
295. Le Breton Y, Belew AT, Valdes KM, Islam E, Curry P, Tettelin H, 
Shirtliff ME, El-Sayed NM, McIver KS. 2015. Essential Genes in the Core 
Genome of the Human Pathogen Streptococcus pyogenes. Scientific Reports 
5:9838. 
296. Aziz RK, Edwards RA, Taylor WW, Low DE, McGeer A, Kotb M. 2005. 
Mosaic prophages with horizontally acquired genes account for the emergence 
and diversification of the globally disseminated M1T1 clone of Streptococcus 
pyogenes. Journal of Bacteriology 187:3311-3318. 
297. Loughman JA, Caparon MG. 2007. Comparative functional analysis of the 
lac operons in Streptococcus pyogenes. Molecular Microbiology 64:269-280. 
298. Kazmi SU, Kansal R, Aziz RK, Hooshdaran M, Norrby-Teglund A, Low 
DE, Halim AB, Kotb M. 2001. Reciprocal, temporal expression of SpeA and 
SpeB by invasive M1T1 group a streptococcal isolates in vivo. Infection and 
Immunity 69:4988-4995. 
299. Sumby P, Porcella SF, Madrigal AG, Barbian KD, Virtaneva K, Ricklefs 
SM, Sturdevant DE, Graham MR, Vuopio-Varkila J, Hoe NP, Musser 
JM. 2005. Evolutionary origin and emergence of a highly successful clone of 
serotype M1 group A streptococcus involved multiple horizontal gene transfer 
events. Journal of Infectious Diseases 192:771-782. 
300. Hirst RA, Sikand KS, Rutman A, Mitchell TJ, Andrew PW, O'Callaghan 
C. 2000. Relative roles of pneumolysin and hydrogen peroxide from 
Streptococcus pneumoniae in inhibition of ependymal ciliary beat frequency. 
Infection and Immunity 68:1557-1562. 
301. Pericone CD, Overweg K, Hermans PW, Weiser JN. 2000. Inhibitory and 




pneumoniae on other inhabitants of the upper respiratory tract. Infection and 
Immunity 68:3990-3997. 
302. Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M. 
2006. Interference between Streptococcus pneumoniae and Staphylococcus 
aureus: In vitro hydrogen peroxide-mediated killing by Streptococcus 
pneumoniae. Journal of Bacteriology 188:4996-5001. 
303. Anbalagan S, Chaussee MS. 2013. Transcriptional regulation of a 
bacteriophage encoded extracellular DNase (Spd-3) by Rgg in Streptococcus 
pyogenes. PLoS One 8:e61312. 
304. Maamary PG, Ben Zakour NL, Cole JN, Hollands A, Aziz RK, Barnett 
TC, Cork AJ, Henningham A, Sanderson-Smith M, McArthur JD, 
Venturini C, Gillen CM, Kirk JK, Johnson DR, Taylor WL, Kaplan EL, 
Kotb M, Nizet V, Beatson SA, Walker MJ. 2012. Tracing the evolutionary 
history of the pandemic group A streptococcal M1T1 clone. FASEB Journal 
26:4675-4684. 
305. Horstmann N, Sahasrabhojane P, Saldana M, Ajami NJ, Flores AR, 
Sumby P, Liu CG, Yao H, Su X, Thompson E, Shelburne SA. 2015. 
Characterization of the effect of the histidine kinase CovS on response 
regulator phosphorylation in group A Streptococcus. Infection and Immunity 
83:1068-1077. 
306. Bessen DE, Sotir CM, Readdy TL, Hollingshead SK. 1996. Genetic 
correlates of throat and skin isolates of group A streptococci. Journal of 
Infectious Diseases 173:896-900. 
307. Andersson G, McIver K, Heden LO, Scott JR. 1996. Complementation of 
divergent mga genes in group A streptococcus. Gene 175:77-81. 
308. Vahling CM, McIver KS. 2006. Domains required for transcriptional 
activation show conservation in the Mga family of virulence gene regulators. 
Journal of Bacteriology 188:863-873. 
309. Yung DL, McIver KS, Scott JR, Hollingshead SK. 1999. Attenuated 
expression of the mga virulence regulon in an M serotype 50 mouse-virulent 
group A streptococcal strain. Infection and Immunity 67:6691-6694. 
310. Kruszewski AM, Hausse LL, Hondorp EH. 2013. The Group A 
Streptococcus Mga virulence regulator: determination of C-terminal amino 
acids respnsible for oligomeriation and transcriptional activation. Bachelors of 
Science. University of Maryland, College Park. 
311. Karimova G, Ullmann A, Ladant D. 2000. A bacterial two-hybrid system 
that exploits a cAMP signaling cascade in Escherichia coli. Methods in 
Enzymology 328:59-73. 
312. Xu J, Li M, Kim D, Xu Y. 2003. RAPTOR: optimal protein threading by 
linear programming. Jorunal of Bioinformatics and Computational Biology 
1:95-117. 
313. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC 
Bioinformatics 9:40. 
314. Chivian D, Kim DE, Malmstrom L, Bradley P, Robertson T, Murphy P, 
Strauss CE, Bonneau R, Rohl CA, Baker D. 2003. Automated prediction of 




315. Yung DL, Hollingshead SK. 1996. DNA sequencing and gene expression of 
the emm gene cluster in an M50 group A streptococcus strain virulent for 
mice. Infection and Immunity 64:2193-2200. 
316. Vahling CM, McIver KS. 2005. Identification of residues responsible for the 
defective virulence gene regulator Mga produced by a natural mutant of 
Streptococcus pyogenes. Journal of Bacteriology 187. 
317. Van den Bogert B, Boekhorst J, Herrmann R, Smid EJ, Zoetendal EG, 
Kleerebezem M. 2013. Comparative genomics analysis of Streptococcus 
isolates from the human small intestine reveals their adaptation to a highly 
dynamic ecosystem. PloS One 8:e83418. 
318. Kreft J, Vazquez-Boland JA. 2001. Regulation of virulence genes in 
Listeria. International Journal of Medical Microbiology 291:145-157. 
319. Ferenci T, Kornberg HL. 1971. Role of fructose-1,6-diphosphatase in 
fructose utilization by Escherichia coli. FEBS Letters 14:360-363. 
320. Kim HK, Missiakas D, Schneewind O. 2014. Mouse models for infectious 
diseases caused by Staphylococcus aureus. Journal of Immunology Methods 
410:88-99. 
321. Mestas J, Hughes CC. 2004. Of mice and not men: differences between 
mouse and human immunology. Journal of Immunology 172:2731-2738. 
322. Kugelberg E, Norstrom T, Petersen TK, Duvold T, Andersson DI, 
Hughes D. 2005. Establishment of a superficial skin infection model in mice 
by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrobial 
Agents and Chemotherapy 49:3435-3441. 
323. Roberts S, Scott JR, Husmann LK, Zurawski CA. 2006. Murine models of 
Streptococcus pyogenes infection. Curr Protoc Microbiol Chapter 9:Unit 9D 
5. 
324. Scaramuzzino DA, McNiff JM, Bessen DE. 2000. Humanized in vivo model 
for streptococcal impetigo. Infection and Immunity 68:2880-2887. 
325. Gladysheva IP, Turner RB, Sazonova IY, Liu L, Reed GL. 2003. 
Coevolutionary patterns in plasminogen activation. Proceedings of the 
National Academy of Sciences of the United States of America 100:9168-
9172. 
326. Khil J, Im M, Heath A, Ringdahl U, Mundada L, Cary Engleberg N, Fay 
WP. 2003. Plasminogen enhances virulence of group A streptococci by 
streptokinase-dependent and streptokinase-independent mechanisms. Journal 
of Infectious Diseases 188:497-505. 
327. Accardo P, Sanchez-Corral P, Criado O, Garcia E, Rodriguez de 
Cordoba S. 1996. Binding of human complement component C4b-binding 
protein (C4BP) to Streptococcus pyogenes involves the C4b-binding site. 
Journal of Immunology 157:4935-4939. 
328. McArthur JD, Walker MJ. 2006. Domains of group A streptococcal M 
protein that confer resistance to phagocytosis, opsonization and protection: 
implications for vaccine development. Molecular microbiology 59:1-4. 
329. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, 




critical host pathogenicity factor for group A streptococcal infection. Science 
305:1283-1286. 
330. Ermert D, Shaughnessy J, Joeris T, Kaplan J, Pang CJ, Kurt-Jones EA, 
Rice PA, Ram S, Blom AM. 2015. Virulence of Group A Streptococci Is 
Enhanced by Human Complement Inhibitors. PLoS Pathogens 11:e1005043. 
331. Proft T, Moffatt SL, Berkahn CJ, Fraser JD. 1999. Identification and 
characterization of novel superantigens from Streptococcus pyogenes. Journal 
of Experimental Medicine 189:89-102. 
332. Deutscher J, Francke C, Postma PW. 2006. How phosphotransferase 
system-related protein phosphorylation regulates carbohydrate metabolism in 
bacteria. Microbiology and Molecular Biology Reviews 70:939-1031. 
333. Vadeboncoeur C, Pelletier M. 1997. The phosphoenolpyruvate:sugar 
phosphotransferase system of oral streptococci and its role in the control of 
sugar metabolism. FEMS Microbiology Reviews 19:187-207. 
334. Cvitkovitch DG, Boyd DA, Thevenot T, Hamilton IR. 1995. Glucose 
transport by a mutant of Streptococcus mutans unable to accumulate sugars 
via the phosphoenolpyruvate phosphotransferase system. Journal of 
Bacteriology 177:2251-2258. 
335. Bidossi A, Mulas L, Decorosi F, Colomba L, Ricci S, Pozzi G, Deutscher 
J, Viti C, Oggioni MR. 2012. A functional genomics approach to establish 
the complement of carbohydrate transporters in Streptococcus pneumoniae. 
PLoS One 7:e33320. 
336. Kant S, Agarwal S, Pancholi P, Pancholi V. 2015. The Streptococcus 
pyogenes orphan protein tyrosine phosphatase, SP-PTP, possesses dual 
specificity and essential virulence regulatory functions. Molecular 
Microbiology 97:515-540. 
337. Greenberg DB, Stulke J, Saier MH, Jr. 2002. Domain analysis of 
transcriptional regulators bearing PTS regulatory domains. Research in 
Microbiology 153:519-526. 
 
